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ABSTRACT 
 
The development of new drugs is a long, complex and expensive process that 
involves the evaluation of pharmacokinetic and pharmacodynamic properties of the 
new molecule in different stages. In the early stages of drug development, in vitro 
methods for the high-throughput screening of new molecules’ properties are 
commonly used, with the aim of having preliminary data about the potential 
pharmacological activity of a molecule and also its pharmacokinetics. When chiral 
molecules are employed, both pharmacokinetic and pharmacodynamic properties 
can show a certain degree of enantioselectivity due to the interaction with optically 
active biomacromolecules (Brocks, 2006), so the methods applied in these preclinical 
early stages must allow evaluating these properties in an enantioselective way. This 
need comes from the growing interest of the pharmaceutical industry in the 
development of single-enantiomer formulations, and also from the regulations 
concerning racemic drugs, which indicate that enantioselective analysis should be 
performed also over racemates (Food and Drug Administration, 1992; European 
Medicines Agency, 1993). 
Capillary electrophoresis (CE) is a convenient analytical technique to be applied for 
these preclinical studies. It provides advantageous possibilities for the chiral analysis 
of small molecules and also for the in-line evaluation of some pharmacokinetic and 
pharmacodynamic processes, such as the binding of drugs to plasma proteins or 
their behavior in different enzymatic reactions. Its main features, which are 
extremely interesting for these applications, are speediness of analysis, low 
consumption of chemicals and reagents, ease of automation, high peak efficiencies 
and low environmental impact (Lin et al., 2003). 
The main purpose of this Thesis is the development and application of capillary 
electrophoretic methodologies for the in vitro enantioselective evaluation of 
pharmacological properties of drugs, in order to provide to the pharmaceutical 
industry fast and reliable alternatives for the preclinical stages of drug development. 
It is divided into three main parts: development of methods and theoretical studies 
for chiral separations of xenobiotics by CE (Papers I-IV), evaluation of the 
Abstract 
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enantioselective binding of drugs to plasma proteins (Papers V-VII) and study of 
enzymatic reactions by electrophoretically mediated microanalysis, EMMA (Papers 
VIII-X). 
A powerful chiral selector, the highly sulfated β-cyclodextrin (HS-β-CD), has been 
widely used along this Thesis to perform enantioseparations. So, the first and second 
studies of this Thesis are theoretical; about its enantiorecognition ability. In Paper I, 
apparent binding constants between HS-β-CD and enantiomers of eight psychoactive 
drugs were estimated by electrokinetic chromatography-complete filling technique 
(EKC-CFT). The experimental mobility data of both enantiomers were fitted vs. the 
cyclodextrin concentration using a non-linear model that allows the estimation of 
apparent binding constants and overall limit mobilities. From these estimations, it 
was possible to calculate the thermodynamic (αt) and electrophoretic (αe) 
enantioselectivities of the separation process. The results show that this cyclodextrin 
strongly binds to the enantiomers of these basic drugs, with high enantioselectivity 
in most of the cases. The binding constants of HS-β-CD to the studied drugs are 
equal or higher than those found in the literature for other compounds (Vaccher et 
al., 2005, Lipka et al., 2007). 
Both thermodynamic (due to the difference between the apparent binding constants 
of the enantiomers) and electrophoretic (related to the difference between the 
overall complex enantiomer-CD mobilities) enantioselectivities were found to be 
responsible for the enantioseparation with the HS-β-CD, with a major contribution of 
αt . However, in one of the cases, where no thermodynamic enantioselectivity was 
found, only the electrophoretic one was enough to achieve complete separation of 
the enantiomers. The use of complete filling technique for the evaluation of binding 
constants, which is discussed in this Thesis, is presented as an alternative to 
conventional electrokinetic chromatography with a saving on chiral selector of 
around 99%. 
The second Paper included in this Thesis is a quantitative structure-property 
relationship study that models the enantiorecognition ability of the HS-β-CD for basic 
compounds in EKC, by relating the resolution obtained for forty xenobiotics (drugs 
and pesticides) with some of their structural properties. This is an attempt to provide 
Abstract 
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researchers in the field of enantioseparations an alternative to the usually employed 
trial-and-error procedures for the development of chiral methods. A discriminant-
partial least squares analysis over a single response variable (DPLS1) has been 
performed using a categorical resolution (Rs) value as y-vector and the structural 
properties of the xenobiotics as X-matrix. Only four structural variables were 
selected as significant in the final model: logarithm of octanol-water partition 
coefficient estimated at pH 7.4 (lgD), polar surface area (PSA), number of hydrogen 
bond donors (HBD) and acceptors (HBA). From the de-scaled coefficients of the 
model, an explicit equation that relates the categorical Rs with these four variables 
was obtained: Rs = 2.354 + 0.095lgD – 0.008PSA – 0.159HBD – 0.137HBA. This 
model shows an explained variance of 72.4%. 
For those xenobiotics whose predicted Rs is not so high (i.e., expected chiral 
separation only under concrete experimental conditions) a multivariate optimization 
of the most influential experimental conditions affecting enantioseparation 
(cyclodextrin concentration, pH of the background electrolyte (BGE) and capillary 
temperature) has been proposed, via a Box-Behnken experimental design and a 
posterior adjust of the experimental results to a PLS2 model, which allows 
estimating the migration time and the Rs for each set of experimental conditions. 
Paper III is an application of the enantioseparation of the antidepressant fluoxetine 
with HS-β-CD to the chiral analysis of three pharmaceutical formulations. The 
separation conditions were adjusted in order to avoid a matrix interference and a 
suitable EKC-CFT method has been obtained, which allows the quantification of both 
fluoxetine enantiomers in less than 2 min with a Rs of 2.4. A partial validation of the 
chiral analytical method was performed following the guidance of the International 
Conference on Harmonization (ICH) and the US Pharmacopeia in terms of identity, 
linearity, precision and accuracy. Good analytical features were obtained: 
determination coefficients (R2) of 0.996 for the calibration curves of both 
enantiomers, relative standard deviations (RSD) less than 20%, obtained under 
intermediate precision conditions, and recoveries of 92 ± 13 and 105 ± 6 % for the 
first and second eluted enantiomers, respectively. For all samples, the content of 
racemic fluoxetine was within specifications of the US Pharmacopeia (20 mg ± 15%), 
Abstract 
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and stereoisomer ratios were around 1. So, the suitability of HS-β-CD for the 
enantioseparation of basic drugs has been proved here, not only with theoretical 
studies but also with an application to chiral pharmaceutical analysis. 
An approach of non-aqueous capillary electrophoresis (NACE) to the chiral 
separation of drugs, developed during a research stay in the Katholieke Universiteit 
of Leuven, is described in Paper IV. It responded to the interest on developing 
analysis methods based on non-aqueous systems that could be able to determine 
new active pharmaceutical ingredients (APIs) which are non-soluble in aqueous or 
methanolic mediums. Many drugs in the pipeline suggested by combinatorial 
chemistry show low aqueous solubility due to high molecular weight. If a badly 
soluble lead molecule has very good potency and low toxicity, the drug might go into 
further development anyway, and in these cases chiral methods for their analytical 
control may be developed. In this work, the use of dimethyl sulfoxide (DMSO) is 
proposed as an alternative to the most commonly used BGEs of alcoholic nature, due 
to its lower volatility and hazardousness, and better solvent properties for drugs with 
low polarity. However, it may be taken into account that the enantioseparation is 
disfavored in the DMSO medium because the intermolecular forces responsible for 
the enantiorecognition are weaker in organic media (Chankvetadze and Blaschke, 
2001). 
The enantioseparation of three drugs, verapamil, pindolol and fenfluramine, has 
been performed with this NACE methodology, using univariate optimization in order 
to select the best separation conditions. Finally, DMSO-based BGEs containing a 
variable amount of methanol (0-30%), 0.5-1 M HAc, 125 mM NH4Ac and 40 mM 
carboxymethyl-γ-cyclodextrin were selected, with a capillary temperature of 15 ºC 
and a separation voltage of 30 kV. Using these conditions, Rs values of 1.5, 2.0 and 
1.2 were obtained for verapamil, pindolol and fenfluramine, respectively. The electric 
current was stable during all the separations performed, despite the fact that one of 
the most common drawbacks of NACE is current breakdowns. 
Papers V-VII of this Thesis deal with the enantioselective evaluation of an important 
pharmacokinetic property at the level of drugs distribution, the protein binding. The 
amount of drug that binds to plasma proteins, as well as the strength of this binding, 
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influences considerably the availability of the drug for reaching target organs and 
also for being eliminated. As plasma proteins are optically active molecules, chiral 
drugs can show different binding properties between enantiomers. Therefore, the 
development of fast and reliable procedures for the in vitro evaluation of 
enantioselective drug-protein binding is interesting for the pharmaceutical industry 
research. The most abundant protein in human plasma is albumin (HSA), and it 
presents a high degree of enantioselectivity in its binding with drugs.  
In this Thesis, the evaluation of enantioselective binding of drugs to HSA and total 
plasma proteins has been performed by ultrafiltration followed by chiral analysis by 
EKC. In ultrafiltration, a pre-equilibrated drug-protein mixture is filtered through a 
membrane that retains the protein and only allows the pass of the unbound drug 
fraction. This unbound fraction is then analyzed, here using chiral EKC. 
Paper V points out some weak aspects of the experimental methodologies and 
mathematical models previously published for the study of protein binding (Katrahalli 
et al., 2010; Fielding et al., 2005), and proposes a novel strategy for a reliable 
binding evaluation. An extended discussion concerning the different mathematical 
approaches to protein binding is performed, using the enantioselective binding of the 
antidepressant fluoxetine to HSA as an example. The analysis of fluoxetine 
enantiomers has been performed here using HS-β-CD as chiral selector in CFT, in a 
30 mM phosphate buffer of pH 7.0. The separation temperature and voltage have 
been fixed at 30 ºC and 15 kV. 
The proposed strategy implies working close to physiological conditions, thus 
keeping always the ratio between the drug concentration (D) and the protein 
concentration (P) lower than 0.5, and P near the physiological level (around 475 
µM). In this situation, a simple binding model that assumes that only one kind of 
binding site is occupied in the protein molecule and the stoichiometry of the binding 
is 1:1 can be used, always confirming these assumptions via other equations. Also, 
data were inspected in order to detect and eliminate outliers that could affect the 
reliability of the estimations. Enantiomer-protein binding constants (K1) have been 
estimated for fluoxetine, as well as the enantioselectivity, defined as the ratio 
between binding constants. 
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Finally, the percentage of protein binding (PB%), which is an interesting parameter 
from a pharmacokinetic point of view, has been also estimated for both fluoxetine 
enantiomers, being 95.2 and 90.0% for the first and second eluted enantiomers, 
respectively. The correspondent enantioselectivity is around 2, in favor of the first 
eluted enantiomer. 
Still in the field of enantioselective drug-protein interactions, Papers VI and VII study 
the enantioselective binding of the hypnotic zopiclone and the antidepressant 
nomifensine to HSA and total plasma proteins, also by ultrafiltration and chiral EKC 
using the partial (PFT) or complete filling techniques. In Paper VI, the 
enantioseparation of zopiclone with carboxymethyl-β-cyclodextrin (CM-β-CD) is 
adjusted for the analysis of the unbound fractions after ultrafiltration. A solution 
containing 30 mM CM-β-CD in 50 mM Tris buffer at pH 6.0 has been used as chiral 
selector in PFT, injecting it at 0.5 psi during 99 s prior to samples injection. The 
chiral separation has been performed at 25 ºC by applying 15 kV. The mathematical 
approaches and experimental designs developed in Paper V have been also applied 
here to calculate the binding constants, enantioselectivity and protein binding. The 
PB% values to HSA were found to be 47 and 36% for S- and R-zopiclone, 
respectively, and to total plasma proteins 45 and 49%, respectively. These values 
were in agreement with those reported in the literature for racemic zopiclone, 
around 45% (Gaillot et al., 1983; Spanish Drug Agency, 2011). 
The enantioselective binding of nomifensine to HSA and total plasma proteins is 
evaluated in Paper VII, in this case using 30 mM heptakis-(2,3,6-O-methyl)-β-
cyclodextrin as chiral selector in CFT for the enantioseparation of the unbound 
fraction, with the same BGE and voltage as in Paper VI but with a capillary 
temperature of 50 ºC. The experimental design of calibration curves and samples 
was repeated in two independent sessions in order to check the inter-day precision 
of the procedure. As no significant differences were found between the data of both 
working sessions, all data were used together for estimations. The PB% to HSA was 
estimated at 40 and 63% for the first and second eluted enantiomers respectively. 
For the binding to total plasma proteins, the estimated values were 63 and 64% 
respectively. By comparing these values, it can be concluded that the second eluted 
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enantiomer of nomifensine binds mainly to HSA while the first enantiomer binds also 
to other plasma proteins. 
The experimental design and mathematical approaches proposed in this Thesis for a 
reliable estimation of enantioselective protein binding with ultrafiltration and chiral 
EKC have demonstrated to be a robust tool which allows obtaining good in vitro 
estimates in near-physiological conditions, thus providing valuable data from a 
pharmacokinetic point of view. Enantioselective protein binding data for fluoxetine, 
zopiclone and nomifensine have been estimated here, thus completing the 
information available in the literature about these drugs. 
The third part of this Thesis is related to the development of in-capillary enzymatic 
reactions by electrophoretically mediated microanalysis (EMMA). In EMMA the 
reagents are sequentially introduced in an electrophoretic capillary and left to mix 
and react for a fixed time. The separation of substrates, enzymes and products is 
then performed by electrophoresis. The main advantage of EMMA is that the 
reaction takes place in a nanoliter scale, so the consumption of reagents is 
extremely low. Furthermore, it is fully automated since the reaction and the 
separation take part in a unique step inside the capillary, which is another important 
advantage for screening procedures. 
In Paper VIII an EMMA screening methodology for the evaluation of 
acetylcholinesterase (AChE) inhibitors has been developed and applied to the study 
of five drugs with known inhibitory activity. Tacrine has been used as model 
compound in order to optimize the method conditions. The progress of the 
enzymatic reaction of the hydrolysis of acetylthiocholine in presence of AChE and the 
inhibitors has been determined by measuring the peak area of the reaction product 
thiocholine. A “sandwich” injection has been performed by injecting the substrate 
plug between two enzyme plugs. The plugs’ mixing has been performed by simple 
diffusion, with an incubation time of 2 min. The BGE for the reaction and separation 
was 30 mM borate-phosphate buffer at pH 8.0, the capillary temperature has been 
set at 37 ºC and the separation voltage at 15 kV. Due to the dilution of solutes in 
the EMMA methodology, a correction may be performed in calculations to achieve 
accurate results. Here, a dilution factor is estimated by comparing the calculated 
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inhibitory potency of tacrine with that reported with the reference method 
(Andrisano et al., 2001), and applied then to all calculations. 
The proposed screening methodology has proved to be useful for the estimation of 
inhibitory constants, inhibitory potency, a qualitative approach to the inhibition 
mechanism and the percentage of inhibition of tacrine, edrophonium, neostigmine, 
pyridostigmine and eserine. The screening results show that according to their 
percentage of inhibition under fixed conditions, the order of inhibitor potency for 
these compounds is tacrine > edrophonium > neostigmine > eserine > 
pyridostigmine. This screening procedure, with an analysis time shorter than 5 min, 
can be employed for the evaluation of new potential AChE inhibitors. 
Continuing with the use of EMMA methodologies for the evaluation of drug-enzyme 
interactions, Papers IX and X are studies of enantioselective metabolism by different 
isoforms of the cytochrome P450. In these studies, the capillary acts simultaneously 
as reactor and chiral separation system, thus providing enantioselective information 
with a fast, fully automated assay. The chiral separation is performed in both cases 
using HS-β-CD and the partial filling technique. 
Paper IX deals with the enantioselective metabolism of the Ca+2-channel blocker 
verapamil by CYP3A4, the most important isoform of cytochrome P450 in humans. 
Different possibilities for the EMMA assay have been considered and variables have 
been optimized prior to calculation of the Michaelis-Menten parameters for the 
enantioselective metabolism kinetics. The selected experimental conditions for the 
EMMA assay included a “sandwich” injection of the substrate plug between two 
enzyme plugs, and two plugs of incubation buffer before and after the “sandwich” in 
order to give to the enzyme its adequate reaction medium. The mixing of plugs has 
been performed by simple diffusion during an incubation time of 5 min. After that, 
the separation of all the reaction mixture, including the enantiomers of verapamil 
and its major metabolite norverapamil, has been performed in the same capillary 
with the following conditions: 50 mM phosphate at pH 8.8 as BGE, 2.5% HS-β-CD 
injected at 10 psi/2 min, 25ºC and 20 kV with a little pressure of 0.2 psi in order to 
shorter the migration times. The result is a fully automated methodology that allows 
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the enantioselective evaluation of verapamil metabolism by CYP3A4 in less than 35 
min including capillary preconditioning, injection, incubation and separation. 
Michaelis-Menten parameters (Km and Vmax) have been calculated for the overall 
enantioselective metabolism of verapamil by CYP3A4. Km values have been 
estimated as 51 ± 9 and 47 ± 9 µM for S- and R-verapamil, respectively, while Vmax 
estimates were 22 ± 2 and 21 ± 2 pmol·min-1·(pmol CYP)-1 for S- and R-verapamil, 
respectively. Intrinsic clearances, defined as the amount of plasma from which a 
xenobiotic is removed in a certain time, and estimated in vitro as Vmax/Km (Kroemer 
et al., 1992), have been also calculated for both enantiomers. 
The enantioselective metabolism of fluoxetine by other CYP450 isoform, CYP2D6, is 
estimated in Paper X following the same methodology as in the previous work. The 
EMMA conditions from Paper IX were directly applied, while the separation 
conditions were adjusted in order to separate the enantiomers of fluoxetine and its 
major metabolite norfluoxetine. The influence of the most important variable on the 
enantioseparation, the concentration of HS-β-CD, was studied and a final 
concentration of 1.25% was selected for the separation of the reaction mixture. The 
other separation conditions were kept as in Paper IX. Kinetic parameters have been 
estimated by non-linear fitting of experimental data to the Michaelis-Menten 
equation. Km values were found to be 30 ± 3 µM for S-fluoxetine and 39 ± 5 µM for 
R-fluoxetine. Vmax estimates were 28.6 ± 1.2 and 34 ± 2 pmol·min
-1·(pmol CYP)-1 for 
S- and R-fluoxetine, respectively. The kinetic assay was repeated using a single 
enantiomer (R-fluoxetine) instead of the racemic mixture. Similar results were 
obtained indicating that the use of the racemate is a good option for obtaining 
enantioselective estimations. 
The usefulness of EMMA as screening methodology for the in vitro evaluation, 
enantioselective or not, of drug-enzyme interactions has been proved in this Thesis. 
The developed methods allow to estimate kinetic and inhibition parameters in fast 
assays with low consumption of reagents and samples. The coupling of EMMA with 
the enantioseparation of substrates and products in a unique step carried out in the 
CE system provides valuable enantioselective information about the pharmacokinetic 
or pharmacodynamic processes evaluated. 
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All the methods proposed and applied in this Thesis (chiral separations, prediction 
models, enantioselective protein binding evaluation and drug-enzyme interaction) 
can be applied in the pharmaceutical industry to obtain useful in vitro information in 
the preclinical phases of drug development and for the enantioselective quality 
control of raw materials, synthesis intermediates and final products. 
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RESUMEN 
 
El desarrollo de nuevos fármacos es un proceso largo, complejo y costoso que 
incluye la evaluación en diferentes etapas de propiedades farmacocinéticas y 
farmacodinámicas de la nueva molécula. En las primeras etapas del desarrollo de un 
fármaco es habitual el uso de métodos in vitro para el cribado de alto rendimiento 
de las propiedades de nuevas moléculas, con el objetivo de obtener datos 
preliminares sobre la potencial actividad farmacológica de una molécula y sobre su 
farmacocinética. Cuando se emplean moléculas quirales, tanto sus propiedades 
farmacocinéticas como las farmacodinámicas pueden presentar un cierto grado de 
enantioselectividad debido a la interacción con biomacromoléculas ópticamente 
activas (Brocks, 2006), por lo que los métodos aplicados en estas primeras etapas 
preclínicas deben permitir la evaluación de estas propiedades de una manera 
enantioselectiva. Esta necesidad proviene del creciente interés de la industria 
farmacéutica en el desarrollo de formulaciones enantioméricamente puras, y 
también de las normativas en torno a medicamentos racémicos, que indican que el 
control de calidad realizado sobre estos fármacos también debe ser enantioselectivo 
(Food and Drug Administration, 1992; European Medicines Agency, 1993). 
La electroforesis capilar (CE, del inglés capillary electrophoresis) es una técnica 
analítica conveniente para abordar estos estudios preclínicos. Proporciona ventajosas 
posibilidades para el análisis quiral de moléculas pequeñas y para la evaluación en 
línea de numerosos procesos farmacocinéticos y farmacodinámicos, como la unión 
de fármacos a las proteínas plasmáticas o su comportamiento en diferentes 
reacciones enzimáticas. Sus principales características, extremadamente interesantes 
para estas aplicaciones, son rapidez de análisis, bajo consumo de reactivos y 
muestras, facilidad de automatización, elevadas eficacias de pico y bajo impacto 
medioambiental (Lin y col., 2003). 
El principal objetivo de esta Tesis es el desarrollo y aplicación de metodologías 
electroforéticas para la evaluación enantioselectiva in vitro de propiedades 
farmacológicas de medicamentos, con el fin de proporcionar a la industria 
farmacéutica alternativas rápidas y fiables en las fases preclínicas del desarrollo de 
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nuevos fármacos. Esta Tesis se divide en tres bloques principales: desarrollo de 
métodos y estudios teóricos para la separación quiral de xenobióticos mediante 
electroforesis capilar (Artículos I-IV), evaluación de la unión enantioselectiva de 
fármacos a las proteínas plasmáticas (Artículos V-VII) y estudio de reacciones 
enzimáticas empleando microanálisis mediante electroforesis (EMMA, del inglés 
electrophoretically mediated microanalysis) (Artículos VIII-X). 
Los dos primeros trabajos incluidos en esta Tesis son estudios teóricos sobre la 
capacidad de enantioreconocimiento de la β-ciclodextrina altamente sulfatada (HS-β-
CD, del inglés highly sulfated β-cyclodextrin), potente selector quiral que se ha 
utilizado en una gran parte de las separaciones quirales desarrolladas en esta Tesis. 
En el Artículo I se han estimado constantes de unión aparentes entre la HS-β-CD y 
los enantiómeros de ocho fármacos psicoactivos empleando cromatografía 
electrocinética y la técnica del llenado completo del capilar (EKC-CFT, del inglés 
electrokinetic chromatography-complete filling technique). Los datos experimentales 
de movilidad electroforética de ambos enantiómeros se representaron frente a la 
concentración de ciclodextrina empleando un modelo de ajuste no lineal que permite 
la estimación de constantes de unión aparentes y movilidades límite. A partir de 
estas estimaciones se calcularon las enantioselectividades termodinámica (αt) y 
electroforética (αe) del proceso de separación. Los resultados mostraron que esta 
ciclodextrina se une fuertemente a los enantiómeros de los ocho fármacos básicos 
seleccionados, con elevada enantioselectividad en la mayoría de los casos. Las 
constantes aparentes de unión de la HS-β-CD a los fármacos estudiados son iguales 
o mayores que las descritas en la bibliografía para otros compuestos (Vaccher y col., 
2005, Lipka y col., 2007). 
Ambas enantoselectividades, termodinámica (relacionada con las diferencias entre 
las constantes de unión aparentes de ambos enantiómeros) y electroforética (debida 
a las diferentes movilidades de los complejos enantiómero-ciclodextrina), resultaron 
ser responsables de la separación quiral con HS-β-CD, aunque con una mayor 
contribución de αt.. Sin embargo, en uno de los casos en el que no se vio 
enantioselectividad termodinámica, los enantiómeros se resolvieron completamente 
debido únicamente a la enantioselectividad electroforética. Por otro lado, el uso de la 
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técnica del llenado completo del capilar para la evaluación de constantes de unión se 
presenta en esta Tesis como una alternativa a la cromatografía electrocinética 
convencional con un ahorro en selector quiral en torno al 99%. 
El segundo Artículo incluido en esta Tesis es un estudio de relación cuantitativa 
estructura-actividad que modela la capacidad de enantioreconocimiento de la HS-β-
CD para compuestos básicos en EKC, relacionando la resolución obtenida para 
cuarenta xenobióticos (fármacos y plaguicidas) con algunas de sus propiedades 
estructurales. Este trabajo proporciona a los investigadores en el campo de las 
separaciones quirales una alternativa a los procedimientos habituales de ensayo y 
error para el desarrollo de métodos enantioselectivos. Se llevó a cabo una regresión 
de mínimos cuadrados parciales discriminante sobre una variable respuesta (DPLS1, 
del inglés discriminant-partial least squares) empleando como vector y un valor 
categórico de resolución (Rs) y como matriz X las propiedades estructurales de los 
xenobióticos. Únicamente se seleccionaron cuatro variables estructurales como 
significativas en el modelo final: logaritmo del coeficiente de partición octanol-agua 
estimado a pH 7,4 (lgD), área superficial polar (PSA), número de dadores (HBD) y 
aceptores (HBA) de enlaces de hidrógeno. A partir de los coeficientes no escalados 
del modelo, se obtuvo una ecuación explícita que relaciona el valor categórico de Rs 
con las cuatro variables estructurales seleccionadas: Rs = 2,354 + 0,095lgD – 
0,008PSA – 0,159HBD – 0,137HBA. El modelo seleccionado presentó una varianza 
explicada del 72,4%. 
Para aquellos xenobióticos cuya Rs predicha no es muy elevada, que puede 
interpretarse como posible separación quiral pero sólo en determinadas condiciones 
experimentales, se propuso una optimización multivariante de las tres condiciones 
experimentales más influyentes en la enantioseparación (concentración de 
ciclodextrina, pH del tampón de separación (BGE, del inglés background electrolyte) 
y temperatura del capilar), a través de un diseño experimental Box-Behnken y un 
ajuste posterior de los resultados experimentales a un modelo PLS2, que permite la 
estimación del tiempo de migración y la resolución para cada conjunto de 
condiciones experimentales. 
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El Artículo III es una aplicación de la enantioseparación del antidepresivo fluoxetina 
con HS-β-CD al análisis quiral de tres formulaciones farmacéuticas. Las condiciones 
de separación se optimizaron para evitar una interferencia de la matriz y se obtuvo 
un método de separación adecuado mediante EKC-CFT que permite la cuantificación 
de ambos enantiómeros de fluoxetina en menos de 2 minutos con un valor de Rs de 
2,4. Se llevó a cabo una validación parcial del método quiral siguiendo las 
indicaciones de la International Conference on Harmonization (ICH) y de la US 
Pharmacopeia sobre identidad, linearidad, precisión y exactitud. Se obtuvieron 
buenas características analíticas: coeficientes de determinación (R2) de 0,996 para 
las curvas de calibrado de ambos enantiómeros, desviaciones estándar relativas 
(RSD, del inglés relative standard deviation) inferiores al 20%, obtenidas en 
condiciones de precisión intermedia, y recuperaciones de 92 ± 13 y 105 ± 6 % para 
el primer y segundo enantiómero eluídos, respectivamente. Para todas las muestras 
se obtuvo un contenido en fluoxetina racémica dentro de las especificaciones de la 
US Pharmacopeia (20 mg ± 15%), con relaciones estereoisoméricas en torno a 1. Así 
pues, en esta Tesis se ha demostrado la idoneidad de la HS-β-CD para la 
enantioseparación de fármacos básicos, no sólo con estudios teóricos sino también 
con una aplicación al análisis quiral de productos farmacéuticos. 
En el Artículo IV se describe una aplicación de la electroforesis capilar no acuosa 
(NACE, del inglés non-aqueous capillary electrophoresis) a la separación quiral de 
fármacos, llevada a cabo durante una estancia de investigación en la Katholieke 
Universiteit of Leuven. Este trabajo responde al interés en desarrollar metodologías 
basadas en sistemas no acuosos que sean capaces de disolver y analizar nuevos 
principios activos que sean insolubles en medios acuosos o metanólicos. Muchos 
fármacos en desarrollo sugeridos por aplicación de la química combinatoria 
presentan baja solubilidad en agua debida a un elevado peso molecular. Si una 
molécula objetivo poco soluble en medios acuosos presenta buena potencia y baja 
toxicidad, puede resultar de interés  continuar en fase de desarrollo a pesar de esta 
baja solubilidad y en estos casos se requieren métodos de análisis quiral para su 
control analítico. En este trabajo se propuso el uso de dimetilsulfóxido (DMSO) como 
alternativa a los BGEs de naturaleza alcohólica más comúnmente empleados, debido 
a su baja volatilidad y toxicidad y mejores propiedades disolventes para moléculas 
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poco polares. Sin embargo, debe tenerse en cuenta que la enantioseparación en 
DMSO se encuentra desfavorecida debido a que las fuerzas intermoleculares 
responsables del enantioreconocimiento son más débiles en medios orgánicos 
(Chankvetadze y Blaschke, 2001). 
Se llevó a cabo la separación quiral de tres fármacos, verapamilo, pindolol y 
fenfluramina, mediante NACE y empleando una optimización univariante para la 
selección de las mejores condiciones experimentales. Finalmente, se seleccionaron 
BGEs basados en DMSO y que contenían proporciones variables de metanol (0-
30%), HAc 0,5-1 M, NH4Ac 125 mM y carboximetil-γ-ciclodextrina 40 mM, con una 
temperatura de separación de 15 ºC y un potencial aplicado de 30 kV. Empleando 
estas condiciones se obtuvieron valores de Rs de 1,5; 2,0 y 1,2 para verapamilo, 
pindolol y fenfluramina, respectivamente. La corriente fue estable durante todas las 
separaciones llevadas a cabo, a pesar de que uno de los principales problemas de 
NACE son los frecuentes cortes de corriente. 
Los Artículos V-VII de esta Tesis se refieren a la evaluación enantioselectiva de una 
importante propiedad farmacocinética al nivel de la distribución de fármacos, la 
unión a proteínas plasmáticas. La cantidad de un fármaco que se une a las proteínas 
plasmáticas, así como la fuerza de esta unión, influyen considerablemente en la 
disponibilidad de los fármacos para alcanzar órganos diana y también para su 
eliminación. Dado que las proteínas plasmáticas son moléculas ópticamente activas, 
los fármacos quirales pueden presentar diferencias en las propiedades de unión de 
sus enantiómeros a éstas. Así pues, el desarrollo de metodologías rápidas y fiables 
para la evaluación in vitro de la unión enantioselectiva de fármacos a las proteínas 
plasmáticas resulta de gran interés para la investigación en la industria farmacéutica. 
La proteína más abundante en el plasma humano es la albúmina (HSA, del inglés 
human serum albumin), que presenta un elevado grado de enantioselectividad en su 
unión a fármacos.  
En esta Tesis se ha evaluado la unión enantioselectiva de fármacos a HSA y al total 
de las proteínas plasmáticas mediante ultrafiltración seguida de análisis quiral 
mediante EKC. En la ultrafiltración se filtra una mezcla pre-equilibrada de fármaco y 
proteína a través de una membrana que retiene la proteína y sólo permite el paso de 
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la fracción libre de fármaco. Esta fracción libre se analiza posteriormente, en este 
caso empleando EKC quiral. 
El Artículo V destaca algunos aspectos débiles de las metodologías experimentales y 
modelos matemáticos previamente publicados para el estudio de la unión a 
proteínas plasmáticas (Katrahalli y col., 2010; Fielding y col., 2005), y propone una 
estrategia novedosa para una evaluación fiable de la unión a proteínas. Se lleva a 
cabo una amplia discusión acerca de los diferentes modelos matemáticos de unión a 
proteínas, empleando como ejemplo la unión enantioselectiva del antidepresivo 
fluoxetina a HSA. El análisis enantioselectivo de fluoxetina se realizó empleando HS-
β-CD como selector quiral en el modo de llenado completo del capilar, en un tampón 
fosfato 30 mM de pH 7,0. La temperatura y el potencial de separación se fijaron a 
30 ºC y 15 kV respectivamente. 
La estrategia propuesta implica trabajar en condiciones cercanas a las fisiológicas, 
por tanto, manteniendo el cociente entre la concentración de fármaco (D) y la de 
proteína (P) por debajo de 0,5; y P cerca del nivel fisiológico (en torno a 475 µM). 
En estas condiciones, se puede emplear un modelo simple de unión que considera 
que sólo se ocupa un tipo de sitio de unión en la molécula de proteína y que la 
estequiometría de dicha unión es 1:1, siempre y cuando estas consideraciones se 
confirmen a través de otras ecuaciones. Además, los datos fueron evaluados con el 
fin de detectar y eliminar valores anómalos que pudieran afectar a la fiabilidad de las 
estimaciones. Se estimaron para ambos enantiómeros de fluoxetina constantes de 
unión enantiómero-proteína (K1), así como la enantioselectividad en el proceso de 
unión, definida como el cociente entre ambas constantes. 
Finalmente, se estimó para ambos enantiómeros el porcentaje de unión a proteína 
(PB%, del inglés protein binding), que es un parámetro interesante desde un punto 
de vista farmacocinético. Se obtuvieron porcentajes de 95,2 y 90,0% para el primero 
y segundo enantiómero eluídos, respectivamente. Se obtuvo una enantioselectividad 
en torno a 2 en favor del primer enantiómero eluído. 
Todavía en el campo de las interacciones enantioselectivas fármaco-proteína, los 
Artículos VI y VII estudian la unión enantioselectiva del hipnótico zopiclona y del 
antidepresivo nomifensina a HSA y al total de las proteínas plasmáticas, de nuevo 
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mediante ultrafiltración y EKC quiral. En el Artículo VI, la enantioseparación de 
zopiclona con carboximetil-β-ciclodextrina (CM-β-CD) se ajustó para el análisis de la 
fracción de fármaco libre post-ultrafiltración. Se empleó como selector quiral una 
disolución de CM-β-CD 30 mM en tampón Tris 50 mM de pH 6,0, que se inyectó en 
el modo de llenado parcial del capilar aplicando una presión de 0,5 psi durante 99 s 
antes de la inyección de muestra. La separación quiral se llevó a cabo a 25 ºC 
aplicando un potencial de 15 kV. Los modelos matemáticos y diseños experimentales 
desarrollados en el Artículo V se aplicaron aquí para el cálculo de las constantes de 
unión, enantioselectividad y porcentaje de unión a las proteínas plasmáticas. Los 
valores de PB% a HSA fueron 47 y 36% para S- y R-zopiclona, respectivamente, 
mientras que los valores de PB% al total de las proteínas plasmáticas fueron 45 y 
49%, respectivamente. Estos valores concuerdan con el PB% descrito en la 
bibliografía para zopiclona racémica, en torno al 45% (Gaillot y col., 1983; Agencia 
Española del Medicamento, 2011). 
La unión enantioselectiva de nomifensina a HSA y al total de las proteínas 
plasmáticas se evaluó en el Artículo VII, en este caso usando heptakis-(2,3,6-O-
metil)-β-ciclodextrina 30 mM como selector quiral en el modo de llenado completo 
del capilar, con el mismo BGE y potencial de separación del Artículo VI pero con una 
temperatura del capilar de 50 ºC. El diseño experimental para la obtención de curvas 
de calibrado y análisis de muestras se repitió en dos sesiones independientes con el 
fin de evaluar la precisión inter-día del procedimiento. Como no se encontraron 
diferencias significativas entre los datos de ambas sesiones de trabajo, todos los 
datos se emplearon en conjunto para realizar las estimaciones. El PB% a HSA 
estimado fue de 40 y 63% para el primer y segundo enantiómero eluídos, 
respectivamente. Para la unión al total de proteínas plasmáticas, los valores 
estimados fueron de 63 y 64% respectivamente. Comparando estos valores, puede 
concluirse que el segundo enantiómero eluído de la nomifensina se une 
principalmente a la HSA, mientras que el primero se une también a otras proteínas 
plasmáticas. 
El diseño experimental y los modelos matemáticos propuestos en esta Tesis para 
una estimación fiable de la unión enantioselectiva de fármacos a las proteínas 
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plasmáticas mediante ultrafiltración y EKC han demostrado ser una herramienta 
robusta que permite la obtención de buenas estimaciones in vitro en condiciones 
cercanas a las fisiológicas, proporcionando por lo tanto datos valiosos desde un 
punto de vista farmacocinético. En esta Tesis se han estimado datos de unión 
enantioselectiva de fluoxetina, zopiclona y nomifensina a las proteínas plasmáticas, 
completando la información disponible en la bibliografía sobre estos fármacos. 
La tercera parte de esta Tesis se dedica al desarrollo de reacciones enzimáticas en el 
interior del capilar empleando la metodología EMMA. En EMMA los reactivos se 
introducen secuencialmente en el capilar electroforético y se dejan mezclar y 
reaccionar durante un tiempo determinado. Después se lleva a cabo la separación de 
sustratos, enzimas y productos mediante electroforesis. La principal ventaja de la 
metodología EMMA es que la reacción tiene lugar a escala de nanolitros, por lo que 
el consumo de reactivos y muestras es extremadamente bajo. Además, es una 
metodología completamente automatizada, ya que la reacción y la separación tienen 
lugar en una única etapa en el interior del capilar, lo que constituye otra importante 
ventaja para su empleo en procedimientos de cribado. 
En el Artículo VIII se desarrolla una metodología de cribado mediante EMMA para la 
evaluación de inhibidores de la acetilcolinesterasa (AChE), y se aplica al estudio de 
cinco fármacos de actividad inhibidora conocida. Para la optimización de condiciones 
del método se empleó tacrina como fármaco modelo. El avance de la reacción 
enzimática de hidrólisis de acetiltiocolina en presencia de AChE y de los diferentes 
inhibidores se determinó midiendo el área de pico del producto de reacción tiocolina. 
Se llevó a cabo una inyección en “sándwich”, introduciendo una zona de sustrato 
entre dos zonas de enzima. El mezclado de las zonas se llevó a cabo mediante 
difusión simple, con un tiempo de incubación de 2 minutos. El tampón empleado 
para la reacción y la separación fue borato-fosfato 30 mM a pH 8,0; la temperatura 
del capilar se fijó a 37 ºC y el potencial de separación a 15 kV. Debido a la dilución 
de los solutos en la metodología EMMA, se realizó una corrección en los cálculos 
para obtener una buena exactitud en los resultados. Se estimó un factor de dilución 
comparando la potencia inhibitoria de la tacrina calculada en este trabajo con la 
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descrita en la bibliografía empleando el método de referencia (Andrisano y col., 
2001). Dicho factor se aplicó posteriormente a todos los cálculos realizados. 
La metodología de cribado propuesta ha demostrado ser de utilidad para la 
estimación de constantes de inhibición, potencia inhibitoria, una aproximación 
cualitativa al mecanismo de inhibición y el porcentaje de inhibición de tacrina, 
edrophonium, neostigmina, piridostigmina y eserina. Los resultados del cribado 
muestran que, de acuerdo con su porcentaje de inhibición en condiciones prefijadas, 
el orden de potencia inhibitoria para estos compuestos es tacrina > edrophonium > 
neostigmina > eserina > piridostigmina. Esta metodología de cribado, con un tiempo 
de análisis inferior a 5 minutos, puede ser empleada para la evaluación de nuevas 
moléculas que sean inhibidores potenciales de la AChE. 
Continuando con el uso de la metodología EMMA para la evaluación de interacciones 
fármaco-enzima, los Artículos IX y X son estudios de metabolismo enantioselectivo 
empleando diferentes isoformas del citocromo P450. En estos estudios, el capilar 
actúa simultáneamente como reactor y como sistema de separación quiral, de modo 
que proporciona información enantioselectiva a través de un ensayo rápido y 
completamente automatizado. La separación quiral se lleva a cabo en ambos casos 
usando HS-β-CD y la técnica del llenado parcial del capilar. 
El Artículo IX hace referencia al metabolismo enantioselectivo de verapamilo, 
bloqueante de canales de Ca+2, mediante CYP3A4, la isoforma más importante del 
citocromo P450 en humanos. En este artículo se consideraron diferentes 
posibilidades para el ensayo mediante EMMA y se optimizaron variables 
experimentales previamente al cálculo de los parámetros cinéticos de Michaelis-
Menten para el metabolismo enantioselectivo del verapamilo. Las condiciones 
experimentales seleccionadas incluyeron una inyección tipo “sándwich” de la zona de 
sustrato entre dos zonas de enzima, y la inyección de dos zonas de tampón de 
incubación antes y después del “sándwich” con el fin de proporcionar a la enzima su 
medio de reacción adecuado. El mezclado de las zonas se llevó a cabo mediante 
difusión simple durante un tiempo de incubación de 5 min. A continuación se llevó a 
cabo la separación de toda la mezcla de reacción incluyendo los enantiómeros del 
verapamilo y su metabolito principal norverapamilo en el mismo capilar, empleando 
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las siguientes condiciones experimentales: fosfato 50 mM de pH 8,8 como BGE, HS-
β-CD al 2,5% inyectada a 10 psi/2 min, 25 ºC y separación a 20 kV con una 
pequeña presión de 0,2 psi con el fin de acortar los tiempos de migración. El 
resultado es una metodología completamente automatizada que permite la 
evaluación enantioselectiva del metabolismo de verapamilo por el CYP3A4 en menos 
de 35 minutos, incluyendo el acondicionamiento previo del capilar, inyección, 
incubación y separación. 
A partir de la ecuación de Michaelis-Menten se calcularon parámetros cinéticos (Km y 
Vmax) para el metabolismo global de verapamilo por el CYP3A4. Los valores de Km 
estimados fueron de 51 ± 9 y 47 ± 9 µM para S- y R-verapamilo, respectivamente, 
mientras que los valores de Vmax obtenidos fueron 22 ± 2 y 21 ± 2 pmol·min
-1·(pmol 
CYP)-1 para S- y R-verapamilo, respectivamente. También se calcularon para cada 
enantiómero valores de aclaramiento intrínseco, definido como la cantidad de 
plasma de la cual el fármaco es eliminado por unidad de tiempo, y estimado in vitro 
como el cociente entre Vmax y Km (Kroemer y col., 1992). 
El metabolismo enantioselectivo de fluoxetina mediante otra isoforma del CYP450, 
CYP2D6, se evaluó en el Artículo X siguiendo la misma metodología que en el trabajo 
anterior. Las condiciones del ensayo EMMA empleadas en el Artículo IX se aplicaron 
directamente, mientras que las condiciones de separación se ajustaron con el fin de 
separar los enantiómeros de fluoxetina y su metabolito principal norfluoxetina. Se 
estudió la influencia de la variable experimental más importante en la 
enantioseparación, la concentración de HS-β-CD, y se seleccionó una concentración 
final de 1,25% para la separación de la mezcla de reacción. Las otras condiciones de 
separación fueron las empleadas en el Artículo IX. Se estimaron parámetros cinéticos 
mediante un ajuste no lineal de los datos experimentales a la ecuación de Michaelis-
Menten. Los valores de Km obtenidos fueron de 30 ± 3 µM para S-fluoxetina y 39 ± 5 
µM para R-fluoxetina, mientras que las Vmax estimadas fueron de 28,6 ± 1,2 y 34 ± 2 
pmol·min-1·(pmol CYP)-1 para S- y R-fluoxetina, respectivamente. El ensayo cinético 
fue repetido empleando un único enantiómero (R-fluoxetina) en lugar de la mezcla 
racémica. Se obtuvieron resultados similares, lo que indica que el uso del racemato 
es una buena opción para la obtención de estimaciones enantioselectivas. 
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En esta Tesis se ha demostrado la utilidad de EMMA como metodología de cribado 
para la evaluación in vitro, enantioselectiva o no, de interacciones fármaco-enzima. 
Los métodos desarrollados permiten la estimación de parámetros cinéticos y de 
inhibición mediante ensayos rápidos con un bajo consumo de reactivos y muestras. 
El acoplamiento de la metodología EMMA con la enantioseparación de sustratos y 
productos en una única etapa llevada a cabo en el equipo de electroforesis capilar 
proporciona valiosa información enantioselectiva sobre los procesos farmacocinéticos 
o farmacodinámicos evaluados. 
Todos los métodos propuestos y aplicados en esta Tesis (separaciones quirales, 
modelos de predicción, evaluación enantioselectiva de la unión a proteínas e 
interacciones fármaco-enzima) son de aplicación en la industria farmacéutica para la 
obtención de información útil in vitro en las fases preclínicas del desarrollo de 
medicamentos, y para el control de calidad enantioselectivo de materias primas, 
intermedios de síntesis y productos finales.  
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I. INTRODUCTION 
I.1. Chirality and its importance in pharmaceutical sciences 
Chirality is a structural characteristic of a molecule whereby it is able to exist in two 
asymmetric forms, which are non-superimposable. These two asymmetric forms are 
known as enantiomers (Figure I.1), and are non-distinguishable by a 
physicochemical point of view due to their identical properties like melting point, 
lipophilicity or acidity constant. 
 
 
Figure I.1: The two enantiomers of a chiral drug (fluoxetine). 
 
However, the body can readily distinguish between such molecules. Because the two 
enantiomers are non-superimposable they have different abilities to bind to 
receptors or enzymes and this confers stereoselectivity to all the processes in which 
a specific site interaction with biomolecules is involved (Evans, 2004). 
An important percentage of commercially available drugs and molecules that are in 
the stage of drug development have a chiral center and could be employed as 
racemates or as pure enantiomers. When a racemic drug enters the human body, 
there are some pharmacokinetic and pharmacodynamic processes that may exhibit a 
certain degree of enantioselectivity, so it could result in different pharmaceutical 
activity of the enantiomers (Brocks, 2006). Due to that, the Food and Drug 
Administration (FDA) (USA) and the European Medicines Agency have developed 
regulations and guidance for the development of chiral drugs and investigation of 
chiral active substances (Food and Drug Administration, 1992; European Medicines 
Agency, 1993). 
The FDA considers that the development of racemates as new drugs may continue 
to be appropriate despite the advances carried out in asymmetric synthesis, which 
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make possible the synthesis of pure enantiomers for some pharmaceuticals. 
However, some considerations should be taken into account in product development 
(Food and Drug Administration, 1992): 
− Appropiate manufacturing and control procedures should be used to 
assure stereoisomeric composition of a product, with respect to identity, 
strength, quality and purity. 
− Pharmacokinetic evaluations that do not use a chiral assay will be 
misleading if the disposition of enantiomers is different. Therefore, 
techniques that quantify individual stereoisomers in pharmacokinetical 
samples should be available early. 
The FDA also indicates that the main pharmacological activities of the isomers 
should be compared in in vitro systems, in animals and/or in humans. The European 
Medicines Agency emphasizes that when new active substances appear promising, 
both enantiomers should be studied separately (European Medicines Agency, 1993) 
in terms of pharmacokinetic and pharmacological properties. This is applicable both 
to racemates and single enantiomer formulations. 
Due to all these reasons, there is a special interest in analytical methods able to 
determine the stereoisomer ratios in synthetic products, pharmaceutical formulations 
and biological samples (Scriba, 2011), and also in methodologies for the in vitro 
evaluation of enantioselective pharmacokinetic and pharmacological properties. 
 
I.1.1. Enantioselectivity in pharmacokinetic processes 
The term pharmacokinetics involves all the processes that take part since a drug 
enters the human body and until the moment it is eliminated by different pathways. 
Pharmacokinetic processes are drug absorption, distribution, metabolism and 
excretion, and all of them can be affected by enantioselectivity. The main 
prerequisite of a biological process for being enantioselective is stereospecific 
recognition of the substrate by a biomolecule responsible for the process (Brocks, 
2006). So, markedly enantioselective are processes that involve interaction with 
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specific sites of biomolecules, like active transport, protein binding or enzymatic 
reactions such as metabolism. 
 
I.1.1.1. Absorption 
The absorption of a drug is the process that takes place from the administration of 
the drug until it reaches the circulatory system. The complexity of the absorption 
process depends on the administration route, which is the way the drug is 
administered to the patient. It can be intravenous, parenteral extravascular (where 
the drug is injected but not directly to a vein, like the intramuscular injections), oral, 
nasal, sublingual, ophthalmic… and each one has an absorption process dependent 
on the tissues and epitheliums the drug may pass. 
Intravenous administration has no absorption since the drug is directly introduced in 
the circulatory system. In other parenteral routes the drug has to reach the blood by 
passing through the vascular endothelium. Most of the existent administration routes 
imply the pass of the drug through epithelial cells, like the intestinal, gastric or nasal 
epithelium (Doménech Berrozpe et al., 1998). Oral administration is by far the most 
common route and most of the drugs orally taken have their absorption window in 
the intestine. So, the mechanisms responsible for intestinal absorption are the most 
frequently studied. 
The main process responsible for the intestinal absorption of the majority of drugs is 
passive diffusion through the intestine membrane, which is due purely to the 
lipophilicity and degree of ionization of the drugs. Since there will be no difference in 
these parameters between two enantiomers, there will be no difference in the extent 
or rate of absorption and passive diffusion can be considered achiral (Evans, 2004). 
When active transport with carrier proteins is responsible for the intestinal 
absorption, however, differences in absorption between enantiomers can be found. 
There have been reported preferential absorptions for the L-isomer of dopamine 
(Lee and Williams, 1990), R-methotrexate (Hendel and Brodthages, 1984), D-
eflornithine (Jansson et al., 2008) and R-fexofenadine (Togami et al., 2012) after 
oral administration. In the case of D-eflornithine, the preferential absorption is for 
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the less potent enantiomer, which may be the cause of the failure of this drug in oral 
treatments (Jansson et al., 2008). 
 
I.1.1.2. Distribution and protein binding 
The distribution of a drug involves its penetration, movement and storage in 
different tissue compartments. The distribution properties of a drug are of vital 
importance, since they determine if the drug can reach the active site and be 
effective. As distribution requires interaction with biomolecules, there is some 
potential for enantioselectivity in its processes. One important process at the 
distribution level is the protein binding (PB). Drugs usually do not travel through the 
circulatory system themselves, but they bind to different plasmatic proteins. This can 
affect their disposition for other processes such as first-pass metabolism, metabolic 
and renal clearance, and distribution to other compartments. Acting as drug carriers, 
plasma proteins facilitate their transport throughout the body but also can limit their 
availability for reaching target organs, since only the free fraction of the drug can 
leave plasma and penetrate membranes. 
When proteins and chiral drugs interact in an enantioselective way, two 
diastereomeric adducts are formed with potential differences in the protein binding 
that may result in different pharmacokinetic profiles for the individual enantiomers 
(Chuang and Otagiri, 2006). For drugs that are highly protein bound, small changes 
in protein binding result in large changes in the free active fraction and thus the 
therapeutic benefit of such compounds can be markedly affected by stereoselective 
protein binding. Enantioselective binding of drugs to human serum albumin (HSA) 
and other plasma proteins has been extensively described in the literature (Martínez-
Gómez et al., 2007a; Brocks, 2006). Stereoselectivity in protein binding has been 
described in the literature for verapamil (Mehvar et al., 2002), warfarin (Yacobi et 
al., 1977), propranolol (Mehvar and Brocks, 2001) and some antihistamines 
(Martínez-Gómez et al., 2007b) among much other drugs. 
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Human serum albumin 
HSA is the most abundant protein in human plasma (60 per cent of the total plasma 
proteins, (Evans, 2004)) and it presents a high degree of enantioselective interaction 
with drugs (Ascoli et al., 2006). Its interaction with xenobiotics is mainly due to 
hydrogen bounds and Van der Waals intermolecular forces, which can be markedly 
different between enantiomers due to the spatial position of the interacting groups 
in the molecules. HSA is a single peptide chain of 585 amino acid residues. Its 3D 
structure, shown in Figure I.2, consists of a monomeric globular protein made out of 
three domains, I, II and III, with a similar helical pattern (He and Carter, 1992; 
Carter and Ho, 1994; Sugio et al., 1999). 
 
 
Figure I.2: Structure of HSA with its two main binding sites for drugs. 
 
Two primary areas of “high affinity” drug binding sites have been defined on 
albumin. These have been denominated the warfarin site (site I) and the 
benzodiazepine site (site II) (Ascoli et al., 2006; Kwong, 1985; Kurz, 1986). Site I is 
the highest-affinity binding site for, among others, anticoagulants and non-steroidal 
anti-inflammatory drugs. Site II is also a specific site for profens, an important family 
of drugs used worldwide as anti-inflammatories. 
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Despite the fact that sites I and II seem to be responsible for most of the drug-HSA 
interactions, crystallographic (Hage and Sengupta, 1998; Hage and Sengupta, 1999) 
and chromatographic studies (Sengupta and Hage, 1999; Hage and Sengupta, 1999) 
confirm the existence of other less important binding sites in the HSA molecule, like 
digitoxin site (site III) or the bilirubin and tamoxifen sites, which are still not well 
identified in the HSA molecule. 
 
α1-acid glycoprotein and other plasma proteins 
The second plasma protein in abundance is α1-acid glycoprotein (AGP). This is a 
monomer of 181 amino acids and is characterized by its high carbohydrate content. 
Binding of drugs to AGP involves hydrophobic rather than electrostatic forces, and 
not only basic but also acidic and neutral drugs bind to AGP. The contribution of AGP 
to the total plasma protein binding of drugs is much lower than HSA’s, due to its 
lower concentration in plasma. The binding of drugs to AGP can be also 
enantioselective. 
Also lipoproteins can show a certain ability to bind hydrophobic drugs, which are 
thought to be partitioning into the lipid core of the protein instead of associating 
with a specific site, so no enantioselectivity may be expected for this interaction 
(Evans, 2004). 
 
I.1.1.3. Metabolism 
The main objective of the organism when exposed to some xenobiotics (including 
drugs) is to remove them from the body as soon as possible. The efficient removal 
of drugs from the organism involves not only their renal excretion but also some 
structural changes in the molecule that are called metabolism. Metabolic reactions 
usually make xenobiotics more polar and easier to be excreted and can be classified 
into two groups attending to the nature of the molecule modification. 
Phase I includes some reactions that generally lead to the introduction or uncovering 
of key functional groups (e.g. OH, COOH, NH2, SH, etc.) increasing the molecule 
polarity, which may facilitate removal from the body. The main enzymatic system 
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responsible for phase I reactions is the cytochrome P450 (CYP), despite other 
enzymes can be also involved. In phase II metabolism there is a conjugation 
between the xenobiotic and some endogenous molecule or group. It increases the 
molecule size favoring its excretion and usually its inactivation. Not all compounds 
suffer phase I and II processes. For some ones this is the case, but others are 
directly eliminated after a phase I metabolic reaction or are directly conjugated by a 
phase II one. Table I.1 summarizes the different reactions involved in phases I and 
II metabolism (Gordon Gibson and Skett, 2001; Doménech Berrozpe et al., 1998). 
 
Table I.1: Phase I and II metabolic reactions. 
Phase I Phase II 
Oxydation Glucuronidation/glucosidation 
Reduction Sulfation 
Hydrolysis Methylation 
Hydration Acetylation 
Dethioacetylation Amino acid conjugation 
Isomerisation Glutathione conjugation 
 Fatty acid conjugation 
 Condensation 
 
Cytochrome P450 
The cytochrome P450s (CYPs) are a superfamily of haemthiolate containing enzymes 
which play a major role in the metabolism of many drugs and other xenobiotics such 
as organic solvents, pesticides, hydrocarbons and carcinogenic substances. The 
name P450 is due to their light absorption at 450 nm when combined with carbon 
monoxide (Doménech Berrozpe et al., 1998). Their structure, with the haem group 
in the center of the molecule, is shown in Figure I.3 (Williams et al., 2003). 
It has been estimated that more than 90 per cent of drug oxidations in humans are 
mediated by CYPs (Lewis, 2003). In addition to their role in drug metabolism, CYPs 
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have important endogenous functions such as the synthesis and regulation of steroid 
hormones, eicosanoids and bile acids. Because of this, CYPs are almost ubiquitous in 
the human body, although the major site of drug metabolism is the liver (Evans, 
2004). 
57 human CYPs have been identified (Lewis, 2004), and are classified with a 
systematic nomenclature that is based on the amino acid sequence on each isoform, 
which does not provide information on the function of the enzymes. The group of 
isoforms majorly involved in human drug metabolism is currently limited to only six: 
CYP1A2, 2C9, 2C19, 2D6, 3A4 and 3A5 (Evans, 2004). CYP3A4 is the most abundant 
isoform in the human liver and is responsible of almost half of P450-mediated 
oxidations of drugs available on the pharmaceutical market as well as a high number 
of clinically significant drug-drug interactions. 
 
 
Figure I.3: Structure of cytochrome P450 (isoform 2C9). 
 
The catalytic cycle of CYP, schematized in Figure I.4 (Kirsty et al., 2006), includes 
the following steps (Ortiz de Montellano, 2005): 
i. Binding of substrate (RH) to the enzyme, sometimes accompanied by a 
spin-state change of the iron, to afford an enzyme-substrate adduct. 
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ii. Reduction of the ferric CYP by an associated reductase with an NADPH-
derived electron to the ferrous CYP. 
iii. Binding of molecular oxygen to the ferrous heme to produce a ferric CYP-
dioxygen complex. 
iv. Second one-electron reduction. 
v. Protonation to arrive at the Fe(III) hydroperoxy complex. 
vi. Protonation and heterolytic cleavage of the O-O bond with concurrent 
production of a water molecule to form a reactive iron-oxo intermediate. 
vii. Oxygen-atom transfer from this iron-oxo complex to the bound substrate to 
form the oxygenated product complex. 
viii. Product dissociation. 
 
 
Figure I.4: The catalytic cycle of cytochrome P450. 
 
In this catalytic cycle, the reductase redox partner of CYP (P450 reductase) supplies 
sequentially reducing equivalents employing reduced nicotinamide adenine 
Introduction 
 
12 
 
dinucleotide phosphate (NADPH) as a cofactor. Protons employed in protonation 
steps are taken from the reaction medium. The general equation for a P450-
mediated mono-oxygenation, that summarizes this cycle, is generally reported as 
follows: 
 +  + 	 +
 →  +	
 +   (I.1) 
where RH is the substrate, ROH the oxidized product, and NADPH/NADP+ the 
reduced/oxidized forms of nicotinamide adenine dinucleotide phosphate. 
Although CYPs have broad substrate specificity, they show significant 
stereoselectivity of metabolism towards chiral substrates. A good example illustrating 
this enantioselectivity is the case of the anticoagulant warfarin, for which the 
clearance (amount of plasma from which a drug is removed in a certain time) of the 
R-enantiomer is 42 per cent greater than that of the S-enantiomer (Toon et al., 
1987). This should be due to the fact that CYP3A4 metabolizes R-warfarin and 
CYP2C9, whose amount in human liver is lower than that of the 3A4 isoform, 
metabolizes the S-enantiomer (Rettie et al., 1988). There have been also reported 
enantioselective hepatic clearances for the β-blocker propranolol (Walle et al., 1988), 
the calcium channel antagonist verapamil (Eichelbaum et al., 1984; Thöm et al., 
2012) and the antiarrhythmic propafenone (Afshar and Thormann, 2006). Some 
proton pump inhibitors (omeprazole, lansoprazole, pantoprazole or tenatoprazole) 
are also enantioselectively metabolized by different isoforms of CYP (Zhou et al., 
2008). 
Unless the main enzymatic system responsible for drug metabolism is the CYP, there 
are some other enzymes involved in phases I and II metabolism, and their reactions 
can also exhibit enantioselectivity. There have been reported enantioselective N-
oxygenations for chlorpheniramine and verapamil catalyzed by flavin-containing 
monooxygenases (FMOs), which are also important phase I metabolic enzymes 
(Cashman et al., 1992; Cashman, 1989). Metabolic pathways for different 
amphetamines have found to be also enantioselective, since different elimination has 
been reported for their enantiomers in vivo. Metabolism of these compounds 
involves different enzymes, starting with CYP, and continuing with different 
pathways including another phase I reaction with catechol-O-methyl transferase and 
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some phase II conjugations by sulfotransferases and glucuronyltransferases. All of 
them have found to exhibit a certain degree of enantioselectivity (Schwaninger et 
al., 2012). 
 
I.1.1.4. Renal clearance 
Renal clearance is the amount of plasma from which a drug is removed by a renal 
pathway in a certain time. Enantioselectivity in renal clearance of drugs will only be 
found if they are actively secreted by tubular transporters, which may have different 
affinity for the enantiomers. This is the case of disopyramide (Lima et al., 1985) and 
terbutaline (Borgstrom et al., 1989). Also enantioselective renal clearance has been 
reported for the antihelmintic albendazole (Lanchote et al., 2004). Nevertheless, the 
majority of drugs are filtered in the glomerulus and not actively secreted, so there 
will be no difference in the elimination of enantiomers (Evans, 2004). 
 
I.1.2. Enantioselectivity in pharmacodynamic properties 
Pharmacodynamics is the brand of pharmaceutical sciences that studies all the 
effects that a drug has over the organism. As the pharmacological activity of a drug 
involves in most of the cases its specific interaction with biomolecules (receptors, 
carriers, enzymes…), it becomes obvious that many differences in the 
pharmacodynamic properties of chiral drugs will be found. The case of thalidomide is 
a well-known example of the different pharmacological activity of two enantiomers. 
Thalidomide was employed in the 50s for the treatment of nausea in pregnant 
woman. In 1961 it was withdrawn from the pharmaceutical market because of its 
teratogenic effects (Kumar et al., 2012), and it was discovered that despite the R-
enantiomer had the desirable pharmacological activity, the S- one was highly 
teratogenic in humans (Caillet et al., 2012). 
The different behavior of thalidomide enantiomers reflects the importance of chirality 
in drug development. There are many other cases in which both enantiomers of a 
chiral drug act in a different way when introduced into the human body. Sometimes 
one of the enantiomers is active while the other has no pharmacological activity 
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(only the S-enantiomer of the hypnotic drug zopiclone is active (Monti and Pandi-
Perumal, 2007), and the S-enantiomers of profens are responsible for the 
cyclooxygenase inhibitory activity (Klegerisa et al., 2004)). In other cases one of 
them exhibits stronger activity (the S-enantiomer of the antidepressant citalopram is 
approximately 150 times more potent as a reuptake inhibitor than R-citalopram in 
vitro (Leonard and Taylor, 2010)). They can also have different pharmacological 
effects (dextromethorphan is widely employed as an antitussive agent and 
levomethorphan is a narcotic (Kikura-Hanajiri et al., 2011)). Finally, one enantiomer 
can be active and the other responsible for the side effects of the drug, like the case 
of thalidomide. 
Nowadays, there is an increasingly interest in the introduction of pure enantiomers 
in the pharmaceutical market. Apparently new drugs such as dextroketoprofen 
(analgesic), eszopiclone (hypnotic), esomeprazole (proton pump inhibitor) or 
escitalopram (antidepressant) are only the active enantiomers of the racemic 
ketoprofen, zopiclone, omeprazole and citalopram, also commercialized. A great 
effort is being done in the study of enantioselective pharmacological as well as 
pharmacokinetic properties, in order to obtain drugs with higher potency, better 
safety profiles and fewer side effects. 
 
I.2. Chiral analysis 
The importance of chirality in pharmaceutical sciences has been widely discussed 
during this Introduction. As a consequence, different methods for the chiral analysis 
of drugs have been developed employing diverse methodologies. 
Chiral separations can be carried out employing direct or indirect methodologies. The 
indirect way implies derivatization of enantiomers with an enantiomerically pure 
reagent, and the formation of diastereoisomers that can be separated with classical 
separation techniques. The direct approach consists on the formation of transitory 
complexes between the enantiomers and a chiral molecule (called chiral selector) in 
a separation system. Chiral recognition in direct methods can be due to electrostatic 
forces, hydrogen bounds, Van der Waals forces, hydrophobic interactions or 
inclusion phenomena. The direct way is easier, faster and cheaper than the indirect 
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one, so nowadays is the preferred for carrying out chiral separations, especially in 
analytical scale (Martínez Gómez, 2007c). 
The most usually employed analytical techniques for performing direct separations 
are thin-layer chromatography (TLC), high-performance liquid chromatography 
(HPLC), gas chromatography (GC) and capillary electrophoresis (CE). The first direct 
enantioseparation was carried out by GC with a chiral stationary phase (CSP) in 1966 
(Gil-Av et al., 1966). The enantiomers of an amino acid were separated there. Since 
then, applications have been developed with a broad variety of performances: 
inclusion of the chiral selector in the stationary phase or in the mobile phase, 
development of chiral columns for HPLC and GC, development and research on new 
families of chiral selectors and, more recently, synthesis of monolithic chiral 
stationary phases and the introduction of nanomaterials in different separation 
techniques. 
Nowadays most of the applications are carried out by HPLC and CE. Nevertheless, a 
recent review remarks the importance of TLC also in this field, due to its simplicity, 
flexibility and low cost. Chiral TLC is performed using chiral stationary phases, both 
commercial and home-made. The most frequently used CSPs are home-made of 
cellulose derivatives: microcrystalline cellulose triacetate and cellulose tribenzoate 
(Del Bubba et al., 2013). Their main disadvantage is their lack of reproducibility. 
In HPLC, the chiral selector can be in the stationary phase (CSP) or added to the 
mobile phase. Numerous chiral molecules are employed as CSPs: polysaccharide 
derivatives (cellulose, amylose), which are the most commonly employed, synthetic 
polymers, proteins (HSA, AGP), cyclodextrins and crown ethers among others 
(Lämmerhofer, 2010). A recent trend is the use of monolithic chiral columns for 
micro- and nano-LC (Healey and Ghanem, 2013), which can be home-made with the 
same chiral selectors available in commercial CSPs (cyclodextrins, polysaccharides, 
proteins…). Less employed is the addition of chiral selectors to the mobile phase, 
due to the high consumption of chiral selector. For this methodology, the use of 
nano-LC is a good alternative since the working flow rate is of a few hundred 
nanoliters per minute (Rocco et al., 2013). These new possibilities have improved 
the performance of HPLC as an analytical technique for chiral analysis. 
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However, chiral CE is considered superior to chiral HPLC by many authors, because 
chiral HPLC is suffering from low peak capacity (broad peaks), problems with system 
stability (often normal phase HPLC), pressure sensitivity of columns (often cellulose-
based chiral columns) and long separation times (Ahuja and Jimidar, 2008). CE is 
nowadays the technique of choice for analytical-scale enantioseparations, due to its 
numerous advantages as separation technique and the broad variety of chiral 
selectors available for performing separations in many different CE modes. The next 
section of this Introduction deals with the separation features of CE and its 
applications in chiral analysis. 
Another recent trend in enantioseparations which merits special mention is the use 
of nanomaterials in different separation techniques. This use has several advantages 
such as the easy modification of the nanomaterials with chiral selectors, to be used 
as chiral stationary or pseudo-stationary phases; the increment on column capacity, 
separation selectivity, stability and efficiency for chiral chromatographic separations, 
and the unique surface properties of nanomaterials that allow the development of 
simple, rapid and sensitive sensors for chiral recognition (Chang et al., 2012). 
Mesoporous silica nanomaterials have been successfully employed for chiral 
separations in HPLC (Guo et al., 2010) and CE (Dong et al., 2008); gold 
nanoparticles modified with β-cyclodextrin and bovine serum albumin in CE (Li et al., 
2011; Li et al., 2009); and carbon nanotubes with different surface modifications in 
TLC (Yu et al., 2011), GC (Zhao et al., 2011) and CE (Moliner-Martínez et al., 2007). 
 
I.3. Capillary electrophoresis for chiral analysis and enzymatic studies 
Capillary electrophoresis is a powerful separation technique whose basic separation 
principle is the different mobility of ions when affected by an electric field. Since the 
first application of an open-tubular glass capillary as electrophoretic separation 
system, which was carried out by Jorgenson and Lukacs in 1981 (Jorgenson and 
Lukacs, 1981), several improvements in the CE instrumentation have been done and 
applications of CE in different fields like analysis of clinical, pharmaceutical or 
environmental samples, separation of enantiomers, in-capillary reactions, 
separations of peptides, proteins and DNA and much others have been developed. 
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The main advantages of CE, which make it a technique of choice for several 
applications, are its short analysis time, low consumption of samples and reagents, 
high separation efficiency, versatility of conditions and performances that can be 
employed, easy conditioning of the column, compatibility with different detection 
systems and ease of automation (Lin et al., 2003; Zhu et al., 1999). Its main 
bottlenecks, when compared with liquid and gas chromatography, are less sensitivity 
(due to the small detection window) and less reproducibility (due to the injection 
procedure). However, different strategies have been developed to get over these 
disadvantages and nowadays CE can be successfully employed for many 
applications. 
The CE instrumentation is relatively simple: it consists on a fused silica capillary 
whose extremes dip into two vials full of an electrolyte solution. Also two electrodes 
dip into these two vials and are connected to a high power source that applies the 
electric voltage to the system. The instrument is completed with a detection system 
and a computer for data acquisition. Figure I.5 shows a scheme of the CE 
instrument. 
 
Figure I.5: Scheme of a CE system. 
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For samples injection, one of the electrolyte vials is replaced by the sample vial and 
some pressure or voltage is applied to it. The injection is called hydrodynamic when 
carried out by pressure, or electrokinetic when done by voltage. The actual CE 
systems allow injecting by both sides of the capillary, changing the polarity of the 
separation and separating simultaneously by voltage and pressure. They also allow 
the control of the capillary temperature (which is an important variable for 
separations) and sometimes also the sample storage temperature. All these 
characteristics increase notably the possibilities for development of new applications. 
 
I.3.1. Principles of separation in CE 
There are several modalities of CE with different separation mechanisms. In the 
simplest way, capillary zone electrophoresis (CZE), the separation of molecules is 
mainly due to two phenomena that contribute to their mobility through the capillary. 
The first phenomenon is the self-mobility of ions when introduced in an electric field, 
whereby positive molecules will migrate to the cathode, negatives to the anode and 
neutral ones will not migrate. The migration velocity is a function of the molecule 
charge/mass ratio. The second phenomenon is called electroosmotic flow (EOF), and 
will be briefly explained below. 
Electroosmosis is a basic phenomenon in all electrophoretic separation processes. It 
can be described as the relative movement of a liquid to a fixed charged surface 
caused by an electric field. It takes place when a voltage is applied to a liquid 
system that is in close contact with a charged surface, as is the case of CE in a fused 
silica capillary (Kuhn and Hoffstetter-Kuhn, 1993). The capillary wall in a fused silica 
capillary is covered by silanol (Si-OH) groups, which are deprotonated when the pH 
of the background electrolyte (BGE) is above 4.0. Higher pH values lead to a more 
negative capillary wall. 
The magnitude and the direction of the EOF depend on the composition of the 
capillary and the nature of the solution within the tube. Empirically it was discovered 
that the phase with the higher dielectric constant is positively polarized versus the 
other. Due to its extremely high dielectric constant, water is usually positively 
polarized in comparison to the fused silica surface, and a thin double layer appears 
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in the capillary wall. If an electric field is applied across the fused silica capillary, the 
mobile ions of the solution migrate with their hydrate water towards the cathode 
resulting in a flow of the whole solution (Kuhn and Hoffstetter-Kuhn, 1993). 
At working pHs above 4.0, as a consequence of the combination of the EOF and 
their self electrophoretic mobility, all molecules migrate to the detector being the 
typical elution order the following: positively charged molecules (from smaller to 
bigger), neutral, and negatively charged ones (from bigger to smaller). This 
migration order is schematically represented in Figure I.6. 
 
 
Figure I.6: Migration order in capillary electrophoresis. 
 
I.3.2. Chiral analysis in CE 
Chiral separations by CE are due to a chromatographic principle, not an 
electrophoretic one. As described in section I.3.1, two phenomena are responsible 
for the mobility in a CE system (the electrophoretic mobility of molecules, due to 
their charge/mass ratio, and the electroosmotic flow), and none of them are 
enantioselective. Thereby, the enantioseparation takes place due to the different 
non-covalent molecular interaction of the enantiomers with a chiral selector, whose 
electrophoretic mobility is different to that of the enantiomers (Chankvetadze and 
Blaschke, 2001). All the enantioseparations in CE may be unified under the term 
capillary electrokinetic chromatography (EKC), introduced by Terabe and coworkers 
in 1985 (Terabe et al., 1985), where a pseudo-stationary phase takes part in the 
separation of compounds. In chiral EKC the host-guest complexation between the 
selector (pseudo-stationary phase) and the enantiomers is responsible for the 
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enantiodiferentiation and the electrophoresis and electroosmosis permit differential 
migrations of the host-guest complexes. 
 
I.3.2.1. Chiral selectors in CE 
Different chiral selectors have been employed in EKC for carrying out 
enantioseparations, including natural, semisynthetic and synthetic ones. Some of the 
most commonly used chiral selectors are the following: 
− Proteins: HSA, bovine serum albumin (BSA), AGP and ovomucoid protein 
(OVM) have been widely employed with this purpose. Proteins show a broad 
range of enantioselectivity due to multiple possibilities of intermolecular 
interactions with the chiral compounds (Martínez-Gómez et al., 2007d). 
Their main drawback, which can be overcome with an adequate capillary 
cleaning, is the variability of the results due to unspecific adsorption of 
proteins to the capillary wall. 
− Cyclodextrins (CDs): polysaccharides with cyclic structure, formed by 6 
(α-CD), 7 (β-CD) and 8 (γ-CD) glucose units (Figure I.7). Together with 
these three native CDs, there are actually several derivatized ones in which 
the –OH residues have been substituted by different functional groups in 
order to increase the interaction with chiral molecules. 
 
 
Figure I.7: Structure and dimensions of the three native CDs. 
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− Micellar polymers: polymers recently synthesized whose micelles are 
formed by covalent bounds, so there is not a micellar critic concentration. 
This kind of selectors, like poly(sodium N-undecenoxy carbonyl-L-leucinate) 
(poly-L-SUCL) or poly(sodium N-undecenoxy carbonyl-LL-leucyl-valinate) 
(poly-LL-SUCLV), have been employed for the enantioseparation in CE-MS 
(Sánchez-Hernández et al., 2008; Kahle and Foley, 2007). 
− Crown ethers: synthetic chiral selectors that are employed for the 
enantioseparation of analytes with a primary amine group, like amino acids. 
The enantiorecognition mechanism is the formation of hydrogen bounds 
between the O atom of the ether and the H atom of the amine group 
(Schmid and Gübitz, 2004). 
− Glycopeptides: natural antibiotics like vancomycin, ristocetin A and 
teicoplanin. Widely employed due to their high enantioselectivity and the 
broad range of compounds they can resolve (Kahle and Foley, 2007; Ward 
and Farris, 2001). 
− Metallic complexes with chiral ligands: chelates of metallic ions such 
as Cu(II), Zn(II), Ni(II) and two chiral ligands, usually amino acids, have 
been employed to enantioseparate analytes like amino acids or amino 
alcohols by an ligand exchange mechanism (Schmid and Gübitz, 1996). 
− Chiral surfactants: bile salts like sodium cholate, deoxycholate or 
deoxytaurocholate have been employed for the separation of binaphthyl 
derivatives, diltiazem analogues and local anesthetics (Nishi et al., 1990; 
Amini et al., 1996). Other synthetic chiral surfactants with a chiral amino 
acid or carbohydrate and an alkyl hydrophobic chain have been also 
employed as chiral selectors (Martínez Gómez, 2007c). 
− Others: alkaloids, maltodextrins, macrocyclic antibiotics, different 
polysaccharides, bacteria… 
The most employed selectors for chiral separation in EKC are cyclodextrins (Rudaz et 
al., 2004; Sánchez-Hernández et al., 2008). CDs form inclusion complexes with 
numerous compounds and their nature, hydrophilic in the outside and hydrophobic 
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in the inside, allows high water solubility and capacity of interaction with very 
different compounds (Cserháti, 2008). Other important advantage of CDs is their UV 
transparency. Due to the broad range of neutral, anionic and cationic derivatized 
CDs available in the commercial market, and the possibility of employing dual 
systems with mixtures of CDs, there is a broad enantiorecognition capacity with 
these selectors (Matthijs et al., 2004). Charged CD derivatives at very low 
concentration may allow the separation of oppositely charged chiral molecules due 
to the counter-current mobility of the chiral selector and the selectand in the 
capillary, which maximizes the interaction between the chiral molecule and the 
cyclodextrin (Chankvetadze et al., 1994). Several chiral molecules including drugs, 
plaguicides, amino acids and other compounds of interest have been separated in 
the literature employing cyclodextrins. Enantioseparations employing different 
cyclodextrin derivatives can be found in several review papers (Jáč and Scriba, 2013; 
Scriba, 2008; Gübitz and Schmid, 2008; Cucinotta et al., 2010). 
 
I.3.2.2. Modes of CE employed for chiral analysis 
The most traditional way to perform an enantioseparation in EKC is to fill the 
capillary and both the inlet and outlet vials with a background electrolyte containing 
a chiral selector, and let the analyte interact with the chiral selector during its 
migration to the detector. This usually provides good separations, but is sometimes 
unaffordable when expensive chiral selectors are employed. Some other alternative 
modes and their main advantages are briefly discussed below (Chankvetadze and 
Blaschke, 2001). 
− Partial- (PFT) and complete (CFT) filling techniques: The partial 
filling technique has been proposed by Valtcheva and coworkers in 1993 
(Valtcheva et al., 1993). It involves the filling of a separation capillary only 
in part with a solution containing a chiral selector, while the rest of the 
capillary and the two separation vials contain a background electrolyte free 
of it. When the voltage is applied, the racemic drug migrates through the 
chiral selector plug and the separation is performed (Figure I.8). Its main 
advantages are the extremely low consumption of chiral selector (only 
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nanoliters of the solution in each run), the possibility of coupling the CE with 
MS detection (since the chiral selector does not arrive to the MS), and the 
possibility of employing chiral selectors with UV absorption (not the case of 
cyclodextrins). However, there is less analyte-selector interaction than in the 
conventional mode and the selector plug length (SPL) is a new variable that 
has to be adjusted carefully to perform the separation. 
 
 
Figure I.8: Schematic representation of the enantioseparation by PFT. 
   
 Complete filling technique is a variation of that in which the capillary is 
completely filled with the chiral selector but the separation vials also remain 
free of it. It shares the advantage of low consumption of chiral selector. If 
the chiral selector possesses self electrophoretic mobility in the opposite 
direction to the chiral analyte, it is called counter-current technique 
(Chankvetadze and Blaschke, 2001). 
− Mobility counterbalanced mode: In this mode the separation is 
enhanced by applying a pressure or vacuum that makes the bulk flow to 
move in the opposite direction to the analyte electrophoretic mobility. The 
opposite forces can strongly increase the separation factor (Chankvetadze et 
al., 1999). 
− Carrier-mode separations: In the carrier mode a chiral selector is not 
only the responsible for the separation but also for the transport of the 
analytes to the detector. Its most important advantage is that the analyte 
only migrates to the detector when it is associated with the chiral selector. 
CD E2
++ -E1+ D
CD E2
++ -DE1+
D+ DCD
EOF
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Charged chiral selectors, which possess their self electrophoretic mobility, 
may be used as carriers in CE (Terabe, 1989). 
− Enantioseparation in nonaqueous CE (NACE): The use of organic 
solvents instead of water to make nonaqueous buffers for CE offers certain 
advantages, like better solubility and stability of some analytes and chiral 
selectors, less current and Joule heating, or easier coupling to MS detection. 
However, the interaction between the enantiomers and the chiral selector 
could be decreased comparing with aqueous buffers, because the 
intermolecular forces responsible for the complexation are disfavored in 
organic solvents (Chankvetadze and Blaschke, 2001). Therefore, the use of 
NACE becomes interesting principally with analytes or selectors that are 
non-soluble in an aqueous medium. 
− Micellar electrokinetic chromatography (MEKC): MEKC, proposed by 
Terabe and coworkers in 1984 (Terabe et al., 1984), consists on the use of 
micelles as pseudostationary phase in the background electrolyte to achieve 
separations based on the different partition coefficient of the analytes in the 
aqueous and micellar media (Dey et al., 2004). When the micelles are 
formed by chiral surfactants, they can be employed to perform 
enantioseparations. Chiral surfactants employed in MEKC are digitonin, 
saponin, bile salts and others natural or synthetic. There is another option 
to perform chiral separations by MEKC: the combination of a chiral selector 
and a non-chiral surfactant in a background electrolyte. In this case, the 
micelles are added to improve the solubility of the analyte and/or the 
selectivity of the separation. 
 
I.3.2.3. Selector-selectand binding studies 
The chromatographic principles of enantioseparations include non-covalent 
interactions between the chiral selector and the selectand. When cyclodextrins are 
employed as chiral selectors, the phenomenon responsible for the enantioseparation 
is the formation of transitory complexes between the enantiomers and the 
cyclodextrin, usually with the introduction of the enantiomers in the hydrophobic 
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cavity of the CD. A thermodynamic equilibrium is established therefore between the 
free enantiomers and the complexed forms. 
The determination of the constants that characterize the interactions of enantiomers 
with chiral selectors is helpful in chiral separations research, in order to control the 
complexation equilibrium, and better understand the separation mechanism and 
molecular interactions. The knowledge about the molecular mechanisms responsible 
for the chiral separation could be useful for predicting how different chiral selectors 
will behave in the separation of compounds of interest. Nowadays chiral separations 
are usually performed by carrying out some trial-and-error tests, but some time, 
effort and money can be saved if the knowledge about separation mechanisms and 
molecular interactions allows predicting the selector-selectand interaction. 
In EKC with CDs as chiral selectors, the enantiomers form diastereomeric complexes 
with the CD whose electrophoretic mobilities (µ) are different than those of the free 
enantiomers. The observed electrophoretic mobility for a single enantiomer can be 
expressed with the following equation: 
 =
[ − ]
[] + [ − ] · 
 + [][] + [ − ] · 
 +   (I.2) 
where [E] and [E-CD] are respectively the free and complexed enantiomer 
concentrations, µCD is the mobility of the E-CD complex, µ0 is the mobility of the free 
enantiomer and µEOF is the mobility of the electroosmotic flow. 
Assuming a 1:1 stoichiometry, which is the most common situation when the CD 
concentration is much larger than that of the enantiomer, the equilibrium constant 
for the enantiomer-CD complexation can be expressed by this equation:     
 =
[ − ]
[]	[]   (I.3) 
where [CD] is the cyclodextrin concentration. Combining I.2 and I.3: 
 =
[]
1 + [] · 
 + 11 + [] · 
 +   (I.4) 
and rearranging terms, an equation that relates the effective mobility with the CD 
concentration is obtained: 
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From this expression, the difference between the effective mobilities of two 
enantiomers can be calculated as: 
∆ = " −  =
 + ""[]
1 + "[] −
 + []
1 + []  
 (I.6) 
where µ1 and µ2 are the effective mobilities of the first and second eluted 
enantiomers, respectively. K1 and K2 are the binding constants between the 
enantiomers and the chiral selector, µ0 is the mobility of the free analyte, and µ1CD 
and µ2CD are the mobilities of the complexes E1-CD and E2-CD, respectively. To 
achieve a chiral separation, the difference between the mobilities of both 
enantiomers has to be nonzero (∆µ ≠ 0) (Chankvetadze, 2007). According to Eq. I.6, 
this situation can be found with two different mechanisms: 
− The residence time in the free and complexed forms is different for both 
enantiomers. This residence time is defined by the binding constants, so in this 
case K1 ≠ K2 (thermodynamic enantioselectivity). 
− Both enantiomers remain the same time in the free and complexed forms, so K1 
= K2 = K. In this situation, the mobilities of the enantiomer-CD complexes may 
be different, so µ1CD ≠ µ2CD (electrophoretic enantioselectivity). 
Among these two phenomena, the most commonly responsible for chiral separation 
in EKC is the first one, in which the binding constants are different, or a combination 
of both (Chankvetadze, 2007). 
Binding studies have been carried out between compounds of pharmaceutical and 
environmental interest and different chiral selectors like AGP (Amini et al., 1997), 
chiral antibiotics like vancomycin, teicoplanin and ristocetin (Machour et al., 2005), 
or several cyclodextrins. Among others, there have been calculated binding 
constants of β-CD to naphthalene sulphonate derivatives (Hsiao et al., 2006) and 
aromatase inhibitors (Foulon et al., 2004), methyl-β-CD to orciprenaline (Amini et 
al., 1999a) and local anesthetics (Amini and Paulsen-Sörman, 1997), hydroxypropyl-
β-CD to fenoxyacids (Martín-Biosca et al., 2001) and aromatase inhibitors (Foulon et 
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al., 2004), sulfated-β-CD to modafinil (Al Azzam et al., 2010), carboxymethyl-β-CD 
to alkylnaphthalene derivatives (Wu and Ding, 2005) and highly sulfated γ-CD to 
tramadol (Rudaz et al., 2004). 
 
I.3.3. Enzymatic reactions in CE: Electrophoretically mediated 
microanalysis 
Enzymes are biologic catalysts, responsible for all the biochemical reactions that take 
place in live organisms. In enzymatic reactions a substrate (endogenous molecule, 
drug or other xenobiotic) is transformed to one or more products via the formation 
of an enzyme-substrate complex. As other chemical catalysts, the enzymes are not 
consumed in the reaction development. Several enzymes are extremely interesting 
from a pharmaceutical and clinical point of view, since enzymatic disorders are a 
common cause of diseases and consequently they are target of numerous drugs. 
New target enzymes and their substrates, inhibitors and cofactors are object of 
extensive research every year. 
For enzymatic studies, CE has been classically employed only as separation system 
after off-line reactions. However, the use of CE not only for the separation but also 
for performing the reaction inside the capillary allows to decrease notably the 
volume of reagents employed (from microliters to only few nanoliters in each assay), 
which is interesting in the study of enzymatic reactions since enzymes and 
substrates use to be expensive, and to increase the automation of the process since 
the injection, mixing, reaction, separation and detection can be done in a unique 
step (Hai et al., 2012). This in-capillary reaction procedure is known as 
electrophoretically mediated microanalysis (EMMA). 
In the EMMA procedure an enzyme solution is injected into the capillary and it is 
allowed to mix with the substrate solution and react before the separation. The most 
frequent mechanism for mixing the reagents is to apply an electric field to make the 
substrate and enzyme zones interpenetrate due to their differences in 
electrophoretic mobility. This is known as EMMA plug-plug mode (Figure I.9a). One 
of the problems of this methodology is the high variability in peak areas of reagents 
and reaction products due to slight variations in the in-capillary contact period of the 
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enzyme and substrate plugs, which affect the extent of the reaction (Van Dyck et al., 
2003). 
As an alternative to the classical plug-plug mode, the at-inlet EMMA procedure has 
been proposed. In this modality, the mixing of the enzyme and substrate plugs takes 
place by simple diffusion and they react for a given time in the inlet part of the 
capillary (Figure I.9b). This is especially interesting for enzymes that lose activity 
when exposed to an electric field. Classically, it has been described that longitudinal 
diffusion is responsible for the mixing of plugs in at-inlet EMMA. However, this is a 
slow process and can be not efficient if more than two plugs are involved in the 
reaction. 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
          Substrate 
          Mixture 
 Enzyme  
 Product 
Figure I.9: Scheme of the plugs injection and mixing in the different EMMA modes: 
(a) plug-plug, (b) at inlet, (c) TDLFP and (d) RPS.  
 
Recently, Okhonin and coworkers have described an alternative mode of mixing, 
which is called transverse diffusion of laminar flow profiles (TDLFP) (Okhonin et al., 
+ -
+ -
+ -
+ -
+ -
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2005). In this mode, the plugs are introduced consecutively in the capillary by 
pressure and, due to the laminar nature of flow inside the capillary, the nondiffused 
plugs have parabolic profiles with predominantly longitudinal interfaces between 
them, and transverse diffusion is responsible for the mixing (Figure I.9c). They also 
developed mathematical models to estimate the mixing process and to show the 
concentration profile of each reagent in the capillary. 
In practice, when the plugs in at-inlet EMMA are small (standard injection plugs of 
0.5 psi during 3 or 5 s), there is no difference between the experimental injection 
sequences shown in literature for at-inlet EMMA and TDLFP, so it follows that in at-
inlet EMMA also transverse diffusion (which is more efficient than the longitudinal 
one due to the higher contact surface between plugs) can be responsible for the 
mixing. 
Other alternative to the classical plug-plug mode, which is called rapid polarity 
switching (RPS) (Figure I.9d), consists in applying a series of positive and negative 
potentials to the capillary to have some shaking effect that increases the plugs 
mixing (Sanders et al., 2005). A classification of the different modalities of EMMA, 
attending to their mixing procedure, is shown in Figure I.10. 
 
 
Figure I.10: Classification of EMMA modes. 
 
In all the EMMA modes, usually the background electrolyte is not the same as the 
incubation medium in which substrates, enzymes and cofactors are dissolved, and its 
pH or components can affect the enzymatic activity. In order to preserve the correct 
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enzymatic activity and provide an adequate medium for the reaction turnover, two 
plugs of incubation buffer can be injected before and after the reaction plugs. This 
practice has been called “partial filling technique” in the literature (Hai et al., 2012), 
but may not be confused with the partial filling of a chiral selector described in 
section I.3.2.2. 
EMMA in its different modalities has been employed for some enzymatic reactions to 
study enzyme kinetics, inhibition of enzymes, and to determine substrates and 
enzymes in different biological samples (Hai et al., 2012). The evaluation of the 
enzymatic activities of alkaline phosphatase (Sun et al., 2006) and yeast alcohol 
dehydrogenase (Urban et al., 2007) has been reported by EMMA. Also metabolic 
reactions, such as the kinetics of cytochrome P450 with testosterone and nifedipine 
as substrates (Zhang et al., 2008), or the chiral metabolism of cimetidine by flavin-
containing monooxigenases (Hai et al., 2009), can be found in the literature. Due to 
its intrinsic characteristics such as fast analysis, low consumption of enzymes and 
reagents, and ease of automation, EMMA has been also employed for screening 
procedures, in order to evaluate inhibitors of hexokinase (Wang and Kang, 2009) or 
acetylcholinesterase (AChE) (Tang et al., 2007). Also other chemical reactions (not 
only enzymatic) can be carried out using this methodology. More applications of 
EMMA can be found in two recent review papers concerning this topic (Fan and 
Scriba, 2010; Hai et al., 2012). 
 
I.4. In vitro evaluation of pharmacokinetic and pharmacodynamic 
properties 
Preliminary studies in the discovery and development process of new drugs include 
the in vitro evaluation of the biological activity of candidate compounds. Efficacy, 
potency and toxicity, as well as pharmacokinetic profiles, have to be evaluated in in 
vitro models before reaching the more expensive and time-consuming in vivo 
studies. Figure I.11 shows a diagram of the drug discovery process where is seen 
that in vitro screening procedures and methodologies for pharmacokinetics 
evaluation play an important role (Evans, 2004). Proteins and enzymes, cell cultures, 
tissues and whole organs can be employed with this purpose. 
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Figure I.11: Process diagram representing some steps of drug discovery. 
 
I.4.1. Protein binding 
The in vitro measurement of drug binding to plasma proteins is used to calculate 
pharmacokinetic parameters and make predictions on the pharmacokinetic behavior 
of the drug. It is therefore highly important to estimate the binding ability to plasma 
proteins in the early stages of drug discovery. Different approaches have been 
proposed for the evaluation of protein binding of drugs, and they can be classified 
into two main categories: separative and non-separative methods (Figure I.12) 
(Vuignier et al., 2010). The first group involves the separation of the free ligand 
from the bound species and the determination of the drug in one fraction or both of 
them. As the determination usually implies the use of analytical techniques, it can be 
performed in an enantioselective way by using chiral separation systems 
(chromatographic or electrophoretic). The second group is based on the detection of 
a change in some physicochemical properties of the drug or the protein due to the 
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binding. Among all of them, equilibrium dialysis (ED) is by far the more widely used 
method to study ligand-protein interactions (Evans, 2004), and it has been 
presented as the reference method for PB measurements. 
 
 
Figure I.12: Classification of methodologies applied to drug-protein binding studies. 
 
Separative methods 
Equilibrium dialysis is based on establishment of an equilibrium state between a 
protein compartment and buffer compartment which are separated by a membrane 
that has a known molecular weight cut-off and is permeable only for a low-molecular 
weight ligand (Oravcová et al., 1996). In this methodology, after the equilibrium has 
been reached the concentration of the free ligand is equal on both sides of the 
membrane. The drug concentration is measured then in the fluids from both 
compartments, and the percent of binding can be expressed as (Evans, 2004): 
%$%&'( = ) − *) · 100 
 (I.7) 
where Ct and Cu are, respectively, the concentrations of drug in the protein and 
buffer reservoirs. 
Methods for investigation of 
drug-protein binding
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Despite the fact that ED has been considered the reference method for PB 
estimations, it suffers from many drawbacks (Vuignier et al., 2010). The equilibration 
times are too long (12-48 h) and preliminary studies have to be carried out to make 
sure the time is enough for reaching equilibrium. Another problem is the volume 
shift associated with the oncotic pressure due to the presence of proteins, which can 
be up to 30%. Also nonspecific adsorption of drugs to the cell walls and dialysis 
membrane can happen. 
Ultrafiltration (UF) is an alternative to ED where the drug-protein mixture is 
filtered through a membrane under the application of a negative pressure by 
centrifugation. This methodology is faster and cheaper than ED and it is broadly 
employed due to the availability of some commercial filtration devices. However, 
nonspecific retention of the drug to the filtration membrane is also a problem for UF. 
The percentage of binding follows the same expression than for ED (Eq. I.7), but in 
this case Ct is the total concentration of drug before the experiment and Cu is the 
concentration of drug in the ultrafiltrate (unbound fraction). 
With ultracentrifugation, the drug-protein mixture is placed in a high speed 
centrifugal field, until all the protein and drug-protein complex sediment to the 
bottom of the tube and the free drug remains in the supernatant. The percentage of 
binding can be calculated in the same way as in UF. Its main advantage is that the 
drawbacks due to membranes are eliminated, but the equipment needed is more 
expensive than those for ED and UF, and there is also some error due to the partial 
sedimentation of the free drug, which is larger for drugs with higher molecular 
weights. Due to these disadvantages, ultracentrifugation is less extended than the 
other separative methods. 
Parallel artificial membrane permeability assay (PAMPA) is a recently 
described methodology based on a 96-well filter plate coated with an artificial 
membrane made of phospholipids or organic solvents that separates two 
compartments, one with the drug and the protein and other with only fresh buffer. 
PAMPA is similar to ED but has some advantages in comparison with it: as the 
estimation of binding constants is based on a kinetic approach, it is not necessary to 
reach equilibrium, so it is faster; the nonspecific binding of the drug to the 
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membranes can be self-corrected by calculations, and as the membrane is not water 
permeable, there is no volume shift. The 96-well format employed makes 
automation of the procedure easy (Lázaro et al., 2008). 
In all these approaches, after the separation of fractions it becomes necessary a 
second step with an analytical method that allows the quantification of either the 
free or the bound fraction. This is usually carried out by LC or CE, and also chiral 
methods can be employed to estimate the enantioselectivity in the protein binding. 
However, LC and CE can be also employed themselves for drug-protein binding 
estimations. 
There are two LC possibilities for assessing drug-protein interactions: size-exclusion 
chromatography (SEC), where the protein and drug-protein complex elute first due 
to their larger size and the free drug (smaller) elutes later, and high-performance 
affinity chromatography (HPAC), where the protein is immobilized on the stationary 
phase and the retention time of the drug can be employed for the estimation of 
protein binding (Vuignier et al., 2010). SEC is rarely used nowadays due to some 
drawbacks such as low column efficiency and short column lifetimes. HPAC has more 
advantages, since only a small amount of protein is needed and can be reused for 
some experiments, enantioselective information can be achieved if the column 
separates the enantiomers, and automation is easy. Protein immobilization is the 
most critical aspect that has to be taken into account in this methodology. 
CE can be also employed for the estimation of PB. Several approaches have been 
described, in which the protein, the drug or their mixture can be injected or included 
in the background electrolyte. Among all of them, the two most employed are frontal 
analysis (FA) and affinity capillary electrophoresis (ACE) (Vuignier et al., 2010). 
In FA, the protein and the drug are mixed in the sample vial and a large amount of 
sample is injected in the capillary (10-20% of the effective capillary length). The 
injection of large volumes gives rise to the appearance of plateaus instead of peaks. 
The height of the free drug plateau is proportional to the free drug concentration in 
the sample. 
In ACE, the capillary is filled with buffer containing the protein in different 
concentrations and the free drug is injected as small plug. The migration time of the 
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drug depends on the protein concentration and the affinity constant can be 
calculated from the change in the electrophoretic mobility of the drug upon 
complexation. More information about separative and chromatographic techniques 
for protein binding evaluation can be found in a review paper concerning this topic 
(Escuder-Gilabert et al., 2009). 
 
Non-separative methods 
Spectroscopic methods used in PB studies (UV-visible, fluorescence, infrared, 
nuclear magnetic resonance, optical rotatory dispersion and circular dichroism) are 
based on changes in the electronic and spectroscopic energy levels of the ligand or 
the protein due to the complexation process. These methods can be performed in 
solution, so they give true equilibrium measurements (Vuignier et al., 2010). They 
can provide structural information about the protein, the drug and the complexation 
process and currently they are being used in combination with computational 
methods (molecular docking) to obtain a clear image of the drug-protein interaction. 
Two calorimetric techniques have been employed to study protein binding, 
isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC). In 
ITC, successive additions of drug to a protein solution are done and the heat release 
in the complexation process is measured. In DSC, a drug-protein mixture is heated 
and the measurement is based on the stabilization of the native form of the protein 
due to the complexation with the drug. The drug-protein complex is more stable and 
requires more heating than the free protein to be denatured. Both techniques are 
slow and require a large amount of material to do accurate measurements, so their 
main interest is that they provide thermodynamic information about the binding 
process (Vuignier et al., 2010). 
Surface plasmon resonance (SPR) has been also employed to evaluate protein 
binding. It involves immobilizing the protein on a metal surface and monitoring its 
interaction with the drug that flows over the surface by the measurement of changes 
in the refractive index in the immediate vicinity of the surface layer due to the 
binding process. The changes in the angle of the reflected light are proportional to 
the mass in the surface. This is schematically shown in Figure I.13 (Cooper, 2002). 
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Figure I.13: Scheme of a surface plasmon resonance instrument. 
 
SPR can provide kinetic information about the binding process and is able to 
characterize binding reactions in real time. Other advantage is the small amount of 
materials used (usually chip devices). 
 
Mathematical models in protein binding 
The reversible binding interaction between a drug and a protein has been usually 
described by the following model: 
, = $	 =
 − (
	 =-' 
 (
1   (
.
 /"
  (I.8) 
where r is the fraction of bound xenobiotic per molecule of protein, b is the bound 
concentration of drug after equilibrium, P is the total protein concentration, D is the 
total drug concentration, d is the free concentration of drug after equilibrium, m is 
the number of classes of independent active sites in the protein, n is the number of 
binding sites of one class per protein molecule (apparent stoichiometry), and K is the 
binding constant of the drug-protein interaction. For example, for the molecule of 
albumin, whose structure has been described in section I.1.1.2, m represents the 
different sites described in the molecule (site I, II, III…). 
From this general model, where Ki and ni have to be estimated for the m classes of 
binding sites, making the estimations difficult to perform, some simplifications have 
been derived assuming different situations. 
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− m = 2 (two main classes of binding sites): 
, = '"
"(
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"(
 '
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(
  (I.9) 
The main disadvantage of this equation is that different combinations of n1, K1, n2 
and K2 estimates are feasible, so the validity of the calculated values may be 
checked. 
− m = 1 (only one main class of binding sites): 
, = '"
"(
1  "(
  (I.10) 
This equation can suffer from the same problem as the m = 2 model, since more 
than one single set of suitable n1 and K1 values can be found (Šoltés and Mach, 
2002). 
From this model, several linear equations have been derived (Table I.2). However, 
linear plots can provide mathematically inconsistent results, since r and d appear 
both as independent and dependent variables. These mathematical models lack of 
robustness, so little differences in the experimental data will provide big changes in 
the estimations. 
 
Table I.2: Linear models for protein binding estimations. 
Model Equation  
Klotz 
1
, =
1
'" +
1
'"" ·
1
( (I.11) 
Scatchard     
,
( = '"" − ", (I.12) 
y-reciprocal     
(
, =
1
'"" +
1
'" ( (I.13) 
 
All these mathematical approaches can be employed also in the case of single 
enantiomers to obtain enantioselective estimations of n1 and K1. 
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I.4.2. Drug metabolism 
The use of in vitro techniques to study drug metabolism provides relevant 
information about the metabolites likely to be formed in vivo and about potential 
clinical interactions by induction or inhibition of metabolic enzymes. It also provides 
pharmacokinetic data useful in the first stages of drug development. As the liver is 
the major site for biotransformation, usually in vitro systems are focused on the liver 
and the enzymes it contains, so there can be different preparations which vary in 
their levels of cellular integrity, from single enzymes to whole liver perfusion (Evans, 
2004). Figure I.14 shows the different possibilities for performing metabolic studies, 
including two in vivo approaches that will not be discussed here. They are compared 
in terms of complexity, easiness of application, ethics and similarity to the in vivo 
true situation (Brandon et al., 2003). In vitro studies focus on both metabolism 
phases I and II, especially on CYP metabolic reactions. These are the most common 
phase I ones and also the most frequently affected by drug-drug interactions. 
Nevertheless, other enzymatic systems are also studied and, of course, the more 
complex the in vitro model is, the more global information about the metabolic 
process can be found, but at the same time the less information about each 
individual enzyme behavior is provided. 
 
 
Figure I.14: In vitro and in vivo metabolism models used in drug development. 
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The most complex in vitro system employed for the evaluation of drug metabolism is 
the perfused liver. An isolated perfused liver is considered to be the best 
representation of the in vivo situation. However, it has never been used with human 
liver and only a few times with animal livers. In this system, the animal is killed and 
its liver is preserved in a thermostatized bath, and usually perfused with Krebs-
Henseleit buffer (a mixture of glucose, albumin, sodium chloride and other 
components of the human serum). Different procedures have been extensively 
described for carrying out these studies (Brauer et al., 1959; Mischinger et al., 
1992). 
Despite its important advantages such as the possibility of collecting bile for analysis, 
the presence of all cell types that can be found in a real liver (not only hepatocytes), 
and the three-dimensional architecture of the model, its drawbacks made this 
system less atractive as in vitro model. In this model, the liver is available for only 
few hours and it is a delicate system, difficult to handle. The impossibility of using 
human livers is also an important drawback for the purpose of the evaluation of drug 
metabolism, because animal livers not always reproduce reliably the human 
metabolism. In practice, this model is especially useful when there is interest in the 
collection and analysis of the bile secretion (Brandon et al., 2003). 
Liver slices, which are precision-cut with special devices, share the advantages of 
the perfused liver in terms of the presence of all types of cells and the three-
dimensional architecture of the liver. This allows an assessment of the infuence of 
cell diversity and cell-cell interaction on drug metabolism, and the maintenance of 
drug transport pathways (Hariparsad et al., 2006). It has also another advantage 
that is the less amount of animal liver needed for each study. Its inconvenients are 
also similar to the perfused liver, since it is and expensive methodology difficult to 
handle with, and the availability of the slices without losing their enzymatic activity is 
just of few days. Another important drawback is the inadequate penetration of the 
medium into the inner part of the slice. 
Primary hepatocytes are a popular in vitro system for drug biotransformation 
research due to their strong resemblance of in vivo human liver. They can be 
obtained from human (usually after partial resection) or animal livers, and then 
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immediately employed or cryopreserved for their further use. Cryopreservation is 
interesting especially for human hepatocytes since the availability of human livers is 
limited and this technique allows to have them commercialy available (Hengstler et 
al., 2000), with their phase I and II enzymatic activity preserved. This is an 
important advantage of hepatocytes over the liver slices and perfused liver. 
Disadvantages of this in vitro system are the absence of other cell types present in 
vivo, and the interindividual variation between pools of different liver cells. This can 
be overcomed by using mixtures of hepatocytes from multiple donors, which provide 
an average of the enzyme content. Primary hepatocytes of different animal species 
can be also employed to choose the best animal in vivo model with the most 
resemblance with the human metabolic pathway (Brandon et al., 2003). 
Different cell lines have been developed and are commercially available for in vitro 
metabolic studies. Liver cell lines are isolated from hepatic tumors, such as 
hepatoma or hepatocellular carcinoma, and can be more easily cultured than the 
primary hepatocytes. However, liver cell lines are unpopular in drug 
biotransformation research due to their lack of phase I and II enzymes expression 
(Brandon et al., 2003). The most frequently cell line used is Hep G2, obtained from 
an hepatocellular carcinoma. This shows a certain activity of different CYP isoforms 
that can be increased by induction. 
Transgenic cell lines are an alternative to liver cell lines that increases the enzyme 
content of the cells to make them useful for biotransformation studies. Cells are 
transfected with one or more isoforms of CYP and uridine 5'-diphospho-
glucuronosyltransferase (UGT), which allow studying the influence of different 
isoforms in the whole metabolic process (Gasser et al., 1999). They can be also 
employed to generate metabolites for structure elucidation or pharmacological 
characterization. 
On the other hand, at a subcellular level different fractions can be obtained from a 
liver homogenate by centrifugation. These fractions can be used separately to 
perform in vitro biotransformation studies. Figure I.15 shows a scheme of the 
different subcellular fractions that can be obtained from the liver tissue and a simple 
overview of the separation procedure (BD Gentest Tissue Fractions Brochure, 2010). 
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The most complex subcellular in vitro system available is liver S9 fraction. The S9 
fraction is defined by the Internatonal Union of Pure and Applied Chemistry (IUPAC) 
as the supernatant fraction obtained from an organ (usually liver) homogenate by 
centrifuging at 9000 g for 20 min in a suitable medium; this fraction contains cytosol 
and microsomes (Duffus et al., 2007).  The microsomes are vesicles of the 
hepatocyte endoplasmic reticulum that contain CYP, FMO and UGT enzymes. In the 
cytosolic fraction, several soluble phase II enzymes are present, like N-acetyl 
transferase, glutathione S-transferase and sulfotransferase. In the S9 fraction all 
these enzymatic systems are present, so it offers a more complete representation of 
the metabolic profile than the use of microsomes or cytosol separately. All the 
cofactors needed for the enzymatic reactions may be added to this system: NADPH 
or a NADPH regenerating system for CYPs, and many other cofactors such as acetyl 
coenzyme A (acetyl CoA) or glutathione for phase II enzymes (Brandon et al., 2003). 
Figure I.15: Overview of the procedure for obtaining liver subcellular fractions. 
 
Human liver microsomes (HLMs) are the most popular in vitro model employed 
for biotransformation studies. They are obtained also by differential centrifugation of 
the liver homogenate, and, as described before, contain CYP, FMO and UGT 
enzymes. They are well-characterized by the suppliers and easily employable.  
Interindividual variation of the enzyme content and activity can be avoided 
employing pooled microsomes that represent an average enzyme activity that can be 
considered representative. The companies that commercialize the HLMs have pools 
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with different characteristics of gender or enzyme polymorphism that allow providing 
averaged data but also study interindividual differences. They have large pools with 
small variability to allow carrying out long studies without significant differences (BD 
Gentest Tissue Fractions Brochure, 2010). As described for primary hepatocytes, 
microsomes of different animal species can be employed to choose the best in vivo 
animal model for resembling human metabolism. 
Liver cytosol fractions can be also employed individually to study phase II 
metabolic reactions. The use of these fractions individually instead of the S9 fraction 
allows to better understand each reaction separately, and makes easier the 
identification of metabolites that can be in a very low concentration in the S9 
fraction, since the enzyme content is higher in the HLMs and cytosol than in the S9 
fraction. Both for HLMs and liver cytosol fractions, the adequate cofactors for each 
enzymatic reaction may be added to the biotransformation medium. 
The last and simplest in vitro model for the study of drug metabolism is 
supersomes. Supersomes are vesicles of the hepatocyte endoplasmic reticulum of 
transfected insect cells. Insect cells lack endogenous CYP and UGT activity, so the 
expression of the human CYP and UGT enzymes is baculovirus mediated. At present, 
all common human CYPs, co-expressed with NADPH-cytochrome P450 reductase and 
cytochrome b5 are offered in supersomes. Also UGTs are commercially available. 
Supersomes are a valuable supplement to HLM (Huang et al., 2000), and can be 
used in the same way. Their main advantage is that no human liver is necessary for 
their production. They can be used not only for biotransformation studies but also to 
evaluate drug-drug interactions and to study the influence of CYP polymorphisms on 
drug biotransformation pattern (Brandon et al., 2003). 
Subcellular fractions such as HLMs or supersomes can be employed for performing in 
vitro assays in solution, usually followed by the determination of substrates or 
products by analytical procedures, which can be also enantioselective if information 
about single enantiomers is required. Recently they have been also used by several 
authors in EMMA procedures, in which the reaction and the detection are performed 
in the same electrophoretic capillary (see section I.3.3). 
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Mathematical models in drug metabolism 
Metabolic reactions are enzymatic ones, so they follow the mathematical approaches 
employed in enzymatic studies. The first equilibrium models were proposed by Henri 
in 1903 and by Michaelis and Menten in 1913. Later, Briggs and Haldane introduced 
in 1925 the steady state assumption which is a more realistic approach of the 
conditions employed in experimental studies (Copeland, 2005). 
The enzymatic reactions in which one substrate forms one product can be described 
with the following general model: 
 + 0 ⇌ 0 →  + 	   (I.14) 
where E is the enzyme, S the substrate, ES the enzyme-substrate complex and P the 
product. Each reaction has its own kinetic constant (k1 and k-1 for the formation and 
dissociation of the ES complex, and k2 for the formation of product), so the velocities 
of formation and dissociation of the ES complex can be defined as follows: 
Formation: 23 = 4"[][0]                  (I.15) 
Dissociation: 25 = 46"[0] + 4[0]               (I.16) 
Steady state conditions assume that the concentration of the ES complex is held 
constant by a balance between the rates of its formation and dissociation. This is 
experimentally achieved by having a large molar excess of substrate over enzyme 
concentration. The formation and dissociation velocities (Eqs. I.15 and I.16) are thus 
equal, and after some mathematical treatment of these expressions and variables 
transformation an equation that relates the initial velocity (V0) to the substrate 
concentration is derived (Nelson and Cox, 2006). This is commonly known as 
Michaelis-Menten equation: 
2 =
2.78[0]
. + [0]  (I.17) 
The terms Vmax and Km are the kinetic parameters of the enzymatic reaction. Vmax 
represents the maximum reaction velocity (at infinite substrate concentration) and 
Km, which is a mathematical combination of k1, k-1 and k2, represents the 
concentration of substrate at which the velocity is half the Vmax. 
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Experimental data have to be adjusted to Michaelis-Menten equation by non-linear 
fitting. There is also a linear model derived from it, which is known as Lineweaver-
Burk plot (Eq. I.18). It suffers from the same drawbacks previously discussed for 
linear models in protein binding, so, if non-linear fitting is possible, linear plots 
should be avoided. 
1
2 =
.
2.78[0] +
1
2.78  (I.18) 
Metabolic enzymes are usually compared in terms of their Km for different substrates 
transformation, which is a measurement of the enzyme-substrate affinity. 
 
I.4.3. Enzyme inhibition 
Enzymes are target of approximately 50% of the commercialized drugs. Most of the 
essential biochemical processes are catalyzed by enzymes, so they can be 
responsible for disease states. Enzymes are susceptible to be inhibited by small 
molecules and they are commonly the target of new drug discovery efforts. So, 
methods for the in vitro evaluation of enzyme inhibition are also important for the 
preclinical phases of drug development. High-throughput screening (HTS) is 
nowadays the most common method for identifying promising compounds, and is 
frequently applied to evaluate the potential inhibition of target enzymes by large 
libraries of molecules. The most common approach is to measure the reduction on 
the enzyme activity in presence of the candidate compound. 
Several HTS strategies have been described recently, such as fluorescence or 
radiometric techniques, assays with surface plasmon resonance, or separation 
techniques such as LC or CE (Shanmuganathan and Britz-McKibbin, 2013), using 
similar approaches than those described for the evaluation of protein binding (see 
section I.4.1). Both LC and CE techniques can be employed for the detection of 
substrates, products and/or inhibitors after off-line incubation of the enzyme with a 
model substrate and its candidate inhibitors, and also by on-line methodologies. 
Immobilized enzyme-reactor columns and capillaries have been developed, such as a 
monolithic capillary column with AChE for inhibitors screening by nano-LC (Forsberg 
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et al., 2011), or a tyrosinase microreactor in CE (Jiang et al., 2013). In CE, the use 
of EMMA for the screening of enzyme inhibition is also a common approach, 
employed for several enzymes such as transferases, hydrolases, oxidoreductases or 
isomerases (Shanmuganathan and Britz-McKibbin, 2013). 
Finally, also computational methodologies have been developed for HTS of potential 
inhibitors, despite these techniques provide only initial information about their 
potential as drug candidates and may be always followed by experimental 
procedures. An artificial neuronal network has been developed for the screening of 
cyclooxygenase inhibitors (Gálvez-Llompart et al., 2013) and molecular docking has 
been employed for evaluating monoaminooxygenase-B inhibitors (Yelekçi et al., 
2013), among others. 
 
Mathematical models in enzyme inhibition 
The inhibition process is a reversible equilibrium where the inhibitor can bind to the 
free enzyme, the enzyme-substrate complex or both (Figure I.16). 
 
 
Figure I.16: Equilibrium scheme of the reversible enzyme inhibition. 
 
A general mathematical approach has been developed with some simplifications that 
can be applied depending on the type of inhibition studied. The general model is a 
modification of the Michaelis-Menten equation: 
2 =
2.78[0]
9. + 9:[0]  (I.19) 
E + S ES
+ 
I
EI
+ 
I
ESI
E + P
Km
Km
Ki K’i
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where α and α’ are the modifying factors defined by the inhibitor concentration, [I], 
and its two dissociation constants, Ki (for the binding to the free enzyme) and K’i (for 
the binding to the enzyme-substrate complex): 
9 = 1 + [;]   (I.20) 
9′ = 1 + [;]:   (I.21) 
The general equation (Eq. I.19) is applied to the inhibitors that bind both to the 
enzyme and the enzyme-substrate complex, which are known as non-competitive 
inhibitors. 
Competitive inhibitors can only bind to the free form of the enzyme, so they 
“compete” with the substrate for the free enzyme. In this situation, K’i becomes 
infinite and α’ = 1, so the general model can be rewritten as follows: 
2 =
2.78[0]
9. + [0]  (I.22) 
It may be taken into account that the competitive inhibition does not imply that the 
substrate and the inhibitor bind to the same site of the enzyme. The inhibitor can 
bind to other site and modify the configuration of the active site impeding the 
binding of the substrate (Copeland, 2005). 
The third situation that can be found is that the inhibitor can only bind to the ES 
complex. This is called uncompetitive inhibition, and, in this case, the term α 
becomes 1 and the model is simplified as follows: 
2 =
2.78[0]
. + 9:[0]  (I.23) 
Inhibition constants can be calculated by using the described models. Another 
interesting parameter in enzyme inhibition is the IC50, defined as the concentration 
of inhibitor that inhibits 50% of the enzyme activity. The percentage of inhibition can 
be calculated as follows: 
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%='ℎ=$=?=%' = 100 − ([	] [	] · 100)  (I.24) 
where [P]i and [P]0 are, respectively, the product concentrations in presence and 
absence of the inhibitor. By plotting the percentage of inhibition versus the logarithm 
of the inhibitor concentration, a sigmoid curve is obtained, where the inflexion point 
is the value of the IC50. 
 
I.5. Drugs and pesticides in study 
All xenobiotics (drugs and pesticides) employed in this Thesis are summarized in 
Tables I.3 and I.4. Their chemical structures, minus logarithm of acidity constant 
(pKa) and molecular weight (MW) values are also shown in these tables. For chiral 
compounds, the asymmetric carbon is marked with a (). 
 
Table I.3: Drugs in study in this Thesis. 
Drug Structure pKa MW (g·mol
-1) 
AChE inhibitors    
Edrophonium 
 
8.59 166.2 
Eserine 
 
6.59 275.3 
Neostigmine 
 
- 223.3 
Pyridostigmine 
 
- 181.2 
Tacrine 
 
8.95 198.3 
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Table I.3: (Continued) 
Drug Structure pKa MW (g·mol
-1) 
Antidepressants    
Bupropion 
 
8.22 239.7 
Fluoxetine 
 
9.80 309.3 
Nomifensine 
 
8.88 238.3 
Viloxazine 
 
8.19 237.3 
Antihistamines    
Brompheniramine 
 
9.48 319.2 
Carbinoxamine 
 
8.87 290.1 
Chlorcyclizine 
 
8.00 300.8 
Cl
N
O
N*
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Table I.3: (Continued) 
Drug Structure pKa MW (g·mol
-1) 
Antihistamines    
Chlorpheniramine 
 
9.47 274.8 
Clemastine 
 
9.55 343.9 
Dimethindene 
 
9.70 292.4 
Doxylamine 
 
8.87 270.2 
Ethopropazine 
 
9.60 312.4 
Hydroxyzine 
 
7.82 374.0 
 
 
 
N
N
*
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Table I.3: (Continued) 
Drug Structure pKa MW (g·mol
-1) 
Antihistamines    
Methotrimeprazine 
 
9.42 328.5 
Orphenadrine 
 
8.87 269.0 
Phenindamine 
 
9.00 261.3 
Promethazine 
 
9.05 284.4 
Terfenadine 
 
9.02 471.7 
Trimeprazine 
 
9.42 298.4 
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Table I.3: (Continued) 
Drug Structure pKa MW (g·mol
-1) 
Anti-obesity    
Fenfluramine 
 
10.22 231.3 
β-blockers    
Acebutolol 
 
9.57 336.4 
Alprenolol 
 
9.65  
Atenolol 
 
9.67 266.3 
Carteolol 
 
9.76 292.4 
Metoprolol 
 
9.67 267.4 
Oxprenolol 
 
9.5 265.3 
Pindolol 
 
9.67 247.3 
Propranolol 
 
9.45 259.3 
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Table I.3: (Continued) 
Drug Structure pKa MW (g·mol
-1) 
β-blockers   
Sotalol 
 
9.43 272.4 
Timolol 
 
9.76 316.4 
Ca+2-channel blockers   
Verapamil 
 
9.68 454.6 
Hypnotics    
Zopiclone 
 
6.89 388.8 
Local anesthetics    
Bupivacaine 
 
8.10 288.4 
Mepivacaine 
 
7.70 246.3 
Prilocaine 
 
7.89 220.0 
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Table I.3: (Continued) 
Drug Structure pKa MW (g·mol
-1) 
Local anesthetics   
Propanocaine 
 
7.53 311.0 
 
Table I.4: Pesticides in study in this Thesis. 
Pesticide Structure pKa MW (g·mol
-1) 
Benalaxyl 
 
- 325.0 
Cyproconazole 
 
2.26 291.8 
Hexaconazole 
 
2.26 314.2 
Imazalil 
 
6.77 296.0 
Myclobutanil 
 
2.27 288.1 
Penconazole 
 
2.28 284.2 
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II. OBJECTIVES 
 
This Thesis is part of a research line developed by our research group in the last 
years, consisting on the development of high-throughput methodologies for the 
chromatographic and electrophoretic evaluation of specific and non-specific 
interactions between xenobiotics and biomacromolecules, and in some cases the 
enantioselectivity shown by these interactions. The purpose of this research line is to 
provide to the pharmaceutical and chemical industry fast and reliable in vitro 
methodologies to evaluate the xenobiotic-biomacromolecule interaction, which can 
be interesting for the preclinical phases of drug development and for the 
development of new xenobiotics such as pesticides. The use of in vitro 
methodologies that minimize the use of animals in laboratory experimentation is an 
actual trend due to all the regulations trying to replace in vivo experiments by in 
vitro ones which provide information of the same quality, and reserve in vivo trials 
for the last steps of drug development in which they are necessary. 
The main aim of this Thesis is the development of high-throughput electrophoretic 
systems that could be employed as screening methodologies for the characterization 
of the interaction of drugs with different biomacromolecules involved in 
pharmacokinetic and pharmacological processes, and for the study of 
pharmacological differences between the enantiomers of chiral drugs. This general 
purpose can be divided into three more specific objectives: 
 
1. Development of enantioselective methods for the chiral separation of 
drugs by electrokinetic chromatography 
This objective comprises the development of chiral methods for enantioseparation of 
drugs by the CE modality of electrokinetic chromatography. With this purpose, 
different neutral and anionic cyclodextrins will be employed as chiral selectors using 
the complete and partial filling techniques. Selector-selectand binding studies will be 
carried out to better understand the complexation mechanism responsible for the 
chiral separations. The developed methods will be applied to the determination of 
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drug enantiomers in pharmaceuticals. A non-aqueous CE system will be also 
proposed as an alternative for performing enantioseparations. 
 
2. Development of high-throughput electrophoretic systems for the in 
vitro evaluation of the interaction between drugs and different 
biomacromolecules 
This objective includes the development and improvement of methodologies for the 
evaluation of the interaction between drugs and plasma proteins (HSA and total 
plasma proteins), the inhibitory activity of some acetylcholinesterase inhibitors, and 
the interaction between drugs and metabolic enzymes (cytochrome P450), with the 
goal of achieving fast, reliable and reproducible methods that could be applied in 
drug development processes. The evaluation of the drug-protein interaction will be 
performed by ultrafiltration followed by chiral EKC. For the different enzymatic 
reactions evaluated, the EMMA methodology, which allows the reaction, separation 
and detection of the components inside the capillary, is proposed. 
 
3. Development of high-throughput electrophoretic systems for the in 
vitro evaluation of the enantioselectivity of drugs in some distribution and 
metabolism processes 
Due to the little amount of information available about stereoselectivity in the 
interaction of chiral drugs with biomacromolecules and its important impact over 
their pharmacodynamics, pharmacokinetics and toxicity, this objective involves the 
development of electrophoretic methodologies that allow the evaluation of the 
differential behavior of drug enantiomers in their interaction with plasmatic proteins 
and metabolic enzymes. With this purpose, the chiral methods developed in the first 
objective will be joined with some of the methodologies developed in the second 
one. 
III. METHODOLOGY 
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III. METHODOLOGY 
III.1. Instrumentation 
Three different CE systems have been employed in the development of this Thesis: 
two P/ACE MDQ Capillary Electrophoresis systems from Beckman Coulter (Fullerton, 
CA, USA), both equipped with diode array detectors, and 32Karat software version 
8.0, and a HP3D CE system (Hewlett-Packard, Waldbronn, Germany), also equipped 
with a diode array detector, and HP3D Chemstation software. 
Fused-silica capillaries of 50 and 75 µm inner diameter (i.d.) and 363 µm outer 
diameter (o.d.) have been employed, with effective lengths varying from 21 and 50 
cm, depending on the application. The capillaries were from Beckman Coulter 
(Fullerton, CA, USA) or from Agilent Technologies (Waldbronn, Germany). 
The selection of the detection wavelength for each compound was based on 
reported data or previous work of our research group. When no reported data were 
available, the UV spectra were recorded in a first experience in order to choose the 
adequate detection wavelength. 
All the electrophoretic solutions and samples were filtered through 0.45 µm pore size 
nylon membranes (Micron Separation, Westboro, MA, USA) and degassed in an 
ultrasonic bath (JP Selecta, Barcelona, Spain) prior to use. The pH of the buffer 
solutions was adjusted with a Crison Micro pH 2000 pH-meter (Instrumentos Crison, 
Barcelona, Spain). All solutions were prepared with Ultra Clear TWF UV deionized 
water (SG Water, Barsbüttel, Germany). 
In protein binding studies, ultrafiltration was carried out through Microcon YM-10 
cellulose filters, with a molecular weight cut-off of 10 kDa (Millipore Corporation, 
Bedford, MA, USA). The filtering devices had a volume capacity of 0.5 mL. A 
centrifuge Heraeus Biofuge Strate (Heraeus, Madrid, Spain) with capacity for 24 
samples and temperature control was employed for the ultrafiltration. Samples were 
incubated in a Selecta thermostatized bath (JP Selecta, Barcelona, Spain). 
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III.2. Chemicals and reagents 
The reagents employed in this Thesis are summarized in Table III.1, with their 
commercial suppliers and the section(s) of this Thesis where they have been 
employed. All the reagents are of analytical grade. 
 
Table III.1: Summary of all reagents and chemicals employed in this Thesis. 
Chemical / reagent Supplier Section(s) 
Drugs and metabolites   
Acebutolol hydrochloride Italfarmaco* IV.1.2. 
Alprenolol hydrochloride Sigma IV.3.1. 
Atenolol Zeneca Farma* IV.1.2. 
Brompheniramine maleate Sigma IV.1.2. 
Bupropion hydrochloride Sigma IV.1.1. 
IV.1.2. 
Carbinoxamine maleate Sigma IV.1.2. 
Carteolol hydrochloride Miquel-Otsuka* IV.1.2. 
Celiprolol hydrochloride Rhone-Poulenc* IV.1.2. 
Chlorcyclizine hydrochloride Sigma IV.1.2. 
Chlorpheniramine maleate Sigma IV.1.2. 
Clemastine fumarate Sigma IV.1.2. 
Dimethindene maleate Novartis* IV.1.1. 
IV.1.2. 
Doxylamine succinate Sigma IV.1.2. 
Edrophonium chloride Sigma IV.3.1. 
Eserine Sigma IV.3.1. 
Ethopropazine hydrochloride Sigma IV.1.2. 
Fluoxetine hydrochloride Alter* IV.1.1. 
IV.1.2. 
IV.1.3. 
IV.2.1. 
IV.3.3. 
Fenfluramine hydrochloride VUB* IV.1.4. 
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Table III.1: (Continued) 
Chemical / reagent Supplier Section(s) 
Drugs and metabolites   
Hydroxyzine hydrochloride Sigma IV.1.2. 
Labetalol hydrochloride Sigma IV.1.2. 
Metoprolol tartrate Ciba Geigy* IV.1.2. 
Methotrimeprazine maleate Sigma IV.1.2. 
Nadolol Squibb* IV.1.2. 
Neostigmine bromide Sigma IV.3.1. 
Nomifensine maleate Sigma IV.1.1. 
IV.1.2. 
IV.2.3. 
Norfluoxetine hydrochloride Sigma IV.3.3. 
Norverapamil hydrochloride Sigma IV.3.2. 
Orphenadrine hydrochloride Sigma IV.1.1. 
IV.1.2. 
Oxprenolol hydrochloride Ciba Geigy* IV.1.2. 
Phenindamine tartrate Sigma IV.1.2. 
Pindolol Sigma IV.1.2. 
IV.1.4. 
Promethazine hydrochloride Guinama IV.1.1. 
IV.1.2. 
Propranolol chlorhydrate ICI Farma* IV.1.2. 
Pyridostigmine bromide Sigma IV.3.1. 
R-fluoxetine hydrochloride Sigma IV.3.3. 
R-verapamil hydrochloride Sigma IV.3.2. 
Sotalol hydrochloride Sigma IV.1.2. 
Tacrine Sigma IV.3.1. 
Terfenadine Sigma IV.1.1. 
IV.1.2. 
Timolol maleate Merck* IV.1.2. 
Trimeprazine hemi(+)-tartrate Sigma IV.1.2. 
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Table III.1: (Continued) 
Chemical / reagent Supplier Section(s) 
Drugs and metabolites   
Verapamil hydrochloride Sigma IV.1.2. 
IV.1.4. 
IV.3.2. 
Viloxazine Astra Zeneca* IV.1.1. 
IV.1.2. 
Zopiclone Aventis Pharma* IV.2.2. 
Pesticides   
Benalaxyl Dr. Ehrenstofer IV.1.2. 
Cyproconazole Dr. Ehrenstofer IV.1.2. 
Hexaconazole Dr. Ehrenstofer IV.1.2. 
Imazalil Dr. Ehrenstofer IV.1.2. 
Myclobutanil Dr. Ehrenstofer IV.1.2. 
Penconazole Dr. Ehrenstofer IV.1.2. 
Proteins, enzymes and cofactors   
AChE from Electrophorus electricus (EC.3.1.1.7.) Sigma IV.3.1. 
Acetolthiocholine chloride (AThCh) Acros Organics IV.3.1. 
Human CYP2D6*1 + P450 Reductase 
SUPERSOMESTM 
BD Gentest IV.3.3. 
Human CYP3A4 + P450 Reductase + Cytochrome b5 
SUPERSOMESTM 
BD Gentest IV.3.2. 
Human serum albumin Fraction V Sigma IV.2.1. 
IV.2.2. 
IV.2.3. 
Lyophilized human sera Sigma IV.2.2. 
IV.2.3. 
NADPH Sigma IV.3.2. 
NADPH Regenerating System Solution A 
(Content: 26 mM NADP+, 66 mM Glucose-6-
phosphate (G6P) and 66 mM MgCl2 in H2O) 
BD Gentest IV.3.2. 
IV.3.3. 
NADPH Regenerating System Solution B 
(Content: 40 U/mL Glucose-6-phosphate 
dehydrogenase (G6PDH)  in 5 mM sodium citrate) 
BD Gentest IV.3.2. 
IV.3.3. 
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Table III.1: (Continued) 
Chemical / reagent Supplier Section(s) 
Cyclodextrins   
Carboxymethyl-β-cyclodextrin (CM-β-CD) Cyclolab IV.2.2. 
Carboxymethyl-γ-cyclodextrin (CM-γ-CD) Cyclolab IV.1.4. 
Heptakis-(2,3,6-tri-O-methyl)-β-cyclodextrin (TM-β-
CD) 
Fluka IV.2.3. 
Highly sulfated β-cyclodextrin (HS-β-CD), 20% m/v 
aqueous solution 
Beckman Coulter IV.1.1. 
IV.1.2. 
IV.1.3. 
IV.2.1. 
IV.3.2. 
IV.3.3. 
General chemicals   
Acetic acid Scharlau IV.1.4. 
Ammonium acetate Scharlau IV.1.4. 
Boric acid Scharlau IV.3.1. 
Dimethyl sulfoxide (DMSO) Scharlau IV.1.4. 
Hydrochloric acid 37% Scharlau IV.2.2. 
IV.2.3. 
Magnesium sulfate heptahydrate Scharlau IV.3.1. 
Methanol Scharlau IV. -all- 
Potassium dihydrogen phosphate Panreac IV.2.2. 
IV.2.3. 
Potassium hydroxide, pellets Panreac IV.2.2. 
IV.2.3. 
Sodium dihydrogen phosphate dihydrate Fluka IV.1.1. 
IV.1.2. 
IV.1.3. 
IV.2.1. 
IV.3.1. 
IV.3.2. 
IV.3.3. 
Sodium hydroxide, pellets Scharlau IV. -all- 
Tris-(hydroxymethyl)-aminomethane (Tris) Scharlau IV.2.2. 
IV.2.3. 
*Kindly donated by the mentioned pharmaceutical laboratory. 
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Location of the suppliers: 
− Acros Organics (Geel, Belgium) 
− Alter (Madrid, Spain) 
− Astra Zeneca (Chesire, United Kingdom) 
− Aventis Pharma (Madrid, Spain) 
− BD Gentest (Erembodegem, Belgium) 
− Beckman Coulter (Fullerton, CA, USA) 
− Ciba Geigy (Barcelona, Spain) 
− Cyclolab (Budapest, Hungary) 
− Fluka (Buchs, Switzerland) 
− Guinama (Valencia, Spain) 
− ICI Farma (Madrid, Spain) 
− Italfarmaco (Madrid, Spain) 
− Miquel-Otsuka (Barcelona, Spain) 
− Novartis (Nyon, Switzerland) 
− Panreac (Barcelona, Spain) 
− Rhone-Poulenc (Madrid, Spain) 
− Scharlau (Barcelona, Spain) 
− Sigma (St. Louis, MO, USA) 
− Squibb (Barcelona, Spain) 
− VUB: Vrije Universiteit Brussel (Brussels, Belgium) 
− Zeneca Farma (Madrid, Spain) 
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III.3. Experimental procedures 
III.3.1. Capillary conditioning 
The activation of new capillaries was a standard procedure applied in all cases. It 
consisted on 15 min rinse with 1 M NaOH at 60 ºC, followed by 10 min rinse with 
deionized water at 25 ºC and 10 min rinse with the corresponding BGE at working 
temperature. The pressure applied in all rinsing steps was 20 psi. 
In order to achieve repeatable results in CE different cleaning procedures have been 
employed in this Thesis depending on the application and the capillary length, but all 
of them comprised rinsing the capillary in four steps: (i) deionized water, (ii) NaOH, 
(iii) deionized water and (iv) BGE. 
When proteins were injected into the capillary (protein binding and metabolism 
studies), a 1 M NaOH solution was employed in order to prevent their adsorption to 
the capillary wall, which may result in high variability in migration times and peak 
shapes. For the rest of applications, the concentration of NaOH was 0.1 M. An extra 
rinse with MeOH was added to the NACE experiences before the BGE rinse. 
 
III.3.2. Procedure for the chiral separation of xenobiotics 
The chiral separations performed in this Thesis have been done by different 
modalities of EKC, using neutral or anionic cyclodextrins as chiral selectors and the 
partial or complete filling techniques, where the separation BGE vials remain free of 
chiral selector. In those cases the capillary was (partially or completely) filled with a 
solution of the CD in the BGE, followed by hydrodynamic injection of the racemic 
xenobiotic. Only in the NACE application (section IV.1.4), the cyclodextrin had to be 
added also to the separation vials (conventional EKC mode), in order to enhance the 
interaction between the racemic drugs and the chiral selector, which is disfavored in 
organic media. Then, the separations have been performed in normal polarity by 
applying different voltages. In some cases, the separation was performed by 
applying both voltage and a little pressure, in order to shorten migration times and 
improve peaks shape. 
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Table III.2 summarizes the general experimental conditions employed in this Thesis 
for the chiral separation of xenobiotics. More details about each xenobiotic 
enantioseparation can be found in the corresponding studies in section IV. 
 
Table III.2: General conditions employed for the enantioseparation of xenobiotics. 
Chiral selector 
TM-β-CD (neutral), CM-β-CD, CM-γ-CD and HS-β-CD 
(anionic) 
BGE 
Tris or phosphate buffers, pH 6.0-8.8 (aqueous CE) 
DMSO/MeOH with NH4Ac and HAc (NACE) 
CD injection 
Variable pressure/time combinations for PFT. 10 
psi/1 min for CFT. 
Drug injection Hydrodynamic (0.5 psi/5s) 
Capillary temperature 15-45 ºC 
Separation voltage 15-30 kV (normal polarity) 
Separation pressure 0-0.4 psi 
Detection wavelength 200-220 nm (aqueous CE), 270 nm (NACE) 
 
 
III.3.3. Procedure for protein binding studies 
The evaluation of the enantioselective binding of xenobiotics to HSA and total 
plasma proteins has been performed by ultrafiltration. With this purpose, different 
mixtures containing the racemic xenobiotic and HSA or human sera in different 
concentration ranges have been prepared in microvials (total mixture volume: 500 
µL). 
Samples were incubated at 36.5 ºC in a thermostatized bath during 30 min, in order 
to reach the binding equilibrium, and then ultrafiltrated through cellulose 
membranes using commercial filtration devices in a thermostatized centrifuge at 
9000 rpm during 30 min. The ultrafiltrated fraction (unbound fraction of the drug) 
was directly injected in the CE system using for each xenobiotic its optimum 
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separation conditions. Figure III.1 shows a scheme of the procedure employed in 
this Thesis for protein binding studies. 
 
 
Figure III.1: UF-EKC procedure for the evaluation of enantioselective protein 
binding of drugs. 
 
The calculation of the concentration of drug in the unbound fraction was done by 
interpolating the experimental peak area in calibration curves previously obtained for 
each enantiomer. When some non-specific adsorption of the xenobiotic onto the 
filtration devices was observed, the calibration curves were prepared following the 
same experimental procedure in order to correct the effect of this non-specific 
adsorption. 
 
III.3.4. Procedure for electrophoretically mediated microanalysis 
The fundaments of EMMA have been widely discussed in the introduction of this 
Thesis. This technique consists on the use of the electrophoretic capillary 
simultaneously as a microreactor and as a separation column, so the mixture, 
incubation and separation can be performed in a unique, fully-automated step. As 
the enzymatic reaction takes part at a nanoscale, it is very important to adjust the 
incubation conditions in order to allow the reaction progress. 
Two enzymatic reactions have been evaluated in this Thesis by EMMA: the hydrolysis 
of acetylthiocholine by AChE in order to evaluate AChE inhibitors and the 
enantioselective metabolism of chiral substrates by different isoforms of the 
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cytochrome P450. A general procedure was followed with individual conditions 
adapted for each reaction. 
The selected modality was at-inlet EMMA, in which the substrates, enzymes and 
cofactors are successively injected in the inlet part of the capillary, mixed by simple 
diffusion, allowed to react during a given incubation time, and finally separated by 
CE. Table III.3 summarizes the experimental conditions employed for both 
enzymatic reactions, since the buffers, injection sequences, concentrations and 
incubation conditions may be individually selected. In the case of the evaluation of 
CYP metabolism, a chiral separation has been performed after the EMMA incubation, 
adapting separation conditions previously developed. 
 
Table III.3: Experimental conditions employed in the EMMA assays performed in 
this Thesis. 
 AChE CYP450 
Injection sequence 1) Water (2s) 
2) 0.4 mg·mL-1 AChE (5s) 
3) Substrate + inhibitor(5s) 
4) 0.4 mg·mL-1 AChE (5s) 
5) Water (2s) 
All steps at 50 mbar 
1) Incubation buffer (20s) 
2) CYP + Sol. B* (3s) 
3) Substrate + Sol. A* (7s) 
4) CYP + Sol. B* (3s) 
5) Incubation buffer (10s) 
All steps at 0.5 psi 
Incubation buffer 30 mM borate-phosphate, 
pH 8.0 
100 mM potassium 
phosphate, pH 7.4 
Incubation temperature 37 ºC 37 ºC 
Incubation time 2 min 5 min 
Background electrolyte 30 mM borate-phosphate, 
pH 8.0 
50 mM sodium phosphate, 
pH 8.8 
Separation voltage 15 kV 20 kV 
Separation temperature 37 ºC 25 ºC 
*Solutions A and B are the two parts of a NADPH regeneration system, that forms 
NADPH in situ. Their compositions are described in section III.2. NADPH is needed 
as a cofactor of the cytochrome P450 reaction, as stated in section I.1.1.3 (Eq. I.1). 
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III.4. Software and calculations 
Effective electrophoretic mobilities were calculated in all cases using the following 
expression: 
 =  ·  
1

 −
1

 
 (III.1) 
where L is the total capillary length, l is the length of the capillary from the inlet end 
to the detector, V is the applied voltage, and ti and t0 are the measured migration 
times of the analyte and EOF marker, respectively. 
Enantiomers resolution (Rs) was calculated as follows: 
 = 1.18 
 − 
 +  
 (III.2) 
where t1 and t2 are, respectively, the migration times of the first and second eluted 
enantiomers, and w1 and w2 are their peak widths at 50% of peak height. 
The following software has been used for data treatment and calculations: 
− Microsoft Excel®: for data collecting and statistics. 
− Statgraphics®: for fitting of non-linear models. 
− Matlab®: for estimations of binding and kinetic constants. 
− The Unscrambler®: for multivariate analysis. 
− Grapher®: for representing x,y data. 
− Accelrys Draw®: for drawing the chemical structures. 
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IV. RESULTS AND DISCUSSION 
The results obtained in this Thesis have been grouped into three main blocks. The 
first one has been devoted to chiral separations of xenobiotics by CE, and includes 
theoretical studies about the chiral separation, an application to the determination of 
enantiomers in pharmaceutical samples, and a chiral NACE study. The second block 
includes enantioselective protein binding studies, where the binding of drugs to HSA 
and total plasma proteins has been evaluated by ultrafiltration followed by EKC-PFT 
enantioseparation. Finally, enzymatic studies by EMMA have been included in the 
third section, where EMMA methodologies, coupled or not with a posterior in-line 
enantioseparation of the studied drugs, have been developed and proposed as fast 
screening methods for the evaluation of drugs behavior in enzymatic reactions. 
 
IV.1. Chiral separations of xenobiotics by capillary electrophoresis 
As stated in the Introduction of this Thesis, one important application of CE is the 
chiral separation of small molecules (drugs and other xenobiotics) using different 
chiral selectors. The most widely used chiral selectors are cyclodextrins, due to their 
excellent enantioseparation abilities. In this Thesis, the CD of choice for 
enantioseparations is in most of the cases the HS-β-CD, an anionic cyclodextrin with 
an average content of 12 sulfate groups per molecule (Figure IV.1). Its high density 
of negative charge makes it an excellent chiral selector for neutral and positively 
charged compounds, since it remains anionic at a broad pH range. 
 
 
Figure IV.1: Structure of the HS-β-CD. 
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However, it may be taken into account that this is not a single-isomer cyclodextrin, 
but a mixture mainly composed of 12-sulfated isomers with identical mobilities. This 
feature, that is usually advantageous for enantioseparations due to the sum of 
different separation equilibriums with each isomer, cannot be forgotten when 
mechanistic or modeling studies are performed. 
The free enantiomers (usually positively charged for basic drugs) form complexes 
with the anionic CD with overall negative charge, and these negative complexes 
have opposite electrophoretic mobility to that of the enantiomers themselves. The 
different affinity of the enantiomers for the CD is usually responsible for their 
separation (thermodynamic enantioselectivity). When the amount of CD in the 
capillary is increased, the equilibrium between the free and complexed forms (Figure 
IV.2) is shifted to the enantiomer-CD complex, thus decreasing the effective 
mobilities of the enantiomers (sum of the mobilities of the free and complexed forms 
and the EOF mobility, see Eq. I.2) and increasing the migration times. 
 
 
Figure IV.2: Schematic representation of the electrophoretic mobilities of the free 
enantiomers, the CD and their complexes, as well as the EOF mobility, in normal 
polarity. 
 
Several variables influence the enantioseparation of compounds using cyclodextrins 
as chiral selectors. Some of them affect the equilibrium between the free and 
complexed forms of the enantiomers and others affect electrophoretic parameters 
that result in a modification on the enantioseparation. The main effects of the 
experimental variables on the enantioseparation of neutral and basic xenobiotics 
with CDs are discussed below, and some of them are shown in Figure IV.3. 
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The selection of the adequate cyclodextrin is usually a trial-and-error screening 
procedure, and, if some interaction between a concrete CD and the enantiomers is 
noticed, the study goes further into other experimental variables. It can be taken 
into account for the CD selection that charged CDs usually have stronger interaction 
with both neutral and charged compounds due to electrostatic forces that take part 
in the complexation equilibrium. 
The cyclodextrin concentration and, in partial filling technique, the selector plug 
length, are both highly influential variables related to the amount of CD in the 
capillary. As explained above, an increase on the amount of CD in the capillary 
(higher concentration or longer SPL) favors the enantiomer-CD complexation and 
usually improves the enantioseparation (Figure IV.3a). With anionic CDs, the most 
usually employed in this Thesis, longer migration times are obtained due to the 
decrease of the enantiomers’ effective mobility, so the CD concentration may be 
high enough to achieve complete enantioresolution but as low as possible to not 
increase the analysis time and also the analysis cost. 
The pH of the BGE is also a very influential variable on the enantioseparation. It 
affects the magnitude of the EOF, so it influences considerably the effective 
mobilities of both the enantiomers and the CD. Working in normal polarity at pHs 
equal or higher than 6 usually allows that the enantiomer-CD complexes, negatively 
charged in most of the cases, reach the detector due to the EOF mobility (Figure 
IV.3b). On the other hand, the pH of the BGE affects not only the EOF but also the 
charge of the CD and enantiomers. The ideal situation for enhancing the interaction 
is that they have opposite charge, so the pH of the BGE can be adjusted with this 
purpose. The selection of the buffers that compose the BGE will be thus influenced 
by the working pH, since there may be selected a buffer whose pKa is nearly the 
desired pH. It can be taken into account that higher buffer concentrations will 
diminish the electrophoretic and electroosmotic mobilities and will enlarge migration 
times, which can also affect the enantioresolution. 
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(a) (b)  
  
(c)  (d)  
 
Figure IV.3: Overview of the effects of experimental variables on enantioseparation 
using CDs as chiral selectors. (a) Effect of the SPL on the separation of zopiclone 
enantiomers (BGE: 50 mM Tris at pH 6.0; 25 ºC, 15 kV, chiral selector: 30 mM CM-
β-CD, injected at 0.5 psi for different times). (b) Effect of the pH on the separation 
of fluoxetine enantiomers (BGE: 30 mM phosphate, 25 ºC, 15 kV, chiral selector: 
0.25% HS-β-CD injected at 5 psi/1min). (c) Effect of the temperature on the 
enantioseparation of nomifensine (BGE: 50 mM Tris at pH 6.0; 15 kV, chiral selector: 
30 mM TM-β-CD injected at 10 psi/1 min). (d) Effect of the temperature on the 
separation of viloxazine enantiomers (BGE: 30 mM phosphate at pH 7.0; 25 ºC, 15 
kV, chiral selector: 1% HS-β-CD injected at 5 psi/1 min). 
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Temperature has a big influence on the enantiomers mobility (Figures IV.3c and d). 
Higher temperatures decrease the BGE viscosity, thus increasing the velocity of the 
EOF and decreasing all the migration times. As a consequence of the faster 
migration, usually Rs values are lower at high temperatures because the two peaks 
are closer (Figure IV.3d). Also, temperature affects the equilibrium of the 
enantiomer-CD complexation, so it can strongly affect the enantioseparation. This 
effect, related to the specific complexation equilibrium, will vary between molecules 
and should be checked individually. 
Finally, the voltage applied for the separations affects the migration times and also 
the peaks efficiency. Higher voltages will decrease the migration times, so the 
enantiomers will be closer. However, if they gain in efficiency the Rs can improve. 
This will depend on the individual situation. 
In this Thesis, the enantioseparation of several neutral and basic xenobiotics has 
been performed using different neutral and anionic cyclodextrins as chiral selectors. 
The effects explained above have been taking into account in order to achieve good 
resolution of the enantiomers. Table IV.1 summarizes the selected experimental 
conditions for the enantioseparation of compounds in each case and the Rs values 
obtained. 
 
Table IV.1: Overview of all the enantioseparations performed in this Thesis. 
Compound Chiral selector BGE T (ºC) V (kV) Rs 
Benalaxyl 0.5% HS-β-CD 50 mM NaH2PO4, pH 7 40 15 4.1 
Brompheniramine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 1.4 
Bupivacaine 1.5% HS-β-CD 50 mM NaH2PO4, pH 7 15 15 1.6 
Bupropion 1% HS-β-CD 30 mM NaH2PO4, pH 7 25 15 6.1 
Carbinoxamine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 14.5 
Chlorcyclizine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 3.1 
Chlorpheniramine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 8.1 
Clemastine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 1.5 
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Table IV.1: (Continued) 
Compound Chiral selector BGE T (ºC) V (kV) Rs 
Dimethindene 1% HS-β-CD 30 mM NaH2PO4, pH 7 35 15 10.2 
Doxylamine 1% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 5.5 
Ethopropazine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 5.7 
Fenfluramine 40 mM CM-γ-CD 125 mM NH4Ac, 0.5 M 
HAc in DMSO 
15 30 1.2 
Fluoxetine 0.1% HS-β-CD 30 mM NaH2PO4, pH 7 35 15 9.2 
Hexaconazole 2% HS-β-CD 50 mM NaH2PO4, pH 7 40 15 1.7 
Hydroxyzine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 3.0 
Imazalil 0.5% HS-β-CD 50 mM NaH2PO4, pH 7 40 15 3.7 
Mepivacaine 1.5% HS-β-CD 50 mM NaH2PO4, pH 7 15 15 2.8 
Nomifensine 0.1% HS-β-CD 30 mM NaH2PO4, pH 7 35 15 29.4 
 30 mM TM-β-CD 50 mM Tris, pH 6 50 15 1.7 
Norfluoxetine 1.25% HS-β-CD 50 mM NaH2PO4, pH 8.8 25 20 _
a 
Norverapamil 2.5% HS-β-CD 50 mM NaH2PO4, pH 8.8 25 20 _
a 
Orphenadrine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 35 15 5.8 
Oxprenolol 1% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 3.0 
Penconazole 2% HS-β-CD 50 mM NaH2PO4, pH 7 25 15 2.1 
Phenindamine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 22.3 
Pindolol 1% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 2.5 
 40 mM CM-γ-CD 125 mM NH4Ac, 0.5 M 
HAc in DMSO/MeOH 
70:30 
15 30 2.0 
Prilocaine 1% HS-β-CD 50 mM NaH2PO4, pH 6 35 15 3.5 
Promethazine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 15 15 3.2 
Propanocaine 0.4% HS-β-CD 50 mM NaH2PO4, pH 6 25 15 4.1 
Sotalol 1% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 2.6 
Trimeprazine 0.25% HS-β-CD 50 mM NaH2PO4, pH 7 25 20 1.9 
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Table IV.1: (Continued) 
Compound Chiral selector BGE T (ºC) V (kV) Rs 
Verapamil 2.5% HS-β-CD 50 mM NaH2PO4, pH 8.8 25 20 _
a 
 40 mM CM-γ-CD 125 mM NH4Ac, 1 M 
HAc in DMSO/MeOH 
80:20 
15 30 1.5 
Viloxazine 1% HS-β-CD 30 mM NaH2PO4, pH 7 15 15 3.0 
Zopiclone 30 mM CM-β-CD 50 mM Tris, pH 6 25 15 2.1 
aIn the separation of drugs and metabolites together, Rs between enantiomers was 
not calculated because drug and metabolite enantiomers were interspersed. 
However, there was complete resolution of the four peaks in all cases. 
 
Four studies have been included in this section, covering different topics related to 
chiral separations by CE. The first and second ones are theoretical studies about the 
use of HS-β-CD as chiral selector, concerning the binding mechanisms responsible 
for the enantioseparation and a quantitative structure-property relationship (QSPR) 
model to predict the ability of this CD to separate the enantiomers of new 
compounds in certain conditions. The third study is an application of the 
enantioseparation to the chiral analysis of commercial pharmaceutical formulations 
of the antidepressant fluoxetine. The last one is an approach to the use of a non-
common solvent (DMSO) for NACE enantioseparations. 
 
IV.1.1. Characterizing the interaction between enantiomers of eight 
psychoactive drugs and highly sulfated-β-cyclodextrin by counter-current 
capillary electrophoresis (Paper I) 
In this work, apparent binding constants have been calculated for the interaction 
between HS-β-CD and the enantiomers of eight psychoactive drugs. The calculation 
of these binding constants provides information about the affinity of the CD for 
these types of compounds and can help to better understand the mechanisms 
responsible for the enantioseparation. 
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The most common situation when binding studies are performed is to carry out the 
chiral separation in conventional EKC, including the CD in the BGE and filling the 
capillary and the separation vials with it. In this case, the mathematical models 
described in section I.3.2.3 of this Thesis, developed by Wren and Rowe in 1992 
(Wren and Rowe, 1992), are adequate for the estimation of binding constants. In 
PFT (Amini et al., 1999a; Amini et al., 1999b) apparent binding constants have been 
evaluated by varying the plug length of the chiral selector and studying the effect of 
the selector plug length on the enantiomers mobility. These models are more 
complex and require the estimation of the capillary fraction filled with the selector, 
since the mobility of the enantiomers is a sum of their mobility in the separation 
zone and their mobility in the rest of the capillary (filled only with BGE). 
In this Thesis we have performed the binding studies using CFT, which allows saving 
a considerable amount of CD with respect to the conventional EKC but does not 
have the complicated mathematic treatment described for the estimation of binding 
constants by PFT in the case of the enantiomers do not leave the CD zone during 
their migration to the detector, since all the enantiomers migration takes part in the 
separation zone. 
By estimation of the EOF mobility (3.88-5.99·10-8 m2·V-1·s-1) at working conditions 
(30 mM phosphate buffer, pH 7.0, 15 kV and normal polarity), and comparing it with 
the CD electrophoretic mobility (-3.33·10-8 m2·V-1·s-1, published by Chen and 
coworkers (Chen et al., 2001)), we have concluded that the EOF will slowly push the 
CD to the detector. Also, as the studied compounds are basic (pKa values between 
8.1 and 9.7) and thus positively charged at the working pH, they migrate faster than 
the CD and do not leave the CD zone during the electrophoretic development (see 
Figure IV.2 for a schematic view of all the electrophoretic mobilities). So, the data 
treatment can be the same as in EKC and the considerations applied to PFT over the 
migration of the enantiomers in two different capillary zones, with and without chiral 
selector, are not necessary. 
Another consideration that should be taken into account is the fact, previously 
commented, that the HS-β-CD is a mixture of 12-sulfated isomers, and individual 
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equilibriums with each isomer will take place. The mathematical model for multi-CD 
systems (Dubský et al., 2010) proving that the mixture behaves like a single CD is 
similar to that described by Wren and Rowe: 
 = 
 + 	[]
1 + 	[]  
 (IV.1) 
where [CD] is the total HS-β-CD concentration and K’i and µiCD are the overall 
apparent binding constants and the overall limit mobilities, respectively, defined as: 
	 =


  (IV.2) 
 = ∑ 

	  
 (IV.3) 
where χq is the molar fraction of the qth selector isomer in the mixture, Kiq is the 
individual apparent complexation constant with the ith enantiomer (i = 1 or 2) and 
qth isomer of CD, and µiq is the individual mobility of the ith enantiomer-qth CD 
complex. 
In order to estimate K’ and µCD values, the effective mobility of the enantiomers, 
obtained using eight CD concentrations between 0 and 2%, was fitted to the CD 
concentration using the non-linear model of Eq. IV.1. Three capillary temperatures 
(15, 25 and 35 ºC) have been used and a fitted model was obtained for each 
capillary temperature. The models obtained at 35 ºC for the eight drugs studied 
(bupropion (BUP), dimethindene (DIM), fluoxetine (FLX), nomifensine (NMF), 
orphenadrine (ORP), promethazine (PRO), terfenadine (TER) and viloxazine (VLX)) 
can be seen in Figure IV.4, and the corresponding estimated values in Table IV.2. 
Similar relationships were obtained at 15 and 25 ºC (see Paper I). In all cases, the 
fitted models showed good determination coefficients (R2 > 0.99). 
 
 
 
Results and discussion 
 
84 
 
(a) 
 
(b) 
 
(c) 
 
 
(d) 
 
 
(e) 
 
(f) 
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Figure IV.4: Non-linear models for the enantioselective binding constants at 35 ºC 
of the eight drugs studied: (a) BUP, (b) DIM, (c) FLX, (d) NMF, (e) ORP, (f) PRO, (g) 
TER and (h) VLX (E1,, solid line; E2, , dashed line). 
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Table IV.2: Interaction parameters for the enantiomers of the eight studied chiral 
drugs at 35 ºC. 
Drug K1 (M
-1) K2 (M
-1) αt 
µ1CD·108 
(m2·V-1·s-1) 
µ2CD·108 
(m2·V-1·s-1) 
αe 
BUP 620 ± 70 710 ± 70 1.2 -3.9 ± 0.3 -4.1 ± 0.2 1.1 
DIM 460 ± 50 660 ± 100 1.2 -4.1 ± 0.3 -4.5 ± 0.4 1.1 
FLX 4500 ± 1200 16000 ± 4000 3.6 -4.5 ± 0.4 -4.1 ± 0.2 0.9 
NMF 1470 ± 110 10700 ± 600 7.3 -4.74 ± 0.16 -5.06 ± 0.08 1.1 
ORP 2900 ± 200 4930 ± 90 1.7 -4.74 ± 0.17 -4.43 ± 0.04 0.9 
PRO 2000 ± 200 2100 ± 200 1.1 -4.3 ± 0.2 -4.3 ± 0.2 1.0 
TER 17700 ± 600 18800 ± 300 1.1 -4.69 ± 0.02 -4.68 ± 0.02 1.0 
VLX 310 ± 40 310 ± 40 1.0 -1.7 ± 0.2 -2.1 ± 0.2 1.2 
 
As can be seen in Table IV.2, the highest binding constants were obtained for 
terfenadine, but with very low enantioselectivity values. The large size of this 
molecule may prevent its inclusion in the CD cavity, where the enantiorecognition 
occurs, also explaining its low Rs (< 1.5) in all cases. On the other hand, also high 
binding constants were obtained for fluoxetine and nomifensine, in this case with 
high thermodynamic enantioselectivities. Rs values for both drugs were also high 
(between 5.1 and 11.1 for FLX, and between 11.6 and 34.1 for NMF). High Rs values 
(Rs >> 1.5) were found in all cases except terfenadine. The K’ values obtained here 
were similar or higher than those found in the literature for this CD (Vaccher et al., 
2005, Lipka et al., 2007), suggesting that it interacts strongly with the studied 
compounds. 
Two possible mechanisms can be responsible for the enantioseparation: one related 
to the differences between the apparent binding constants of the enantiomers 
(thermodynamic enantioselectivity, αt = K’2/K’1), and other to the differences on 
their overall limit mobilities (electrophoretic enantioselectivity, αe = µ2CD/µ1CD). A 
quantitative relationship between these enantioselectivities (not previously reported 
in the literature) is described here by means of Eq. IV.4: 
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We have also estimated both enantioselectivities and we can conclude that the 
mechanism mainly responsible for these enantioseparations is the thermodynamic 
one, with values far from 1 in most of the cases, and specially high for nomifensine 
and fluoxetine (see Table IV.2). The electrophoretic selectivity, despite having less 
influence in most of the drugs, is the responsible for the enantioseparation of 
viloxazine, showing that when no (or little) thermodynamic enantioselectivity exists 
chiral separation is also possible. In conclusion, the enantioseparation of these basic 
drugs with HS-β-CD in EKC-CFT responds to a mixed mechanism in which 
thermodynamic enantioselectivity plays the major role but electrophoretic 
enantioselectivity has also a certain contribution. 
As the binding constants and enantioselectivities were evaluated at three different 
temperatures, we can also see the effect of temperature on them. As a general 
trend, K’ values decreased with higher temperatures. For example, for the first 
enantiomer of bupropion K’ were 670, 630 and 620 M-1 with 15, 25 and 35ºC, while 
for its second enantiomer they were 790, 740 and 710 M-1, respectively. On the 
other hand, enantioselectivity values αt and αe practically did not change with 
temperature, except for nomifensine and fluoxetine. For these compounds, the 
quantitative relationship expected from Eq. IV.4 can be observed: αt (as Rs) 
increases with temperature while αe shows the opposite trend. 
From the overall apparent binding constants and limit mobilities, the optimum [CD] 
for each enantioseparation, defined as the [CD] that provides the highest mobility 
difference between enantiomers, can be estimated using the following equation 
(Dubský et al., 2010): 
[] = −
∆ ± ∆ − 1⨅ ∆ ∆ !
∆ !  
 (IV.5) 
where ∆µ = µ2r,CD – µ1r,CD (where µir,CD = µiCD – µi0), ∆µK = µ2r,CDK’2 – µ1r,CDK’1, ∆~µK =  
µ2r,CDK’1 – µ1r,CDK’2, and Kpi = K’1K’2. 
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In the cases where the thermodynamic mechanism is responsible for separation and 
considering the limit mobilities of two enantiomers identical (µ1CD = µ2CD), Eq. IV.5 
can be simplified to: 
[] = 1"	 · 	
  (IV.6) 
Both estimations have been done in this work, and the optimum CD concentrations 
obtained at 35 ºC for the eight studied drugs are shown in Table IV.3. The same 
study for 15 and 25 ºC can be found in Paper I. 
 
Table IV.3: Optimum CD concentrations estimated for the enantioseparation of 
eight psychoactive drugs at 35 ºC via two different equations. 
Drug 
[CD]opt (m/v)  
Eq. IV.5 Eq. IV.6 
BUP 0.59 0.36 
DIM 0.62 0.43 
FLX 0.02 0.03 
NMF 0.06 0.06 
ORP 0.05 0.06 
PRO 0.12 0.12 
TER 0.01 0.01 
VLX – 0.76 
 
In general, values obtained with both equations are relatively similar, confirming the 
major contribution of thermodynamic enantioselectivity to the enantioseparation. 
More differences between both values were found for the compounds that interact 
weakly with the CD (BUP, DIM and VLX). For viloxazine no estimation was possible 
using Eq. IV.5, suggesting that no optimum concentration exists and confirming that 
in this case electrophoretic enantioselectivity is responsible for the 
enantioseparation. 
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IV.1.2. Modeling the chiral resolution ability of highly sulfated β-
cyclodextrin for basic compounds in electrokinetic chromatography (Paper 
II) 
The development of methods for enantioseparation of chiral xenobiotics usually 
implies expensive and time-consuming trial-and-error procedures. However, 
interesting information for future researchers could be whether chiral compounds 
will be suitable for being enantioseparated with a concrete chiral selector. In this 
work, we have modeled the enantioresolution ability of the HS-β-CD, which has 
proved to be a good chiral selector for basic compounds, in order to establish a 
relationship between structural properties of new candidate compounds and their 
theoretical enantioseparation with HS-β-CD. 
With this purpose, a simple QSPR model has been performed, based on easily 
available structural properties of forty selected compounds (34 drugs and 6 
pesticides, see Table IV.4), and their enantioresolution under relatively similar EKC-
CFT conditions with HS-β-CD (BGEs 30 or 50 mM phosphate buffers, with pH values 
between 7.0 and 8.8; CD concentrations between 0.25 and 2% (m/v), voltages of 
15-20 kV and capillary temperatures between 25 and 40 ºC). Rs data were obtained 
experimentally for this model using an EKC-CFT screening procedure or taken from 
some previously published papers of our research group. In that screening, the 
experimental conditions were as follows: BGE, 50 mM phosphate buffer, pH 7.0; 
capillary temperature 25 ºC, voltage 20 kV and 1% HS-β-CD injected at 10 psi/1 min 
(filled capillary). For those cases that showed a strong interaction with the CD, no 
peaks were seen with the 1% HS-β-CD, so the injection was repeated using a 0.25% 
HS-β-CD solution. 
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Table IV.4: Compounds included in the QSPR model performed, numbered as they 
appear in the model. Their categorical Rs values, as well as the values of the four 
variables selected in the final model (lgD, PSA, HBD and HBA), are also included. 
Name Number Rs lgD PSA HBD HBA 
Brompheniramine 1 2 1.3 16.1 0 2 
Carbinoxamine 2 2 1.4 25.4 0 3 
Clemastine 3 2 2.7 12.5 0 2 
Chlorcyclizine 4 2 2.9 6.5 0 2 
Chlorpheniramine 5 2 1.0 16.1 0 2 
Dimetindene 6 2 1.7 16.1 0 2 
Doxylamine 7 2 1.1 25.4 0 3 
Hydroxyzine 8 2 2.3 35.9 1 4 
Orphenadrine 9 2 2.0 12.5 0 2 
Phenindamine 10 2 2.7 3.2 0 1 
Terfenadine 11 0 3.6 43.7 2 3 
Methotrimeprazine 12 0 3.0 41.0 0 3 
Ethopropazine 13 2 3.6 31.8 0 2 
Promethazine 14 2 3.4 31.8 0 2 
Trimeprazine 15 2 3.1 31.8 0 2 
Acebutolol 16 0 -0.3 87.7 3 6 
Atenolol 17 0 -1.8 84.6 4 5 
Carteolol 18 0 -0.7 70.6 3 5 
Timolol 19 0 -0.6 107.9 2 7 
Metoprolol 20 1 -0.5 50.7 2 4 
Propranolol 21 1 0.8 41.5 2 3 
Pindolol 22 2 -0.5 57.3 3 4 
Oxprenolol 23 2 0.1 50.7 2 4 
Sotalol 24 2 -1.7 86.8 3 5 
Nomifensine 25 2 0.3 29.3 2 2 
Bupropion 26 2 2.1 29.1 1 4 
Viloxazine 27 2 0.1 39.7 1 4 
Fluoxetine 28 2 1.4 21.3 1 2 
Imazalil 29 2 3.5 27.1 0 3 
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Table IV.4: (Continued) 
Name Number Rs lgD PSA HBD HBA 
Benalaxyl 30 2 3.3 46.6 0 4 
Hexaconazole 31 2 3.9 50.9 1 4 
Penconazole 32 2 4.6 76.4 0 3 
Cyproconazole 33 1 2.8 50.9 1 4 
Myclobutanil 34 1 3.1 54.5 0 4 
Catechin 35 2 0.6 110.4 5 6 
Verapamil 36 2 2.5 64.0 0 6 
Prilocaine 37 2 1.6 41.1 2 3 
Mepivacaine 38 2 1.3 32.3 1 3 
Bupivacaine 39 - 2.9 32.3 1 3 
Propanocaine 40 2 2.3 29.5 0 3 
 
Due to the partially different conditions of the Rs data, we decided to treat them not 
as quantitative but as categorical (Rs = 0 for non-resolved enantiomers; Rs = 1 for 
partial resolution and Rs = 2 for completely resolved enantiomers). 15 structural 
variables, taken from the ChemSpider chemical structure database (ChemSpider, 
2013), were used as X-matrix: x1: logarithm of octanol–water partition coefficient 
(lgP), x2: lgP estimated at pH 7.4 (lgD), x3: polar surface area (PSA), x4 and x5: 
hydrogen bond donors (HBD) and acceptors (HBA), x6: polarizability (POL), x7: 
molar refractivity (MR), x8: molar volume (MV), x9: molecular surface area (MSA), 
x10: van der Waals Volume (VW), x11: dreiding energy (DE), x12: orbital 
electronegativity of the chiral carbon atom (OEC), x13: molecular mass (MM), x14: 
maximal projection area (MA) and x15: rotatable bonds (RB). The model was 
performed using the Unscrambler® software and a simple decision-making strategy. 
A principal component analysis (PCA) was initially performed on the structure 
parameters (X-matrix), in order to detect highly influential compounds that could be 
eliminated from the further regression model. Leave-one-out cross-validation was 
used as validation strategy. Instead of ks (suggested by the software) a manual 
selection of the optimum number of principal components (PCs) (ko) was performed. 
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It was set to 2, coinciding with the first local maximum explained X-variance in 
cross-validation (EVCV), 60.7%. The corresponding explained variance (EV) was 
72.6%. 
 
(a) 
 
(b) 
 
Figure IV.5: PCA (a) influence and (b) X-loadings plots corresponding to the 2-PC 
model performed. 
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Figure IV.5 shows the influence and loading plots for the 2-PC model. The influence 
plot (residual X-variance vs. leverage) is used to detect atypical data, potential 
outliers of the model. As can be seen, a compact group with low-leverage and low-
residual is observed, and compounds 36 and 11 appear as highly influential on the 
latent structure (high-leverage high-residual). Other less influential compounds are 
33 (high-residual) and 32, 35 and 39 with medium-residual values. All these atypical 
compounds present a non-similar structural parameters profile and should be taken 
into account in the model development. 
The loadings plot shows the distribution of variables over the 2 PCs. It can be seen 
in this plot that variables 6, 7, 8, 9, 10, 11, 13 and 14 are highly correlated, all 
forming low angles respect to the PC1 axis, which indicates that these variables 
provide redundant information. 
A discriminant-partial least squares analysis over a single response variable (DPLS1) 
was performed, using the categorical Rs (y-vector) and the structure data (X-
matrix). 39 compounds were used as calibration set, excluding bupivacaine that was 
subsequently predicted once an optimum model was obtained. 
A sequential model simplification was carried out, both eliminating outlier 
compounds and non-significant variables. The objectives for the selected model 
were: 
− An ideal number (ki) of latent variables (LV); in this case ki = 1, since there 
is a single response variable (Rs). 
− A predictive power (Pp) equal or higher than 55%. 
− All variables being significant (scaled regression coefficients, b ± U(b), not 
crossing the “0” axis). 
Four plots of the DPLS1 analysis were chosen to help in the decision-making process 
(Figure IV.6): (a) Scaled b-coefficients of X-variables, plus their uncertainty limits, b 
± U(b), for model stability evaluation. (b) Bi-plot of LV2 vs. LV1, showing both scores 
(compounds) and loadings (variables), thus their relative “correlation”. (c) EV and 
EVCV bars for global model performance. (d) Validation plot, showing predicted vs. 
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measured y-values (both calibration and crossvalidation ones; y and yCV data, 
respectively, for each compound). 
 
(a) (b) 
  
(c) (d) 
  
Figure IV.6: Plots corresponding to one of the simplification steps of the DPLS1 
model performed. (a) Scaled b-coefficients of X-variables, plus their uncertainty 
limits, b ± U(b). (b) Bi-plot of LV2 vs. LV1, showing both scores (compounds) and 
loadings (variables). (c) EV and EVCV bars for global model performance. (d) 
Validation plot, showing predicted vs. measured y-values. 
 
In successive steps, the model was simplified by applying two rules: the elimination 
of outlier compounds that were badly predicted, and the elimination of non-
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significant variables (removing up to 3 variables if the predictive power of the model 
was less than 55%, or selecting only the significant variables if the Pp was adequate 
and ki = 1). 
For example, in the scaled b-coefficients plot of Fig. IV.6, it can be seen that only 4 
variables are significant: lgD (x2), PSA (x3), HBD (x4) and HBA (x5). So, in this 
simplification step all the others were eliminated. It can be seen also in the 
validation plot that the model discriminates between the Rs = 0 and the Rs > 0 
groups, which is an indication of the usefulness of the model. The plots 
corresponding to the final model, obtained after 7 simplification steps, are shown in 
Figure IV.7, which fits all the above mentioned objectives: ki = 1, EV = 72.4%, Pp = 
67.2% and all variables significant. 
 
 
Figure IV.7: Plots corresponding to the final DPLS1 model performed. 
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De-scaled regression coefficients (b) were obtained from this DPLS1 model to derive 
a practical explicit model, which allows simply predicting a categorical Rs with the 
HS-β-CD from 4 structural properties: 
Rs = 2.354 + 0.095lgD – 0.008PSA – 0.159HBD – 0.137HBA 
This model was used to predict Rs for bupivacaine, obtaining a categorical value of 
1.8. This 1 < Rs < 2 value suggests that enantioresolution is possible, but probably 
under specific experimental conditions. So, we propose the use of a pre-optimized 
experimental design (Box-Behnken) for a multivariate optimization of the three most 
influential EKC variables on the chiral separation (CD concentration, pH of the BGE 
and temperature). The Box-Behnken design for three experimental factors includes 
15 experiments with three levels for each experimental factor (in this work, [HS-β-
CD] 0.5-1.5%, pH 6.0-8.0 and temperature 15-35 ºC) and three replicates of the 
central point. 
A PLS2 model was performed using the experimental variables (CD concentration, 
pH of the BGE and temperature) as X-matrix and two response variables: Rs and tE2 
(migration time of the second eluted enantiomer, to control the analysis time). As 
before, explicit equations for the estimation of Rs and tE2 were obtained from the de-
scaled coefficients: 
Rs = 3.497 + 0.269CD – 0.034T – 0.268pH 
tE2 = 14.05 + 1.96CD – 0.247T – 0.149pH 
As expected, CD is positively correlated with both response variables, while pH and T 
are negatively correlated. These effects can be easily explained from an 
electrophoretic point of view taking into account the separation mechanism, which 
implies the formation of anionic inclusion complexes with the cyclodextrin. Higher CD 
concentrations lead to longer migration times, because the equilibrium of the free-
complexed drug is shifted to the complexed form (see Fig. IV.2); a higher Rs is 
reasonable because the complexed form is who migrates enantioselectively. For the 
increase of T, shorter migration times are logical for both enantiomers due to the 
decrease of viscosity of the BGE and the consequent increase of current. Therefore, 
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if both enantiomers migrate faster, less Rs is coherent. The same effect is observed 
with the pH, since higher pH implies higher EOF mobility, accelerating the migration 
of both enantiomers and decreasing the Rs value. 
With these equations, simulated Rs and tE2 data could be generated in order to 
select the optimum experimental conditions (Rs around 2 with a short analysis time). 
In this work, simulations were performed for predicting the enantioresolution of 
bupivacaine: different values were given to the variables CD, T and pH, and Rs and 
tE2 were estimated from the explicit equations previously obtained. As an example, 
for CD = 2% (m/v), T = 15 ºC and pH = 6, Rs is estimated as 1.92 and tE2 as 13.4 
min, which is a good combination to be verified experimentally. So, these conditions 
could be selected to attempt the enantioseparation of bupivacaine. 
 
IV.1.3. Determination of fluoxetine enantiomers in pharmaceutical 
formulations by electrokinetic chromatography-counter current technique 
(Paper III) 
Fluoxetine is a selective serotonin-reuptake inhibitor, widely employed around the 
world as an antidepressant, but also indicated for other psychiatric disorders such as 
obsessive compulsive disorder or bulimia nervosa. Despite it is used as a racemate, 
stereospecificity associated with its interactions with the serotonin-reuptake carrier 
has been described. Methods for its chiral analysis become thus important for the 
pharmaceutical industry. In this work, an enantioselective method for the analysis of 
fluoxetine enantiomers in pharmaceuticals by EKC-counter current technique using 
HS-β-CD as chiral selector has been developed. It was optimized for a matrix 
including an interfering compound and applied to the analysis of three 
pharmaceutical formulations. Two of the samples were fluoxetine pills (Fluoxetina 
Teva® and Fluoxetina Mabo®) and the third one (Prozac®) was presented in tablets. 
The procedure for the analysis of samples is schematically shown in Figure IV.8. 
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Figure IV.8: Scheme of the experimental procedure used for the chiral analysis of 
fluoxetine in pharmaceutical formulations by EKC-CFT. 
 
In preliminary studies, the following EKC-CFT conditions (previously developed by 
our research group) were tested here for the pharmaceutical samples: effective 
capillary length: 21 cm; BGE: 30 mM phosphate buffer, pH 7.0; 0.25% HS-β-CD 
injected at 2 psi/1 min; capillary temperature 30 ºC and separation voltage 15 kV 
(with a little pressure of 0.3 psi in order to improve peak shapes). Using these 
conditions, which allow the chiral separation of fluoxetine with HS-β-CD in less than 
4 minutes, an interference peak overlapped with the first enantiomer in Prozac® 
samples (Figure IV.9a). 
Modifications in separation conditions were tested to improve the separation and 
efficiency of the electrophoretic peaks, trying to avoid this interference. For this 
purpose, voltages ranged between 5 and 25 kV were assayed using as BGE a 30 mM 
phosphate solution at pH 7.0, 7.5 and 8.0, and in all experiences 0.25% HS-β-CD. 
As expected, an increased voltage yielded shorter migration times and higher 
efficiencies and resolution. However, the generation of Joule heat may limit the 
theoretical gain in resolution and efficiency with voltage. For fluoxetine, migration 
times of both enantiomers became shorter at higher voltages while resolution 
slightly decreased, being Rs > 1.8 in all cases. An increased voltage had also a good 
effect on the enantioseparation between the first eluted enantiomer and the 
interference peak, so 25 kV was selected as the separation voltage. On the other 
hand, the increase on pH values had no significant influence on migration times, but 
improved the resolution and in most cases the efficiency. Moreover, the application 
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of a pressure of 0.3 psi to the inlet vial during the electrophoretic processes led to 
higher efficiency, with an improvement in peak shapes. 
 
 
Figure IV.9: Electropherograms corresponding to the enantioseparation of 
fluoxetine in Prozac® samples (a) before and (b) after the optimization of the 
separation conditions. 
 
From the results obtained, an applied voltage of 25 kV, a pressure of 0.3 psi and a 
30 mM phosphate solution at pH 8.0 as BGE were selected. Using these conditions, 
complete enantioseparation of fluoxetine (Rs = 2.4) was achieved in less than 2 min 
(see Figure IV.9b). These separation conditions were adequate also for the analysis 
of the other pharmaceutical formulations (Fluoxetina Teva® and Fluoxetina Mabo®). 
Once the separation conditions were selected, a partial validation of the method was 
performed, taking into account the features recommended by the International 
Conference on Harmonization (ICH) for analytical methods, and the requirements of 
the US Pharmacopeia. For the quantification of the analyte in the major-minor 
concentration level (this case), the ICH recommends to study the following features 
in a partial validation: confirmation of analyte identity (specificity), accuracy (or 
1.0 2.0 3.0 4.0
Time (min)
(a)
(b)
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recovery), precision (preferable in intermediate precision conditions) and linearity (in 
the practical range; the full linear range is not mandatory). Here, the confirmation of 
analyte identity was performed by recording the spectra along peak elution. The 
accuracy, precision and linearity results are shown in Table IV.5. As can be seen in 
this table, good analytical features were obtained, following the criteria of the 
Spanish accreditation entity, ENAC, for linearity (R2 > 0.995 for chromatographic and 
related techniques), and the requirements of the US Pharmacopeia for recovery (85-
115%). For all samples, analyzed with only a single replicate, which is the most 
common situation in testing laboratories, the content of racemic fluoxetine was 
within specifications of the US Pharmacopeia (± 15% criterion), and stereoisomer 
ratios were around 1 (Table IV.6). 
 
Table IV.5: Main analytical features of the proposed chiral method. 
Features Fluoxetine-E1 Fluoxetine-E2 
Linearity   
Linear range 5-50 mg·L-1 5-50 mg·L-1 
Linear equation 
(determination coefficient, R2) 
y = 112.83 + 54.44x 
(0.996) 
y = 97.12 + 49.27x 
(0.996) 
Precision (n = 3)   
Sample result 11.8 ± 1.7 mg 11.1 ± 1.9 mg 
Intermediate precision (RSD) 14.8% 17.3% 
Accuracy (fortification assay)   
Intermediate recovery 92 ± 13 105 ± 6 
 
Table IV.6: Results of the sample analysis of three pharmaceutical formulations 
containing racemic fluoxetine (labeled content: 20 mg). 
Pharmaceutical 
Rac-
Fluoxetine 
Fluoxetine-
E1 
Fluoxetine-
E2 
Stereoisomer 
ratio (E1/E2) 
Fluoxetina Mabo® 21.0 mg 10.6 mg 10.4 mg 1.02 
Prozac® 20.1 mg 9.0 mg 11.1 mg 0.82 
Fluoxetina Teva® 21.4 mg 11.0 mg 10.4 mg 1.06 
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IV.1.4. Chiral separations by non-aqueous capillary electrophoresis in 
DMSO-based background electrolytes (Paper IV) 
This work, performed in the Katholieke Universiteit of Leuven, responded to the 
interest on developing non-aqueous systems that could be able to dissolve new 
active pharmaceutical ingredients (APIs) which are non-soluble in aqueous systems 
and could be also non-soluble in methanolic mediums. DMSO is presented as an 
alternative to alcohols in chiral NACE, and a univariate optimization of the chiral 
separation is performed. In this case, the individual study of variables is considered 
interesting because there is still a certain lack of knowledge on the behavior of NACE 
systems. 
The main advantages of DMSO that make it a promising solvent for NACE are its 
high dielectric constant, low toxicity and lack of volatility and hazardousness. 
Alcoholic BGEs are usually volatile, and this may affect the BGE composition and 
cause current breakdowns. In this work, current was highly stable in all cases. 
Chiral separation of three drugs (verapamil, pindolol and fenfluramine) was 
performed, using a DMSO-based BGE and CM-γ-CD as chiral selector. A small 
percentage of methanol was added to the BGE in order to increase the current and 
facilitate the dissolution of the electrolytes, ammonium acetate and acetic acid. So, 
initial experimental conditions were: BGE, DMSO-MeOH 80:20, with 50 mM NH4Ac, 1 
M HAc and 40 mM CM-γ-CD; capillary temperature 25 ºC and applied voltage 20 kV. 
With these conditions, partial resolutions of the three drugs were achieved, so they 
were adjusted in order to improve enantioseparations. The effects of separation 
temperature and voltage as well as the concentration of all the BGE components on 
the drugs enantioresolution were studied individually and combined in order to 
obtain the best separation conditions. It may be taken into account that 
enantioseparations in DMSO media are a priori disfavored due to the weak 
intermolecular interactions between chiral selectors and enantiomers in these 
organic media. 
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(a) 
 
(b) 
 
Figure IV.10: Effect of (a) temperature and (b) voltage on the enantioseparation 
() and migration time of the second eluted enantiomer () of verapamil by chiral 
NACE. Other experimental conditions: BGE DMSO/MeOH 80:20, 50 mM NH4Ac, 1 M 
HAc, 40 mM CM-γ-CD. Voltage in (a): 25 kV. Temperature in (b): 15 ºC. 
 
The capillary temperature was ranged between 15 and 45 ºC. Higher temperatures 
led in all cases to shorter migration times and, as a consequence, worse 
enantioresolutions, as can be seen in Figure IV.10a for the enantioseparation of 
verapamil. Consequently, despite analysis times were longer, the lowest possible 
temperature was selected in all cases (15 ºC). On the other hand, the increase on 
separation voltage (range: 20-30 kV) decreased the migration times, which usually 
decreases enantioresolution, and improved the peaks efficiency, which usually 
improves the Rs, thus the Rs values were practically not affected by the voltage due 
to the combination of both effects, as can be seen for verapamil in Figure IV.10b. 
The highest possible voltage (30 kV) was selected here as best option because it 
provided the shortest analysis times. 
The HS-β-CD concentration in the BGE was ranged between 10 and 70 mM. This 
uses to be the most influential variable on enantioseparations, since, as has been 
previously described, the complexation between the CD and the enantiomers is 
responsible for the chiral separation. Here, a maximum Rs value was observed for 
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the three drugs studied at about 40 mM (slightly better 50 mM for verapamil, but 40 
mM was enough), and higher concentrations provided worse enantioresolutions 
(Figure IV.11). 
 
 
Figure IV.11: Effect of the CM-γ-CD concentration on the enantioseparation of () 
verapamil, () pindolol and () fenfluramine. 
 
The physicochemical properties of DMSO and MeOH are quite different: MeOH has 
lower dielectric constant (ε), much lower viscosity (η), lower boiling point, and lower 
autoprotolysis constant (pKauto), which implies that more ions in solution will be 
found in methanolic BGEs. So, the percentage of MeOH will modify considerably the 
physicochemical properties of the BGE and will strongly affect the enantioseparation. 
In this work, since our main aim was to employ a DMSO-based BGE, the percentage 
of MeOH was varied from 0 to 30%, so the main component of the BGE was DMSO 
in all conditions. 
A decrease in MeOH percentage increases the migration times of all compounds. In 
the case of verapamil best Rs is obtained with 20% MeOH, so it is selected as 
optimum. For pindolol there is a clear decrease in Rs when the MeOH percentage is 
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decreased so 30% is selected as best option since it combines better Rs with shorter 
migration time. The case of fenfluramine is the opposite; the split of peaks is larger 
without MeOH so a pure DMSO BGE is selected as best option. 
The differences between the three compounds in the optimum MeOH percentage 
should be due to a dual mechanism that affects the enantioresolution: on one hand, 
the increase in MeOH increases the ε/η ratio of the BGE, which is a measure of the 
speed of the analysis, and decreases in consequence the migration times, so, if 
peaks migrate faster, less Rs can be expected a priori (this is the case of 
fenfluramine). On the other hand, as DMSO is an aprotic solvent, the increase of 
MeOH can increase the ionization degree of the drugs, enhancing the interaction 
with the anionic CD (the case of pindolol). For verapamil, both opposite effects lead 
to an intermediate BGE composition (DMSO/MeOH 80:20) as the best option. 
The NH4Ac concentration (25-125 mM in this work) showed a notable effect on the 
Rs. The increase on NH4Ac concentration, despite increasing the current, led to 
longer migration times, due to a decrease on the electrophoretic and electroosmotic 
mobilities, which is perhaps more important here than in aqueous media. 
Considerably better enantioselectivities were found with high NH4Ac concentrations, 
so 125 mM was selected for all the enantioseparations. The HAc concentration (0.5-
1.5 M) had slight effect on the enantioseparation; 1 M was selected for pindolol and 
fenfluramine and 0.5 M for verapamil, because these conditions provided in each 
case slightly better separations. The final conditions selected, as well as the 
corresponding electropherograms, can be found in Table IV.7. 
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Table IV.7: Final separation conditions in chiral NACE for the three drugs studied. 
 Verapamil Pindolol Fenfluramine 
T (ºC) 15 15 15 
V (kV) 30 30 30 
[CM-γ-CD] (mM) 40 40 40 
%MeOH 20 30 0 
[NH4Ac] (mM) 125 125 125 
[HAc] (M) 1 0.5 0.5 
Rs 1.5 2.0 1.2 
tE2 (min) 43 25 42 
Current (µA) 25 29 17 
Electropherogram 
  
 
 
IV.2. Study of enantioselective binding of drugs to plasma proteins 
As stated in the introduction of this Thesis, HSA is the most abundant protein in 
human plasma (60% of the protein content, with a plasmatic concentration of 35-45 
g·L-1). It binds a wide number of xenobiotics with a certain degree of 
enantioselectivity in most of the cases. Consequently, the knowledge about the 
binding of xenobiotics to HSA is interesting from a pharmacokinetic point of view, 
since most of the interactions and displacements of protein binding will take place 
with the HSA molecule, and can be enantioselective. 
40 42 44
Time (min) 23 24 25 26Time (min)
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The protein binding of drugs is a well-known pharmacokinetic parameter which has 
to be evaluated during the drug development process. However, in most of the 
cases, no enantioselective information can be found in the literature for the protein 
binding of chiral drugs. Thus, the development of methodologies for the in vitro 
evaluation of enantioselective protein binding is an interesting field in bioanalytical 
chemistry. Moreover, an adequate mathematical treatment of the experimental data 
is important in order to obtain accurate estimations. 
In this section, the evaluation of enantioselective binding of drugs to HSA and total 
plasma proteins is described in three studies about this topic. The first one, 
concerning the binding of the antidepressant fluoxetine to HSA, points out some 
weak aspects of the experimental methodologies and mathematical models 
previously published for the estimation of protein binding, and proposes a novel 
strategy for a reliable binding affinity evaluation. The second and third studies 
evaluate the binding of the hypnotic drug zopiclone and the antidepressant 
nomifensine to HSA and total plasma proteins, using the new mathematical 
approaches discussed in the first one. 
 
IV.2.1. Evaluation of enantioselective binding of fluoxetine to human 
serum albumin by ultrafiltration and CE – Experimental design and quality 
considerations (Paper V) 
In this work a discussion concerning the different experimental designs and 
mathematical approaches to HSA binding estimations is performed, using the HSA 
binding of the antidepressant fluoxetine as an example. The methodology used for 
the protein binding study is ultrafiltration followed by chiral separation of the 
unbound fraction by EKC-CFT with HS-β-CD as chiral selector. The experimental 
details are described in the Methodology section of this Thesis. Figure IV.12 shows 
the electropherogram corresponding to the chiral separation of fluoxetine 
enantiomers in a standard solution and in an ultrafiltrate (unbound fraction). 
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Figure IV.12: Electropherograms corresponding to a sample containing 200 µM 
racemic FLX (total drug) and the unbound fraction after ultrafiltration. Experimental 
conditions: BGE 30 mM phosphate, pH 7.0. 0.25% HS-β-CD as chiral selector, rinsed 
2 psi/1 min. Separation at 30 ºC, 15 kV + 0.3 psi. 
 
The first consideration that should be taken into account is that the in vitro system 
used for the binding study must simulate, as well as possible, the in vivo situation in 
order to obtain reliable estimates. Estimations done far from physiological conditions 
could provide results far from the real situation. Based on literature information 
about the steady-state concentration (Css) of fluoxetine in human plasma (around 
0.2 µM of racemic FLX in a normal dosage situation) and the albumin plasmatic 
concentration (500-600 µM), an estimation of the in vivo D/P ratio was performed 
(D: total drug concentration; P: total protein concentration), showing that in a 
physiological normal situation D/P << 1. 
From the general model for binding constants estimation (Eq. I.8), which considers 
that the protein molecule can have m kinds of binding sites with n sites of each kind, 
it is very difficult to estimate reliable affinity constants or apparent stoichiometries of 
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the binding process, due to its complexity. Thus, simplifications of Eq. I.8 become 
necessary, considering m = 2 (Eq. I.9) or m = 1 (Eq. I.10). These 4- and 2-
parameter equations are simpler than the general model, but it may be taken into 
account that the assumptions performed (m = 1 or 2) should be checked for 
consistent estimations. In vivo, where D <<< P, the most probable situation is that 
the drug only binds to a kind of binding site in the protein, so m = 1. Furthermore, 
as there is a considerable excess of protein over the amount of drug in plasma, the 
stoichiometry of the binding will probably be 1:1 (only one molecule of drug per 
molecule of protein), so n1 = 1. If the in vitro model tries to assembly the in vivo 
conditions and keeps the D/P ratio low enough, these assumptions can be also done 
in vitro and simplify the calculations considerably without losing reliability. 
Experimental designs, defining the concentration ranges of D and P and the number 
of concentration levels, may thus be planned taking into account this consideration. 
There can be found in the literature experiments that use a fixed P level and 
different D levels in a broad range that covers several orders of magnitude. The 
main drawback of these designs is that they do not keep the D/P ratio < 1, using 
frequently D > P in some points. In contrast, we propose to perform two 
experimental designs, one keeping constant the concentration of protein and varying 
the drug (the most usual design) and other keeping the concentration of drug and 
varying the HSA level. The aim of performing two experimental designs is to have 
independent results and control the possible effect of varying the P-concentration on 
the estimations. In this work, we have performed both designs keeping the D/P ratio 
 ≤ 0.5 and adjusting the lowest D levels taking into account the approximate 
quantification limits for dE1 and dE2. So, in the P-constant design, D was ranged 
between 100 and 200 µM (P = 475 µM), and in the D-constant design, P was 
between 250 and 500 µM (D = 125 µM). All mixtures have been prepared and 
evaluated in duplicate in order to control (and eliminate, if necessary) atypical 
experimental data. 
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Prior to K1 estimations, outliers’ identification and elimination is necessary since 
outlier values can considerably affect the K1 estimates. A possibility is to inspect 
directly the experimental data (d values) but it is preferable to evaluate outliers 
directly on the K1 estimates. With this purpose, we propose to perform individual 
estimations of K1 from each d-D-P data, via Eq. IV.7 (which provisionally assumes n1 
= 1, this may be confirmed later): 
 = 1$ ·
%
1 − %  (IV.7) 
and check which K1 or log K1 values are far from the average value or median. This 
has been done in this work using the Grubbs test, a suitable approach to evaluate 
one (single) or two (double) extreme data. Here, the application of the Grubbs test 
(α = 2.5%, 2 tails) confirmed that the point ID = 13 was an outlier (see Figure 
IV.13), so it was eliminated from further estimations. No other points were 
considered as outliers by applying this test. 
 
 
Figure IV.13: Log K1 values estimated for E1 (o) and E2 (+) from Eq. IV.7 using 
individual d-D-P data corresponding to the fluoxetine-HSA binding. Horizontal lines 
indicate the averaged values (after elimination of point ID = 13). 
 
In Figure IV.13 it can also be observed that no significant differences exist between 
the estimation of K1 via a P-constant design (points ID = 1-10) or a D-constant one 
(points ID = 11-18). So, it can be concluded that the usual P-constant design should 
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be enough to provide reliable estimates if P is near physiological values and the D/P 
ratio is kept in its adequate range. 
In this work, different equations have been checked and compared in terms of 
quality of estimations and robustness, in order to obtain a reliable estimation of the 
enantioselective protein binding and also to provide a working protocol for future 
protein binding estimations. 
Eq. IV.7 allows performing individual K1 estimations from independent d-D-P data. 
This is interesting also because it allows performing an estimation of the uncertainty 
of K1 estimates. The only consideration that should be taken into account is that the 
assumption n1 = 1 must be confirmed to accept the data from Eq. IV.7 (despite it is 
the most probable situation in our experimental design). In order to confirm this 
assumption two possibilities are proposed. The first one is a linear equation derived 
from Eq. IV.7: 
&'( %1 − % = &'( + &'(	($)  (IV.8) 
With this equation, plotting log(r/(1-r) vs. log(d), slope = 1 verifies the assumption 
n1 = 1. Here, slopes of 1.0 and 1.1 were obtained for E1 and E2 respectively using 
data from the P-constant design, and 1.1 and 0.9 with data from the D-constant 
design, thus confirming that n1 = 1 and the validity of Eq. IV.7. 
The other possibility proposed for the confirmation of the n1 = 1 assumption is the 
use of a 2-parameter model developed by a former member of our research group: 
a non-linear equation derived from Eq. I.10, in which d is a dependent variable of D 
and P (Martínez-Pla et al., 2004). Here, n1 and K1 can be estimated using non-linear 
approaches; however, several sets of values can be found (same problem as in Eq. 
I.10): 
$ = −(1 −  + ,-) ± "(1 −  + ,-) + 42   (IV.9) 
This problem is less relevant here, since Eq. IV.9 is proposed only with checking 
purposes and the estimations of K1 (and subsequently n1) are derived from Eq. IV.7. 
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Eq. IV.9 is an alternative to the most popular linear approaches (Eqs. I.11-13, in 
Table I.2) which could provide inconsistent results, especially with short D-ranges 
(as in the experimental design proposed here in order to keep D/P < 0.5). Here the 
linear models have been also evaluated by adjusting data of E2 (P-constant design) 
to Eqs. I.11-13, obtaining inconsistent and erratic values. Log K1 and n1 values 
estimated from the Klotz plot (Eq. I.11) were 3.7 and 2.0, and from Scatchard (Eq. 
I.12) and y-reciprocal (Eq. I.13) plots the estimates were 3.5 and 4.1, and 3.9 and 
1.5, respectively. Also, as these estimations are done from the slope and intercept of 
the linear models, the elimination of one point will have important consequences on 
the estimates, which lack of any robustness. 
It may be taken into account that Eq. IV.9 requires a concrete experimental design 
in order to adjust d vs. D or d vs. P, keeping constant the other variable (Fig. 
IV.14a). However, estimations can be performed with all the joined data (d vs. D 
and P) by plotting a response surface (Fig. IV.14b). 
 
(a) (b) (c) 
Figure IV.14: Three different plots derived from Eq. IV.9: (a) d vs. D plot (P-
constant design, data from E2), (b) response surface plot (d vs. D and P, data from 
E2) and (c) d vs. P plots (D-constant design) adjusted simultaneously for both 
enantiomers using a competitive model (o, E1; x, E2). 
 
All these estimations have been performed considering an independent model where 
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enantiomers compete for the free binding sites and consequently the binding of one 
enantiomer will be affected by the binding of the other one, can be also considered. 
From these two possibilities, the most probable when low D/P ratios are used is the 
independent one, since the amount of HSA is quite bigger and each enantiomer will 
easily find free binding sites. Nevertheless, in this work both possibilities are 
considered. 
The competitive model is a modification of Eq. IV.9 which considers the 
concentrations of both enantiomers in the mixture (Eqs. IV.10 and IV.11 for 
estimating KE1 and KE2, respectively): 
$0 = −(1 − 0 + ,0- + 0$0) ± "(1 − 0 + ,- + 0$0)
 + 4
20  
(IV.10)
$0 = −(1 − 0 + ,0- + 0$0) ± "(1 − 0 + ,- + 0$0)
 + 4
20  
(IV.11)
In order to avoid bad estimations of the parameters by using these equations 
separately, a SIMPLEX algorithm that simultaneously optimizes both equations has 
been designed. The corresponding d vs. P plots for both enantiomers are shown in 
Fig. IV.14c. Table IV.8 summarizes all the log K1 estimates obtained in this work 
using the different equations proposed. 
 
Table IV.8: Log K1 estimated values obtained with the different mathematical 
models proposed. 
Model Eq. Conditions log KE1 log KE2 
Independent IV.7 All data 4.51 ± 0.08 4.17 ± 0.06 
 IV.9 P-constant 4.47 4.15 
  D-constant 4.57 4.20 
  All data 4.53 4.18 
Competitive IV.10 and 11 P-constant 4.67 4.37 
 IV.10 and 11 D-constant 4.87 4.52 
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As can be noticed from Table IV.8, no differences were found between the 
estimations performed with the independent and competitive models for the 
fluoxetine-HSA binding, suggesting that, as expected, at low D/P ratios no 
competition between the enantiomers takes place and independent estimations via 
Eqs. IV.7 and IV.9 are enough to obtain reliable binding constants. 
From the results obtained in this work a quality protocol for performing enantiomer-
protein binding studies is proposed in order to obtain robust estimates in future 
protein binding studies. This protocol includes the following steps: 
(i) Elimination of outliers (Eq. IV.7) 
(ii) Verification of n1 = 1 (Eq. IV.8) and consequent acceptation of the KE1 and 
KE2 estimates of Eq. IV.7. 
(iii) Estimation of KE1 and KE2 via Eqs. IV.7 and IV.9 (independent model) or via 
Eqs. IV.10 and IV.11 (competitive model, less usual in the proposed 
experimental design). 
On the other hand, the enantioselectivity degree (ES) is an important parameter of 
the enantiomer-binding studies that can be estimated from the ratio KE1/KE2. ES for 
fluoxetine enantiomers has been estimated as 2.20 using data from the independent 
model and 2.14 using data from the competitive one, so the binding of FLX 
enantiomers to HSA can be considered enantioselective. 
Finally, other parameter that is interesting from a pharmacokinetic point of view is 
the percentage of protein binding (PB%), which may be estimated at physiological 
conditions. It can be calculated as: 
-1% =  − $ · 100  (IV.12) 
which is an expression analogue to Eq. I.7. 
From the D and P physiological levels found in the literature, d was estimated via Eq. 
IV.9 and used for the calculation of PB%. PB% estimates were 95.2 and 90.0% for 
E1 and E2, respectively. These values are consistent with that reported for racemic 
FLX (94.75%). 
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IV.2.2. On the zopiclone enantioselective binding to human albumin and 
plasma proteins. An electrokinetic chromatography approach (Paper VI) 
Zopiclone is a non-benzodiazepine hypnotic drug used for the treatment of insomnia. 
It increases the inhibitor effect of the neurotransmitter GABA (γ-aminobutyric acid) 
by binding to the GABAA channel. It has been demonstrated that the hypnotic 
activity resides in the S-enantiomer, while R-zopiclone has no effect. Consequently 
eszopiclone, a new drug consisting on the pure S-enantiomer, has been recently 
commercialized. 
Information about plasma protein binding of zopiclone is available in the literature, 
but there are considerable differences between the previously published results 
(PB% varying from 45 to 85% for the racemate, and only one enantioselective 
estimation but using experimental conditions very far from physiological ones). So, a 
reliable in vitro estimation of the enantioselective binding of zopiclone to HSA and 
other plasma proteins results interesting since there may be differences between the 
pharmacokinetics of the enantiomers. 
The evaluation of enantioselective protein binding of zopiclone has been performed 
by ultrafiltration followed by chiral separation of the unbound fraction by EKC-PFT 
(the same methodology described before for fluoxetine). Here, the chiral separation 
has been carried out with CM-β-CD, an anionic cyclodextrin which strongly interacts 
with basic compounds like zopiclone (pKa = 6.9). 
Initially, the effect of some experimental conditions on the chiral EKC-PFT separation 
has been studied. A preliminary study of the pH and BGE composition showed that 
best resolution, signal-to-noise ratio and analysis time were obtained using 50 mM 
Tris at pH 6.0 over other buffers such as citrate, 2-(N-morpholino)ethanesulfonic 
acid (MES) or phosphate.  
Figure IV.15 shows the effects of the CM-β-CD concentration and the SPL on the 
enantioseparation of zopiclone. As shown in Fig. IV.15a, an increase on the CD 
concentration increases the migration time and enhances the resolution. With 20 mM 
CM-β-CD the enantiomers are completely separated, but the first one overlaps with a  
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change in the baseline signal that could hamper its measurement. 30 mM CM-β-CD 
provides the best results in terms of resolution, migration times and peaks shape, so 
this concentration is selected for further studies.The effect of the SPL, which is 
shown in Fig. IV.15b, is very similar to that of the CD concentration. Larger amounts 
of CD injected in the capillary lead to longer migration times and better Rs values. 
Complete enantioresolution is reached with an injection of 30 mM CM-β-CD at 0.5 
psi/99s, so this SPL is selected. 
Temperature is considered a key parameter in the chiral separation because it can 
affect peaks efficiency, BGE viscosity and the enantiomer-chiral selector interaction, 
consequently modifying the chiral resolution. Temperatures of 15, 25 and 40 ºC 
were tested, using the previously selected conditions of CM-β-CD concentration (30 
mM) and SPL (0.5 psi/99s). A decrease in migration times of the enantiomers and 
EOF upon increasing the temperature was observed, due to the decrease of the BGE 
viscosity and also to changes in the enantiomers-CD interaction. The reduction of 
migration times resulted in a decrease in the Rs of enantiomers, being the Rs values 
of 2.8, 2.4 and 1.7 for 15, 25 and 40 ºC respectively. In all cases complete 
resolution of the enantiomers was achieved, so a capillary temperature of 25 ºC was 
selected for the enantioseparations. 
Previously, in Paper V, we have demonstrated that the use of a P-constant design 
with the D/P ratio kept lower than 0.5 is adequate to obtain reliable estimates of the 
HSA-enantiomers affinity constants. In this work, for the evaluation of the 
enantioselective protein binding of zopiclone to HSA, an experimental design with a 
constant P value near the physiological concentration (450 µM) and 5 D levels in a 
short D-concentration interval (100-200 µM, 3 independent replicates of each level, 
total 15 individual samples) was used. The D/P ratios were from 0.22 to 0.44, in all 
cases lower than 0.5. 
In order to estimate the enantioselectivity and protein binding of zopiclone to HSA, a 
previously described protocol was used (see section IV.2.1), including the 
identification and elimination of outliers, the estimation of K1 values for each 
enantiomer and the verification of the n1 = 1 approach via different equations. 
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(a) 
 
(b) 
 
Figure IV.15: Effect of (a) CM-β-CD concentration and (b) SPL on the separation of 
zopiclone enantiomers by EKC-PFT. Other experimental conditions: BGE 50 mM Tris, 
pH 6.0. Separation at 25 ºC, 15 kV. 
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Outlier experimental data were eliminated here using a z-score approach, which is a 
robust alternative to other tests for outliers. This is a convenient method for data 
that are expected to follow a near-normal distribution but are suspected to contain a 
small proportion of errors. A robust estimation of the z-score has been performed by 
using the median and MADe (more robust statistics than those commonly used, 
mean and standard deviation), for each log K1i estimate obtained from Eq. IV.7: 
4 = &'( −56$78,9:6   (IV.13) 
Habitually, zi > 3 are considered unsatisfactory, while zi > 2 are considered 
doubtable values. A fixed criterion of zi > 2.5 was used in this work to eliminate a 
point in a round. After elimination of one or more outlier values, new median and 
MADe estimations are performed via Eq. IV.7 and the z-score test is repeated since 
no outliers are found. The final log K1 estimates for each enantiomer are shown as 
median ± MADe (see Table IV.9). 
After outliers elimination, Eq. IV.9 was used to confirm n1 = 1 for both enantiomers 
and to estimate also K1. Log K1 estimates obtained using Eq. IV.7 and Eq. IV.9 are 
shown in Table IV.9. 
 
Table IV.9: Protein binding parameters estimated for the enantioselective 
zopiclone-HSA binding. 
Enantiomer log K1 (Eq. IV.7) log K1 (Eq. IV.9) PB% ES 
S-zopiclone 3.38 ± 0.14 3.37 47 1.95 
R-zopiclone 3.09 ± 0.19 3.14 36  
 
As can be seen in Table IV.9, the estimations of log K1 obtained by using both 
equations are very similar. This fact confirmed that estimations made using Eq. IV.7 
could be considered acceptable values. In addition the estimation from Eq. IV.7 
increases the control over individual data allowing the application of univariate 
statistics instead of a regression model with a single estimation. 
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The percentage of protein binding has been calculated here considering D = 0.2 µM 
and P = 600 µM (physiological conditions estimated in the fluoxetine study) and 
using Eq. IV.12. The values obtained are also shown in Table IV.9, as well as the 
enantioselectivity obtained as K1,S/K1,R. From the obtained ES value, around 2, it can 
be concluded that S-zopiclone has higher affinity to the HSA molecule than its 
antipode. 
Finally, an estimation of the binding of zopiclone enantiomers to all the plasma 
proteins was performed using lyophilized human sera. For this purpose, samples 
containing racemic zopiclone and plasma with a relationship aqueous/plasma 
solution 100:300 (v/v) were prepared in triplicate and analyzed following the UF and 
EKC-PFT methodology described. PB% of 45 ± 3 and 49 ± 6 were found for S- and 
R-ZPC, respectively, values which agree with the PB% found in the literature for 
racemic zopiclone, 45% (Gaillot et al., 1983; Spanish Drug Agency, 2011). 
Comparing these results with those obtained for HSA, we can conclude that the S- 
enantiomer mainly binds to HSA while R-zopiclone binds also to other plasma 
proteins. 
 
IV.2.3. Electrokinetic chromatographic estimation of the enantioselective 
binding of nomifensine to human serum albumin and total plasma proteins 
(Paper VII) 
Nomifensine is an isoquinoline derivative that prevents dopamine reuptake into 
synaptosomes. It is now mainly used in scientific research as a model of dopamine 
reuptake inhibitors, after its withdrawal as antidepressant in 1986. A clinical 
application of nomifensine in Parkinson’s disease (PD) study and diagnosis has been 
described. PD can be evaluated by studying the dopamine pathways using positron 
emission tomography (PET) with different tracers to image the presynaptic and 
postsynaptic sites of dopaminergic system. PET can also contribute to the differential 
diagnosis of PD when clinical features are not clear. One of the tracers that have 
been used for presynaptic assessment is [11C]nomifensine, which inhibits the 
reuptake of the released dopamine by blocking the dopamine reuptake sites 
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(dopamine transporters, DATs) in presynaptic nerve terminals. The use of 
nomifensine as PET tracer is affected by its distribution between blood and central 
nervous system, where protein binding plays an important role. So, the study of its 
enantioselective protein binding may be helpful in this context, since differences 
between the DAT-blocking activities of the enantiomers have been reported in the 
literature. 
In this work, the enantioselective binding of nomifensine to HSA and total plasma 
proteins has been evaluated using the methodology and equations previously 
described. The separation of nomifensine enantiomers has been performed by EKC-
CFT using TM-β-CD, a neutral cyclodextrin, as chiral selector. A minimum Rs of 1.7 
was obtained for nomifensine enantiomers, in migration times around 3 min. Figure 
IV.16 shows the electropherograms obtained under the selected experimental 
conditions. 
 
 
Figure IV.16: Enantioseparation of nomifensine enantiomers in a standard solution 
(pink) and in an ultrafiltrate (unbound fraction, purple) by EKC-CFT. Experimental 
conditions: 50 mM Tris buffer at pH 6.0 as BGE, 30 mM TM-β-CD in BGE injected at 
10 psi/1 min, separation voltage 15 kV and capillary temperature 50 ºC. 
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A P-constant experimental design was used for the evaluation of nomifensine-HSA 
enantioselective binding, keeping the D/P ratio < 0.5. P was fixed near the 
physiological concentration and D was varied between 70 and 200 µM of each 
enantiomer (5 concentration levels, 3 replicates per level). The inter-day 
repeatability was controlled by repeating the complete experimental design in two 
independent working sessions. The previously described z-score approach has been 
applied here for the elimination of outlier values, combining data from both working 
sessions for the calculation of the median K1 and its MADe.  
After outliers elimination, the robust log K1 estimates via Eq. IV.7 (median ± MADe) 
were 3.24 ± 0.10 and 3.67 ± 0.08 for E1 and E2, respectively. The assumption n1 =1 
of Eq. IV.7 was confirmed by the estimation of K1 and n1 via Eq. IV.9. A SIMPLEX 
search was started with n1 = 1 and log K1 = 4, allowing only integer n1 values. 
These log K1 estimates were 3.23 ± 0.11 and 3.64 ± 0.09 for E1 and E2, 
respectively, which are in agreement with the values calculated from Eq. IV.7. Also, 
the n1 estimated value was 1 for both enantiomers, verifying the assumption. It may 
be noticed that these uncertainties have been obtained under intermediate precision 
conditions (two independent working sessions). 
Enantioselectivity, defined as the ratio between affinity constants (KE2/KE1), was 
estimated as 2.7 ± 0.1, indicating higher affinity of the second eluted enantiomer for 
the HSA molecule. However, as the difference between the log K1 values of the 
enantiomers was no so high, this enantioselectivity was checked through hypothesis 
testing. Statistical comparison of log KE1 and log KE2, using both a parametric test for 
means and a non-parametric one for medians, indicated significant differences (p < 
0.05) between the averaged affinity estimates, so significant enantioselectivity was 
demonstrated. The same result was obtained by comparing the ES value with 1. 
The estimation of enantioselective PB% to the HSA molecule at the physiological 
level was performed with Eq. IV.12. Also the enantioselective PB% to total plasma 
proteins was calculated by incubating racemic nomifensine with human sera and 
applying the same methodology described for HSA (UF followed by chiral EKC-CFT). 
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The results for the protein binding of nomifensine enantiomers to HSA and total 
plasma proteins are shown in Table IV.10. 
 
Table IV.10: PB% estimates for nomifensine enantiomers to human serum albumin 
and total plasma proteins. 
 PB% (E1) PB% (E2) 
To HSA 40 ± 5 63 ± 4 
To plasma proteins 58 ± 7 64 ± 4 
 
From the PB% estimates shown in Table IV.10, we can see that probably the first 
eluted enantiomer binds not only to HSA but also to other plasma proteins. 
However, the role of HSA is the most important in its protein binding. For E2, the 
values of PB% obtained for HSA and total plasma proteins are similar, so this 
enantiomer binds a priori only to HSA. 
 
IV.3. Study of enzymatic reactions by capillary electrophoresis 
Several diseases are caused by enzymatic disorders (excess or lack of activity, bad 
regulation, bad expression…) and consequently enzymes are a common target of 
drugs. Every year new candidate drugs are evaluated as inhibitors, substrates or 
modulators of different enzymes, and with this purpose screening methods are 
required in the pharmaceutical industry. As stated in the Introduction of this Thesis, 
CE in the EMMA modality is a good technique for high-throughput screening due to 
its speediness, ease of automation and extremely low consumption of reagents and 
enzymes (usually very expensive). Also, CE offers the possibility of coupling chiral 
analysis of substrates, inhibitors or metabolites to the EMMA assay, thus providing 
enantioselective information about the enzymatic reaction. 
The present section of this Thesis deals with two different in-capillary enzymatic 
reactions that have been evaluated using the EMMA methodology: the degradation 
of acetylthiocholine by the enzyme acetylcholinesterase (Paper VIII) and the 
Results and discussion 
 
121 
 
enantioselective metabolism of verapamil and fluoxetine by two different isoforms of 
the cytochrome P450, CYP3A4 and CYP2D6 (Papers IX and X respectively). In EMMA 
all the reagents are introduced sequentially in the capillary, which acts 
simultaneously as a micro-reactor and as a separation system. The reaction takes 
place in a nanoliter scale, which has the previously commented advantage of 
extremely low consumption of expensive reagents, but the disadvantage of being 
difficult to control and measure. Extensive experimental work is required in order to 
optimize and control all the variables that affect an EMMA reaction and its 
subsequent separation by electrophoresis. 
 
IV.3.1: Screening of acetylcholinesterase inhibitors by CE after enzymatic 
reaction at capillary inlet (Paper VIII) 
AChE is a hydrolytic enzyme that catalyzes the degradation of the neurotransmitter 
acetylcholine (ACh) in the central nervous system. The decrease of ACh level in the 
synaptic spaces has been related to the Alzheimer’s disease, so a possibility for its 
treatment is the inhibition of the AChE activity, in order to increase these ACh levels. 
The activity of some AChE inhibitors has been evaluated here with the aim of 
developing a fast and fully automated method for high-throughput screening of 
possible new candidate drugs. 
In order to choose the best EMMA conditions for the proposed method, tacrine, 
whose activity as AChE inhibitor is well-known, was selected as model compound for 
the optimization process. The experimental conditions for the enzymatic assay were 
taken from literature (Tang et al., 2007) (see Methodology section) and the progress 
of the enzymatic reaction was measured using the peak area of the formed product 
thiocholine (TCh) at 230 nm. 
After some attempts with the plug-plug EMMA mode, where the injected plugs are 
mixed by application of a small voltage, we noticed a high variability in the results 
that was not corrected with the addition of an internal standard (alprenolol). So, we 
attributed the variability to the mixing procedure and decided to change to the at-
inlet EMMA mode, where the mixing takes part by simple diffusion of the injected 
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plugs. A sandwich at-inlet EMMA procedure was proposed, introducing the substrate 
solution, with or without inhibitor, between two enzyme plugs. Two water plugs 
were injected before and after the reaction mixture in order to stack the reagents in 
a capillary zone, and the reagents were allowed to mix and react during a fixed 
waiting time. Figure IV.17 shows the typical electropherograms obtained after the 
AChE enzymatic reaction with and without the inhibitor edrophonium. In absence of 
the inhibitor (blue line), all the substrate is converted to TCh and the AThCh peak 
does not appear, while in presence of 100 µM edrophonium (red line) the formed 
product diminishes and the substrate peak appears indicating an incomplete 
substrate-product conversion. 
 
 
 
Figure IV.17: Electropherograms corresponding to the AChE enzymatic reaction in 
absence (blue line) and presence (red line) of the inhibitor edrophonium. 
Experimental conditions: 0.4 mg·mL-1 AChE, 10 mM AThCh with 20 mM MgSO4, 30 
mM borate-phosphate buffer, pH 8.0 as BGE (the same buffer as for the enzymatic 
reaction), capillary temperature 37 ºC and separation voltage 15 kV. 
 
The incubation time is an important variable that should be studied in at-inlet EMMA, 
since during this time the enzyme and substrate plugs are mixed by simple diffusion 
and react in the capillary. A very short time will not allow the reaction to take part, 
but a very long one has the disadvantages of peaks diffusion and longer analysis 
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time, which is an important drawback for screening procedures. Figure IV.18 shows 
the effect of the incubation time on the inhibition of AChE. As can be seen, 
maximum inhibition percentage was achieved after two minutes of incubation, so 
this time was selected for further experiences. 
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Figure IV.18: Effect of the incubation time on the percentage of inhibition using 
tacrine () 5 µM and () 10 µM. Experimental conditions as described in Fig. IV.17. 
 
In order to obtain accurate kinetic data, it may be taken into account that the mixing 
of different plugs leads to a dilution of the substrate in the reaction zone. In this 
work, we have estimated a dilution factor that relates the actual substrate 
concentration in the reaction zone and the substrate concentration in the injected 
solution. With this purpose, an inhibition plot of tacrine was constructed in order to 
obtain its IC50 value, by performing assays in the tacrine range 10
-3-103 µM (other 
conditions previously described). The IC50 value obtained in this work (9.16 µM) was 
compared with those reported in the literature using the reference method for AChE 
inhibition, named Ellman method (around 0.25 µM; Andrisano et al., 2001). 
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Assuming the reported IC50 as reference true value, a dilution factor (f) of 0.03 was 
estimated and then applied to all calculations. 
Taking into account the dilution at the capillary inlet to correct both the substrate 
and the inhibitor concentrations the general model for enzyme inhibition (Eq. I.19) 
can be rewritten as: 
; =
( 1	);<=>[?]
( 	) 1@ A + 	[?]
= 	 8	[?]B + [?]  (IV.14) 
Ki could be determined by plotting the ratio of the fitted parameters (b/a) against 
the inhibitor injected concentration, as the ratio of the replot intercept to the replot 
slope, combining Eq. IV.14 with the definitions of α and α’ (Eqs. I.20 and I.21): 
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In order to study the applicability of the proposed methodology the inhibition 
potency of tacrine and other known AChE inhibitors was evaluated. With this 
purpose, the reaction was performed using different substrate and inhibitor 
concentrations. Firstly, Ki values for tacrine and edrophonium were estimated from 
Eqs. IV.14 and IV.15. The obtained values were 0.138 ± 0.012 and 3.3 ± 0.2 µM for 
tacrine and edrophonium, respectively, in agreement with those reported using the 
Ellman official method. 
Once inhibition constants were obtained, the inhibition mechanisms of tacrine and 
edrophonium were qualitatively evaluated. With this purpose, Lineweaver-Burk plots 
(the linear form of the Michaelis-Menten equation, Eq. I.19, conveniently modified 
for inhibition studies) were constructed for different inhibitor concentrations of both 
drugs (Figure IV.19). 
In the Lineweaver-Burk plot, the slope represents the ratio Km/Vmax and the intercept 
is 1/Vmax. So, the change on slopes and intercepts with different inhibitor 
concentrations provides information about the inhibition mechanism. 
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For tacrine, both the slope and the intercept increase with higher inhibitor 
concentration, so the Vmax is decreased and the Km is increased. This behavior 
corresponds to a mixed inhibition mechanism, which affects both to the Km and Vmax. 
On the other hand, the plot of edrophonium shows increasing slopes but unvaried 
intercepts, which means that the Vmax remains constant and the Km increases. This is 
a typical plot of competitive inhibition. 
These results well reflect the relative potency of the inhibitors and their mechanism 
of action, suggesting that this assay could be suitable for the first screening of new 
potential AChE inhibitors. 
 
 
Figure IV.19: Lineweaver-Burk plots for the enzymatic reaction of AChE inhibited 
by () 0 µM, () 5 µM and () 10 µM tacrine (A) and () 0 µM, () 10 µM, () 50 
µM and () 100 µM edrophonium (B). 
 
IC50 values, a measure of the inhibitory potency, were also obtained for 
edrophonium and neostigmine. With this purpose increasing inhibitor concentrations 
(10-3-103 µM) were injected using a fixed AThCh concentration of 10 mM. Both 
inhibition plots, as well as the IC50 values obtained, are shown in Figure IV.20. 
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a) b) 
Figure IV.20: Inhibition plots for (a) edrophonium and (b) neostigmine. 
Experimental conditions as described in Fig. IV.17. 
 
Finally, a method for a fast screening of potential new AChE inhibitors is proposed. 
This method consists on using the methodology previously described with fixed 
concentrations of 10 mM AThCh and 10 µM inhibitor, and calculating the inhibition 
percent of the candidate molecule at that concentration. This screening has been 
performed here for five known AChE inhibitors, thus providing information about 
their relative potency. The results of the screening are summarized in Table IV.11. 
 
Table IV.11: Inhibitor screening results. 
Compound % of inhibition 
Tacrine 54.2 
Edrophonium 33.7 
Neostigmine 31.1 
Pyridostigmine 6.1 
Eserine 20.1 
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According to the results shown in Table IV.11, the order of inhibitory potency was 
tacrine > edrophonium > neostigmine > eserine > pyridostigmine. The screening 
methodology developed and applied here has proved to be useful for the in vitro 
evaluation of AChE inhibitors (or new candidates) in terms of their Ki, inhibition 
mechanism or inhibitory potency. 
 
IV.3.2. In-line capillary electrophoretic evaluation of the enantioselective 
metabolism of verapamil by cytochrome P3A4 (Paper IX) 
Other application of EMMA, very interesting from a pharmacokinetic point of view, is 
the evaluation of drugs metabolism by individual enzymatic systems. The 
metabolism of a drug by different enzymes influences its plasmatic levels, half-life 
and disposition for reaching target organs and systems. This information should be 
estimated for candidate compounds in a fast and non-expensive way, being EMMA a 
good alternative for this purpose due to its previously commented features as 
screening procedure. 
In this work, the enantioselective metabolism of verapamil by CYP3A4, the major 
CYP isoform in humans, is evaluated. Verapamil, a Ca+2-channel blocker with anti-
arrhythmic activity, is a model compound for several metabolic studies. EMMA 
reaction conditions and the separation and verapamil and norverapamil enantiomers 
by means of HS-β-CD and the partial filling technique were optimized. 
The oxidation of drugs by the CYP450 system (Eq. I.1, Introduction) requires NADPH 
as a cofactor. Theoretically, NADPH is consumed in the enzymatic reaction and 
forms the oxidized product, NADP+, in a molar equivalence with the substrate-
product conversion. So, many authors have used in EMMA the NADP+/NADPH 
system to evaluate the reaction turnover by quantifying the NADPH depletion or the 
NADP+ formation. This approach is not useful for evaluating enantioselective 
metabolism but, as it is supposed to be the easiest way of measuring metabolic 
reactions, we tried to start the EMMA study with it. Very erratic results were 
obtained, suggesting that the formation of NADP+ was due not only to the enzymatic 
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reaction but also to other possible effects, and we decided to study carefully the 
behavior of the NADP+/NADPH system. 
One of the main drawbacks of the commercially available NADPH (powder) is its lack 
of stability. It has been reported in the literature that a considerable amount of 
NADP+ and other degradation products is non-specifically formed in a NADPH 
solution (Zhang et al., 2006). So, in order to evaluate if the NADP+ formation was 
really due to the metabolism of verapamil by CYP3A4, the area of NADP+ was 
measured after incubation in at-inlet EMMA conditions with and without verapamil 
(Figure IV.21). 
 
 
Figure IV.21: Effect of the incubation time on the NADP+ formation at different 
verapamil concentrations: () 0 µM, () 100 µM and () 200 µM. Experimental 
conditions as described in the Methodology section (Table III.3), but adding NADPH 
to the substrate solution instead of using solutions A and B. 
 
This figure shows that at longer incubation times the formation of NADP+ is 
increased, as expected. However, no significant differences are observed between 
the NADP+ formation without and with verapamil (100 or 200 µM) in the reaction 
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mixture, suggesting that the NADP+ formation corresponds to a non-specific 
degradation of the NADPH. So, this system was discarded for the quantification of 
the reaction turnover and a NADPH regenerating system (two independent solutions 
that form NADPH in situ, see Methodology section) was used for further studies in 
order to avoid problems related to the NADPH stability. 
Firstly, the plug-plug and the at-inlet EMMA modes were assayed. Best results were 
obtained using the at-inlet mode, so a “sandwich” injection similar to that used in 
the AChE study, with a substrate plug between two enzyme plugs, was proposed. 
Two plugs of incubation buffer were added before and after the “sandwich” plugs in 
order to give to the enzyme its adequate reaction medium. The scheme of the EMMA 
configuration used in these studies is shown in Figure IV.22. 
 
 
Figure IV.22: Scheme of the reaction and separation zones in the proposed 
enantioselective EMMA assay. 
 
Two different zones can be distinguished in the capillary: the separation zone filled 
with a HS-β-CD solution in the BGE and the reaction zone, at the inlet part, where all 
the plugs of the EMMA sequence are injected and left to mix and react during a fixed 
incubation time. In these conditions, the mixture of reagents is due both to 
longitudinal and transverse diffusion. After reaction, a voltage is applied for the 
separation of substrates, products and enzymes. 
The NADPH regenerating system employed in this work comprises two solutions (A 
and B) that allow the in situ NADPH formation. Solution A contains G6P, NADP+ and 
D
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MgCl2 and solution B contains G6PDH. When these solutions are put into contact, the 
G6PDH oxidizes G6P and forms NADPH, which can act as cofactor for the CYP3A4 
reaction. Two configurations were tested for the inclusion of these solutions in the 
CYP and substrate vials. In the first one, both solutions A and B were included in the 
substrate vial, to form NADPH before the injection in the CE system. This strategy 
allows the immediate starting of the reaction due to the fact that the NADPH formed 
is present when the CYP and verapamil plugs contact in the capillary, but it presents 
the disadvantage of a possible degradation of NADPH. The other configuration 
studied consisted on the in-line formation of NADPH by the inclusion of solution B in 
the CYP vial and solution A in the verapamil vial, which allows always the presence 
of native NADPH but can retard the beginning of the enzymatic CYP reaction. Both 
configurations lead to the same metabolite (norverapamil) formation in short 
incubation times, so the in-line formation of NADPH was selected in order to 
preserve NADPH from degradation (see the solutions composition in Fig. IV.22). 
With the aim of having a good reaction turnover in the shortest possible incubation 
time, we have optimized the in-capillary incubation time and the substrate injection. 
With this purpose, 200 µM verapamil solutions were incubated changing the 
incubation times or the substrate plugs, and keeping the other experimental 
conditions as described in the Methodology section. These experiences were carried 
out in achiral mode, without chiral selector in the separation zone, using separation 
conditions taken from literature (Zhang et al., 2005): 50 mM sodium phosphate at 
pH 8.8 as BGE, capillary temperature 25 ºC and separation voltage 20 kV. 
The optimum incubation time depends on the enzyme and the concrete conditions of 
the assay, and it may be taken into account the linear range of each enzyme, since 
at longer incubation times they lose activity. Here, incubation times between 1 and 
30 minutes were tested, based on the specifications of the commercial CYP and the 
previously published papers concerning this topic. The formation of the major 
product, norverapamil, was selected as response variable. From 1 to 5 min it 
increased considerably, but from 5 to 30 there was only a slight increase in the 
amount of norverapamil formed. Also, at longer incubation times there was an 
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important peak broadening due to the diffusion, so 5 min was selected as the best 
incubation time for further studies. 
The length of the substrate plug (substrate injection) may be adjusted to maximize 
the reaction turnover but taking into account that very large plugs will not allow a 
complete mixing of the substrate with the enzyme. Here, three substrate plugs of 3, 
5 and 7 s were tested (with a fixed pressure of 0.5 psi), and it was seen that the 
area of norverapamil formed was larger with the 7 s injection, so this injection plug 
was selected for the substrate. 
Once the EMMA conditions were fixed, the EMMA assay was coupled to the 
enantioseparation of verapamil and norverapamil in order to measure the 
enantioselective metabolism of verapamil by CYP3A4. Using the same BGE and 
conditions, HS-β-CD was tested as chiral selector due to its widely proved good 
enantioseparation abilities, using the partial filling technique. Solutions of 0.25-2.5% 
(m/v) HS-β-CD in the BGE were tested. With 0.25% CD, no separation of verapamil 
and norverapamil enantiomers was achieved. Using 2% HS-β-CD each pair of 
enantiomers was separated but S-norverapamil and R-verapamil overlapped. A 2.5% 
CD solution provided good enantioseparation of the four peaks with migration times 
of 18.2, 19.9, 20.6 and 21.5 min for S-verapamil, S-norverapamil, R-verapamil and 
R-norverapamil, respectively. In order to shorten these migration times, a little 
pressure of 0.2 psi was added to the separation voltages and the new migration 
times were 9.8, 10.5, 10.8 and 11.2 min, respectively. The separation of the four 
peaks as well as the NADP+ and NADPH can be seen in Figure IV.23. Using the 
selected conditions the total analysis time (including preconditioning, injection, 
incubation and separation) was less than 35 min/sample. 
The developed methodology was applied to estimate the kinetic Michaelis-Menten 
parameters for the metabolism of verapamil enantiomers by CYP3A4. With this 
purpose, six solutions containing verapamil in the concentration range 20-200 µM 
(10-100 µM of each enantiomer) were prepared in duplicate. The experiment was 
repeated in two different days in order to estimate the uncertainty under 
intermediate precision conditions. In order to obtain the verapamil peaks in the 
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same diffusion conditions as in the enzymatic assay, calibration curves for 
quantifying verapamil enantiomers were prepared in both sessions following the 
proposed methodology. Solution A was not included to avoid the advance of the 
enzymatic reaction, and corrected peak area was used as response variable. The 
quantification of the reaction turnover was done considering the consumption of 
verapamil enantiomers, so these results correspond to the overall metabolism of 
verapamil by CYP3A4 and not only to the norverapamil formation. Table IV.12 shows 
the calibration statistics obtained for each enantiomer in both working sessions 
together with their confidence intervals. As can be seen, adequate regression 
coefficients were obtained in all cases. Calculations for each experimental data set 
were done using its corresponding calibration curve. 
 
 
Figure IV.23: Electropherogram corresponding to the separation of the 
components of the proposed EMMA assay (VER: verapamil; NOR: norverapamil). 
EMMA conditions: incubation buffer 100 mM potassium phosphate, pH 7.4; 200 nM 
CYP3A4; capillary temperature 37 ºC and injection sequence as described in Table 
III.3 and in Fig. IV.22). 
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Table IV.12: Calibration statistics for S- and R-verapamil. 
  b0 ± ts b1 ± ts R2 
Session 1 S-VER -50 ± 80 15.9 ± 0.8 0.996 
 R-VER -40 ± 80 13.8 ± 0.8 0.994 
Session 2 S-VER -1 ± 60 20.1 ± 0.6 0.998 
 R-VER -1 ± 60 19.2 ± 0.6 0.997 
b0, intercept; b1, slope; ts, confidence interval at the 95% probability level; R
2, 
determination coefficient. 
 
In order to calculate the velocity rate data the amount of moles of verapamil 
transformed was estimated by calculating the injected volume of substrate via the 
following equation: 
;'& = ∆- · $
D · E · F
128 · H · I   (IV.16) 
where Vol (m3) is the injected volume, ∆P (Pa) is the applied pressure, d (m) is the 
internal diameter of the capillary, t (s) is the duration of pressure application,  η 
(Pa·s) is the viscosity of the injected solution and L (m) is the total capillary length. 
Velocity rate data (expressed in pmol·min-1·(pmol CYP)-1) were plotted thus vs. the 
initial enantiomer substrate concentration, [S] (µM), combining data from both 
experimental sessions (Michaelis-Menten plot, Eq. I.17). So, these results become 
more realistic than those obtained from a single experiment. Figure IV.24 shows the 
Michaelis-Menten plots for the metabolism of both verapamil enantiomers by 
CYP3A4. From the non-linear fitting of experimental data to the Michaelis-Menten 
equation Km and Vmax were estimated. Km values were 51 ± 9 and 47 ± 9 µM for S- 
and R-verapamil, respectively, while Vmax estimates were 22 ± 2 and 21 ± 2 
pmol·min-1·(pmol CYP)-1, respectively. The enantioselectivity, calculated as the ratio 
between the Vmax values of both enantiomers, was 1.08 in favour of the S-
enantiomer, which is slightly more metabolized than the R one. 
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(a) 
 
(b) 
 
Figure IV.24: Michaelis-Menten plots for the metabolism of (a) S-verapamil and (b) 
R-verapamil by CYP3A4. 
 
An interesting parameter from a pharmacokinetic point of view is the intrinsic 
clearance, defined as the amount of plasma from which a xenobiotic is removed in a 
certain time. It reflects the capacity of the body to remove a xenobiotic. The in vitro 
intrinsic clearance Cli can be estimated from the Km and Vmax values as Vmax/Km. Here, 
Cli values were estimated as 55 ± 10 and 55 ± 11 mL·min
-1·(mg CYP)-1 for S- and R-
verapamil, respectively. These values are in agreement with those found in the 
literature (Kroemer et al., 1992). 
 
IV.3.3. Fast evaluation of enantioselective drug metabolism by 
electrophoretically mediated microanalysis: application to fluoxetine 
metabolism by cytochrome P2D6 (Paper X) 
In this work, the methodology developed in the previous paper for the 
enantioselective evaluation of drugs metabolism, that joins an EMMA assay for the 
enzymatic reaction and a chiral separation of drug and metabolite by EKC-PFT, is 
applied to the study of fluoxetine metabolism by CYP2D6 (another isoform of 
cytochrome P450). 
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For this purpose, the conditions proposed in the previous paper were applied to 
carry out the EMMA enzymatic reaction (see Fig. IV.22 and Methodology section). 
Conditions for the enantioseparation of fluoxetine and its metabolite norfluoxetine 
were adjusted to achieve adequate chiral resolution. Based on previous experiences, 
concentrations of HS-β-CD (prepared in the BGE 50 mM sodium phosphate at pH 
8.8) in the range 0.1-1.25% (m/v) were assayed and a pressure of 0.4 psi was 
applied during separation. 
 
 
Figure IV.24: Electropherograms corresponding to the separation of the reaction 
mixture using different HS-β-CD concentrations: (a) 0.1%, (b) 0.15% and (c) 0.5%. 
Experimental conditions: BGE, 50 mM sodium phosphate at pH 8.8, 25 ºC, 20 kV. 
 
Figure IV.24 shows some of the results obtained using different HS-β-CD 
concentrations. As can be seen, with 0.1% HS-β-CD (a) the enantiomers of 
fluoxetine and norfluoxetine were separated but they overlapped with the peaks 
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corresponding to the CYP2D6. With 0.15% HS-β-CD (b) the peak of R-fluoxetine 
overlaps with the NADP+ peak (see Figure IV.26 for all peaks identification). 
Increasing the CD concentration to 0.5%, the fluoxetine and norfluoxetine 
enantiomers migrate after the NADP+/NADPH system, but S-norfluoxetine overlaps 
with the NADPH peak. Finally, with a HS-β-CD concentration of 1.25% (m/v) all the 
peaks in the reaction mixture were baseline resolved and fluoxetine enantiomers 
able to be quantified. The electropherogram corresponding to the final separation 
conditions is shown in Figure IV.26. 
 
 
Figure IV.26: Electropherogram showing the separation of the reaction mixture 
with 1.25% HS-β-CD. Other experimental conditions as described in Fig. IV.25. 
 
Once the separation conditions were adjusted, an experimental design was planned 
in order to obtain the Michaelis-Menten plots for the enantioselective fluoxetine 
metabolism by CYP2D6. The EMMA assay was carried out with seven concentration 
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levels of racemic fluoxetine in the range 10-200 µM, each one with two independent 
replicates. The complete experiment was repeated in two days in order to obtain the 
data under intermediate precision conditions. All data were used together for 
estimations. 
The interday precision of the proposed methodology was evaluated. Averaged 
intermediate precision results for peak areas of calibration curves and samples were 
9 and 16%, which can be considered acceptable taking into account the low 
concentrations used and the intrinsic variability of enzymatic reactions. 
Velocity rate data were adjusted to the Michaelis-Menten equation (Eq. I.17) for 
each fluoxetine enantiomer employing a Mardquardt algorithm. The corresponding 
Michaelis-Menten plots for S- and R-fluoxetine are shown in Figure IV.27. 
From these plots, kinetic parameters for the metabolism of both enantiomers have 
been estimated. Km values (mean ± SD) were 30 ± 3 and 39 ± 5 µM for S- and R-
fluoxetine, respectively. Vmax estimates were 28.6 ± 1.2 pmol·min
-1·(pmol CYP)-1 
(3630 ± 150 pmol·min-1·(mg CYP)-1) and 34 ± 2 pmol·min-1·(pmol CYP)-1 (4300 ± 
200 pmol·min-1·(mg CYP)-1) for S- and R-fluoxetine, respectively. These results show 
a slight enantioselectivity in favor of R-fluoxetine, estimated as the ratio between 
their Vmax values (Vmax-R/Vmax-S) and giving a value of 1.18. Considerable differences 
between these results and those reported in the literature in a previous study of 
enantioselective metabolism of fluoxetine by CYP2D6 (Margolis et al., 2000) were 
found. These differences can be attributed to the different enzyme sources and 
experimental methodologies, which strongly affect the estimations. 
The in vitro intrinsic clearance has been estimated here as Vmax/Km, and the values 
obtained were 121 ± 13 mL·min-1·(mg CYP)-1 and 111 ± 16 mL·min-1·(mg CYP)-1 for 
S- and R-fluoxetine, respectively. 
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 (a) 
(b) 
Figure IV.27: Michaelis-Menten plots for the metabolism of (a) S-fluoxetine and (b) 
R-fluoxetine by CYP2D6. 
 
Finally, in order to check a possible interaction between the enantiomers in their 
metabolism, an experiment was carried out incubating only a single enantiomer, R-
fluoxetine. The kinetic parameters obtained were: Km, 38 ± 9 µM and Vmax, 33 ± 4 
pmol·min-1·(pmol CYP)-1. The differences with the estimates obtained using the 
racemate were very low (1.6% for Km and 3.9% for Vmax) so we can conclude that 
the use of a racemate for the evaluation of enantioselective metabolism of a drug 
provides the same results than the use of single enantiomers, with the advantage of 
that no single enantiomers are needed. 
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V. CONCLUSIONS 
 
This Thesis deals with two important application fields of capillary electrophoresis: 
chiral analysis and bioanalytical applications. The advantages of CE for these 
applications have been extensively proved along the research papers discussed here. 
Fast, economic and fully automated methods have been developed and applied to 
chiral separations and enantioselective evaluation of pharmacokinetic and 
pharmacodynamic properties of drugs. The most relevant conclusions that can be 
extracted from this work are summarized here: 
• HS-β-CD has proved to be an excellent chiral selector for neutral and basic 
compounds. It has provided good enantioresolution values for most of the chiral 
compounds tested, using the partial and complete filling techniques. The 
enantioseparations performed with HS-β-CD have been successfully applied to 
the analysis of pharmaceutical samples, the analysis of ultrafiltrates from 
protein-drug mixtures and coupled to EMMA assays. 
• Apparent binding constants between drugs and the HS-β-CD, calculated using 
non-linear regression, show that a strong interaction takes place between the 
HS-β-CD and the enantiomers of the eight psychoactive drugs studied. It has 
been demonstrated that enantioseparation with this CD is due to two different 
mechanisms, thermodynamic (the most usual) and electrophoretic 
enantioselectivity (less common but also enough to provide complete 
enantioresolution). 
• The use of complete filling technique instead of conventional EKC is proposed 
for the evaluation of enantiomer-chiral selector binding constants. Its main 
advantage is a saving on chiral selector of about 99%. Except for the NACE 
application, all the enantioseparations in this Thesis have been performed by 
CFT or PFT, being the consumption of cyclodextrins extremely low. 
• A relationship between some structural properties of basic xenobiotics and their 
enantioresolution with HS-β-CD, established by multivariate analysis, shows the 
ability of this CD as chiral selector. The most influential structural properties on 
the enantioresolution with HS-β-CD are lgD, PSA, HBD and HBA. From these 
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properties, predictions of categorical resolutions can be done via a simple direct 
equation developed in this Thesis. 
• DMSO has proved to be an alternative for chiral NACE when the commonly used 
alcoholic BGEs could not be used due to volatility, solubility or current 
breakdown problems. CM-γ-CD has been successfully employed as chiral 
selector in NACE in a DMSO-based background electrolyte, with stable currents 
during all the electrophoretic developments. Despite the weaker selector-
selectand interactions compared with aqueous media, baseline resolutions were 
achieved suggesting that the BGEs proposed in this work can be used in chiral 
NACE. 
• A robust mathematical data treatment for the evaluation of protein binding is 
proposed, avoiding inconsistent equations that have been used in the past. The 
new protocol including outliers’ identification and elimination, estimation of 
affinity constants with their uncertainty and verification of some assumptions 
done about the binding process also provides some quality suggestions about 
adequate conditions for the experimental design. 
• The enantioselective binding of fluoxetine to HSA and of zopiclone and 
nomifensine to HSA and total plasma proteins has been evaluated in this Thesis 
via ultrafiltration and chiral EKC, using the experimental design and protocol 
developed here. In all cases, a certain degree of enantioselectivity has been 
found in their binding with the HSA molecule. 
• An EMMA methodology for the screening of AChE inhibitors has been developed. 
This methodology allows obtaining inhibition constants, IC50 estimations and to 
determine the mechanism of the inhibition. Experimental conditions for 
screening new candidate drugs are established, with the percent of inhibition as 
measure of the inhibitor potency. The proposed methodology is applied to the 
screening of five known AChE inhibitors, being the order of their inhibitor 
potencies: tacrine > edrophonium > neostigmine > eserine > pyridostigmine. 
• The EMMA procedure and the chiral separation by EKC-PFT have been combined 
in order to develop a methodology that allows the enantioselective estimation of 
drugs metabolism by different isoforms of the cytochrome P450. Some 
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experimental variables of the EMMA procedure, as well as the 
enantioseparations with HS-β-CD, have been adjusted in order to obtain a fast, 
simple and fully automated methodology with an extremely low consumption of 
enzymes, substrates and chiral selectors (usually expensive). The complete 
method, including capillary preconditioning, injection, incubation and chiral 
separation takes less than 35 min. 
• Michaelis-Menten parameters, estimated for the metabolism of verapamil 
enantiomers by CYP3A4 and fluoxetine enantiomers by CYP2D6, show in both 
cases a slight enantioselectivity in the metabolism process. From the kinetic data 
an estimation of the in vitro intrinsic clearance has been performed also for the 
enantiomers of both drugs. 
The results obtained in this Thesis show that capillary electrophoresis can be a 
powerful technique for all the studies that may be performed in the pre-clinical 
stages of the development of new drugs. Methods for the chiral analysis of new 
molecules can be easily developed using the prediction model of enantioresolution 
performed for HS-β-CD. EMMA has good features for the fast screening of candidate 
drugs in terms of their pharmacological activity, and also for evaluating relevant 
pharmacokinetic properties such as their metabolism by enzymatic systems. In 
combination with UF, chiral EKC provides accurate estimations of the 
enantioselective protein binding of drugs. In summary, the in vitro procedures 
developed in this Thesis provide an overview of the potential behavior of new 
molecules in their interaction with live systems, which is valuable information in 
order to save effort and money with in vivo studies. 
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Characterizing the interaction between
enantiomers of eight psychoactive drugs
and highly sulfated-b-cyclodextrin by
counter-current capillary electrophoresis
Lucía Asensi-Bernardia, Laura Escuder-Gilaberta, Yolanda Martín-Bioscaa,
Salvador Sagradoa,b and María José Medina-Hernándeza*
ABSTRACT: The estimation of apparent binding constants and limit mobilities of the complexes of the enantiomers that character-
ize the interaction of enantiomers with chiral selectors, in this case highly sulfated b-cyclodextrin, was approached using a simple
and economic electrophoretic modality, the complete ﬁlling technique (CFT) in counter-current mode. The enantiomers of eight
psychoactive drugs, four antihistamines (dimethindene, promethazine, orphenadrine and terfenadine) and four antidepressants
(bupropion, ﬂuoxetine, nomifensine and viloxazine) were separated for the ﬁrst time for this cyclodextrin (CD). Estimations of
thermodynamic and electrophoretic enantioselectivies were also performed. Results indicate that, in general, thermodynamic
enantioselectivity is the main component explaining the high resolution found, but also one case suggests that electrophoretic
enantioselectivity itself is enough to obtain a satisfactory resolution. CFT results advantageous compared with conventional
capillary electrophoresis (CE) and partial ﬁlling technique (PFT) for the study of the interaction between drugs and chiral selectors.
It combines the use of a simple ﬁtting model (as in CE), when the enantiomers do not exit the chiral selector plug during the
separation (i.e. mobility of electroosmotic ﬂow larger than mobility of CD), and drastic reduction of the consumption (and cost;
~99.7%) of the CD reagent (as in PFT) compared with the conventional CE. Copyright © 2013 John Wiley & Sons, Ltd.
Keywords: overall apparent binding constants; overall limit mobilities; thermodynamic and electrophoretic enantioselectivities;
capillary electrophoresis; complete ﬁlling technique; highly sulfated b-cyclodextrin
Introduction
A research area of current interest is the development of
stereoselective analytical methods able to determine the stereo-
isomer ratios in synthetic products, pharmaceutical formulations
and biological samples owing to the high degree of stere-
oselectivity of pharmacological and pharmacokinetic processes
(Scriba, 2011). Capillary electrophoresis (CE) is one of the most
employed analytical techniques for chiral analysis, owing to its
high efﬁcacy, short analysis time, low reagent consumption and
ease of automation (Chankvetadze, 2007).
Among the different chiral selectors used in CE, cyclodextrins
(CDs) are widely used owing to the wide arsenal of CDs of different
natures (native, derivatives, anionic, cationic or neutral) available,
which enables chiral separation of a large number of chiral
compounds. Characterizing the interactions of enantiomers with
CDs is helpful in chiral separations research for a better under-
standing of the separation mechanism and molecular interactions
and the prediction of migration behavior (Al Azzam et al., 2010;
Pang et al., 2009; Chen and Weber, 2008). In these studies estima-
tions of the association constants enantiomer–CD are performed.
Such information is also valuable in studies where CDs are used
as macromolecular hosts for explaining inclusion phenomena or
encapsulation within CD nanocavities.
Direct enantioseparation with CE can be performed by adding
a chiral selector to the background electrolyte (BGE). An alterna-
tive to this conventional technique is the use of partial (PFT) and
complete (CFT) ﬁlling techniques in which the capillary is
(partially or totally, respectively) ﬁlled with chiral selector
solution prior to injection of the analyte, while the BGE remains
without chiral agent. PFT allows using chiral selectors to which
given detectors have a signiﬁcant response, as well as to avoid
contamination of the ion-source when CE is coupled to mass
spectrometry. The most important property of PFT and CFT,
compared with the conventional technique, is its reduced
expense owing to the drastic reduction of the chiral selector
consumption (Amini et al., 1999b; Chankvetadze and Blaschke,
2001). A special form of PFT and CFT, when the chiral selector
and analyte possess opposite charges and move in the capillary
* Correspondence to: María José Medina-Hernández, Departamento de
Química Analítica, Universidad de Valencia, Burjassot, Valencia, Spain.
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in opposite direction, has been called counter-current separa-
tion (Chankvetadze et al., 1994).
Highly sulfated cyclodextrins (HS-CDs) are a relatively recent
family of CDs with good enantiomeric separation ability of nu-
merous acidic, neutral and basic analytes (Perrin et al., 2001;
Matthijs et al., 2002; Verleysen et al., 1999; Chen et al., 2001;
Vescina et al., 2002; Vaccher et al., 2005; Rudaz et al., 2004;
Foulon et al., 2002; Lipka et al., 2007; Danel et al., 2005). These
CDs have a high density of negative charge in a broad pH range,
so their electrophoretic mobility makes them adequate for
counter-current separations. The opposite mobility of the
analyte and the cyclodextrin greatly increases their interaction.
In fact, it has been reported that maximum enantioselectivity
values are obtained when analytes and CDs have opposite
mobilities (Chankvetadze et al., 1994; Rudaz et al., 2003).
The aim of this study was to evaluate the enantioselective
interaction data (afﬁnity constants and mobilities of enantiomers,
and thermodynamic and electrophoretic enantioselectivity values)
of four antihistaminic and four antidepressant drugs with highly
sulfated b-cyclodextrin (HS-b-CD), using advantageously counter-
current CE-CFT, a modality not used before for this purpose. Using
CFT could ensure that enantiomers do not exit to the CD plug
during the electrophoretic separation, simplifying the calculations.
Materials and methods
Instrumentation
A Beckman P/ACE MDQ Capillary Electrophoresis System
equipped with a DAD (Beckman Coulter, Fullterton, CA, USA)
and 32Karat software version 8.0 was used throughout. A
50mm inner diameter (i.d.) fused-silica capillary with total and
effective lengths of 60.2 and 50 cm, respectively, was employed
(Beckman Coulter, Fullterton, CA, USA). Electrophoretic solutions
and samples were ﬁltered through 0.45 mm pore size nylon
membranes (Micron Separation, Westboro, MA, USA) and
degassed in an ultrasonic bath (JP Selecta, Barcelona, Spain)
prior to use. A Crison Micro pH 2000 pH meter from Crison
Instruments (Barcelona, Spain) was employed to adjust the pH
of buffer solutions.
Chemicals and solutions
All reagents were of analytical grade. NaH2PO4  2H2O was from
Fluka (Buchs, Switzerland); HS-b-CD (20% w/v) aqueous solution
was purchased from Beckman Coulter (Fullterton, CA, USA); Ultra
Clear TWF UV deionized water (SG Water, Barsbüttel, Germany)
was used to prepare solutions.
Orphenadrine hydrochloride (ORP), terfenadine (TER), bupropion
hydrochloride (BUP) and nomifensine maleate (NMF) were pur-
chased from Sigma (St Louis, MO, USA). Promethazine hydrochlo-
ride was purchased from Guinama (Valencia, Spain). Dimethindene
maleate (DIM) was kindly donated by Novartis (Madrid, Spain)
and ﬂuoxetine hydrochloride (FLX) by Alter (Madrid, Spain).
Viloxazine (VLX) was also kindly donated by Astra Zeneca
(Chesire, UK).
BGE containing 30mM phosphate at pH 7.0 was obtained by
dissolving the appropriate amount of NaH2PO4  2H2O in water
and adjusting the pH with 1 M NaOH; 200mM solutions of the
racemic drugs were prepared in BGE to be injected into the elec-
trophoretic system. These solutions were obtained by dilution
from 1000 mM stock ones, prepared by weighing the appropriate
amount of each drug, dissolving it in the minimum volume of
methanol necessary and bringing it to ﬁnal volume with BGE.
The small amount of methanol present in the ﬁnal solutions
was used as an electroosmotic ﬂow (EOF) marker.
Methodology
In order to obtain good peak shapes and reproducible migration
data, the capillary was conditioned prior to each injection. In all
cases, the conditioning run included the following steps: (a)
1min rinse with deionized water; (b) 2min rinse with 0.1 M
NaOH; (c) 1min rinse with deionized water; and (d) 2min rinse
with BGE at 20 psi.
For the evaluation of the enantioselective interaction between
psychoactive drugs and the HS-b-CD, chiral separation of the
racemic drugs was carried out employing eight concentrations
of HS-b-CD between 0 and 2% (0, 0.05, 0.1, 0.25, 0.5, 0.75, 1
and 2%), and three capillary temperatures (15, 25 and 35C).
Other working conditions were kept constant at following
values: BGE, 30mM phosphate at pH 7.0; applied voltage, 15 kV;
CD injection, 10 psi per 2min (ﬁlled capillary); analyte injection,
0.5 psi per 5 s; detection wavelength, 220 nm.
Software and calculations
Effective electrophoretic mobilities, mi, were calculated from:
mi ¼
Ll
V
1
ti
 1
t0
 
(1)
where L is the total capillary length, l the length of the capillary
from the inlet end to the detector, V is the applied voltage, and ti
and t0 are the measured migration times of the analyte and EOF
marker, respectively. STATGRAPHICSW Plus 5.1 was employed for
nonlinear ﬁtting.
Results and discussion
Enantioseparation of psychoactive drugs
Figure 1 shows the chemical structures of the eight psychoactive
drugs in study. Their pKa values are between 8.1 and 9.7, so they
are positively charged at working conditions (pH 7), leading to a
high interaction with the anionic HS-b-CD favoured by their
migration through the CD plug. Figure 1 also shows some elec-
tropherograms corresponding to the enantiomer resolution
obtained under different experimental conditions. As can be
observed in Fig. 1, except for terfenadine, baseline resolution
was achieved for all the analytes studied and high Rs values
were obtained. The Rs values obtained were similar to or higher
than those reported in the literature for these compounds with
other cyclodextrins, but obtained in most cases using higher
CD concentrations than here (Castro-Puyana et al., 2008; Van
Eeckhaut et al., 2004; Matsunaga et al., 2002; Inoue and Chang,
2003; Rudaz et al., 2003; Bonato et al., 2003; Perrin et al., 2001;
Li and Vigh, 2004; Asensi-Bernardi et al., 2010; Yang et al., 2005;
Liao et al., 2007; Chen et al., 2002; Wei et al., 2005).
Electroosmotic ﬂow mobility (mEOF) in the working conditions was
estimated as between 3.81 108 and 5.99 108m2V1 s1 from
experimental data. These values are higher than the opposite CDmo-
bility (mCD), obtained from the literature (3.33 108m2V1 s1;
Chen et al., 2001). EOF pushes the CD and its complexes to the
Chiral interaction parameters with HS-b-cyclodextrin by CE
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Figure 1. Electropherograms showing the chiral separation of each psychoactive drug, with the [CD] and temperature employed in each case. Other
experimental conditions are: BGE, 30mM phosphate buffer, pH 7.0; applied voltage, 15 kV.
L. Asensi-Bernardi et al.
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detector, against their mobilities, whereas the free enantiomers
migrate faster than the CD plug tha tis always inside it (an inter-
esting feature; see below). The complexation equilibrium is
shifted by the CD concentration and affects the effective mobil-
ity of the enantiomers, resulting in differences in the Rs and
migration time values. For normal polarity, the enantiomer
forming a more stable complex with HS-b-CD elutes second
from the capillary.
The effect of HS-b-CD concentration and temperature on
the enantiomeric resolution (Rs) was investigated. As can be
expected, in all cases the increase in HS-b-CD concentration
leads to longer analysis times and higher negative mobility of
the enantiomers, owing to the negative charge of the formed
complexes. In fact, for some drugs, the peak of the second
enantiomer could not be seen after 50min of voltage applica-
tion. For all compounds Rs improved with higher CD concentra-
tions. However, very different results were obtained for each
compound, for example, the TER enantiomers were partially
resolved (Rs< 1.5) for all the HS-b-CD concentrations assayed,
while excellent resolution values (Rs> 10) were obtained for
DIM, NMF and FLX at very low CD concentration. The increase
in capillary temperature led to shorter analysis times whereas
Rs increased for some compounds (e.g. NMF, FLX) and decreased
for other ones (e.g. DIM, BUP). The different behaviors could be
explained by the effects of temperature on peak efﬁciency,
buffer viscosity or selector–selectand interactions (Martín-Biosca
et al., 2001).
Determination of interaction parameters for enantiomers
The commercial HS-b-CD used in the present study was a
mixture mainly composed of 12-sulfated isomers with identical
mobilities (Chen et al., 2001; Rudaz et al., 2004). For estimating
the interaction parameters of enantiomers, we used the model
describing CE enantioseparation with multi-CD systems proving
that the mixture of HS-b-CDs behaves as only one CD (Dubský
et al., 2010). The model assumes that each individual analyte–
CD interaction is fast and fully independent of other interactions;
the analyte-CD ratio is 1:1 and the analyte concentration is low
enough to not considerably change the concentration of free
CDs. This provides an expression similar to the fundamental
one introduced by Wren and Rowe (1992) for the multi HS-b-
CD system:
mi ¼
m0i þ mCDi K
0
i CD½ 
1þ K 0 i CD½  (2)
where [CD] is the total concentration of HS-b-CD and K0 i and mCDi
are the overall apparent binding constants and the overall limit
mobilities, respectively, deﬁned as:
K
0
i ¼
Xq
1
wqKqi (3)
mCDi ¼
X
q
wqKqi m
q
i
K 0 i
(4)
where wq is the molar fraction of the qth selector isomer in the
mixture, Kqi is the individual apparent complexation constant
with the ith enantiomer (i=1 or 2) and qth isomer of CD (Rudaz
et al., 2004; Dubský et al., 2010), and mqi is the individual mobility
of the ith enantiomer–qth CD complex.
In PFT (Amini et al., 1999a, 1999b), the effective electropho-
retic mobility of the solute is the sum of its mobility within the
plug (composed of the electrophoretic mobilities of the free
and complexed solute) and outside the plug (in the BGE); in fact,
apparent binding constants have been evaluated by varying the
plug length (Amini and Westerlund, 1998; Amini et al., 1999a,
1999b; Machour et al., 2005; Ali et al., 2003). This becomes
unnecessary under the CFT mEOF>mCD conditions used in this
work, since the capillary is completely ﬁlled with the chiral
selector and the enantiomers do not leave the CD plug during
their migration. Thus, the extra PFT term, corresponding to
mobility outside the plug, becomes zero in CFT and can be
eliminated, simplifying the expression of the observed mobility.
Consequently, in CFT equation (2) could be applied in order to
evaluate K0 (as in conventional CE).
On the other hand, in CFT (as in PFT), the change in the mobil-
ities owing to differences in the buffer composition across the
capillary during the separation process should considered,
which could provide possible variations of mobility during
the separation (e.g. this justiﬁes K0 being named ‘apparent’).
However, results in the literature suggest that comparable
mobilities are obtained in PFT and conventional CE (Amini
et al., 1999a, 1999b), which should be extrapolated to the inter-
mediate CFT approach.
In order to estimate K0 and mCDi values, effective mobility of the
enantiomers was ﬁtted vs [CD] (in molar units on the basis of an
average molar mass of 2360 gmol1 for a substitution degree of
12 sulfates mol1; Chen et al., 2001) to equation (2). Nonlinear
estimation was preferred instead of the most popular linear
equations, owing to its expected higher robustness (Asensi-
Bernardi et al., 2010) and the possible lack of accuracy and
precision of linear models owing to errors derived from variable
transformation (Foulon et al., 2004). The obtained ﬁtted models
have good correlation coefﬁcients, R2> 0.99 in most of the
cases, suggesting that equation (2) appropriately reﬂects the
behavior of the compounds in the HS-b-CD system.
Two possible mechanisms or a combination of both can
explain the differences in the effective mobilities of enantiomers
in the presence of a chiral selector, which is the separation of
enantiomers of a compound. The ﬁrst one is related to the
differences between the apparent binding constants of
enantiomers (thermodynamic enantioselectivity at= K02/K01).
The second one is related to the differences in the overall limit
mobilities of the complexes of the enantiomers (electrophoretic
enantioselectivity (ae=m
CD
2 /m
CD
1 ), or both of them (Dubský et al.,
2010). In this paper thermodynamic and electrophoretic
enantioselectivity parameters were also estimated. Combining
equations (3) and (4) a new relation between these
enantioselectivity values, not previously reported in quantitative
form, arises:
ae ¼ m
CD
2
mCD1
¼
X
q
wqKq2m
q
2X
q
wqKq1m
q
1
1
at
(5)
Table 1 shows the estimated parameters of psychoactive
drugs at three working temperatures. The highest binding
constants were obtained for TER, but with very low values of
enantioselectivity (thermodynamic and electrophoretic). The large
size of this molecule may prevent its inclusion into the hydropho-
bic cavity of the cyclodextrin, where the enantiorecognitionoccurs,
Chiral interaction parameters with HS-b-cyclodextrin by CE
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also explaining the low Rs values obtained (Rs< 1.5). On the other
hand, maximum at values were achieved for NMF (at 25C),
followed by FLX (at 35C), which also exhibit relatively high K0
values.
As can be observed in Table 1, except for VLX, at values
were higher than those for ae, which suggests that the
thermodynamic mechanism plays a more important role in the
enantiomeric separation of the studied compounds with
the commercial HS-b-CD used in the present study. However,
VLX is an example of how good enantioseparations (Rs> 2)
can be achieved mainly owing to differences in overall limit
mobilities of enantiomers (ae=1.2), although this is a mixed
effect [equation (5)].
Additionally, as can be seen in Table 1, the values of the
binding constants decreased with increasing temperature, as a
general trend. Exceptions to this trend could be attributed to
the combination of low Ki-values and small differences in Ki
and the Ki uncertainties. For compounds with lower afﬁnity for
the CD (BUP, DIM and VLX), minor differences were found at
the three temperatures studied.
On the other hand, enantioselectivity values, at and ae, practi-
cally do not change with temperature except for NMF and FLX.
Precisely for these compounds, the quantitative relationship
expected from equation (5) can be observed; at (as Rs) increases
with the temperature, while ae shows the opposite trend.
Although we have not found literature binding data for
the analytes studied in this work, some reported values are avail-
able for other basic compounds (Vaccher et al., 2005; Rudaz
et al., 2004; Foulon et al., 2002; Lipka et al., 2007; Danel et al.,
2005). The K0 values of enantiomer-HS-b-CD in Table 1 are similar
to or higher than those in the literature, conﬁrming the extraor-
dinarily good enantioseparation capabilities of this commercial
mixture cyclodextrin.
The optimum [CD] for each separation, deﬁned as the [CD]
that provides the highest mobility difference between enantio-
mers (maximum Δm), can be estimated from the overall apparent
binding constants in Table 1 by means of equation (6) (Dubský
et al., 2010).
CD½ opt ¼ 
Δm 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Δ2m  1KΠ ΔmKΔemK
q
ΔemK (6)
where Δm ¼ mr;CD2  mr;CD1 (where mr;CDi ¼ mCDi  m0i ), ΔmK ¼
mr;CD2 K
0
2  mr;CD1 K
0
1 , ΔemK ¼ mr;CD2 K 0 1  mr;CD1 K 0 2 , and KΠ= K01K02.
Where the thermodynamic mechanism is responsible for separa-
tion and considering the limit mobilities of two enantiomers
identical (mCD1 ¼ mCD2 ), equation (6) could be simpliﬁed to obtain
the simplest equation introduced by Wren and Rowe (1992):
CD½ opt ¼
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
K 0 1K 0 2
p (7)
The estimated [CD]opt values using both equations (6) and (7) are
also included in Table 1. In general, values obtained with both
equations were similar, conﬁrming a greater contribution of the
thermodynamic mechanism in the enantioseparation of the drugs
studied. The compounds that showed more differences (BUP, DIM
and VLX) were those that interact more weakly with the cyclodex-
trin, particularly the last one, for which equation (6) results in
negative solutions indicating that no optimum HS-b-CD concen-
tration exists. This fact also conﬁrms that for this compound the
differences between limit mobilities of two enantiomers are
responsible for the enantioseparation.
Conclusions
HS-b-CD has proved to be an effective chiral selector for the
separation of enantiomers of four antihistamines and four anti-
depressants by CE-CFT, since good resolutions have been
achieved in most of the cases (Rs> 1.5 for seven of the studied
compounds). The overall apparent binding constants, estimated
by nonlinear ﬁtting, indicate that these drugs interact strongly
with the cyclodextrin. The thermodynamic mechanism plays a
more important role in the enantiomeric separation, with high
thermodynamic enantioselectivity particularly in the cases of
nomifensine, ﬂuoxetine and orphenadrine. Only in the case of
viloxazine (at=1, ae= 1.2) is the electrophoretic enantioselective
mechanism probably responsible for enantioseparation, provid-
ing also a good resolution. Matched with literature data for other
basic compounds, comparable or higher binding constant and
comparable or better resolution were observed with the com-
pounds studied in this work, suggesting the adequacy of the
CFT approach.
CFT is proposed as an advantageous alternative to conven-
tional CE and PFT for the study of the interaction between drugs
and chiral selectors. It has the advantage of PFT of reduced cost
compared with conventional CE, but allows use of the simple
model of CE, when the mobility of electroosmotic ﬂow is larger
than mobility of CD, thus the enantiomers do not exit the chiral
selector plug during the separation. As an averaged estimation,
the amount of CD solution needed for each injection is 2mL in
conventional CE and 5 mL in CFT. Assuming a cost of CD solu-
tions of ~ €0.5mL1, the cost of each injection will be close to
€1 for conventional CE, and only €0.0025 for CFT (saving 99.7%).
Along with its interest as separation mechanism key, the
estimation of afﬁnity constants characterizing the interactions
of molecules with CDs is usual in biomedical processes, where
CDs participate as macromolecular hosts, for explaining inclu-
sion phenomena or encapsulation within CD nanocavities, useful
for example in controlled release. However, in both research
areas, there are still few chiral studies. The easy and economic
method used here should promote the inclusion of the chiral
component in these ﬁelds.
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a  b  s t  r  a  c t
Despite the  fact  that extensive research  in  the  ﬁeld of  enantioseparations  by  capillary  electrophoresis
has been carried out, it is  difﬁcult  to  predict  whether  a  concrete  chiral  selector  would  be  useful  for  the
separation of a  racemic  compound.  Hence,  several experimental  effort  is  necessary to  test  the  abilities
of individual chiral  selectors,  usually by  trial  and  error procedures. Thus, the  enantioseparation  of a  new
racemate becomes  a time-  and  money-consuming  task. In this work, the  ability  of  highly  sulfated -
cyclodextrin (HS--CD) as chiral  selector  in electrokinetic  chromatography (EKC)  is  modeled  for the  ﬁrst
time, using exclusively  directly-available  structural  data  of  forty compounds (structurally  unrelated  basic
drugs and pesticides).  A discriminant  partial least  squares (PLS)-based  quantitative  structure–property
relationship (QSPR) approach  is  simpliﬁed,  resulting in  a  consistent,  predictive  and  descriptive model.  It
is converted  into  an explicit  equation able to predict  the  enantioresolution  level (Rs)  of  new  compounds,
from four  structure  properties  available  in  an on-line  open  database:  logarithm  of octanol-water  partition
coefﬁcient estimated at pH  7.4 (lgD),  polar  surface  area  (PSA),  number  of  hydrogen bond  donors  (HBD)
and acceptors  (HBA). For  the  cases  in which  the model  predicts  good  Rs only  in concrete  experimental
conditions, a Box–Behnken  experimental  design  is  proposed  for the  fast PLS-based  optimization  of  the
most inﬂuential  experimental  variables: cyclodextrin  concentration,  temperature  and  pH.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
In  the last years, chirality has become interesting for differ-
ent industries related to chemistry, mainly the pharmaceutical
and agrochemical ones [1]. Therefore, analytical methods for the
determination of single enantiomers in different industrial and
environmental samples are needed. The most often applied meth-
ods in chiral analysis are chromatographic and  electrophoretic
techniques. In the last ones, chiral selectors are usually included
in the background electrolyte, in the so-called electrokinetic chro-
matography (EKC) mode [2].
Among the different chiral selectors used in EKC, cyclodextrins
(CDs) are the most employed due to their good enantiorecog-
nition abilities, good water solubility, UV transparency, and the
wide assortment of different neutral, cationic and anionic CDs with
∗ Corresponding author at: Departamento de Química Analítica, Facultat de  Far-
macia, Universitat de Valencia, C/  Vicent Andrés Estellés s/n, E-46100 Burjassot,
Valencia, Spain. Tel.: +34 963544878; fax: +34  963544953.
E-mail address: sagrado@uv.es (S. Sagrado).
different  functional groups that can be  employed [3]. Their struc-
ture, with a hydrophilic external surface and a  hydrophobic cavity,
allows the formation of diastereomeric complexes with a pair of
enantiomers, which migrate at different velocities through the cap-
illary allowing  the enantioseparation. It has  been reported that
maximum enantioselectivities are achieved when analytes and CDs
have opposite mobilities [4,5].
Highly sulfated -cyclodextrin (HS--CD) is an anionic
cyclodextrin with  an average content of 12 sulfate groups per
molecule [6]. Its  high density of negative charge makes it  an excel-
lent chiral  selector for neutral and positively charged compounds.
However, in spite of its mainly good applicability for chiral separa-
tions, it is still difﬁcult to predict its level of enantioresolution (Rs)
for a concrete compound.
In this context, mathematical models could help to save experi-
mental effort, money and time, if  previous Rs-related experimental
information is available for a set of molecules. A  regression-based
quantitative structure–property relationship (QSPR) implies mod-
eling a  y-X relationship, where the vector y represents a target
property (response or dependent variable; e.g. Rs-related experi-
mental values)  and X represents the matrix of descriptor variables
0021-9673/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.chroma.2013.08.003
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(predictor or independent variables; e.g. structure information)
when related by a particular regression algorithm, e.g. partial
least squares (PLS). The y-X  relationship can be  expressed by
their regression coefﬁcients, b  [7,8]. Simultaneously, the predictive
ability of the model can be  assessed by analyzing the explained
y-variance (EV)  and its cross-validated value (EVCV),  while the b-
coefﬁcients can provide the descriptive ability if combined with
uncertainty estimation, b ± U(b) (jack-kniﬁng, as a part of the cross-
validation process [7,9]). Thus, cross-validation becomes basic to
assure reliability of future y-estimations for new compounds [7,10].
Different strategies have been used in the literature for  devel-
oping QSPR for modeling enantioresolution-related information
in EKC [11–14].  In two  of these works the response variable was
the relative migration times to that of 6-aminonicotinic acid of 12
aromatic amino acids and alkyl esters of  2-phenylglycine, using
(+)-18-crown-6-tetracarboxylic acid as  chiral selector [11,12]. In
the work by Beck et al. [13],  enantiomers mobility differences for
13 -blockers and tryptophan derivatives using sulfated polysac-
charides as chiral selectors are used as  response variable. At
our knowledge, there is only one work that directly models the
Rs parameter as a function of structural information (molecular
mechanics/docking energy descriptors derived form a  combination
of several programs) for 12 structurally related triadimenol analogs
using hydroxypropyl--CD as  chiral selector [14].
In this work, the ability of using HS--CD as chiral selec-
tor for enantioseparation in EKC of structurally unrelated basic
compounds is modeled for the ﬁrst time using exclusively directly-
available structural data. A  QSPR approach is simpliﬁed using
categorized Rs-structure parameters of forty compounds (drugs
and pesticides), based on  discriminant PLS on one single response
(DPLS1). The model is re-expressed for simplicity in the practi-
cal format ‘Rs = f(selected parameters)’. Latent structure (consistent
model complexity) as well as predictive and  descriptive power
criteria are incorporated to the decision making simpliﬁcation pro-
cess.
One particular aim of this work is to explore non-complex
(clear for non-expert users) and easily available approaches. A
single software/regression algorithm (PLS) and a single on-line
(open) database (structure parameters) are used. The obtained
Rs-explicit equation is applied to estimate the chiral resolution
of bupivacaine. Further, a multivariate optimization including the
standard Box–Behnken experimental design, followed by  PLS2 on
two response variables: Rs  and analysis time, is used to derive
again explicit equations for  these two variables as  a function of the
methodological EKC variables: CD concentration, temperature and
electrophoretic buffer pH. These equations are used to estimate the
convenient separation conditions of bupivacaine.
2. Materials and methods
To facilitate the understanding of the statistical aspects, a com-
plete list of abbreviations (including variables) has been  included
in Appendix A.
2.1. Instrumentation
A Beckman P/ACE MDQ  Capillary Electrophoresis System
equipped with a DAD (Beckman Coulter, Fullterton, CA, USA), and
32Karat software version 8.0 was used throughout. A  50 m inner
diameter (i.d.) fused-silica capillary with total and effective lengths
of 60.2 and 50 cm,  respectively, was employed (Beckman Coulter,
Fullterton, CA, USA). Electrophoretic solutions and  samples were
ﬁltered through 0.45 m pore size nylon membranes (Micron Sep-
aration, Westboro, MA,  USA) and degassed in an ultrasonic bath (JP
Selecta, Barcelona, Spain) prior to use.
2.2. Chemicals and solutions
All reagents were of analytical grade. NaH2PO4·2H2O was from
Fluka (Buchs, Switzerland); HS--CD (20% m/v, average number of
12 sulfate groups per  molecule) aqueous solution was  purchased
from Beckman Coulter (Fullterton, CA, USA); Ultra Clear TWF  UV
deionized water (SG Water, Barsbüttel, Germany) was  used to
prepare solutions.
Alprenolol hydrochloride, labetalol hydrochloride, pin-
dolol, sotalol hydrochloride, etopropazine hydrochloride,
metotrimeprazine maleate, trimeprazine hemi(+)-tartrate,
brompheniramine maleate, carbinoxamine maleate, clemastine
fumarate, chlorpheniramine maleate, chlorcyclizine hydrochlo-
ride, doxylamine succinate, hydroxyzine hydrochloride, and
phenindamine tartrate were from Sigma (St. Louis, MO,  USA). All
the rest of drugs tested were kindly donated by several pharma-
ceutical laboratories: oxprenolol hydrochloride and  metoprolol
tartrate by  Ciba Geigy (Barcelona, Spain); propranolol chlorhy-
drate by ICI Farma (Madrid, Spain); carteolol hydrochloride by
Miquel-Otsuka (Barcelona, Spain); timolol maleate by  Merck  Sharp
& Dohme (Madrid, Spain); acebutolol hydrochloride by Italfar-
maco (Madrid,  Spain); atenolol by Zeneca Farma (Madrid, Spain);
celiprolol hydrochloride by Rhone-Poulenc Rorer (Madrid, Spain)
and nadolol by  Squibb (Barcelona, Spain). All racemic pesticides
(benalaxyl, cyproconazole, hexaconazole, imazalil, myclobutanil
and penconazole) were from Dr. Ehrenstofer (Augsburg, Germany).
Background electrolyte (BGE) containing 50 mM  phosphate at
pH 7.0 was obtained by dissolving the appropriate amount of
NaH2PO4·2H2O in water and  adjusting the pH with 1 M NaOH.
200 M solutions of the racemic drugs and pesticides were pre-
pared in BGE to be injected into the electrophoretic system.
2.3. Methodology for the chiral separation of compounds by EKC
Some of the categorical Rs data included in Table 1 were taken
from previously published enantioseparations: ﬂuoxetine (No 28
from Table  1) [15,16],  catechin (No  35) [17], verapamil (No 36) [18]
and several antihistamines and antidepressants (No 6, 9, 11, 14 and
25–28) [19]. For these compounds full resolution of enantiomers
was obtained using 1% m/v  HS--CD  or  lower concentrations. All
the experiments were performed using phosphate buffer in a pH
range of 7.0–8.8  and  separation temperatures of 25–30 ◦C.
In order  to obtain information about the enantioresolution of
all the  other  compounds listed in Table 1  (No 1–5,  7, 8, 10, 12, 13,
15–24, 29–34  and 37–40) a screening EKC procedure was carried
out in  the following experimental conditions: BGE, 50 mM  phos-
phate buffer at  pH 7.0;  capillary temperature, 25 ◦C;  voltage, 20 kV
(normal polarity). Previously to the compound injection, the capil-
lary was completely ﬁlled with a  1% m/v  HS--CD solution prepared
in the BGE, by  rinsing it  at  10 psi for 1  min. In  the cases with strong
interaction with  the HS--CD [19],  no peaks were found with these
conditions, so the experience was  repeated using a 0.25% m/v  HS-
-CD solution.
2.4. Software for calculations
The Unscrambler® v.9.2 multivariate analysis software version
[20] is used for all calculations, based on principal component
analysis (PCA) and PLS models. Two  automatic default features
of the software are used: (i)  signiﬁcant regression coefﬁcients
‘marked’ when their uncertainty limits, i.e.  scaled b  ± U(b), do not
cross the  “0” axis  and  (ii)  selected number of principal components
(PCs) or latent  variables (LVs) of the models (k),  which is  initially
proposed by  the software (ks). Explicit equations, y = bX,  are
obtained using de-scaled (raw) b-coefﬁcients to be  multiplied
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by the original X-variables, also provided by The  Unscrambler®,
including the offset (b0).
2.5. Procedure for QSPR. Simpliﬁcation protocol
The ChemSpider chemical structure database [21] is used to
obtain the values of variables for all  compounds listed in Table 1.
The selected 15 X-variables include the properties: x1: logarithm of
octanol–water partition coefﬁcient (lgP),  x2: lgP estimated at pH  7.4
(lgD), x3: polar surface area (PSA), x4 and  x5: hydrogen bond donors
(HBD) and acceptors (HBA),  respectively, x6:  polarizability (POL),
x7: molar refractivity (MR),  x8:  molar volume (MV), x9: molecular
surface area (MSA), x10:  van der Waals volume (VW),  x11: Dreiding
energy (DE), x12:  orbital electronegativity of the chiral carbon atom
(OEC), x13: molecular mass (MM),  x14: maximal projection area
(MA) and x15: rotatable bonds (RB). Data in Table 1  correspond to
predictions from two programs, ACD/Labs and ChemAxon, included
in the database. Some compounds exhibiting different predictions
over the variables PSA and/or RB from these programs were marked
as doubtful (Table 1, footnote a).
A PCA is performed on the structure parameters in Table 1  (X-
matrix) using autoscaled data. Leave-one-out cross-validation is
used as validation strategy. Instead of ks (software), a manual selec-
tion of the optimum number of PCs  (ko) is performed. The ko value is
set as the lowest k provoking the ﬁrst (local) maximum or a nearly
stabilization of EVCV. The inﬂuence plot (residual variance vs lever-
age) is used to detect atypical data, ordering the compounds by
their degree of inﬂuence on  the X latent structure: (i) high-leverage
and high-residual (highly inﬂuential), (ii) high-leverage, (iii) high-
residual, (iv) medium-residual; in all cases in relative terms, i.e.
respect an eventual low-leverage and  low-residual compact group
of compounds.
Available enantiomeric resolution (Rs),  in EKC using HS--CD,
information for the compounds (excluding bupivacaine, No 39) is
also incorporated in Table 1. Instead of  using the (quantitative)
Rs electrophoretic value, obtained in some cases under different
experimental conditions, thus  not directly comparable, the data
were categorized as 0 (non-resolved enantiomers), 1 (partially
resolved enantiomers) and  2 (fully resolved enantiomers).
A discriminant-PLS analysis over  a single response variable
(DPLS1) is performed, using the categorical Rs (y-vector), and
the structure data (X-matrix; predictor variables). Thirty-nine
compounds with complete y-X data (autoescaled) are used as
calibration set (bupivacaine is excluded). A leave-one-out cross-
validation is performed. Model simpliﬁcation, including sequential
elimination of potential ‘justiﬁed outliers’ and  non-signiﬁcant vari-
ables is applied, in view to obtain a simple representative model.
On each simpliﬁcation step, decisions are taken once the optimum
number of LVs (ko) is adjusted. Manual selection of ko value selec-
tion is performed based on the EVCV-rule described in the PCA
model.
To help in the sequential decision-making process, four plots
are selected: (i) biplot of LV2 vs. LV1,  showing both scores (com-
pounds) and loadings (parameters), thus  their relative correlation.
(ii) EV and EVCV bars for global model performance. (iii) Validation
plot, showing predicted vs. measured y-values (both calibration
and crossvalidation ones; y  and  yCV data, respectively, for each
compound). (iv) Scaled b-coefﬁcients of X-variables, plus their
uncertainty limits, b ± U(b), for model stability evaluation.
During the decision-making process, the representativeness of
the DPLS1 model is assessed by examining three aspects: (i)  the
latent structure consistency: coincident ko and ks values, but also
close to the ‘ideal’ k-value (ki),  is considered an  indicator of  a well-
deﬁned latent structure. In this case, ki = 1, since there is a single
response variable (Rs). (ii) The  predictive power: Pp = 2EVCV − EV
[7].  Pp  ≥ 55%  is  considered acceptable for  the discriminant model
(instead of  60%, suggested for quantitative-PLS models [7]). (iii) The
descriptive ability: a model with all the b-coefﬁcients signiﬁcant is
considered satisfactory (see Section 2.4,  item i). According to this,
the simpliﬁcation of the DPLS1 model, involving both elimination of
possible outliers and variables selection, is performed in successive
steps. In every  step the following rules are applied by order:
• Rule-1: eliminate doubtful compounds (Table 1)  and/or highly
inﬂuential (PCA inﬂuence plot) that appear misclassiﬁed in the
validation plot.
• Rule-2: compare ko and ks values against ki = 1. Check the Pp  esti-
mation against the threshold value (55%). Decide the application
of rule-2a or -2b accordingly.
• Rule-2a: if non-matching k-values (ko /=  ks and/or ko far from
ki = 1) and/or Pp < 55% are obtained, eliminate up to  3 non-
signiﬁcant X-variables showing the lowest b/U(b) ratios.
• Rule-2b: if matching adjusted k-values (ko =  ks ∼ 1) and Pp ≥ 55%
are obtained, select only the ‘marked’ signiﬁcant X-variables.
• Stop criterion: the simpliﬁcation process is stopped when none
of the rules  can be applied.
On the  other hand, some undesirable situations observable in
the bi-plot must  be revised during this process, such as the occur-
rence of  a  doubtful or  inﬂuential compound exclusively correlated
with a single  variable (the compound could be eliminated) or the
presence of two highly correlated X-variables (the variable showing
the lowest  b/U(b) ratio could be eliminated).
2.6. Further use of  categorical enantioresolution estimations
De-scaled PLS coefﬁcients (Section 2.4) for the selected vari-
ables in Section 2.5 are then obtained to derive the explicit y =  bX
equation (i.e. Rs =  f(parameters); including an offset). It is then
applied to estimate Rs  for  bupivacaine (No  39 in Table 1). In gen-
eral, for Rs  ≥ 2 or well below 1, further studies are not  considered.
If Rs  ≥ 2, we suggest using the 1% m/v  CD concentration, and, if
no peaks are observed, decrease it to 0.25%. In  the ∼1  < Rs <  2 case
(probable enantioresolution in particular conditions), or  if conve-
nient/desired, a standard Box–Behnken experimental design, using
the methodological EKC variables concentration of  CD (CD),  tem-
perature (T) and electrophoretic buffer pH (pH) as main factors,
is performed. Using these factors as  X-data and two response vari-
ables, Rs and  t2 (the retention time of the second eluted enantiomer,
thus the  analysis time) as  response Y-matrix, a  PLS2 is then applied.
Again, de-scaled b-coefﬁcients are converted in two explicit equa-
tions for Rs  and t2  as a function of CD,  T and pH.  They are used
to map simulated Rs–t2  data, allowing the selection of convenient
separation conditions satisfying 1.5 <  Rs <  2.
3. Results  and discussion
3.1. Strategy selection
Among the  structure of the solutes, Rs  depends on elec-
trophoretic factors. However, these factors should be more or less
constant if the experimental conditions are similar (as in our case;
see Section 2.3),  so the structural properties of the molecules should
be the discriminant factor providing (or not) enantioseparation. On
the other  hand,  this is one of the reasons why we  decided to  treat
the variable Rs  as categorical instead of quantitative. Moreover, the
use of different CD concentrations provides not directly compara-
ble (numerical) Rs values, and this  was  the main reason why  we
decided to treat the variable Rs as categorical.
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Set-of-variable rules, e.g. Lipinski’s-like ﬁlters [21],  or decision
trees [22] could be used to roughly predict dicotomic (e.g. Yes/No)
or categorical (e.g. 0, 1, 2, as in this case) response variables.
Although these options are possible here, we  have preferred to
derive a predictive explicit equation, which is a practical option
to easily automate future y-estimations. Obviously, such estima-
tion, although numeric, should be seen as a  rough enantioresolution
level value. The classical tool for dealing with categorical response
variables is discriminant analysis [23]. For instance, linear discrim-
inant analysis (LDA) is quite popular, but it  could fail if  non-linear
y-X relationships are present. Other options (including those  using
non-linear discriminant functions) are less common, unavailable in
basic chemometric software packages or more difﬁcult to under-
stand or to use, thus, less operative in view of non-expert users.
On the contrary, PCA and PLS have become popular algorithms.
The simplest and most common PLS algorithm, linear-PLS (the
default option), is able to model some degree of y-X non-linearity
(visible through their scores, u-T). DPLS1 is used as a conventional
PLS, just assigning the categorical response variable (here, Rs)  as
y-variable. Since autoscaled data are used, scaled b-coefﬁcients,
useful during the optimization step to analyze b/U(b) data (Sec-
tion 2.5), are initially obtained; but  once an optimum model is
selected, de-scaled coefﬁcients can be easily obtained [7,9 and
references therein]. Fortunately, all these tasks, applied here on
Table 1 data (next section), can be performed with a single soft-
ware [20], thus a practical equation able to provide y-estimates
without the software. Variable selection (reduction) strategies, sat-
isfying different objectives, are available in the literature [23].
Some software packages offer automatic tools for  selecting vari-
ables for a multiple regression. These tools can be unfamiliar
for many users, not user-friendly and/or insufﬁciently transpar-
ent, affecting the decision-making process. For instance, different
strategies may  provide different reduced models, particularly in
complex situations (such as a discriminant problem). In  addition,
most of the automated approaches are aimed exclusively at obtain-
ing the highest predictive ability, without taking into account the
model stability [7,9,10]. Finally, none of the automatic approaches
allows the elimination of compounds (e.g. doubtful or inﬂuen-
tial ones; as those present in Table 1) together with the variable
reduction, thus increasing the risk of obtaining non-representative
models.
Manual PLS compounds/variable simpliﬁcation, following
systematic rules, allows controlling the process, providing repre-
sentative models and reliable future estimations (new compounds).
A critical aspect to revise during model simpliﬁcation is k since
y-predictions and b ± U(b) outputs depend on such selection. Alter-
natively to automated ks selection [20], inspection of the EVCV
(Section 2.5) allows a manual ko selection. Unfortunately, high ks
(ks  ki = 1) are common. In fact, during model simpliﬁcation, a ko
and ks reduction (and approximation) should be expected, justify-
ing rule 2a (Section 2.5). Note that  high  k-values could reveal the
necessity to describe a non-representative connection between a
given object (sometimes doubtful or inﬂuential) and a single vari-
able.
Respect the multivariate experimental design/optimization
process, response surface analysis is the classical option [23].
Again, software automatic analysis can be unfamiliar for some
users and/or obscure, requiring moderate skills to perform the
effects’ analysis to deal with crossed effects (factors’ multiplication)
and nonlinearities (habitually incorporating the squared factors),
mainly with two response variables (Y  data matrix), where complex
functions are used. Again, in the last case, a simpler strategy is possi-
ble, PLS2, using only the main factors (i.e. experimental conditions)
as X data, partially accommodating the crossed and non-linear
effects as a practical solution. The  PLS-procedure is identical to the
previously described, and in this case,  model simpliﬁcation is not
Fig. 1. The Unscrambler® screen for the PCA  inﬂuence plot  corresponding to a 2-PC
model (ko = 2).
required. As  before, the ﬁnal  output are two direct equations in the
form [Rs,  t2] =  f(CD,  T,  pH) easy to be  applied.
3.2. Modeling the X and y-X data
A preliminary PCA-inspection of the structure data (all  com-
pounds in Table  1)  was performed as described in Section 2.5, using
the autoscaled X-data and leave-one-out cross-validation. The ks
value was 6, coinciding with the absolute maximum EVCV values.
However, ko was set to 2, coinciding with the ﬁrst local maximum
EVCV (60.7%).  The  corresponding EV  was  72.6%. Fig. 1 shows the
inﬂuence plot  for  the 2-PC model. As can be observed, an almost
compact group of objects with low-leverage and low-residual val-
ues is clearly observed (‘similar group’). Compounds No 11 and 36
could be  considered high-leverage and  high-residual (highly inﬂu-
ential on  the latent structure). In fact, both compounds exhibit
high negative scores in PC1,  far from the rest of compounds that
form a relatively homogeneous group in the PC1–PC2 score plot
(not shown). Such inﬂuential effect  was related to the high (or
maximum) values  of several variables in Table 1  for these two com-
pounds. On the other hand, most of the Rs =  2  compounds show
positive PC1  scores indicating that this PC is related with resolu-
tion. Other less inﬂuential compounds are No 33 (high-residual)
and No  32, 35 and  39 with medium-residual values. All these atyp-
ical compounds present a ‘dissimilar’ molecular parameter proﬁle
and should be taken into account during the PLS stage. As expected,
the loading plot  (not shown) indicates that variables x8 and x10
present a high  correlation (see Table 1, footnote b)  and  also appear
correlated with variables x6, x7, x9, x11,  x13 and x14 (all  forming low
angles respect  to the PC1 axis), indicating redundant information.
Table 2  summarizes the simpliﬁcation process of the DPLS1
model, following the rules/tests indicated in Section 2.5. Before
stopping the process (step-7, Table 2),  some relevant situations
were found. In  step-2, split of objects into Rs  =  0 and Rs > 0  groups is
observed in the  validation plot, indicating the practical usefulness
of the model.  In  step-5, a ko =  ks =  2  model, close to the ideal ki =  1
situation (anticipated in Section 3.1), and with reasonable predic-
tive ability (good EV and EVCV combination, and then predictive
power, Pp > 55%) was  obtained. In such conditions, direct selection
of the  four  signiﬁcant variables (x2–x5; lgD,  PSA, HBD and HBA)
was decided (rule-2b). It was observed a clear correlation between
variable x14 and compound No 11 (particular, non-representative,
situation warned in Sections 2.5 and 3.1), so  the elimination of this
variable caused  the misclassiﬁcation of that  compound in step-6.
Since compound No 11 was  previously detected in PCA as highly
inﬂuential, it was removed from the DPLS1 model (rule 1, step-7)
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Table  2
DPLS1 simpliﬁcation including the decision-making process.
Step ko (ks)
EV % (EVCV %)
Pp % (=2EVCV −  EV)  [7]
Main observations
(+) Positive output
(−) Negative output suggesting new steps
Decision
1 2 (2)
46.5 (28.2)
9.9
(−) Misclassiﬁed compounds: 12  and 24  (badly predicted y and yCV)  and 36 (badly
predicted yCV)
Rule 1:  eliminate compounds
12  and 24a and 36b
2 2 (2)
63.7 (56.6)
49.5
(+) Separation of Rs = 0  and Rs > 0 groups in the validation plot
(−) Non-signiﬁcant regression coefﬁcients (i.e. b ±  U(b)  includes 0) exist and poor
predictive power (Pp < 55)
Rule 2a:  eliminate x6 and x7c
3 2 (2)
65.2 (57.1)
49.0
(−) Misclassiﬁed compounds: 22  and 35  (badly predicted yCV) Rule 1:  eliminate compounds
22a and 35a
4 2 (4)
74.0 (67.8)
61.6
(−) Non-signiﬁcant regression coefﬁcients (all b ±  U(b) includes 0)
(−) Non well-deﬁned latent structure (ko /= ks)
Rule 2a:  eliminate x8 and x12c
5 2 (2)
75.4 (69.8)
64.2
(+) Near  adjusted (ko = ks = 2  ∼ ki)  predictive model (Pp >  55)  showing four
signiﬁcant variables: x2–x5
Rule 2b:  retain only x2–x5
6 1 (1)
63.1 (60.4)
57.7
(+) Adjusted (ko = ks = ki = 1)  model
(−) Misclassiﬁed compound 11 (badly predicted y and yCV)
Rule 1:  Eliminate compound
11b
7 1 (1)
72.4 (69.8)
67.2
(+) All  doubtful/inﬂuential compounds are well predicted
(+) Adjusted (ko = ks = ki = 1)  predictive model with good predictive power (Pp > 55)
(+) Good descriptive power (the four variables are signiﬁcant)
Stop criterion: select this
model  as the optimum
a Doubtful compound in Table 1.
b Highly inﬂuential compound in  PCA.
c Variables with the lowest b/U(b).
providing ﬁnally the deﬁnitive DPLS1 model, ﬁtting the stop cri-
terion. It should be noted that the selected model is not able to
separate completely all the calibration compounds with Rs  1  and  2,
however this fact is less important in terms of usefulness, since the
Rs = 0 compounds are well predicted.
The model selected should be seen as  provisional, susceptible
to change (improving its features) if  new Rs-structure data can
be incorporated in the future. However, currently, it  represents a
consistent (ko = ks = ki = 1; the ideal situation), predictive (high vari-
ability of Rs is modeled, EV  =  72.4%; Pp =  67.2%) and  descriptive (all
coefﬁcients are signiﬁcant; Fig. 2) model, thus satisfying the pre-
ﬁxed representativeness (Section 2.5),  for a discriminant problem.
Raw (de-scaled) coefﬁcients were obtained from this DPLS1 model
to derive the practical explicit model (Eq. 1):
Rs = 2.354 + 0.095lgD − 0.008PSA − 0.159HBD −  0.137HBA (1)
Fig. 2. The Unscrambler® screen showing the scaled b-coefﬁcients (weighted; BW)
with uncertainty intervals, corresponding to the optimum DPLS1 model (Step-7,
Table 2). X-variables: 2, logarithm of octanol–water partition coefﬁcient estimated
at  pH 7.4 (lgD); 3, polar surface area (PSA);  4 and 5, number of  hydrogen bond donors
(HBD)  and acceptors (HBA), respectively.
Note that such  de-scaled coefﬁcients do not reveal the impor-
tance of  the  variables (as the scaled ones  do).  Concretely, Fig. 2
suggests a similar importance of PSA, HBD and  HBA (negatively
correlated with Rs) a  slightly lower importance of  lgD (positive
correlation). This suggests that enantioresolution in the EKC-HS-
-CD system is favored by the pH-adjusted hydrophobicity of the
molecule, but is not favored if the molecule presents high polar sur-
face area (formed by polar atoms of  the molecule) and high number
of hydrogen-bonding formation functional groups.
Eq. (1)  is ready to perform predictions of new molecules, from
the on-line  data of these selected variables, once they present con-
sistent estimated parameters with non-inﬂuential PCA-behavior.
Note that although Eq.  (1) is linear (and simple), it  comes from
an intrinsic non-linear relationship (latent and more complex), as
demonstrated in Fig. 3,  which reveals the nature of  the inner u-T
scores relationship, corresponding to the optimum model in this
work (step-7, Table 2). This plot also reveals the discrimination
power of the proposed DPLS1 model. Note that this plot could serve
Fig. 3.  Inner y-X PLS relationship. The median of  u-  and T-scores per Rs-category
are calculated, and then, ﬁtted using a  quadratic model.
158 L. Asensi-Bernardi et al.  /  J. Chromatogr. A  1308 (2013) 152– 160
Table  3
Box–Behnken design for three factors showing the non-randomized coded factors levels distributed in  15 experiments (Ne). The corresponding experimental values were
set  form the range of factors (CD: 0.5–1.5% m/v, T: 15–35 ◦C and pH  6–8). Retention times for the ﬁrst (t1)  and second (t2) eluted enantiomers and Rs for each experiment are
included.  The experimental values t2 and Rs were used as response variables.
Ne CD (%, m/v) T  (◦C) pH  t1  (min) t2 (min) Rs
Code Value Code Value Code Value
1 −1 0.5  −1  15  0  7 11.54 11.8 1.38
2  −1 0.5  0  25  −1 6 7.64 7.73 0.87
3  −1 0.5  0  25  1  8 7.5 7.54 0.53
4  −1 0.5  1  35  0  7 6.5 6.54 0.95
5  0 1.0  −1  15  −1 6 10.58 10.75  1.91
6  0 1.0  −1  15  1  8 10.5 10.71  2.67
7  0 1.0 0  25  0  7 7.26 7.32 0.98
8  0 1.0  0  25  0  7 7.17 7.22 0.66
9  0 1.0  0  25  0  7 6.99 7.03 0.53
10  0 1.0  1  35  1  8 6.63 6.68 0.81
11  0 1.0  1  35  −1 6 6.6 6.69 1.05
12  1 1.5 −1  15  0  7 13.04 13.43 1.61
13  1 1.5 0  25  −1 6 10.66 10.97  1.77
14  1 1.5 0  25  1  8 9.43 9.62 1.00
15  1 1.5 1  35  0  7 7.22 7.37 0.57
as a criterion to compare different simpliﬁed models (outside the
objective of the present work).
3.3. Application case: Optimization of EKC conditions for
enantioresolution of bupivacaine.
Table 1 shows structure data for bupivacaine (No 39; with no
Rs available). For this compound, Eq. 1 provides an estimation
of Rs = 1.8 (this should not be  seen as a metric value, but  as an
indicative value; e.g. Rs >  1.5 or 1  < Rs <  2  and with the meaning of
possible enantioresolution, but probably in particular experimental
conditions, and pending from experimental conﬁrmation). Option-
ally, a more sophisticated analysis could be performed with The
Unscrambler® if the model (after step-7 in Table 2) is saved into
the program. In that case, the software also provides a y-uncertainty
(U(y)) for the estimation [9,20]; 1.8 ± 0.3 in this case,  although less
relevant here due to the categorized Rs  used.
Although the Rs estimate is relatively high (Rs >  1.5), bupiva-
caine appeared as medium-residual in the PCA inﬂuence plot, and
then some caution should be taken with such predictions. Thus, the
1 < Rs < 2 situation indicated in Section 2.5 was considered, requir-
ing a further experimental design. This is equivalent to assume
possible difﬁculties for bupivacaine enantioseparation, i.e.  its base-
line resolution would require particular CD, T and  pH conditions.
Besides Rs,  we preferred controlling also the analysis time, the
variable t2 (the migration time of the second eluted enantiomer),
to make a more valuable decision. Pre-optimized experimental
designs are the adequate option for  multivariate optimization. An
effective (with low-experiments) design is Box–Behnken [22,23].
For instance, the standard Box–Behnken design for  three exper-
imental factors (CD,  T, pH)  can be performed in 15 experiments,
including three center points (replicated results). Table 3  shows
the experimental conditions (coded and  real factors’ levels) and the
EKC results, including the response variables (Rs and t2). The  exper-
iments were randomized, but  for clarity, the intuitive Ne numbers
in Table 3 were used to refer to the experiments. Fig. 4  shows
the electropherogram corresponding to the enantioseparation of
bupivacaine using the experimental conditions: 1.5%, m/v HS--
CD, 15 ◦C and pH 7.0 (Box–Behnken experimental point Ne  = 12,
Table 3). The experimental Rs was 1.61 while t2  was  13.43 min.
A priori, an Rs–t2  correlation could be  expected. To check it, the
experimental Rs vs. t2 data in Table 3  were plotted (not shown)
suggesting a positive correlation. A regression on the data  reveals
relevant information: (i) experiment Ne  6  (with the highest Rs
value) exhibits a large residual, suggesting caution on this result
in  the next stage; (ii) R2 excluding Ne 6  data is 0.64 conﬁrming
the expected moderate correlation; in these cases PLS2 could be
advantageous against PLS1 [24]. In addition, this plot indicated that
complete resolution of bupivacaine enantiomers requires more
than 10 min.
We are now  interested in performing a  rough response surface
analysis, based only in the main factors and assuming some errors
due to  the relatively low number of experiments in the experimen-
tal design.  However, approximate results should be  sufﬁcient for
practical purposes. Initial PLS2 (15 experiments, X: CD,  T and pH,
Y: Rs  and  t2;  autoscaled matrices) conﬁrms that  experiment Ne 6
is not adequate (low y and  yCV estimated values in the validation
plot), suggesting an  error during the experimental process resulting
in a wrongly high Rs value. Again, to  obtain a more representative
model, this ‘experiment’ was  excluded. The subsequent PLS2 shows
reasonably good outputs (e.g. overall EV  close to 70%). The impact of
the factors (scaled coefﬁcients values; not shown) suggests that T
(negatively correlated with Rs and  t2) is the most important fac-
tor. As expected, CD is positively correlated with both response
12 13 14 15
Time (min)
-2
0
2
4
mAU
Fig. 4.  Electropherogram corresponding to  the enantioseparation of  bupivacaine
in one  of the Box–Behnken experimental points (Ne = 12;  Table 3). Experimental
conditions: 1.5%  HS--CD, 15 ◦C, pH 7.0.
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Fig. 5. Simulated Rs vs. t2 map for bupivacaine from Eqs. (2a) and  (2b) (results are
identiﬁed by a simulation number, Ns).  Simulated range for factors were, CD:  1–5%,
T  = 15–25 ◦C and pH 5.5–8. Some particular Ns  are set in  higher font-size (see Table 4
and related text for details). The minimum acceptable Rs (solid  line) and a  more
secure  value (dashed line) are included.
variables, while pH is negatively correlated. These effects can be
easily explained from an electrophoretic point of  view taking into
account the separation mechanism, which implies the formation of
anionic inclusion complexes with the cyclodextrin. The higher the
CD, the longer the migration time, because the equilibrium of the
free-complexed drug is shifted to the complexed form; a higher Rs is
reasonable because the complexed form is who migrates enantios-
electively. For the increase of T,  shorter migration times are logical
for both enantiomers due to the decrease of viscosity of the BGE and
the consequent increase of current. Therefore, if  both enantiomers
migrate faster, less Rs is coherent. The  same effect is observed with
the pH,  since higher pH implies higher EOF mobility, accelerating
the migration of both enantiomers and decreasing the Rs value.
As before, two explicit equations, for Rs  and t2, were obtained
from the de-scaled regression coefﬁcients:
Rs = 3.497 + 0.269CD − 0.034T − 0.268pH (2a)
t2 = 14.05 + 1.96CD − 0.247T  −  0.149pH (2b)
These equations were used to generate simulated Rs  and  t2
data from a selected range of the factors, according to the previous
derived importance of variables (extrapolation was accepted
since only approximate values are searched). Fig. 5  shows the
Rs–t2 map  generated for bupivacaine. Initially, only simulated
numbers (Ns) above Rs >  1.5, but preferably Rs ∼ 2 (more secure),
are relevant, taking into account that  they represent just simulated
estimates from non-error free Eqs. (2a) and (2b). Some Ns  data
have been included in Table 4.  Results from Ns 2  and 6  correspond
to conditions already experimented in Table 3  (Ne  5  and  6, respec-
tively). The case of Ns 6  (Ne 6) corresponds to the experimentally
suspicious high-Rs value detected by  PLS2, and  eliminated there.
In fact, the estimated Rs in Table 4 is 1.12 (<1.5, Fig. 5) conﬁrming
Table 4
Selected simulated results identiﬁed by their simulation number (Ns).  The response
variables t2 and Rs (mapped in  Fig. 4)  were predicted from Eqs.  (2a)  and (2b).
Ns CD (%, m/v) T (◦C) pH  t2 (min) Rs
2 1 15 6 11.4 1.65
6  1 15 8 11.1 1.12
19  2 15 5.5 13.4 2.06
20  2 15 6 13.4 1.92
49  3 25 5.5 12.9 1.99
its error  during the experimental design experiment. An  eventual
acceptation of  the initial apparent good result (Rs =  2.67; Table 3)
would lead  to a waste of time when bupivacaine enantioseparation
would be  tried further. The  estimated analysis time (t2) is however
similar to the experimental one.
In the case of Ns  2 (Ne  5), the experimental and estimated Rs
values are different (1.96 and 1.65; Tables 3  and 4), but indicating
Rs > 1.5  enantioresolution in these conditions (CD = 1% m/v, T =  15 ◦C
and pH  6). Again, t2 is quite similar in both tables. The  advantage of
deriving the map  in Fig. 5  is the possibility of increasing the secu-
rity for further enantioseparation, selecting simulated cases close
to the Rs =  2 line. In this case,  Ns  cases with low t2  are preferable
(e.g. Ns 19,  20, 49). The simulated results for these three cases are
shown in  Table 4. The expected increase of analysis time respect the
acceptable Ns  2 case is about 2  min. Since Rs ∼ 2 in all  these cases, it
is preferable to choose the most practical conditions; for instance,
case Ns  20 requires low CD and a pH 6, closer to the pKa of phosphate
(∼7.2) used  in  the buffer, being therefore the best option.
4. Conclusions
Two simple enantioresolution models for  the Electrokinetic
chromatography-highly sulfated -cyclodextrin (EKC-HS--CD)
system are  developed; one related exclusively to directly-available
structural data  of basic compounds and the other with experi-
mental conditions. In the ﬁrst case, an easily comprehensible PLS
‘model simpliﬁcation’ protocol, involving manual sequential ‘justi-
ﬁed outliers’ elimination and  variable selection is proposed. This
protocol is based on two  rules  and a stop criterion, providing
the preﬁxed ‘model representativeness’ (i.e.  latent structure con-
sistency and  predictive-descriptive power). In  the second case,
an easily comprehensible PLS-based ‘multivariate optimization
scheme’, involving a standard experimental design and like-
multiple response surface analysis, allows a map-based EKC
experimental conditions selection. Both approaches and decision-
making aspects  proposed converges in a single software, easy to
use with  minor skills.
The modeling outputs deﬁne the ability of using HS--CD
as chiral  selector for  enantioseparation in EKC for basic com-
pounds and  provide the key structure properties dominating
their enantioresolution. A  practical simple equation is provided
(Rs =  2.354 +  0.095lgD  − 0.008PSA  − 0.159HBD − 0.137HBA)  to a pri-
ori estimate the  enantioresolution level of a basic molecule in
this system from the four-selected parameters available in an
on-line database. Compounds with close estimated parameters
in ChemSpider (from ACD/Labs and ChemAxon programs) and
low inﬂuential in PCA respect the current latent structure ﬁx the
applicability of this equation. Since the model is trained using a
heterogeneous data set of  basic drugs and pesticides, no more
limitations are expected using new data from basic compounds.
Bupivacaine enantioresolution in this system (never been reported
so far) is predicted with the equation, indicating probable enan-
tioresolution in particular conditions. The further optimization
scheme suggests good enantioresolution in approx. 12 min, under
the following conditions: cyclodextrin concentration in the 1–2%
m/v range, 15 ◦C  and pH 6.
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Appendix A. List of chemometric abbreviations and
variables used
b Vector of regression coefﬁcients relating y and X data. When
scaled they explain the importance of the X-variables in
predicting y
b/U(b) Ratio between the regression coefﬁcient and the estimated
uncertainty value for a  given variable of the X-matrix
b ± U(b) Estimated uncertainty interval for b
CD  Cyclodextrin concentration. Factor used in  the Box–Behnken
design; one of the X-variables used in the PLS2 model for
bupivacaine
DPLS1 Discriminant partial least squares on one single response (here
Rs,  categorical-enantioresolution)
EV  Explained y- or  X-variance (in PLS and PCA, respectively)
EVCV EV in cross-validation
HBA Number of hydrogen bond acceptors
HBD Number of hydrogen bond donors
k  Number of principal component (PCs) of a  PCA model or latent
variables (LVs) of a  PLS model (also called factors)
ki ‘Ideal’ k-value. Here, ki = 1, since there is a single response
variable (categorical-enantioresolution, Rs)
ko Optimum k-value, manually selected as the lowest k provoking
the ﬁrst (local) maximum or  a nearly stabilization of  EVCV
ks k-value initially proposed by the software (here The
Unscrambler® [20])
LV  Latent variable of  a PLS model
Ne  Number of experiment in the Box–Behnken experimental
design of bupivacaine
No Numbered order of compounds
Ns  Simulation number used in  the optimization of  EKC conditions
for enantioresolution of  bupivacaine
PC Principal component of a  PCA model
PCA Principal component analysis
pH  Electrophoretic buffer pH. Factor used in the Box–Behnken
design; one of the X-variables used in the PLS2 model for
bupivacaine
PLS Partial least squares
PLS2 Partial least squares on two  response variables. Here Rs,
enantioresolution, and t2,  migration time of the second eluted
enantiomer for bupivacaine
Pp  Predictive power of  the model. Pp = 2 EVCV–EV [7]
Rs Enantioresolution
T Separation temperature. Factor used in the Box–Behnken
design; one of the X-variables used in the PLS2 model for
bupivacaine
T  Score matrix corresponding to the X-matrix
t1  Migration time of  the ﬁrst eluted enantiomer
t2  Migration time of  the second eluted enantiomer, thus the
analysis time
u Score vector corresponding to  the y-vector
U(b) Estimated uncertainty of  b
X  Matrix of  predictor or  independent variables (here structural
information  of  basic compounds)
xi Vectors used in the matrix-X
y  Vector of response or dependent variable (in DPLS1). Here the
experimental Rs  (categorized)
y Predicted value of the response variable
yCV Predicted value of the response variable in  cross-validation
Y  Matrix of  responses or dependent variables (in PLS2). Here the
experimental Rs  (non-categorized) and t2 for bupivacaine
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Determination of ﬂuoxetine enantiomers in
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chromatography–counter current technique
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ABSTRACT: In this work, an electrokinetic chromatography–counter current procedure for the separation of ﬂuoxetine
enantiomers using highly sulfated b-cyclodextrin was optimized and applied to the determination of the enantiomers in three
pharmaceutical formulations according to the matrix features. Quality criteria were applied to facilitate its transferability to
testing laboratories. Fluoxetine was used therapeutically as the racemate, although a stereospeciﬁcity associated with its
interactions with the neuronal serotonin-uptake carrier was demonstrated. In this context, the development of enantioselective
methods for the chiral analysis of pharmaceuticals allowing stereoisomer ratio estimations has increasing interest in pharmaceutical
industry. The proposed method allows the quantiﬁcation of both enantiomers in less than 2 min with high resolution (Rs =2.4).
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Introduction
Psychoactive drugs are the most used drugs in our society.
Antidepressants, hypnotics and other types are purchased
every day by different kinds of patients. Usually, these drugs
have been synthesized and commercialized as racemic forms,
but today the industry is interested in the introduction of pure
enantiomers in the pharmaceutical market. Owing to the high
degree of stereoselectivity of pharmacological and pharmaco-
kinetic processes, often one of the enantiomers is the most
active while the other may produce side-effects and even
toxicity in some cases. Consequently, the safety and efﬁciency of
many racemic drugs could be improved with single-enantiomer
formulations. Thus, there is a special interest in analytical methods
able to determine the stereoisomer ratios in synthetic products,
pharmaceutical formulations and biological samples (Scriba,
2011). At the level of formulations, the evaluation of such ratios
in themanufacturing process and stability tests is amain objective.
Fluoxetine is a potent and selective inhibitor of the neuronal
serotonin-uptake carrier. It is used therapeutically as a racemate,
although a stereospeciﬁcity associated with its interactions with
the serotonin-uptake carrier has been demonstrated (Robertson
et al., 1988). In fact, although the S- and R-ﬂuoxetine are approxi-
mately equipotent in blocking serotonin reuptake, the enantio-
mers of the main N-demethylated metabolite, norﬂuoxetine,
which are present in the circulation at higher concentrations than
the parent drug, showmarked differences in their pharmacological
activity (Barclay et al., 2011; Inoue and Chang, 2003; Desiderio et al.,
1999). Then, the determination of ﬂuoxetine stereoisomer ratio in
its pharmaceutical formulations becomes relevant.
Capillary electrophoresis (CE) is a powerful technique for
enantiomer separations showing some advantages over HPLC
that include the use of smaller amounts of sample and reagents,
an increased separation efﬁciency, short analysis times and easy
conditioning of the column. One of the most common modes of
chiral CE is electrokinetic chromatography (EKC) in the presence
of a chiral selector in the background electrolyte (BGE). EKC has
been widely employed for the separation of ﬂuoxetine enantiomers
with several anionic cyclodextrins, although no applications have
been described for these separation methods (Inoue and Chang,
2003; Li et al., 2003; Li and Vigh, 2004a, 2004b; Bonato et al., 2001;
Rudaz et al., 2003; Perrin et al., 2001).
Inoue and Chang (2003) achieved good resolutions with
heptakis-(2,3-diacetyl-6-sulfato)-b-cyclodextrin (CD), sulfated-a-CD
and heptakis-(2,3-dimethyl-6-sulfato)-b-CD in analysis times longer
than 20 min. Li et al. (2003) employed carboxymethyl-b-CD with
reverse polarity obtaining Rs 2 in more than 30 min). Using
sulfated-b-CD, good resolution was also obtained in 12 min
(Bonato et al., 2001). Li and Vigh (2004a, 2004b) synthetized
hexakis(2,3-di-O-methyl-6-O-sulfo)-a-CD and hexakis(6-O-sulfo)-a-
CD and applied them to the chiral separation of ﬂuoxetine,
achieving good resolutions in <5 min. The use of partial ﬁlling
technique with highly sulfated g-CD (HS-g-CD) was also reported
by Rudaz et al. (2003) in order to use mass spectrometry detection.
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In this case inﬁnite enantioresolutionwas achieved, preventing the
quantiﬁcation of one of the enantiomers. These authors also
proposed a reverse polarity methodology, which provided an
excellent resolution in<10 min. With the same cyclodextrin Perrin
et al. (2001) developed a short-end injection method with good
features (Rs of 6.2 in 2 min). However, in this method the use of a
high concentration of HS-g-CD in the BGE increased the analysis
cost. In a previous paper, our research group employed highly
sulfated b-cyclodextrin (HS-b-CD) for the separation of ﬂuoxetine
enantiomers in order to evaluate the enantioselective binding of
ﬂuoxetine to human serum albumin, obtaining an Rs of 3.5 in
~4min (Asensi-Bernardi et al., 2010). In that case, there were noma-
trix interferences since the assay only required synthetic samples.
A recently published review shows the interest in capillary
electrophoresis in the chiral analysis of pharmaceuticals
(Suntornsuk, 2010). However, to our knowledge there are no
CE methods reported for the pharmaceutical analysis of
ﬂuoxetine enantiomers and only LC methods with different chiral
stationary phases (Olsen et al., 1998) and a 19F NMR spectroscopic
method (Shamsipur et al., 2007) have been described. With LC, the
best results were for polysaccharide-based chiral stationary
phases, resulting in adequate resolutions but higher retention
times (>15 min). Separations were achieved in normal-phase LC,
so an extraction step had to be added for analysis of pharmaceu-
ticals (Olsen et al., 1998), which are commonlywater-soluble owing
to their composition. Themain inconvenience of the spectroscopic
method is a high consumption of chiral selector, which increases
the analysis cost.
In this work, an EKC methodology using the HS-b-CD in the
counter-current modality has been developed for the chiral
analysis of ﬂuoxetine in pharmaceutical formulations, adapting
the method optimization and the evaluation of ﬁt-for-purpose
features to commercial matrices. In this mode, the entire
capillary is ﬁlled with a chiral selector, while the inlet and outlet
vials are also free of chiral selector in partial-ﬁlling technique
(Chankvetadze and Blaschke, 2001). The counter-current mobility
of the anionic CD and oppositely charged analyte in the separation
capillary allow complete enantioresolution using low concentra-
tions of the chiral selector in very short analysis times (Rudaz
et al., 2004; Chen et al., 2001). Under the selected conditions, ﬁt-
for-purpose analytical features of the developed method were
evaluated and the chiral analysis of three pharmaceuticals contain-
ing racemic ﬂuoxetine (ProzacW, Fluoxetina TevaW and Fluoxetina
MaboW) was performed. The results obtained showed that the
proposed methodology is adequate in terms of speed, cost, resolu-
tion power, precision and accuracy for the quality control of the
enantiomeric composition of ﬂuoxetine in pharmaceuticals.
Transferability of the provided protocol to a laboratory with the
ISO 17025 quality system implemented seems to be feasible.
Materials and methods
Instrumentation
A Beckman P/ACE MDQ Capillary Electrophoresis System with a
diode array detector (Beckman Coulter, Fullterton, CA, USA),
and 32Karat software version 8.0 was used throughout. A 50 mm
inner diameter (i.d.) fused-silica capillary with total and effective
lengths of 31.2 and 21 cm, respectively, was employed (Beckman
Coulter, Fullterton, CA, USA). Electrophoretic solutions and samples
were ﬁltered through 0.45 mmpore size nylonmembranes (Micron
Separation, Westboro, MA, USA) and degassed in an ultrasonic
bath (JP Selecta, Barcelona, Spain) prior to use.
Chemicals
All reagents were of analytical grade. Sodium dihydrogen
phosphate dihydrate was from Fluka (Buchs, Switzerland); highly
sulfated-b-CD (HS-b-CD; 20% w/v) aqueous solution was
purchased from Beckman Coulter (Fullterton, CA, USA). Racemic
ﬂuoxetine was kindly donated by Alter (Madrid, Spain). Ultra Clear
TWF UVdeionizedwater (SGWater, Barsbüttel, Germany) was used
to prepare solutions. BGE containing 30 mM phosphate at pH 8.0
was obtained by dissolving the appropriate amount of sodium
dihydrogen phosphate dihydrate in water and adjusting the pH
with 1 M NaOH.
Methodology
Procedure for the preparation of standards and samples. A
stock standard solution of racemic ﬂuoxetine 200 mg/L was
prepared in BGE. In order to obtain the calibration graphs, working
solutions of ﬂuoxetine containing between 10 and 50 mg/L of
each enantiomer were obtained in duplicate by diluting the stock
solution with BGE.
Samples were obtained from three pharmaceutical formulations
containing racemic ﬂuoxetine: ProzacW 20 mg (tablets), Fluoxetina
MaboW 20mg (pills) and Fluoxetina TevaW 20mg (pills). To prepare
sample solutions, the content of ﬁve units was weighed, powdered
(only for tablets) and mixed homogeneously. Then, the appropriate
amount of the powderwasweighed and dissolved in 100mL of BGE
by immersion in an ultrasonic bath (10 min), to achieve a ﬁnal
concentration of ~20 mg/L of each enantiomer.
Spiked samples were prepared in order to evaluate the accuracy
of the method, by weighing and mixing homogeneously 0.9 g of
sample powder and 0.1 g of standard ﬂuoxetine. From these
powder mixtures, solutions with a ﬁnal concentration of ~40 mg/L
of each enantiomer were prepared similarly to sample solutions.
Capillary conditioning. New capillaries were conditioned for a
15 min ﬂush with 1 M NaOH at 60C. Then they were rinsed for
5 min with deionized water and 10 min with separation buffer at
25C. In order to obtain good peak shapes and reproducible
migration data, the capillary was conditioned prior to each
injection. In all cases, the conditioning run included the following
steps: (1) 30 s rinse with deionized water; (2) 1 min rinse with
0.1 M NaOH; (3) 30 s rinse with deionized water; and (4) 1 min rinse
with the separation buffer at 20 psi.
Procedure for the enantiomeric resolution of ﬂuoxetine by
EKC. A 30 mM phosphate solution of pH 8.0 was used as BGE.
Fluoxetine standards and samples were injected hydrodinamically
at 0.5 psi for 5 s. Before sample injection, the capillary was ﬁlled
with a 0.25% HS-b-CD solution in BGE by applying 2 psi for
1 min. Separation was performed in normal polarity by applying
25 kV. In order to improve the peaks shape and decreasemigration
times, a 0.3 psi pressure was applied into the inlet vial throughout
the analysis, because the combination of voltage and pressure in
the CE separation gives higher efﬁciency. The capillary was
thermostated at 30C and the UV-detection wavelength was set
at 200 nm.
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Results and discussion
Development of an EKC chiral methodology
In preliminary studies, EKC conditions proposed in Asensi-Bernardi
et al. (2010) (30 mM phosphate buffer at pH 7.0, 0.25% HS-b-CD,
30C, 15 kV, with a little pressure of 0.3 psi applied to the inlet vial,
and 220 nm as detection wavelength) were applied to the analysis
of the pharmaceuticals in order to check their suitability in the
present study. For this purpose, sample solutions with approxi-
mately 50 mg/L of racemic ﬂuoxetine were prepared and injected
into the electrophoretic system. Under these conditions, one of the
pharmaceuticals (ProzacW) showed an interfering compound
that co-eluted with the ﬁrst enantiomer (E1), and prevented
its quantiﬁcation. Then, modiﬁcations in separation conditions
were tested to improve the separation and efﬁciency of the
electrophoretic peaks, trying to avoid this interference. For this
purpose, voltages ranged between 5 and 25 kV were assayed
using as BGE a 30 mM phosphate solution at pH 7.0, 7.5 and 8.0.
In addition, the effect of the application of 0.3 psi to the inlet vial
during the electrophoretic processes was also evaluated.
As expected, an increased voltage yielded shorter migration
times and higher efﬁciencies and resolution (Heiger, 1992;
Melanson et al., 2001). However, the generation of Joule heat
may limit the theoretical gain in resolution and efﬁciency with
voltage. For ﬂuoxetine, migration times of both enantiomers
became shorter at higher voltages while resolution slightly
decreased, being Rs> 1.8 in all cases. For E1, the increase of
voltage provoked a decrease on efﬁciency at three pH values
assayed. In the case of the second enantiomer, E2, similar behaviour
was observed at pH 7.0 and 7.5. In contrast, the efﬁciency improved
with the applied voltage for a pH buffer of 8.0. An increased voltage
also had a good effect on the separation between E1 and the inter-
ference peak, so 25 kV was selected as the separation voltage.
On the other hand, the increase of pH values had no signiﬁcant
inﬂuence on migration times, but improved the resolution and in
most cases the efﬁciency. Moreover, the application of a pressure
of 0.3 psi to the inlet vial during the electrophoretic processes
led to higher efﬁciency, with an improvement in peak shapes.
From the results obtained, an applied voltage of 25 kV, a pressure
of 0.3 psi and a 30 mM phosphate solution at pH 8.0 as BGE were
selected for the determination of ﬂuoxetine enantiomers in
pharmaceuticals. These conditions provided short analysis times
(<2 min), high resolutions (Rs = 2.4) and good efﬁciencies for
both enantiomers. Also the ﬁrst enantiomer of ProzacW could be
quantiﬁed without interferences using these working conditions,
as can be seen in Fig. 1.
Application of the developed method to routine analysis of
samples. Quality considerations
Accreditation entities, following ISO 17025 requirements, accept
only validation obtained in accredited testing laboratories for
auditing. This should be taken into account by research labora-
tories when developing analytical methods intended to become
routine methods (Bisetty et al., 2009). From a practical point of
view, a partial-validation selecting the main ﬁt-for-purpose
features can be investigated as previous information for testing
laboratories interested in an externally developed method. This
ﬁt-for-purpose selection should take into account the type of
method (its objective) – in this case, the quantiﬁcation of the
analyte in a major–minor concentration level (one of the four
categories from the International Conference on Harmonization
(ICH) (Sagrado et al., 2005). The features recommended for this
ICH category are: conﬁrmation of analyte identity (speciﬁcity),
accuracy (or recovery), precision (preferably in intermediate
precision conditions) and linearity (in the practical range; the full
lineal range estimation is not mandatory; Sagrado et al., 2005). In
the case of accuracy/precision, accreditation bodies demand
experiments performed in presence of real matrices (e.g. the
Spanish accreditation entity, ENAC). Other features, e.g. detection
or quantiﬁcation limits, were not considered, since they are not
essential for this method-category. Anyway, if a full method
validation is required by the accreditation body, this must be
performed by the testing laboratory.
In this case, we adjusted the conditions to allow the determina-
tion of ﬂuoxetine free of interferences from the matrix. Also, UV
spectra recorded along peak elution were similar (not shown),
indicating peak purity. Therefore, the conﬁrmation of analyte
identity could be considered guaranteed. Table 1 shows the results
on linearity as well as precision (using samples of the pharmaceuti-
cal Fluoxetina MaboW) and recovery (using samples of Fluoxetina
MaboW fortiﬁed with ﬂuoxetine), in both cases, using data from
intermediate precision conditions including data from three
different working sessions, and three independent replicates in
each session. Criteria for linearity (ENAC) and for recovery (US
Pharmacopeia; Vila Jato, 2001) were used to contrast the results.
For practical reasons, most testing laboratories work during
the routine phase, analyzing the samples only one time (single
replicate; Bonet-Domingo et al., 2007), performing new replicates
for conﬁrmation only if the result is out of the preﬁxed limits. Such
practices are currently accepted by accreditation entities. On the
other hand, a veriﬁcation step is always required by these entities.
Following this philosophy, a minimum-effort sequential protocol
(including the previous acceptance criteria) is recommended
for routine laboratories, before the analysis of samples: (1)
method calibration (and application of the R2> 0.995 criterion
for acceptance); (2) method veriﬁcation by means of a fortiﬁcation
1.0 2.0 3.0 4.0
Time (min)
(a)
(b)
Figure 1. Electropherograms corresponding to the chiral analysis of
ProzacW before (a) and after (b) the optimization of separation conditions
performed to avoid interference. Experimental conditions are as described
in the text.
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experiment, i.e. analyzing the sample and the spiked sample
(and application of the recovery in the 85–115% criterion for
acceptance; Sagrado et al., 2005); and (3) ﬁrst sample analysis [note
that the sample results from the fortiﬁcation experiment in (ii) can
be used]; if the sample is within speciﬁcations, declare this status;
otherwise, repeat the sample analysis and take the proper decision
(e.g. if second analysis is outside speciﬁcations, declare this status
for this sample).
Assuming that different samples must be analyzed, steps (2)
and (3) will continue in the working session. Table 2 shows the
starting application of this protocol, simulating the routine
analysis phase with the three different formulations mentioned
above. As can be observed for the three formulations assayed,
the samples will be declared ‘within speciﬁcations’ according
to the US Pharmacopeia criteria. Obviously, the testing laboratories
could apply more complex protocols according with their internal
Standard Operation Procedures.
Conclusions
In this work, an enantioselective method for the analysis of
ﬂuoxetine enantiomers in pharmaceuticals by counter-current
EKC has been developed, optimized for a matrix including an
interfering compound and applied to the analysis of three
pharmaceutical formulations. The developed method allows
quantiﬁcation of both enantiomers in <2 min with good resolu-
tion (Rs = 2.4) and low reagent consumption, and so has good
features to be applied in routine laboratories – better than those
reported in the literature. The proposed strategy is valid for
research laboratories intending to develop new methods as well
as for testing laboratories that must complete it with extra tasks.
This paper can also help routine laboratories implementing
quality systems to prepare their internal Standard Operation
Procedures, based on the recommended protocol. In view of the
current method evaluated in this work, we conclude that it can
be considered provisionally ﬁt for purpose with respect to the
principal ICH features according to the method’s objective. The
results indicate that the method seems to be easily transferable
since it ﬁts currently accepted criteria.
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Table 1. Main analytical features useful for partial validation following International Conference on Harmonization criteria
(Sagrado et al., 2005)
Features Fluoxetine-E1 Fluoxetine-E2
Linearity
Linear range 5–50 mg/L 5–50 mg/L
Order of magnitudea 1 1
Linear equationb y= 112.83 + 54.44x y= 97.12 + 49.27x
Determination coefﬁcient (R2)c 0.996 0.996
Precision (sample analysis, n = 3d)
Sample result 11.8 1.7 mg 11.1 1.9 mg
Intermediate precision (RSD) 14.8% 17.3%
Accuracy (fortiﬁcation assay, n = 3d)
Intermediate recovery 92 13 105 6
aAn order of magnitude >0.5 has been suggested for the concentration interval (Sagrado et al., 2005).
by=Corrected peak area.
cThe current criteria used by ENAC for linearity (chromatography and related techniques) is R2> 0.995.
dThe results are from three mean values in different sessions, each one estimated from three independent assays.
Table 2. Sample analysis of three pharmaceutical formulations according to the recommended protocol for testing laboratoriesa.
The results, expressed in milligrams, are for racemic ﬂuoxetine (differences from the labeled value, 20 mg, are included) and its
enantiomers
Pharmaceutical Racemic ﬂuoxetine (difference, %) Fluoxetine-E1 Fluoxetine-E2 Stereoisomer ratio (E1/E2)
Fluoxetina MaboW 21.0 (4.9)b 10.6 10.4 1.02
ProzacW 20.1 (0.5)b 9.0 11.1 0.81
Fluoxetina TevaW 21.4 (7.0)b 11.0 10.4 1.06
aIn all cases, samples were analyzed after a calibration conform (R2> 0.995) and a veriﬁcation conform (recovery in the 85–115%
range). The veriﬁcation was performed by analyzing the sample and a fortiﬁed sample. The result for the sample was used also for
the sample analysis stage.
bFor the three formulations, the samples will be declared ‘within speciﬁcations’ (differences in the15% interval). In this case they are
also inside the expected range from the paired veriﬁcation program of the AOAC, at the concentration level of this sample, ~0.0001 g/g
([10, +7]%) (Sagrado et al., 2005).
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a b s t r a c t
Capillary electrophoresis (CE) is a powerful technique for enantioseparations due to its high separation
efﬁciency, high versatility, speed of analysis and low consumption of samples and reagents. Non-aqueous
capillary electrophoresis (NACE) appears as a promising technique to perform enantioseparations when
the drugs, chiral selectors or samples are non-water soluble. Chiral separations have been performed by
NACE mainly using alcoholic solvents as BGEs, with problems of current breakdowns and changes in the
BGE composition, due to their high volatility.
In this work, the suitability of DMSO as BGE in NACE has been evaluated. Different experimental
variables affecting the enantioresolution of three drugs have been evaluated, ﬁnally achieving complete
enantioresolution of two drugs (verapamil, Rs¼1.5 and pindolol, Rs¼2.0) and partial resolution of the
third one (fenﬂuramine, Rs¼1.2). DMSO has been demonstrated to be a good alternative to methanolic
BGEs in NACE.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Up to 50% of the commercialized pharmacologically active
compounds are chiral, and differences in the pharmacological
activity and/or the pharmacokinetics of their enantiomers are
possible, due to the interactions with biomacromolecules such as
proteins, enzymes, receptors or carriers that are optically active
[1]. Several drugs have been recently commercialized as pure
enantiomers, after discovering that their pharmacological activity
was, mainly or exclusively, due to one of the enantiomers [2–5].
Also, due to the potential differences between the activities of a
pair of enantiomers, the regulatory authorities declare that enan-
tioselective studies of all new drugs, including single enantiomers
and racemates, are mandatory. For all these reasons, the develop-
ment of methods for the chiral analysis of drugs is of growing
interest for the pharmaceutical industry [6].
Capillary electrophoresis (CE) is a powerful technique for
enantioseparations due to its intrinsic characteristics such as high
separation efﬁciency, high versatility, speed of analysis, low con-
sumption of samples and reagents and low environmental impact
[7]. The most common modality of CE employed for enantiose-
parations is electrokinetic chromatography (EKC), in which a chiral
selector is added to the background electrolyte (BGE) and acts as a
pseudostationary phase. Usually, BGEs are aqueous and the chiral
selectors employed are water soluble.
On the other hand, many candidate drugs are non-water
soluble. This is actually one of the biggest problems for the
pharmaceutical industry these days: the low solubility and dis-
solution rate of new pharmacologically active compounds. Alter-
natives to the classical EKC have been proposed in order to
perform the chiral analysis of non-water soluble compounds:
micellar electrokinetic chromatography (MEKC) and non-aqueous
capillary electrophoresis (NACE) [8]. The use of non-aqueous
solvents in CE (NACE) was introduced by Walbroehl and Jorgenson
in 1984 [9] and the ﬁrst chiral NACE application was presented in
1996 [10]. Chiral NACE can be considered as a complementary
mode to aqueous separation since it facilitates the use of chiral
selectors with a low solubility in water [11]. Another advantage is
that the use of organic solvents enables poorly water soluble
substances to be analyzed, and allows direct injection of organic
extracts obtained after sample treatment [12]. The use of organic
solvents in the background electrolyte (BGE) can enhance the
resolution or the selectivity by tuning of the BGE composition,
since different organic solvents have different acid–base behavior,
which strongly affects the charge of the analytes, a key parameter
for electrophoretic separations [8]. Also, the selector–selectand
interactions are different depending on the solvent medium.
Another advantage of NACE over aqueous CE is that low current
values are obtained, so it is possible to apply high electric ﬁeld
strengths and high ionic strength buffers with no Joule heating,
resulting in high separation efﬁciencies [8,12].
Several methods for the chiral separation by NACE have been
published until now [11,13–19], mainly carried out in alcoholic and
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acetonitrile-based electrolytes, with the disadvantage of high
volatility of the solvents which may affect the BGE composition
during the run and cause current breakdowns. Also, methanol
(MeOH) may be unable to assure the dissolution of poorly water-
soluble and hydrophobic drugs. The use of dimethyl sulfoxide
(DMSO) in NACE has been reported only a few times, mainly in
chip-CE applications [20,21] and only in one case for a chiral
separation [22], where few amino acids were partially or com-
pletely separated employing a cationic cyclodextrin. However,
DMSO has good properties to be employed as a background
electrolyte in NACE, since it has a high dielectric constant
(ε¼46.45), and it is a non-toxic, non-hazardous, non-volatile
solvent [20]. Also, the stability of samples in DMSO is higher than
in alcoholic solvents due to its aprotic character. On the other
hand, there is an important drawback of DMSO for chiral NACE:
selector–selectand interactions, which are mainly intermolecular
forces, are very weak in this medium, so achieving the enantiose-
paration may be difﬁcult and a ﬁne adjustment of the conditions
becomes necessary.
In this work, the suitability of DMSO as BGE for performing
chiral separations in NACE is evaluated, as an alternative that can
be employed when the use of classical methanolic BGEs is not
possible. An anionic cyclodextrin, carboxymethyl-γ-cyclodextrin
(CM-γ-CD) has been employed as chiral selector, and the enantio-
separation of three racemic drugs with different molecular sizes
and functional groups (verapamil, pindolol and fenﬂuramine) has
been studied. The inﬂuence of some experimental variables on the
enantioseparation of these three drugs has been evaluated.
2. Materials and methods
2.1. Instrumentation
A Beckman P/ACE MDQ Capillary Electrophoresis System
equipped with a diode array detector (Beckman Coulter, Fullerton,
CA, USA), and 32Karat software version 8.0 was used throughout.
A 75 mm inner diameter (i.d.) fused-silica capillary with total and
effective lengths of 60.2 and 50 cm, respectively, was employed
(Beckman Coulter, Fullerton, CA, USA). Detection wavelength was
ﬁxed at 270 nm due to the absorbance of UV light by DMSO at
lower wavelengths (the cut-off wavelength for DMSO has been
ﬁxed around 260 nm in the literature). Sample tray temperature in
the CE system was set at 20 1C for all experiments.
2.2. Chemicals and reagents
All reagents were of analytical grade. DMSO, MeOH, ammo-
nium acetate (NH4Ac), acetic acid (HAc) and sodium hydroxide
(NaOH) were from Scharlau (Barcelona, Spain). Carboxymethyl-γ-
cyclodextrin (average degree of substitution 3–5, acidic form)
was from Cyclolab (Budapest, Hungary). Fenﬂuramine hydrochlor-
ide and pindolol were kindly provided by Prof. Y. Vander Heyden,
Vrije Universiteit Brussel, and verapamil hydrochloride by Prof.
J. Crommen, University of Liège.
Background electrolytes were prepared by weighing or mea-
suring the adequate amount of all the additives and bringing to
ﬁnal volume with DMSO. Stock solutions (1 mg mL1) of the
racemic drugs were prepared by weighing the adequate amount
of the drugs and bringing to 10 mL with DMSO. Working solutions
(0.2 mg mL1) were prepared by dilutions of the stock solutions in
DMSO. BGEs and drug solutions were stable at room temperature
for at least 2 weeks. They were ﬁltered through 0.45 μm pore size
nylon membranes (Micron Separations, Westborough, MA, USA)
prior to their injection in the CE system.
2.3. Methodology
2.3.1. Capillary conditioning
New capillaries were conditioned for 15 min by rinsing with
1 M NaOH at 60 1C. Then, they were rinsed for 5 min with
deionized water and 10 min with BGE at 25 1C. At the beginning
and end of each day, the capillary was rinsed with 1 M NaOH for
5 min, water for 5 min, and methanol for 5 min. Between runs, the
capillary was rinsed for 2 min with methanol and 2 min with BGE.
All steps were carried out at 20 psi.
2.3.2. Procedure for the study of enantioseparations by NACE
The initial composition of the background electrolyte was as
follows: DMSO–MeOH 80:20, with 50 mM NH4Ac, 1 M HAc and
40 mM CM-γ-CD. Initial experiments were carried out at 25 1C,
applying a voltage of 20 kV (normal polarity). Experimental con-
ditions for the enantioseparations were varied one by one, keeping
the others at ﬁxed values. After ﬁlling the capillary with the BGE,
drug samples were injected hydrodynamically by applying 0.5 psi
for 5 s. Separations were performed with normal polarity in
all cases.
3. Results and discussion
The selection of initial conditions for the study (see Section
2.3.2.) was based on an overview of the literature about chiral NACE,
in which buffering is done mainly using ammonium acetate/acetic
acid systems. As we expected low current values and a possible lack
of solubility of the buffer salts by using pure DMSO, a percentage of
MeOH was added to the BGE. CM-γ-CD (acidic form) was selected as
chiral selector due to its good solubility in the DMSO medium. It is
important to use the acidic form of the CD because the sodium salt
may be insoluble in non-aqueous solvents.
Using these initial conditions (BGE: DMSO–MeOH 80:20, with
50 mM NH4Ac, 1 M HAc and 40 mM CM-γ-CD; capillary tempera-
ture, 25 1C and applied voltage, 20 kV), partial resolutions of 0.65
for verapamil (VER) and 0.69 for pindolol (PIN) were obtained. For
fenﬂuramine (FEN), a little split of the peak was observed, but an
Rs value could not be calculated. The calculation of Rs values was
done using the following expression:
Rs¼ 2ðt2t1Þ
W2þW1
ð1Þ
where t1 and t2 are, respectively, the migration times of the ﬁrst
(E1) and second (E2) eluted enantiomers, and W1 and W2 are the
peak widths at peak base.
An average current of 12.3 μA was obtained with these
conditions. The current was stable throughout the electrophoretic
development.
A univariate optimization of the experimental conditions for
the enantioseparation of three racemic drugs by NACE was carried
out. This univariate procedure allows to see the effects of the
different experimental variables one by one, and to better under-
stand the mechanisms and effects responsible for the chiral
separation. We consider that the study of the individual inﬂuences
of variables in NACE is important, since there is still a lack of
knowledge about the behavior of organic solvents and different
buffer additives [12], and the way they can affect electrophoretic
parameters such as peak efﬁciencies, selectivity or resolution. Also,
as chiral NACE applications have been mainly studied with
methanolic BGEs, the effects that could happen in a DMSO
medium are still more unknown. So, taking as starting point the
partial Rs obtained with the initial conditions, all experimental
variables were adjusted in order to improve the Rs of enantiomers.
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3.1. Effect of the capillary temperature
Capillary temperature is a key parameter for enantiosepara-
tions since it affects the mobility of the enantiomers and also the
thermodynamic complexation equilibrium between the enantio-
mers and the chiral selector. In this work, capillary temperature
was varied between 15 and 45 1C. As shown in Fig. 1 for VER and
PIN, the enantioresolution of both drugs increases when the
temperature is decreased. A similar effect was observed for FEN,
with an increase in the peak split, but Rs values could not be
calculated. This effect can be explained because a decrease in
capillary temperature will increase the viscosity of the BGE, thus
decreasing the mobility of the enantiomers and the EOF, with the
consequence of higher Rs. Longer migration times are obtained in
all cases with low temperatures: the migration time of the second
enantiomer increases from 20.5 min at 45 1C to 37.1 min at 15 1C in
the case of VER, from 16.6 (45 1C) to 28.6 min (15 1C) for PIN, and
from 15.5 (45 1C) to 27.1 (15 1C) for FEN. A separation temperature
of 15 1C was selected in all cases.
3.2. Effect of the separation voltage
As a consequence of the low currents obtained in NACE, high
voltages can be employed thus improving the migration time of
the enantiomers and the peaks' efﬁciency. Here the voltage ranged
between 20 and 30 kV.
The increase in separation voltage considerably reduced the
migration times of all the drugs, changing from 35–50 min with
20 kV to 23–33 min with 30 kV. This is due to the considerable
increase of the current (from 8.2 μA at 20 kV to 12.6 mA at 30 kV).
Also, the enantioresolution was slightly improved when higher
voltages were employed. Fig. 2 shows the electropherograms
corresponding to the separation of verapamil enantiomers at the
three applied voltages, where the effect of the voltage on the Rs
and migration time can be seen.
3.3. Effect of the CM-γ-CD concentration
The concentration of chiral selector is usually the most inﬂuential
variable on enantioseparations. When cyclodextrins are employed as
chiral selectors, the separation mechanism is the formation of
inclusion complexes of the enantiomers in the hydrophobic cavity
of the cyclodextrin. The complexation equilibrium is affected by the
concentrations of both the drug enantiomers and the cyclodextrins,
so an increase in the CD concentration will favor the formation of
the diastereomeric complexes responsible for the chiral separation.
This is especially important in NACE because the interaction
between the enantiomers and the CD is less favoured in organic
media than in water.
In this work, the concentration of CD is changed between 10
and 70 mM for all drugs. Fig. 3 shows the enantioresolution values
obtained for VER, PIN and FEN with all the CD concentrations. As
shown in the ﬁgure, 10 mM CM-γ-CD was too low to provide any
enantioresolution of drugs. With 20 mM, a partial Rs value is
obtained for VER, but still no Rs was found for PIN and FEN. The
maximum Rs value was obtained for PIN and FEN with 40 mM CM-
γ-CD, decreasing with higher CD concentrations. For VER, the Rs
was slightly higher with 50 mM CM-γ-CD, but 40 mM was enough
to provide good enantioresolution, especially when combined
with the best conditions selected in other variables. So, as the
CD concentration is the most critical variable in terms of analysis
cost, 40 mM was selected as the best concentration for the three
drugs studied.
3.4. Effect of the percentage of methanol
The physicochemical properties of DMSO and MeOH are quite
different: MeOH has lower dielectric constant (ε), much lower
viscosity (η), lower boiling point, and lower autoprotolysis con-
stant (pKauto), which implies that more ions in solution will be
found in methanolic BGEs [8]. So, the percentage of MeOH will
modify considerably the physicochemical properties of the BGE
and will strongly affect the enantioseparation. In this work, since
our main aimwas to employ a DMSO-based BGE, the percentage of
MeOH was varied from 0% to 30%, so the main component of the
BGE was DMSO in all conditions.
A decrease in MeOH percentage increases the migration times of
all compounds. In the case of VER, best Rs is obtained with 20%
MeOH, so it is selected as optimum. For PIN, there is a clear decrease
10 20 30 40 50
T(ºC)
0
0.4
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s
Fig. 1. Effect of the capillary temperature on the enantioresolution of VER (◆, solid
line) and PIN (●, dashed line). Other experimental conditions: BGE DMSO–MeOH
80:20, 50 mM NH4Ac, 1 M HAc, 40 mM CM-γ-CD, applied voltage 25 kV.
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Fig. 2. Electropherograms corresponding to the enantioseparation of VER at three
separation voltages: 20 kV (a), 25 kV (b) and 30 kV (c). Capillary temperature: 15 1C.
Other experimental conditions as in Fig. 1.
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in Rs when the MeOH percentage is decreased (Fig. 4(1), so 30% is
selected as best option since it combines better Rs with shorter
migration time. The case of FEN (Fig. 4(2) is the opposite; the split of
peaks is larger without MeOH so a pure DMSO BGE is selected as
best option.
The differences between the three compounds in the optimum
MeOH percentage should be due to a dual mechanism that affects
the enantioresolution: on the one hand, the increase in MeOH
increases the ε/η ratio of the BGE, which is a measure of the speed
of the analysis, and decreases in consequence the migration times,
so, if peaks migrate faster, less Rs can be expected a priori (this is
the case of FEN). On the other hand, as DMSO is an aprotic solvent,
the increase of MeOH can increase the ionization degree of the
drugs, enhancing the interaction with the anionic CD (the case of
PIN). For VER, both opposite effects lead to an intermediate BGE
composition (DMSO–MeOH 80:20) as the best option.
3.5. Effect of the NH4Ac and HAc concentration
The electrophoretic and electroosmotic mobilities are inversely
proportional to the concentration of salts in the BGE [23], so longer
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0
0.4
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R
s
Fig. 3. Effect of CD concentration on the enantioresolution of VER (◆, solid line),
PIN (●, dashed line) and FEN (▲, semi-dashed line). Capillary temperature 15 1C,
applied voltage 30 kV. Other experimental conditions as in Figs. 1 and 2.
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Fig. 4. Electropherograms corresponding to the enantioseparation of PIN (1) and FEN (2), with different MeOH percentages in the BGE: 0% (a), 10% (b), 20% (c) and 30% (d).
[CM-γ-CD], 40 mM. Other experimental conditions as in Fig. 3.
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Fig. 5. Effect of [NH4Ac] on the enantioresolution of VER (◆, solid line) and PIN (●,
dashed line). MeOH percentage: 20%. Other experimental conditions as in Fig. 4.
Table 1
Experimental conditions selected for the enantioseparation of each drug by NACE,
and the corresponding electrophoretic parameters obtained in each case.
VER PIN FEN
Temperature (1C) 15 15 15
Voltage (kV) 30 30 30
[CM-γ-CD] (mM) 40 40 40
% MeOH 20 30 0
[NH4Ac] (mM) 125 125 125
[HAc] (M) 1 0.5 0.5
Rs 1.5 2.0 1.2
Analysis time (min) 43 25 42
Current (μA) 25 29 17
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migration times and better selectivities are expected when the
buffer concentration is increased. The NH4Ac concentration ranged
in this work from 25 to 125 mM (a BGE without NH4Ac was also
tested, but no stable current was obtained). Better Rs values but
longer migration times were obtained with higher NH4Ac con-
centrations, as expected. Due to the notable improvement on the
Rs of enantiomers (Fig. 5), 125 mM was selected as the best NH4Ac
concentration for all tested compounds.
The HAc concentration was varied between 0.5 and 1.5 M. The
differences in HAc concentration did not affect so much the
migration time and the resolution of enantiomers. Slightly better
Rs values (or peak split, in the case of FEN) were found using 1 M
HAc in the case of VER and 0.5 M for PIN and FEN, so these
conditions were selected.
3.6. Selected conditions
Table 1 summarizes the experimental variables studied and the
best conditions selected for the enantioseparation of VER, PIN and
FEN in this DMSO-based NACE. It also shows the Rs values
obtained for the three drugs, the analysis times of the three
enantioseparations (migration times of the second eluted enan-
tiomers), and the current values obtained. As can be seen in
Table 1, complete enantioresolution of VER and PIN and partial Rs
of FEN were obtained. The electropherograms corresponding to
these best experimental conditions are shown in Fig. 6, together
with the chemical structures of the three drugs.
4. Conclusions
In this work, the suitability of DMSO to be employed as BGE in
NACE has been evaluated. Different experimental conditions were
tested in order to achieve the best enantioseparation conditions
for three racemic drugs: verapamil, pindolol and fenﬂuramine.
Complete enantioresolution was obtained for VER and PIN while a
partial Rs value was obtained for FEN. Best enantioresolutions
were obtained with low capillary temperatures, high separation
voltages and high concentration of salts in the BGE, in general
terms. For the other variables, individual effects may be consid-
ered. The analysis times were lower than 45 min in all cases
(43 min for VER, 25 for PIN and 42 for FEN). These analysis times
are a priori long for an electrophoretic separation, due to the high
viscosity and relatively low ε/η ratio of DMSO, but are comparable
with chromatographic enantioseparations performed with chiral
stationary phases.
It is also remarkable that in all the tested experimental condi-
tions current values were stable and there were no current break-
downs, so DMSO has proved to be a good solvent to be employed in
NACE, combined (or not) with a small percentage of MeOH in order
to modulate the physicochemical properties of the BGE. DMSO
appears to be a good alternative for NACE when, due to solubility,
stability or volatility problems, the commonmethanolic BGEs cannot
be employed.
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Evaluation of enantioselective binding of
ﬂuoxetine to human serum albumin by
ultraﬁltration and CE – Experimental design
and quality considerations
Several pharmacokinetic processes are affected by enantioselectivity (ES). At the level of
distribution, protein binding (PB) is one of the most important. The enantioselective
binding of ﬂuoxetine (FLX) to HSA has been evaluated in this work by ultraﬁltration of
FLX–HSA mixtures and chiral analysis of unbound fractions by EKC-CD. PB, afﬁnity
constants (K) and ES were obtained for both enantiomers of FLX. In order to improve the
consistency of the estimations, the evaluation of afﬁnity constants of each enantiomer
was performed using two designs, one keeping constant the total concentration of
protein and varying the total concentration of the enantiomers, and the other in the
opposite way, in both cases via an unusual short-concentration interval strategy to assure
model validity. Different mathematical approaches were compared and characterised and
some of them, judged as the most consistent under the experimental conditions used,
were selected to provide ﬁnal estimates. Quality considerations include criteria for three
critical aspects: (i) detecting/eliminating outliers, (ii) checking the number of binding
sites in the protein and (iii) evaluating the robustness of each approach. The differences
on estimates from the selected approaches were used as an uncertainty source to delimit
the reported values. The ES of HSA for FLX enantiomers was approximate. Estimates
include the assumptions of independent and competitive models. In the last case, a
SIMPLEX function was designed capable of simultaneously optimizing the non-linear
binding models for both enantiomers, thus improving the consistence of results.
Keywords:
EKC / Enantioselective binding / Fluoxetine / HSA / Quality protocol
DOI 10.1002/elps.201000250
1 Introduction
Drug action is the result of several pharmacokinetic and
pharmacological processes. Most of them present a high
degree of stereoselectivity, resulting in a difference between
the activities of drug enantiomers [1]. Pharmacokinetic
processes affected by enantioselectivity (ES) are drug
absorption, distribution, metabolism and excretion. At the
level of distribution, one important effect is the protein
binding (PB). HSA is the most abundant protein in human
plasma, and it presents a high degree of enantioselective
interaction with drugs [2]. Stereoselectivity in binding with
HSA can have an important effect on the drug disposition
such as ﬁrst-pass metabolism, metabolic and renal clear-
ance, and distribution to other compartments. Most of the
interactions with the HSA occur at two well-deﬁned regions
of the HSA molecule, known as sites I and II [2–4].
When protein and racemic drugs interact, two diastereo-
meric aducts are formed with potential differences in the PB,
which may result in different pharmacokinetic proﬁles for the
individual enantiomers [5]. For the investigation of drug
enantioselective binding, different approaches have been
proposed. The majority of these methodologies include a ﬁrst
step in which the free drug fraction is separate from the bound
drug once the drug-protein equilibrium has been reached
using different techniques, such as the traditional equilibrium
dialysis [3], ultracentrifugation [3] or ultraﬁltration [4]. The
second step includes chiral analysis of enantiomers in the
unbound fraction using different techniques such as LC and
CE and different chiral selectors, for instance using EKC [6].
From a pharmacokinetic point of view the estimation of
the percentage of PB at physiological conditions is an
important parameter. In the case of enantiomers, besides
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their PB, it is also appropriate knowing the ES degree
obtained, e.g. from their afﬁnity constant K values. To obtain
K it is necessary to assume a concrete binding model.
Together with K, the model allows estimating the number of
binding sites per protein molecule, n.
Psychoactive drugs are the most used drugs in our
society. Antidepressants, hypnotics and many other families
are purchased every day by different kinds of patients.
Usually, these drugs have been synthetised and commercia-
lised as racemic forms, but recently the industry is interested
in the introduction of pure enantiomers in the pharmaceu-
tical market. Pharmacokinetic and pharmacological proper-
ties of each enantiomer have to be studied nowadays for these
drugs in pre-clinical phases. Fluoxetine (FLX) is a potent and
selective inhibitor of the neuronal serotonin-uptake carrier
and is a clinically effective antidepressant. FLX is used ther-
apeutically as the racemate although a stereospeciﬁcity asso-
ciated with its interactions with the serotonin-uptake carrier
has been demonstrated [7]. Recently, the interaction between
HSA and FLX has been studied by using different spectro-
scopic techniques, viz., ﬂuorescence, UV–vis absorption,
circular dichroism and FTIR [8]. The reported value of
binding constant, K, of FLX-HSA at 3101K (i.e. 36.841C) was
1.45 103 (log K5 3.16), while the number of binding sites,
n, was almost equal to unity. The results correspond to an
experimental design where HSA was kept constant at 2.5 mM
and the drug was varied from 10 to 100 mM. The authors also
used warfarin, ibuprofen and digitoxin as markers to locate
the has-binding sites, I, II and III, respectively. They found
that the drug competes with warfarin for site I in the
protein (decreasing the K value for FLX, while it
remained almost same in the presence of ibuprofen and
digitoxin). So, they postulated that FLX is most likely bound
to site I.
The interaction between small molecules and HSA is a
complex process. Sometimes this point is disregarded and
bad estimates are frequent [9]. In order to perform estima-
tions, a model should be supposed, including some
assumptions that should be veriﬁed (as far as possible). Also
experimental conditions to a priori ﬁt the assumptions
should be selected. In this paper we have estimated the
afﬁnity constant of enantiomers of FLX for HSA. For this
purpose, a methodology that includes the ultraﬁltration of
pre-equilibrated samples containing HSA and racemic FLX
and the analysis of the unbound drug fraction by EKC with
the highly sulphated-b-CD (HS-b-CD) as chiral selector, was
applied. The afﬁnity constants have been estimated using
two experimental designs involving total enantiomer and
HSA concentrations, selecting a short-concentration interval
strategy in order to avoid conditions far from the physiolo-
gical ones and trying to be consistent with the model
assumptions. Different mathematical approaches were used
evaluating their consistence. Quality considerations were
included involving outliers identiﬁcation/elimination,
assumption veriﬁcation and uncertainty estimation. The ES
of HSA for FLX enantiomers as well as the PB percentage at
physiological conditions were approximate.
2 Materials and methods
2.1 Instrumentation
A Beckman P/ACE MDQ Capillary Electrophoresis System
equipped with a diode array detector (Beckman Coulter,
Fullterton, CA, USA), and 32Karat software version 8.0 was
used throughout. A 50 mm id fused-silica capillary with total and
effective lengths of 31.5 and 21 cm, respectively, was employed
(Beckman Coulter). Electrophoretic solutions and samples were
ﬁltered through 0.45 mm pore size nylon membranes (Micron
Separation, Westboro, MA, USA) and degassed in an ultrasonic
bath (JP Selecta, Barcelona, Spain) prior to use. A Crison Micro
pH 2000 pHmeter from Crison Instruments (Barcelona, Spain)
was employed to adjust the pH of buffer solutions.
A Selecta thermostatised bath (JP Selecta) was used for
samples incubation. For the ultraﬁltration of samples,
Microcon YM-10 cellulose ﬁltres of a molecular weight of
10 000 MVCO (Millipore Corporation, Bedford, MA, USA)
and a centrifuge Heraeus Biofuge Strate (Heraeus, Madrid,
Spain) were used.
2.2 Chemicals and standard solutions
All reagents were of analytical grade. HSA fraction V was
purchased from Sigma (St. Louis, MO, USA); sodium
dihydrogen phosphate dihydrate from Fluka (Buchs, Swit-
zerland); HS-b-CD (20%w/v) aqueous solution was
purchased from Beckman Coulter; Racemic FLX was kindly
donated by Alter (Madrid, Spain). Ultra Clear TWF UV
deionised water (SG Water, Barsbu¨ttel, Germany) was used
to prepare solutions.
Separation buffer in EKC containing phosphate 30 mM
at pH 7.0 was obtained by dissolving the appropriate
amount of sodium dihydrogen phosphate dehydrate in
water and adjusting the pH with 1 M NaOH. Similarly,
phosphate buffer 67 mM of pH 7.4 was prepared for the
study of binding to HSA. Aliquots of 1000 mM HSA stock
solution were daily prepared by weighting the correspond-
ing amount of protein powder and dissolving it with 67 mM
phosphate buffer.
A stock standard solution of FLX 1000 mM was prepared
in the separation buffer. In order to obtain the calibration
graphs for the analysis of samples, working solutions of FLX
containing different concentrations of enantiomers
(between 25 and 250 mM of each enantiomer) were obtained
in duplicate by diluting the stock standard solution with
30 mM phosphate buffer.
2.3 Methodology
2.3.1 Experimental designs
We have planned two experimental designs, one keeping the
concentration of protein constant (P-constant) and varying
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the concentration of FLX and the other one keeping the
concentration of FLX, and therefore of their enantiomers,
constant (D-constant) and varying concentration of protein
(see Table 1). In both designs ﬁve concentration levels were
used and two independent replicates per level, totalling 18
independent mixtures (two of them used in both designs).
2.3.2 Procedure for separation and analysis of
unbound FLX fraction to HSA
Mixtures containing different FLX and HSA concentrations
were prepared in duplicate by dilution of the stock solutions
of drug and protein with phosphate buffer at 67 mM and pH
7.4. All these mixtures were allowed to reach equilibrium for
30 min in a water bath at 36.51C and were ﬁltered through
cellulose ﬁlters by centrifugation at 9000 rpm for 30 min.
Adsorption of the drug on the cellulose ﬁlters was observed,
so the calibration standards were processed via the
methodology used for samples, to account for this effect.
The ultraﬁltrate was directly injected into the EKC system.
2.3.3 Capillary conditioning
New capillaries were conditioned for 15 min ﬂush with 1 M
NaOH at 601C. Then, they were rinsed for 5 min with
deionised water and 10min with separation buffer at 251C.
In order to obtain good peak shapes and reproducible
migration data, the capillary was conditioned prior to each
injection. In all cases, the conditioning run included the
following steps: (i) 30 s rinse with deionised water, (ii) 1 min
rinse with 0.1 M NaOH and (iii) 30 s rinse with deionised
water at 20 psi. Before chiral selector and sample injection
the capillary was also rinsed with the separation buffer for
1 min at 20 psi.
2.3.4 Procedure for enantiomeric resolution of FLX by
EKC and HS-b-CD as chiral selector
For all experiments, a 30 mM phosphate solution of pH 7.0
was used as electrophoretic buffer. A 0.25% HS-b-CD
solution obtained from 20%w/v HS-b-CD by dilution with
the separation buffer was used to carry out the enantio-
resolution of FLX enantiomers. FLX solutions (ultraﬁltrated
fractions; calibration and mixture solutions) were injected
hydrodynamically at 0.5 psi for 5 s. Before sample injection,
the capillary was ﬁlled with the HS-b-CD solution by
applying 2 psi for 1 min. Separation was performed in
normal polarity by applying 15 kV. In order to improve the
peaks shape and decrease migration times, a 0.3 psi
pressure was applied into the inlet vial throughout the
analysis. The capillary was thermostated at 301C and the
UV-detection wavelength was set at 220 nm. In order to
avoid the effect of buffer depletion, buffer vials were
changed after one run (in samples) and two runs (in
calibration standards). Under the selected separation condi-
tions a medium resolution of 3.5 was obtained for the FLX
enantiomers (Fig. 1).
2.4 Software
Routines made/adapted in MATLABs 4.2 were used for
calculations. The results generated were veriﬁed using
EXCELs and STATGRAPHICSs. In some calculations a
SIMPLEX algorithm routine was used (non-linear ﬁtting).
3 Results and discussion
There are numerous papers concerning PB. Unfortunately,
nomenclature is not uniform and sometimes ambiguous
words or symbols are encountered, and some information
remains unclear. To avoid this, Appendix A shows the
nomenclature used along the text concerning the PB process
(in some cases the general nomenclature, valid for
molecules, was adapted to refer to enantiomers). It is also
common in these studies using a single approach to
perform the estimations, with little or null attention to its
consistence. Appendix B shows the equations used for
calculations, as well as comments related to the degree of
consistency involving some assumptions to simplify them.
In this sense, several assumptions are only consistent in the
Table 1. Experimental dataa)
IDb) D (mM) P (mM) dE1 (mM) dE2 (mM)
P-constant design
1 78.9 476.6 7.8 13.9
2 7.3 12.2
3 105.3 7.6 15.7
4 7.8 19.5
5 131.6 11.5 19.9
6 10.4 19.8
7 157.9 17.2 25.8
8 13.8 28.9
9 184.2 18.3 34.4
10 17.6 29.5
D-constant design
11 131.6 250.9 21.8 40.7
12 21.4 38.9
13c) 301.0
14 15.3 30.2
15 351.2 13.7 26.0
16 12.6 25.4
17 401.4 10.8 21.1
18 11.5 23.0
19d) 476.6 11.5 19.9
20d) 10.4 19.8
a) Data were transformed to M units for calculations.
b) Identiﬁcation number to refer to individual data along
the text.
c) Data for ID513 was eliminated for the studies (see Section
3.3).
d) IDs 19 and 20 are repeated from IDs 5 and 6 data, used in both
designs.
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case of low D values (i.e. low D/P ratios; an uncommon
experimental situation in most papers), which habitually
agrees with the physiological situation. We have ﬁrst
investigated the physiological concentrations of FLX and
HSA. Appendix C shows some data related to FLX and HSA
concerning the binding process.
3.1 Pharmacokinetic data and physiological
conditions
Appendix C includes an in-house approximation of the drug
stationary state-plasmatic concentration (Css), based on
pharmacokinetic data for FLX. The approximated value of
Css 0.2 mM (after normal dose) was obtained for the
molecule (so a concentration of 0.1 mM would correspond to
its enantiomers). This is consistent with published data for
enantiomers of FLX. Plasmatic concentration of enantio-
mers of FLX, investigated in 131 adult patients receiving
long-term FLX of 10–60mg/day (mean, 24710mg/day),
provide mean values of 0.186 and 0.067 mM for S-FLX and
R-FLX, respectively [10].
These results allow estimating D under physiological
conditions, i.e. D0.1 mM (for each enantiomer). Since
P600 mM, the physiological D/P ratio could be established
ino0.0002. The low D (and D/P ratio) suggests that several
assumptions indicated in Appendix B should be satisﬁed at
the physiological level, for instance, m5 1 to characterise
the FLX–HSA binding interaction (Appendix B, footnote d).
From the available data of PB for FLX (PB94.75%;
Appendix C), which is assumed to correspond mainly to HSA
under physiologic conditions, a value of K1 could be estimate
from Eq. (6a) (Appendix B). A value of log KFLX54.78 (for
FLX, not their enantiomers) is obtained. The validity of Eq. (6a)
(which assumes K1 doo 1) could be assessed approximating
the free FLX concentration (dFLX), from PB and the
physiological FLX concentration (Css0.2 106M), as indi-
cated in Appendix C; dFLX1 108M; then KFLX dFLX
0.00063oo 1 (Error  0.06%; therefore the assumption is
fulﬁlled). Note that the estimated log KFLX, 4.78, is more than
one order of magnitude higher that the reported one, 3.16 [8],
obtained under experimental conditions far from the physio-
logical ones.
3.2 Experimental design and data
Numerous published papers use large-concentration ranges,
under a single experimental design, for instance, ﬁxing P and
varying D along several of orders of magnitude. Large
D-ranges partially reduce the impact of inconsistent
approaches (e.g. Scatchard plot, [11] and references therein)
on the estimates, but there is not guaranty on the unique-
model validity (Appendix B) and implies working too far from
the real physiological concentrations. For instance, experi-
ments performed at D/P41 (in the opposite of physiological
conditions) are habitual. An example is the data reported from
FLX-HSA binding, using D/P ratios from 4 to 40 [8] (in
contrast to the estimated D/P ratio o0.0002 at physiological
level, Section 3.1). On the other hand, some authors have
reported the inﬂuence of binding parameter estimates with P
[9, 12, 13]; accordingly, the use of P far from the physiological
one could provide useless estimations.
We have adapted the concentrations to the instrument
features, but trying to approximate as close as possible the
physiological concentrations, as well as covering possible
factor-effects on the estimates. Thus, we have established
the following criteria: (i) Combining two experimental
designs, P-constant (varying D) and D-constant (varying P),
to have independent results and to control the possible
P-concentration effect (ii) Fixing the concentration ranges
keeping D/Po1; in the P-constant design the minimum D
was ﬁxed taking into account the approximate quantiﬁcation
limit for d1 and d2, while in the D-constant case, maximum
P was ﬁxed close the physiological concentration (in the
hypoalbuminemia-normal levels frontier [14]).
Previous assays suggest that a value of 10 mM of
racemic FLX (i.e. dFLX) provides the minimum acceptable
signals to quantify the enantiomers (note that this is just an
approximation of the quantiﬁcation limit). Employing log
KFLX4.78 as a provisional estimation for FLX (Section 3.1),
the total DFLX could be estimated re-writing Eq. (4) (i.e.
DFLX5 f (dFLX, P, KFLX), e.g. using dFLX5 10 106M and
P5 500 106M (selected as maximum P). The estimated
minimum DFLX was 200 mM for FLX, which imply a
D100 mM for each enantiomer.
2.0 3.0 4.0 5.0
time (min) 
0.8
1.2
1.6
2.0
2.4
mAU total drug
unbound fraction
Figure 1. Electropherograms obtained for a sample containing
racemic FLX (total drug) and the unbound fraction after FLX-HSA
incubation and ultraﬁltration processes (HSA 476.6 mM). The
enantiomers concentration was 105.3 mM in both cases. Separa-
tion conditions: HS-b-CD 0.25% as chiral selector (rinsed at 2 psi
for 1min), 30mM phosphate buffer, pH 7, 15 kV (10.3 psi) and
301C. The sample was injected hydrodynamically at 0.5 psi for
5 s.
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We pre-selected a D-range from 100 to 200 mM in the
P-constant design to avoid too high D/P ratios. To assure
D/Po1, the pre-selected P range was 250 to 500 mM in the
D-constant design. Therefore we have imposed narrow
experimental ranges for D and P, i.e. a short-concentration
interval strategy. Such decisions imply to take cautions respect
to the consistence of the Appendix B-approaches. Table 1
shows the ﬁnal prepared concentrations (D and P, in mMunits,
although they were transformed in M units to used in the
equation of Appendix B), as well as the measured ones (dE1
and dE2). Since each of the ﬁve concentration levels per design
has two independent replicates, we can control eventual
atypical results. The ﬁnal D/P ratio values in Table 1 vary from
0.17 to 0.52 (larger than the in vivo ones, but at least less than
1, contrasting with the general literature ones) and then, here,
Appendix B assumptions could be reasonably fulﬁlled; for
instance, m51-model for the FLX-HSA interaction, since only
at high concentration, a single drug may populate multiple
sites (m41) on HSA [15].
3.3 Outlier identiﬁcation/elimination
Examples in the literature indicate that an insufﬁcient attention
to possible outliers or their impact on the selected model
estimations is practised. Experimental error in determining d
(see for instance duplicate results in Table 1) has to be taken
into account. Therefore, outliers’ identiﬁcation/elimination
should be a previous basic task. One possible way to explore
outliers could be inspecting the experimental data. For
instance, Fig. 2, visualising the experimental designs, suggests
that points identiﬁcation number (ID) 513 have atypical d
values for both enantiomers. However, since the objective of
measuring the data is to estimate K1, outliers should be
preferably inspected on it.
Let us suppose that n15 1 (as a provisional assump-
tion). In such case, K1 could be estimated by Eq. (4) for each
individual data. Those values relatively far from the average
value (mean or the median of the estimates) could be
potential outliers (e.g. to be submitted to an outliers’ statis-
tical analysis). Figure 3 illustrated such plot for both enan-
tiomers, which clearly identiﬁes the points ID5 13 for E1
and E2 as possible outliers. It should be taken into account
that irrespective of n15 1, this approach could be used to
identify and eliminate outliers, at least in our short-
concentration interval selection.
The Grubbs test is a suitable approach to evaluate one
(single) or two (double) extreme data [16]. Application of the
Grubbs test (a5 2.5%, 2 tails) conﬁrmed that ID5 13 K1-
estimates are outliers. After eliminating ID5 13 data, other
extreme single (ID5 1) or double (ID 1 and 2) data, in the
case of E1, or ID5 1 or ID 1 and 4 data, in the case of E2,
were not outliers, according to the Grubbs criteria. For
further studies the data corresponding to ID5 13 were
eliminated (as indicated in Table 1).
3.4 Consistent and inconsistent/insecure
approaches/estimates
Numerous literature results on PB estimations are obtained
using one of the equations of Appendix B without checking
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Figure 2. Experimental
designs and results for each
enantiomer: (A) P-constant
design and (B) D-constant
design, showing dE1 (o) and
dE2 (1) versus D and P,
respectively. The IDs repre-
sent duplicate experiments
by ﬁve D and P levels for each
experimental design. In all
cases D/Po1.
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their consistence or robustness. Moreover, it could be
considered that some published data are rough or even
erroneous estimates [9]. Appendix B indicates some
problems, intrinsic to the available equations, which may
inﬂuence the estimates. Here, we have used all the
approaches in Appendix B, evaluating the consistence of
the results. Obviously the conclusions must be conﬁned to
the present experimental conditions.
From the experimental data, we have calculated dFLX as
the sum of dE1 and dE2 and used Eq. (6) to estimate KFLX.
The results ranged from 4.10 to 4.26 (excluding the result
from ID5 13). These values are inconsistent since the KFLX
dFLXoo 1 assumption is not fulﬁlled (errors from 20 to
70%). Although Eq. (6) is not valid, due to the relatively
low D/P (o1) ratios used, the estimates are closer to log
KFLX estimated from PB% (4.78; Section 3.2) than that
reported with D/P41 (3.16 [8]). In addition, Eq. (6) also
would require checking the n15 1 assumption, otherwise
the estimate should be [n1 K1] (Eq. (5), Appendix B).
In Section 3.3, Eq. (4) was just used for evaluating
outliers assuming that n15 1. In our opinion, at low D/P
ratios, as occurs with m5 1 [15], n15 1 should be consid-
ered the most probable situation, since the relatively high
concentration of available binding sites. Also, n15 1 was
supported by previous experimental results for FLX [8].
Apart from this, assessing this assumption is appropriate to
gain conﬁdence respect to the K1-stimates acceptance from
Eq. (4) approach. A feasible way could be using Eq. (4a), i.e.
plotting log(r/(1-r)) versus log(d) and checking the slope5 1
(veriﬁcation criterion; Appendix B). Using the P-constant
design (ID numbers 1–10) data in Table 1, the slope (71/2
CI 95%) values were 1.0 (70.3) and 1.1 (70.3), for E1 and
E2, respectively; while using the D-constant design (ID
numbers 11–20, except ID5 13) were 1.1 (70.3) and 0.9
(70.2). This means that the assumption n15 1 can be
accepted, giving also validity of log K1 estimations based
on Eq. (4).
Table 2 shows the mean (7standard deviation) from 17
K1 individual estimates (points ID 13, 19 and 20 were
excluded). In our opinion, Eq. (4) is a robust option due to
the number of data to obtain the mean (or median) and the
possibility of controlling them. In contrast, caution must be
taken to estimates from Eq. (4a) (i.e. log K1 as the intercept
of the plot log(r/(1-r))5 log K11log(d)), because slightly
slope deviations from unity could provide signiﬁcant chan-
ges in the intercept, particularly for short-concentration
interval strategies. For instance, the log K1 values corre-
sponding to the above indicated linear regression slopes
were: 4.55, 4.65, 4.85 and 3.54, respectively (the last value
differs from the other ones). In the same way, elimination of
any point has also notable impact of the estimate. Therefore
Eq. (4a) is a risky non-robust solution to estimate K1 values.
Equation (3d) is a non-linear alternative to the more
popular linear approaches, Eq. (3a–c), to estimate two
parameters: n1 and K1. Table 2 shows the results of D- and
P-constant designs for E1 and E2 enantiomers correspond-
ing to Eq. (3d), when SIMPLEX algorithm includes the
restriction of integer n1 values (see Section 2). In all cases
the n15 1 result was found when ‘starting values’ for the
SIMPLEX search were n15 1, log K15 5 (e.g. based on
results from Eq. (4) in Table 2). As expected, the log K1 agree
well with those obtained from Eq. (4), suggesting that Eq.
(3d) is a consistent approach. However this point deserves
more attention. Figure 4 shows some results associated to
enantiomer E2 (P-constant design data) based on Eq. (3d);
the validation plot for d (Fig. 4A) and the d versus D plot
(Fig. 4B) superimposing on it the ﬁtted model (the best
SIMPLEX solution). Both plots suggest adequate results,
also supported by other available statistics, e.g. R25 0.92.
However, as indicated in Appendix B, several combinations
of n1 and K1 could provide apparently good results. For
instance, eliminating the restriction of integer n1 values,
provided n15 1.9, log K15 3.81 and R
25 0.93 or using
n15 3 and log K15 3 as ‘starting values’ provided n15 8, log
K15 3.13 and R
25 0.92. This could introduce lack of
conﬁdence to the approach, so an independent estimation,
or at least a veriﬁcation, of n1 becomes convenient (e.g. as
that provided by Eq. (4a)).
Equations (3a–c) have recognised mathematical incon-
sistencies and their use is risky ([9, 13] and references
therein); surprisingly, they are still commonly used, parti-
cularly the Scatchard plot (Eq. 3b). Figure 4C shows the
corresponding linear plots to enantiomer E2 (P-constant
design data) based on Eq. (3a–d). It can be observed that
different dispersion degrees (then quality statistics) are
observed between the approaches, which contrast to the fact
that all are derived from Eq. (3) (as Eq. 3d). As consequence,
estimates obtained also differ. For instance n1 values were
2.0, 4.1 and 1.5 and log K1 3.7, 3.5 and 3.9, from Eq. (3a),
(3b) and (3c), respectively. As expected, inconsistent, erratic
in this particular case, n1 values are obtained. Also, it is
evident that elimination of any data point will provide
notable changes in the estimates (based on the slope and the
intercept), and then a lack of robustness.
0 5 10 15
3.5
4
4.5
5
 13
 13
ID
lo
g 
K
Figure 3. Estimated log K1 values for E1 (o) and E2 (1) based on
Eq.(4) (i.e. assuming n15 1; see Appendix B). ID 13 appears as an
outlier. Horizontal lines indicate the mean value (after eliminat-
ing ID5 13 as well as the repeated IDs 19 and 20 data).
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The black line in Fig. 4C is the linear ﬁt of the data. We
have also superimposed (grey line) the linear equation
derived from the estimations based on Eq. (3d) (n15 1 and
log K15 4.15; see Table 2) for comparison. The Klotz plot
(1/r versus 1/d, in which n15 1/intercept) shows an apparent
similar trend between the two lines. However, the slight
difference is enough to move n1 from 1 (Eq. 3d line) to 2
(Eq. 3a line). The other two plots reveal larger differences
between the lines, due mainly to data points IDs 1 and 4.
(Note that Fig. 3 reveals a certain atypical character to these
points in comparison to the rest). After eliminating both
points the aspect of Fig. 4C becomes more favourable (better
agreement between lines), as well as the estimates, for
instance, combining the estimations of Eq. (3a–c) we obtain,
Table 2. Consistent results using some approaches of Appendix B
Model Eq. Conditionsa) Estimated parameters
n1 log KE1 log KE2 Comments
Independent 4 All data 1b) 4.5170.08 4.1770.06 Concrete D-P design unnecessary. Control on individual
results. It allows an estimation of uncertainty
3d P-constant design 1c) 4.47 4.15 Concrete D-P design necessary. Combining the
estimates from designs an estimation of uncertainty
is possibled). It allows estimating PBe)
D-constant design 4.57 4.20
3 (3d) All data (joined designs) 4.53 4.18 Concrete D-P design unnecessary.
Competitive 3d1 and 3d2 P-constant design 4.67 4.37 Concrete D-P design necessary. Combining
the estimates from designs and estimation of
uncertainty is possiblef)
D-constant design 4.87 4.52
a) When D-constant design (ID5 11–20) and joined designs (ID5 1–20) are used, the point ID5 13 was eliminated.
b) n1 5 1 was preﬁxed and veriﬁed by means of Eq. (4a). log K1 Estimates make sense only if veriﬁcation is satisﬁed.
c) n1 was optimised by SIMPLEX but allowing only integer n1 values (restriction). Starting values for SIMPLEX were n1 5 1, log KE1 5 5
y log KE2 5 5.
d) Mean (7standard deviation) was 4.52 (70.07) and 4.18 (70.04) for log KE1 and log KE2, respectively.
e) PB 5 100 (1–d/D), where d could be estimated from Eq. (3d) once n1 and K1 have been estimated; e.g. to estimate PB at physiological
conditions d could be estimated using in Eq. (3d) P5 600.106 M and D5Css/2M (see Appendix C) and an average value of K1 from
Table 2 (here using n15 1).
f) Mean (7standard deviation) was 4.77 (70.14) and 4.45 (70.11) for log KE1 and log KE2, respectively.
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Figure 4. Results corresponding to E2
using the P-constant design (IDs: 1–10):
(A) Validation plot for d (estimated versus
experimental) and (B) d versus D plot
including the experimental data and the
ﬁtted model (solid line) using Eq. (3d)
(optimised by SIMPLEX). (C) Linear plots
(Eq. 3a–c) showing the experimental
results (o) incorporating the linear ﬁt
(black line) as well as the linear model
corresponding to the optimum estimates
from Eq. (3d) (grey line). On these plots
(named according to the equations) points
IDs 1 and 4 have been labelled.
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mean7standard deviation, n15 1.170.2 and log
K15 4.1070.10, values close to those in Table 2. In contrast,
eliminating IDs 1 and 4 data does not affect markedly the
log K1 estimate from Eq. (3d) (4.16 instead of 4.15 in
Table 2). This indicates that Eq. (3d) is more robust than the
linear ones. The use of two designs allows obtaining two
estimates of log K1, then provides a source to estimate the
involved uncertainty (see Table 2, footnote d). As suggests
Fig. 4C, the use of Eq. (3a–c) could serve as an additional
veriﬁcation step, i.e. the eventual coincidence between linear
plots lines and the corresponding from Eq. (3d) will indicate
good data quality.
It is also possible to perform the calculation joining all
the available data irrespective of the experimental design (for
instance, in this case, joining the data from the two
experimental designs) by means of Eq. (3) (or an equivalent
form). One option is to employ again Eq. (3d) to ﬁt entire
response surfaces (d-D-P data) to the experimental data.
Table 2 also includes these results, which are similar with
the previous ones (in fact an average of them), suggesting
that this direct approach is also consistent. Figure 5 shows
the validation plot for d and the response surface optimised
by SIMPLEX, corresponding to E2, showing the degree of ﬁt
to the experimental values superimposed. As expected, this
approach is also robust, i.e. insensitive to elimination of
data. For instance, elimination of data points IDs 1 and 4
provokes a negligible change in log K1 (from 4.179 to 4.184).
In this case, only one estimate of log K1 is obtained, and
then the possibility of directly obtaining uncertainty esti-
mation is not feasible (see Table 2, footnote e).
In our opinion, at low D/P ratios the probability of
competitive binding between enantiomers should be low,
for the same reasons that m5 1 (and n15 1) could be
assumed, i.e. the high concentration of available binding
sites. Only an increase of D (e.g. severe overdose situation)
could vary this reasoning. For instance, in this case (D/P up
0.52), the competitive binding between enantiomers could
not be absolutely avoided. A variant of Eq. (3d) allows eval-
uating competitive models, through Eq. (3d1) or (3d2) [6]. In
order to avoid infra- or over-estimations on the parameters
(by using only one of the equations) we have designed a
SIMPLEX algorithm that simultaneously optimises both
equations. The conditions were the same as in previous
results on Table 2. As an example, Fig. 6 shows the vali-
dation plot for d and the d versus P plot corresponding to
both enantiomers (D-constant design). As before, the use of
two designs allows obtaining two estimates of log K1 (see
Table 2), then provides a source to estimate the involved
uncertainty (Table 2, footnote e).
3.5 ES and PB at physiological conditions
An important aim of performing enantiomer-binding
studies is estimating the ES degree, (see Appendix A), from
KE1 and KE2 estimations. Let us accept the following quality
protocol providing the Table 2 results:
(i) Elimination of outliers (Eq. 4)
(ii) Veriﬁcation of n15 1 (Eq. 4a) and consequent
acceptation of KE1 and KE2-estimates (Eq. 4).
(iii) Estimation of KE1 and KE2 (Eq. 4, 3d and 3 by means of
3d, for an independent model, or Eq. 3d1 and 3d2, for
a competitive model)
(iv) Optionally, additional veriﬁcation steps, e.g. compar-
ison between linear, Eq. (3a–c) (including the eventual
elimination of points), and non-linear, Eq. (3d)
models, as in Fig. 4C.
We combined the mean estimates for each model-type
in Table 2 to obtain the mean7standard deviation values for
the estimates, from which ES was estimated (see Table 3).
A key parameter from a pharmacokinetic point of view
is the estimation of the percentage of PB, at physiological
conditions. Using the constants in Table 3 (independent
model) and the selected physiological conditions,
D5 0.1 106M (see Section 3.1) and P5 600 106M
(see Appendix C), d, for each enantiomer were estimated, by
means of Eq. (3d), and from them PB, as indicated in
Table 2 (footnote e). PB estimates were 95.2 and 90.0% for
E1 and E2, respectively. These values are consistent with the
reported in the literature for FLX (94.75%; Appendix C).
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Figure 5. Results corresponding to E2
using all the data (excluding IDs 13, 19
and 20): (A) Validation plot for d (estimated
versus experimental) and (B) Response
surface d versus D and P (from Eq. 3d,
optimised by SIMPLEX) and experimental
values superimposed.
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Estimations at other desired D-P values (e.g. FLX overdose or
hypoalbuminemia) would be possible.
3.6 Final remarks
Some additional technical details are: (i) the time of 30min for
equilibration was described as adequate in a previous paper
[17]; (ii) due to experimental random errors and probably
capillary-environment changes, e.g. punctual capillary wall
modiﬁcation caused by albumin adsorption, migration times
exhibit little displacements between injections. This fact is
visible in Fig. 1 and the effect was estimated (mean7standard
deviation) from calibration data for E1 and E2 (2.770.2 and
3.570.2min, respectively). However this does not affect the
results based on areas; (iii) from the analytical point of view the
method used was found adequate in terms of linearity and
precision. Calibration lines for E1 and E2 were:
Area588.874123.8005 dE1 and Area565.81511
22.833 dE2, respectively, both models were signiﬁcant
(po0.0001; F-ANOVA51416.5 and 2168.10, respectively)
and do not exhibit lack-of-ﬁt (p40.05). The determination
coefﬁcients were adequate (R250.993 and 0.995, respectively).
A precision study was performed joining the duplicate d data
of both enantiomers (Table 1; excluding outliers and repeated
data-pairs; ID513, 14 and 19, 20). The data were arranged
into a 2 16 matrix, checked for homogeneity of variances
(p (Cochran’s C test)40.05) and submitted to ANOVA, to
extract the relative standard deviation in repeatability condi-
tions [18], RSDr58% (valid for the concentration interval
studied; 7–40 mM).
Table 2 represents a selection of equations from
Appendix B, according to their consistency and robustness
in the present experimental conditions. The low robustness
exhibited by Eq. (4a) or (3a–c) is in part due to the low
concentration interval used here. Obviously, large intervals
would be beneﬁcial not only for these equations, but also for
Eq. (3d) (and 3d1 and 3d2), from a mathematical point of
view. However a gain in robustness based on increasing of
D- or P-ranges (e.g. adding higher D or lower P values) has
the inconvenience of unfavourable D/P ratios (i.e. it
becomes hard to guaranty the validity of the assumed model
along the concentration interval) and, sometimes, it could be
difﬁcult to achieve (e.g. limited technical/instrumental
factors). Therefore, the short-concentration interval strategy
selected here should be seen as a cost–beneﬁt option in
terms of results quality and risk control. It demarcates the
use of each of equation of Appendix B (estimation, veriﬁ-
cation, data consistence). The combination of reasonably
robust equations and designs to increase the control of
individual data compensates the mathematical problems.
Moreover, since the opposite option, large-concentration
interval approach, has been extensively used in the past, in
our opinion, numerous published parameters should be
taken with caution. Finally, in those cases that the n1
estimate can not be assessed, it is preferable to report
the binding capacity (n1 K1; Appendix A, Eq. 5 in
Appendix B).
From the results obtained, some recommendations for
authors (and an exigency for editors accepting papers on
protein-binding) are:
(i) The convenience of reporting the D-P-d data
(as in Table 1), so other researchers could verify the
estimations with alternative approaches (note that n
and K estimations should be limited to the concrete D-
or P-range used).
(ii) The convenience of using alternative approaches to
check for data quality and veriﬁcation before publishing
the estimates.
4 Concluding remarks
When performing PB studies (enantioselective, as in this
case, or not) involving HSA, the mathematical approaches to
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Figure 6. Results corresponding to E1 (o)
and E2 (x) using the data corresponding to
the D-constant design (IDs 11–20, except
ID5 13): (A) Validation plot for d (estimated
versus experimental) and (B) d versus P plot
including the experimental data and the
ﬁtted model (line) using simultaneously Eq.
(3d1) and (3d2) (optimised by SIMPLEX).
Table 3. Afﬁnity constants of enantiomers of FLX and enantio-
selectivity to HSA from data in Table 2
Model type KE1, M
1 KE2, M
1 ES
Independent (3.370.3) 104 (1.5070.07) 104 2.20
Competitive (6.071.9) 104 (2.870.6) 104 2.14
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be selected should be consistent to the selected experimental
design, since they have an effect on the robustness and
reliability of the available equations. Factors to be considered
include enantiomer (or drug) and protein concentrations, D
and P, and then, their interval (which also affect the interval
of other dependent/independent variables used, e.g. d or r
data) and D/P ratios. When possible, assumptions should be
a priori justiﬁed, but also veriﬁed. The approaches selected
have consequences related to both accuracy and uncertainty
of the estimates. Finally, data quality indicators should be
considered (e.g. outliers).
In our opinion, the m5 1, but also n15 1 and non-
competitive model, assumptions for modelling the PB of
most xenobiotics if favoured when experiments are
performed with low D/P ratios; conditions consistent with
the physiological levels of HSA and particularly many drugs
after normal dosage. In such conditions, reliable results
could be obtained using Eq. (4), if the slope of Eq. (4a) is
statistically equal to 1 (particularly using the data corre-
sponding to the central values of the individual log K1 esti-
mations from Eq. 4). Once n15 1 is conﬁrmed, Eq. (3d) or
(3) (e.g. optimised by means of 3d) should alternatively
provide consistent estimations.
From the results in this work, under physiological
conditions or moderate overdose, the enantiomers of FLX
exhibit fair ES (ES2) in favour of the ﬁrst eluted enantio-
mer, which imply also a larger PB (95.2%) with respect to
the less retained one (90.0%).
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Appendix A. Symbols (in alphabetic order) and nomenclature used for the xenobiotic - protein binding process
Symbola) Meaning Comments
b Bound concentration of xenobiotic after the equilibrium It can be obtained from: b5D – d
Css Plasmatic concentration (stationary state) of xenobiotic Normally available as an interval (experimental) or estimated as
an approximate value. Here, since Css was estimated for
the racemic drug, Css/2 corresponds to enantiomers. It could
be used to estimate D in physiological conditions
D Total xenobiotic concentration Designed variable (together with P). Finally, the experimental values
(after preparation) are used in Appendix B. Here, D represents
the total enantiomer concentration
d Free (unbound) concentration of xenobiotic after the equilibrium Normally, the measured variable after application of the analytical
method (here EKC using a cyclodextrin as chiral selector).
Here we use dE1 and dE2 for distinguishing d corresponding
to the ﬁrst and second eluted enantiomers (E1 and
E2, respectively)
K (K1) The afﬁnity constant of the xenobiotic–protein interaction
(in M1 units). K1 refers to the main active site (with the
highest K value)
The inverse of the dissociation constant, KD (K5 1/KD). Here
we use KE1, KE2 to differentiate K1 for E1 and E2, respectively,
allowing estimating the enantioselective binding as: ES5KE1/KE2
m Number of classes of independent active sites in the protein Each class of site (i) accounts for ni binding sites
n (n1) Number of (equivalent) binding sites (of one class) per
protein molecule. In this case only one class
of site was considered with an apparent stoichiometry
of n1
It represents the apparent stoichiometry, thus, the
number of xenobiotic molecules that could bind this site
n.K (n1 K1) Total binding capacity. In this case only one class of site was
considered with a total binding capacity of n1.K1
This could be used when n1 estimation is not reliable
P Total protein concentration Designed variable (together with D). Finally, the experimental
values (after preparation) are used in Appendix B
PB Protein binding (bound fraction of xenobiotic) in
percentage
It can be obtained from: PB5 100 b/D. It depends on D and P that
should be reported when PB is estimated
r Fraction of bound xenobiotic per molecule of protein It can be obtained from: r5 b/P
Other variables are deﬁned in Appendix C. Concentrations must be set in M units to be used in Appendix B.
a) This nomenclature could represent any xenobiotic (e.g. a racemic drug or its enantiomers) interacting with proteins. In this work the
symbols (and some of the comments) refer to an enantiomer of FLX and HSA as the protein. We have used sub-indexes when
necessary, to specify the enantiomers (E1, E2) and the racemic drug (FLX).
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Appendix B. Equations relating the experimental variables (see Appendix A), assuming independent (non-competitive) binding
between E1 and E2 (except in footnote f). Non-speciﬁc and non-cooperative binding were assumed to be negligible.
Although non-speciﬁc binding exists, this assumption could be reasonably valid for low D
Case (assumptions) and equations (Eq.) Comments
m classes of independent active sites,
each with ni binding sites
a)
(1) (2.i)-parameter model (ni and Ki). It could be difﬁcult to obtain reliable estimations
r ¼ bP ¼ DdP ¼
Pm
i¼1 ni
Kid
11Kid
m5 2 (two main classes of active
sites)b)
(2) 4-Parameter model (n1, K1, n2 and K2). It could be difﬁcult to obtain reliable estimations
r ¼ bP ¼ DdP ¼ n1 K1d11K1d1n2
K2d
11K2d
m5 1 (one main active site)c) (3) 2-Parameter model (n1 and K1). Data could be ﬁtted using non-linear approaches, with some
problemsd)
r ¼ bP ¼ DdP ¼ n1 K1d11K1d
(1/r)5 1/n1 1 (1/n1 K1) (1/d) (3a) Linear forms of Eq. 3 (Klotz, Scatchard and y-reciprocal plot). They have some important problems
e)
(r/d)5 n1 K1–K1r (3b)
(d/r)5 (1/n1 K1) 1 (1/n1) d (3c)
d ¼ ð1K1D1n1K1PÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1K1D1n1K1PÞ214K1D
p
2K1
(3d) d-Isolated (dependent variable) non-linear form of Eq. (3). Data could be ﬁtted using non-linear
approaches (e.g. SIMPLEX algorithm). It has some problemsd). A modiﬁcation of this
approach could be used for competitive binding between enantiomersf)
m5 1; n15 1 (apparent stoichiometry = 1
g)) (4) 1-Parameter model (K1). Adapted from Eq. (3)
K1 ¼ 1d r1r
m5 1; K1 d o o 1h) (5) 1-Pseudo-parameter model ([n1.K1]; joining 2 parameters). Adapted from Eq. (3)
n1  K1 ¼ rd ¼ bPd ¼ DdPd
m5 1, n15 1
g); K1 d o o1h) (6) 1-Parameter model (K1). Adapted from Eq. (3). It allows estimating K1 from PBi).
K1 ¼ rd ¼ bPd ¼ DdPd
a) For the site i, ni represent the apparent site stoichiometry.
b) In HSA, among others, two high active sites, I and II, have been described (see Appendix C).
c) Most drugs are found to bind one site according to competitive studies using site-markers. For low D/P ratios (usual under
in vivo conditions) only one site should be in fact occupied.
d) Different combination of n1 and K1 estimates (several local optima) are feasible. n1 and K1 are dependent estimates.
e) Mathematically inconsistent [11], since d is included as dependent and independent variable. n1 and K1 are dependent
estimates. Imprecise data plus short-concentration intervals could provide unreliable estimations.
f) If competitive binding is assumed between two enantiomers (E1 and E2 compete for the same site class; in our opinion, this is
less probable for low D/P ratios), the Eq. for E1 as a function of E2, and vice versa, are [6]:
dE1 ¼
ð1 KE1D1n1KE1P1KE2dE2Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1 KE1D1n1KE1P1KE2dE2Þ214KE1D
q
2KE1
ð3d1Þ
dE2 ¼
ð1 KE2D1n1KE2P1KE1dE1Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1 KE2D1n1KE2P1KE1dE1Þ214KE2D
q
2KE2
ð3d2Þ
g) This assumption should be assessed by, e.g. a linear plot derived from Eq. 4:
logðr=ð1 rÞÞ ¼ logðb=ðP  bÞÞ ¼ log K11logðdÞ ð4aÞ
The plot of log(r/(1-r)) versus log d provides a slope 5 1-straight line (if n15 1 is valid). In our opinion, low D/P ratios (usual under
in vivo conditions) should favour it. Short-concentration intervals could complicate its use.
h) This assumption should be assessed once K1 is estimated. Low d, e.g. low D/P ratios (usual under in vivo conditions), as well
as a low K1 (i.e. low PB), should favour it.
i) Combining PB deﬁnition and Eq. 6:
K1 ¼ PBð100 PBÞ
1
P
ð6aÞ
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Appendix C. Data of the molecules concerning the binding process
Molecule/features Information Comments
FLX, CAS: 54910–89–3
MW 309.3261 g/mola) Used for Css calculations
MW (FLX. HCl) 345.79 g/mol Used for D calculations
PB 94.5%a), 95%b) PB  94.75 %. From the PB deﬁnition, d could be estimated as: d  D
(100 – PB) / 100
Absorption 72%a) Approximate bioavailability, f  0.72 (overestimated; FLX exhibits a ﬁrst-
pass hepatic effect)
Dose (dose-timing) Up to 60 mg/day (e.g. once-daily)b) Dose  60 mg. Dose-timing, t 5 24 h
Half life, t1/2 1–3 days (24–72 h)
a) t1/2  48 h; approximate elimination constant, Kel5 ln 2 / t1/2  0.0144 h1
Volume of distribution, Vd 20–40 L/kgb) Vd  30 L/kg; Human weight  70 kg; Vd  2100 L
Clearance, Cl Cl 5 Kel Vd  30.24 L/h
Css
(see Appendix A) FLX exhibits a nonlinear kinetics Css  (f dose) / (t Cl.)  0.06 mg/L; Css  0.2 mM. (biased; this Eq. is valid
for linear kinetics)
HSA, CAS: 9048-49-1 [9], [19], [20], [21] and references therein
Average MW 66472.2a) Used for P calculations
Plasma concentration 530–750 mM (normal)c) P600 mM (for normal physiological conditions)
Binding capability Endogenous (fatty acids) and
exogenous xenobiotics
Mainly neutral and acidic xenobiotics, but also basic hydrophobic ones
(e.g. FLXa))
Speciﬁcity Flexible, dynamic molecule with
mobile regions able to speciﬁc
binding
For most small molecules, a single-high afﬁnity binding site (high-K) is
usual. Other secondary lower-K sites (multiple binding) and non-
speciﬁc interaction (low-K, n 4 1), could be responsible of bad
estimations, particularly for high D/P
Active sites Main sites, so-called site I and II
(Sudlow Scheme)
Sites I and II are dominated by hydrophobic interactions and to a lesser
extent by structural factors. Other sites have been described (e.g.
digitoxin site, so-called site III, or tamoxifen site, which exhibits
allosteric interactions with site I)
Site I: Unclear binding model (lack of
speciﬁcity and competitive
binding). Confusing results
Tight site for some drugs like warfarin, salicilate or sulphonamide.
These molecules are typical site I markers for competitive studies.
Examples of binding with medium log K values (4–5)
Site II: Tight and speciﬁc binding model,
usually with n5 1 stoichometry
Typical ligands are diazepam, ibuprophen, naproxen, ﬂufenamic acid
or L-tryptophan as well as medium-chain fatty acids. Some of them are typical
site II markers for competitive studies. Examples of competitive binding
a) Data from the DrugBank Database. http://www.drugbank.ca/ (accessed 19-Feb-2010).
b) Data from the Agencia Espan˜ola del Medicamento (Spanish Drug Agency) https://sinaem4.agemed.es/consaem/especialidad.do?
metodo5 verFichaHtml&codigo5 62643&ﬁchaCompleta5S (accessed 19-Feb-2010).
c) Clinically, hypoalbuminemia (up to P/2 of the normal level) is much more frequent than hyperalbuminemia [14].
MW moleculer weight.
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a b s t r a c t
In this work, a methodology for the chiral separation of zopiclone (ZPC) by electrokinetic chromatogra-
phy (EKC) using carboxymethylated--cyclodextrin as chiral selector has been developed and applied to
the evaluation of the enantioselective binding of ZPC enantiomers to HSA and total plasma proteins. Two
mathematical approaches were used to estimate protein binding (PB), afﬁnity constants (K1) and enan-
tioselectivity (ES) for both enantiomers of ZPC. Contradictory results in the literature, mainly related to
plasmaproteinbinding reporteddata, suggest that this is anunresolvedmatter and thatmore information
is needed. Discrepancies and coincidences with previous data are highlighted.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Drug action is the result of a large number of pharmacological
processes that take place in the living systems. It iswell known that
most of these processes present a high degree of enantioselectivity
and thus, the pharmacological characteristics of chiral drugs often
vary between enantiomers [1]. Consequently, in such cases, there is
a special interest within pharmaceutical industry to develop opti-
cally pure drugs, like eszopiclone, the S(+)-enantiomer of zopiclone
(ZPC) [2], once it has been demonstrated that it shares the pharma-
cological properties,whereas the R(−)-enantiomer has nohypnotic
activity [3].
The investigation of enantioselectivity of drugs in their bind-
ing with human plasma proteins represents a great challenge in
clinical pharmacology. When plasma proteins and racemic drugs
interact, two diastereomeric adducts are formed with potential
differences in their protein binding which may result in differ-
ent pharmacokinetic proﬁles for the individual enantiomers [4].
For the investigation of drug enantioselective binding, different
approaches have been proposed. The majority of these method-
ologies include a ﬁrst step in which the free drug fraction is
separated from the bound drug once the drug-protein equilibrium
∗ Corresponding author at: Departamento de Química Analítica, Facultat de Far-
macia, Universitat de Valencia, C/Vicent Andrés Estellés s/n, E-46100 Burjassot,
Valencia, Spain. Tel.: +34 963544878; fax: +34 963544953.
E-mail address: sagrado@uv.es (S. Sagrado).
has been reached using different techniques, such as the traditional
equilibrium dialysis [5], ultracentrifugation [5] or ultraﬁltration
[6]. The second step includes chiral analysis of enantiomers,
habitually on the unbound fraction. In this context, enantiosep-
aration has become one of the most important ﬁelds of modern
analytical andbioanalytical chemistry [7]. Different analytical tech-
niques have been proposed for chiral drugs separation, such as
high-performance chromatography (HPLC), gas chromatography,
capillary electrophoresis or supercritical ﬂuid chromatography [8].
Zopiclone is a non-benzodiazepine hypnotic drug used for treat-
ment of insomnia. Itsmechanismof action consists in binding to the
GABAA channel, increasing the inhibitor effect of GABA (the same
mechanismofbenzodiazepines). The separationof theenantiomers
of ZPC has been achieved by different chromatographic and elec-
trophoretic methods [9–24]. Chromatographic methods included
different chiral stationary phases [9–14] using ﬂuorimetric [9,10]
or UV [14] detection, beta-cyclodextrin bonded phases [15,16] or
mobile phases with cyclodextrins as chiral selectors [17]. Recently,
the chiral separation for the quantitation of eszopiclone using
LC–MS/MS and AGP chiral column was reported [18]. Enantiosepa-
ration of ZPC in CE has been obtained upon the addition of neutral
cyclodextrins as -cyclodextrin [19,20,22], -cyclodextrin [23], or
hydroxypropyl--cyclodextrins [24] to the separation buffer. The
use of cyclodextrin-modiﬁed gold nanoparticles (GNPs) was also
recently reported [21].
Important differences in plasma protein binding (PB) values for
racemic ZPC (45–85% [3,9,25–28]) have been published, suggest-
ing that this information still deserves more attention. A value
0021-9673/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
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45% is available from the Spanish Drug Agency [27] and ﬁgures in
the well-known DrugBank database [28]. Only one reference pro-
vides plasma PB values for R- and S-ZPC (estimated at 4 ◦C) [9],
and another one for S-ZPC (in vivo) [3]; differing in their values.
Particular studies involving individual proteins are not available,
except from [9]; however the reported data on PB to human serum
albumin (HSA) (as well as 1-acid glycoprotein, AGP) are too low
compared with those encountered for plasma. These results, based
on equilibrium dialysis at 4 ◦C and HPLC with chiral columns, also
include afﬁnity constant (K1) to HSA for racemic ZPC and its enan-
tiomers, fromwhich an estimation of enantioselectivity toHSA (not
reportedby the authors in termsof a concrete value) canbederived.
Both, the contradictory data and the lack of contrasted informa-
tion on K1, particularly for ZPC enantiomers, point out the need to
amplify this kind of studies in order to establish amore reliable ZPC
enantioselectivity (ES).
In this paper, the enantioselective binding of ZPC to human
serum albumin (HSA) and plasma proteins is evaluated. HSA is
the most abundant protein in the circulatory system (i.e. with
the largest complexation potential), moreover it exhibits the
highest potential of enantiodifferentiation among the plasmatic
proteins. The proposed methodology comprises the ultraﬁltra-
tion of pre-equilibrated samples containing HSA (or human sera)
and racemic drug and the enantiomeric resolution and analy-
sis of the unbound fraction [6,29,30]. In order to evaluate the
enantioselective binding of ZPC enantiomers, the electrokinetic
chromatography (EKC)-partial ﬁlling technique (PFT) with the
anionic carboxymethylated--cyclodextrin (CM--CD) as chiral
selector was used. EKC-PFT, which involves the ﬁlling of a separa-
tion capillary only in part with a chiral selector, presents several
advantages as the extremely low consumption of cyclodextrin,
since the inlet and outlet vials of the separation system are free
of chiral selector [8]. The use of a cyclodextrin as chiral selector
was preferred here to HSA, used previously by our group (afﬁnity
EKC [29]), due to their broad spectrum of enantioselectivity and
better electrophoretic features (signal-to-noise ratio, resolution,
etc.).
2. Experimental
2.1. Instrumentation
A Beckman P/ACE MDQ Capillary Electrophoresis System
equipped with a diode array detector (Beckman Coulter, Full-
terton, CA, USA), and 32Karat software version 8.0 was used
throughout. A 50m inner diameter (i.d.) fused-silica capillary
with total and effective lengths of 31.5 and 21 cm, respectively,
was employed. Electrophoretic solutions and sampleswere ﬁltered
through 0.45m pore size nylon membranes (Micron Separation,
Westboro, MA, USA) and degassed in an ultrasonic bath (JP Selecta,
Barcelona, Spain) prior to use. A Crison Micro pH 2000 pH meter
fromCrison Instruments (Barcelona, Spain)was employed to adjust
the pH of buffer solutions.
A Selecta thermostatized bath (JP Selecta, Barcelona, Spain) was
used for samples incubation. For the ultraﬁltration of samples,
Microcon YM-10 cellulose ﬁlters of a molecular weight of 10,000
MWCO (Millipore Corporation, Bedford, MA, USA) and a centrifuge
Heraeus Biofuge Strate (Heraeus, Madrid, Spain) were used.
2.2. Chemicals and standard solutions
All reagents were of analytical grade. Human serum albumin
fraction V (HSA) and human sera were purchased from Sigma (St.
Louis, MO, USA); sodium dihydrogen phosphate dihydrate from
Fluka (Buchs, Switzerland); Tris-(hydroxymethyl)-aminomethane
(Tris) was from Scharlab (Barcelona, Spain), carboxymethylated--
cyclodextrin was from CycloLab (Budapest, Hungary). Racemic ZPC
was kindly donated by Aventis Pharma (Madrid, Spain). Ultra Clear
TWFUVdeionizedwater (SGWater, Barsbüttel, Germany)wasused
to prepare solutions.
Separation buffer in EKC containing Tris 50mM at pH 6.0 was
obtained by dissolving the appropriate amount of Tris in water
and adjusting the pH with 1M HCl. For the incubation process
(ZPC–HSA binding) phosphate buffer 67mM of pH 7.4 was pre-
pared by dissolving the appropriate amount of sodium dihydrogen
phosphate dihydrate inwater and adjusting the pHwith 1MNaOH.
Stock solution of 100mM CM--CD was prepared in the separation
buffer. 1000M ZPC and HSA stock solutions were daily prepared
by weighting the corresponding amount of protein powder and
dissolving it with the phosphate buffer.
2.3. Methodology
2.3.1. Capillary conditioning
New capillaries were conditioned for 15min ﬂush with 1M
NaOH at 60 ◦C [29,31]. This treatment removes adsorbates and
refreshes the surface by deprotonation of the silanol groups. Then,
they were rinsed for 5min with deionized water and 10min with
separation buffer at 25 ◦C. In order to obtain good peak shapes and
repeatable migration data, the capillary was conditioned prior to
each injection. In all cases, the conditioning run included the fol-
lowing steps: (i) 1min rinse with deionized water, (ii) 2min rinse
with 0.1M NaOH, and (iii) 1min rinse with deionized water at
20psi. Before chiral selector and sample injection the capillary was
also rinsed with the separation buffer for 2min at 20psi [31]. No
drift in migration time and no peak broadening during a work-
ing session (suggesting that no protein adsorption occurred) were
veriﬁed, indicating the adequacy of the protocol.
2.3.2. Procedure for the enantioseparation of ZPC by EKC using
CM-ˇ-CD
Forall experiments, theTris solutionwasusedaselectrophoretic
buffer. A 30mM CM--CD solution obtained by diluting the stock
solution with the buffer was used. ZPC samples (ultraﬁltrated frac-
tions and standards) were injected hydrodynamically at 0.5psi for
5 s. Before sample injection, the capillary was partially ﬁlled with
the 30mM CM--CD solution by applying 0.5psi for 99 s. Separa-
tion was performed in normal polarity by applying 15kV (higher
voltage would give higher efﬁciency but also lower enantiores-
olution [31]). The capillary was thermostated at 25 ◦C and the
UV-detection wavelength was set at 220nm. The R and S enan-
tiomers were identiﬁed by comparison between our ES data and
the derived from [9] (see Section 3.3.3).
2.3.3. Procedure for the separation and analysis of unbound ZPC
fraction to HSA and plasma proteins
We have planned an experimental design to study the binding
of the enantiomers to HSA, keeping the concentration of protein
nearly physiological values and varying the concentration of ZPC
according to the detector capabilities. 5 concentration levels of ZPC
were used with 3 independent replicates per level, totalling 15
independent mixtures for the studies with HSA. For the evaluation
of the total plasma protein binding, 4 concentration levels of ZPC,
with 3 independent replicates per level, totalling 12 samples, were
used.
Mixtures containing different ZPC concentrations were pre-
pared in triplicate by the dilution of the stock solutions of drug and
protein with the phosphate buffer. HSA concentration was ﬁxed at
475M, and in the plasma samples the relation aqueous/plasma
solution was 100/300 (v/v). All these mixtures were allowed to
reach equilibrium for 30min in a water bath at 36.5 ◦C and were
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ﬁltered through cellulose ﬁlters by centrifugation at 9000 rpm for
30min. The ultraﬁltrate was directly injected into the EKC system.
2.4. Software and calculations
From the experimental data, pseudoeffective (due to the partial
ﬁlling technique) electrophoretic mobilities corrected for elec-
troosmotic ﬂow (EOF) variations were calculated according to the
following equation:
i =
lL
V
(
1
ti
− 1
t0
)
(1)
where L and l are the total capillary length and the length from
the inlet to the detector, respectively, V the run voltage, ti is the
analyte migration time and t0 is the migration time of methanol,
used as non-interacting electroosmotic ﬂow marker. Methanol is
detected at 220nmas aperturbation in the baseline due to a change
in the refractive index. Enantiomeric resolution (Rs) was calculated
according to:
Rs = 1.18(t2 − t1)
w1 + w2
(2)
where t1 and t2 are the migration time of each enantiomer and w1
and w2 represent the peak widths at 50% peak heights.
For the ZPC–HSA binding study routines made/adapted in
MATLAB® 4.2 were used for calculations. The results generated
were veriﬁed using EXCEL® and STATGRAPHICS®. In some calcu-
lations a SIMPLEX algorithm routine was used (non-linear ﬁtting).
We have used two simpliﬁed approaches from the general protein-
binding model considering m classes of independent active sites on
HSA, each with ni binding sites:
r = b
P
= D − d
P
=
m∑
i=1
ni
Kid
1 + Kid
(3)
In this equation, r is the fraction of bound enantiomer per molecule
of protein, b is the bound concentration of enantiomer and P is
the total protein concentration. D and d are the total and free enan-
tiomer concentrations, respectively. All the concentrationsmust be
expressed in molar units (M). For the site i, ni represents the appar-
ent site-stoichiometry. Eq. (3) assumes negligible non-speciﬁc and
non-cooperative binding. Two simpliﬁed approaches were used
here. The ﬁrst simpliﬁed approach assumes m=1 and n1 =1. Both
assumptions should be reasonably valid for low D/P ratios (usual
under in vivo conditions) [31], providing:
K1 =
1
d
r
1 − r (4)
Eq. (4) is a 1-parameter model, allowing K1 estimation for each
individual D–P–d data and then serving as a source for outliers’
identiﬁcation [31]. To verify the previous approach, an alternative
equation, assuming simply m=1 was used, providing:
d = −(1 − K1D + n1K1P) +
√
(1 − K1D + n1K1P)2 + 4K1D
2K1
(5)
Eq. (5) is a d-isolated (dependent variable) non-linear form of Eq.
(3) when m=1. SIMPLEX optimization was used for estimating the
parameters n1 and K1, allowing integer n1 values [31].
3. Results and discussion
3.1. Enantioseparation of ZPC by EKC
Enantioseparation of ZPC in CE has been reported using neutral
cyclodextrins in the separation buffer [19,20,22–24]. Even though
chargedCDswereused initially for the enantioseparationof neutral
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Fig. 1. Effect of the CM--CD concentration on the chiral separation of ZPC enan-
tiomers. Electropherograms correspond to CM--CD at different concentration
levels: (a) 10mM, (b) 20mM, (c) 30mM, (d)40mMand (e) 50mM.Other experimen-
tal conditions: ZPC 500M, injected at 0.5psi during 3 s, CD injection 0.5psi/99 s,
50mM Tris buffer at pH 6, 25 ◦C, 15kV.
compounds they also have shown high enantioselectivity towards
many basic and acidic compounds. It has been reported that maxi-
mumenantioselectivities are obtainedwhenanalytes andCDshave
opposite mobilities [32–34], due to the counter-current mobility
of the chiral selector and the selectand in the separation capillary
[8]. In this paper the use of the anionic carboxymethylated--
cyclodextrin (CM--CD) as chiral selector in EKC using the partial
ﬁlling technique was evaluated accounting to the positive charge
of ZPC in a wide pH range (pKa = 6.9 [35]). The selection of the pH
relied on a compromise between of EOF, chiral selector concentra-
tion and mobility of ZPC enantiomers, depending on the running
buffer pH and driven by their respective pKa. Initial experiments
were carried out with different buffers (citrate, phosphate, Tris and
2-(N-morpholino)ethanesulfonic acid, MES) at pH values between
4 and 8. Among the buffers, Tris at pH 6 provided the best results
in terms of resolution, signal-to-noise ratio and analysis time. This
solution (50mM) was selected as running buffer for the optimiza-
tion process. In these conditions, cationic ZPC migrates through
the selector plug allowing the interaction with the anionic CM--
CD. Detection wavelength was ﬁxed at 220nm. Lower wavelengths
(e.g. 200 and 210nm were also tested) gave worse signal-to-noise
ratio, probably due to the higher contribution of the absorbance of
the selector. In these conditions, the initial experiments suggested
that sufﬁcient enantioresolution and relatively short analysis time
could be achieved; thus we decided to simplify the study employ-
ingunivariate optimization. The effect of CDconcentration, selector
plug length, and temperatureon theenantioresolutionwas studied.
Fig. 1 shows the effect of the concentration of CM--CD. Migration
times of enantiomers increase as the CD concentration increases.
The observedpseudoeffective electrophoreticmobilities are a com-
bination of electrophoretic mobility of both free and complexed
enantiomer. An increase of CD concentration in the capillary pro-
vides higher proportion of anionic complexes, increasing their
negative electrophoreticalmobility and shifting the peaks to longer
migration times. As can be seen, complete separation was obtained
using a 20mM CM--CD concentration. An improvement in enan-
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Fig. 2. Effect of the selector plug length on the pseudoeffective electrophoretic
mobility S-ZPC (- - -) and R-ZPC (—) at different CM--CD concentrations: (©)
10mM; () 20mM; (♦) 30mM; () 40mM; and () 50mM. The solution of CM-
-CD was injected into the capillary by applying 0.5psi for variable times. Other
experimental conditions as in Fig. 1.
tioresolution upon increasing CM--CD concentration is observed,
although the shape of the peaks also becomes poorer; probably due
to the counter current mobilities of the enantiomers and the chiral
selector and the fact that higher CD concentrations provide higher
interaction degree (i.e. wider peaks).
When using the partial ﬁlling technique, one of the most inﬂu-
ential parameters affecting the chiral separation is the amount
(the selector plug length, SPL, and concentration) of chiral selec-
tor introduced into the capillary. To study this effect on the
zopiclone enantioresolution the capillary was ﬁlled with increas-
ing concentrations of CM--CD by applying 0.5psi for 10, 30,
50, 70 or 99 s. Fig. 2 shows the SPL effect on the pseudoeffec-
tive electrophoretic mobility of both enantiomers, at different
concentrations of cyclodextrin. A decrease in pseudoeffective elec-
trophoreticmobility of each enantiomer (or an increase in negative
mobility) and an improvement in enantioresolution are observed
upon increasing the amount of cyclodextrin introduced into the
capillary for all the concentrations assayed. Resolution applying
99 s was sufﬁciently adequate and higher SPL should provide an
increase in the analysis time.
Temperature is considered a key parameter in the chiral sepa-
ration because it can affect the peaks efﬁciency, the buffer viscosity
and the compound-selector interaction, and consequently can
modify the chiral resolution. In this work, temperatures of 15, 25
and 40 ◦C were tested ﬁlling the capillary with a 30mM CM--CD
solution (applying 0.5psi for 99 s). It was observed a decrease in
migration times of enantiomers and EOF upon increasing the tem-
perature, both effects are due to a decrease on the viscosity of the
running buffer and also to changes in solute–cyclodextrin binding
constant. The reduction ofmigration times resulted in a decrease in
the resolution of the enantiomers with increasing temperature (Rs
values of 2.8, 2.4 and 1.7were obtained for 15, 25 and 40 ◦C, respec-
tively), although in all cases a complete chiral separation had been
achieved.
Fromthe resultsobtained theexperimental conditions indicated
in Section 2.3.2 were selected. Fig. 3 shows the electropherogram
obtained with these conditions. As can be seen, a good resolution
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Fig. 3. Electropherogram of racemic ZPC (500M) obtained under experimental
conditions selected: fused silica capillary (50m inner diameter, 31.5 cm total
length, 21 cm effective length); Tris buffer (50mM, pH 6); CM--CD 30mM (injec-
tion 0.5psi/99 s); capillary temperature 25 ◦C; separation voltage, 15kV; absorbance
detection at 220nm.
was obtained for the ZPC enantiomers (Rs=2.1) in an analysis time
lower than 6min.
3.2. Calibration
Calibration standard solutions containing racemic ZPC in the
range 50–500M were prepared in triplicate. Table 1 shows the
regression statistics for the linear regression models, ﬁtted using
the least squares approach, for each enantiomer, using the peak
area corrected by migration time (in order to compensate for
velocity discrepancy between peaks) as dependent variable. It
includes the intercept and slope together with their correspond-
ing conﬁdence intervals. These models were used to estimate d by
interpolating the signals (peak area corrected by migration time)
corresponding to ultraﬁltrates from the ZPC–HSA mixtures.
3.3. Enantioselective binding to HSA and plasma proteins
Mixtures of racemic ZPC andHSAwere designed keeping D/P<1
to assure, as far as possible, model validity [31]. The minimum D
(∼100M) was ﬁxed considering the approximate quantiﬁcation
limit for d, for both S- and R-enantiomers, dS and dR, respec-
tively. P was ﬁxed close the physiological concentration (in the
hypoalbuminemia-normal levels frontier [36]). Table 2 shows the
prepared concentrations (D and P, inM units, although they were
transformed inMunits formodelling), aswell as themeasuredones
(dS and dR). The D/P ratios (from 0.22 to 0.44) should guarantee the
Table 1
Calibration model statisticsa for S- and R-ZPC under the selected separation condi-
tions using peak area corrected by migration time as dependent variable.
b0 ± ts b1 ± ts r
S-ZPC 60 ± 40 2.4 ± 0.2 0.993
R-ZPC 30 ± 20 2.37 ± 0.12 0.998
a b0, intercept; b1, slope; ts, conﬁdence interval at the 95% probability level; r,
correlation coefﬁcient.
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Table 2
Experimental design and results. Experimental P was 449.1M. Data were trans-
formed to M units for calculations. A robust z-score approach (applied to the
corresponding independentK1 estimates)was used to detect/eliminate outliers (see
text for details).
D-level ID D (M) dS (M) dR (M)
1 1 100.8 45.0 52.6
2 100.8 b 82.1
3 100.8 50.3 63.2
2 4 126.0 a 89.7
5 126.0 a a
6 126.0 73.8 89.3
3 7 151.2 76.7 104.9
8 151.2 80.8 116.7
9 151.2 96.5 97.7
4 10 176.4 101.4 127.6
11 176.4 100.2 130.6
12 176.4 91.1 111.2
5 13 201.6 97.7 115.4
14 201.6 118.7 117.9
15 201.6 91.5 103.6
a Data eliminated in the ﬁrst round.
b Data eliminated in the second round.
assumptions made in Section 2.4; for instance, the m=1-model for
the ZPC–HSA interaction, since only at high concentration, a single
drug may populate multiple sites (m>1) on HSA [31,37]. In Table 2,
since each of the ﬁve D-concentration levels has three independent
replicates, we can control atypical results.
3.3.1. Outlier identiﬁcation/elimination in the HSA study
The z-score approach has been proposed as an alternative to
other tests for outliers, as an automatic criterion [38]. Most tests
for outliers depend on good estimates of dispersion, and become
less reliable with real errors present. Robust statistics is a conve-
nient method of handling results when they are expected to follow
a near-normal distribution, but are suspected to contain a small
proportion of errors which are not representative of the bulk of the
data [39]. To gain in security, the median and MADe (a robust esti-
mation of the standard deviation) were used to estimate a robust
z-score, zi for each independent logK1i estimate, from Eq. (4) [31]:
zi =
logK1i − median
MADe
(7)
Habitually, zi >3 are considered unsatisfactory, while zi >2 are
considered doubtable values. Here we have pre-ﬁxed a zi >2.5 cri-
terion to eliminate a point in a round (see Table 2). The ﬁnal median
and MADe are included in Table 3. It should be taken into account
that irrespectively n1 =1 or not, this approach could be used to
identify and eliminate outliers [31].
3.3.2. Afﬁnity constants to HSA
In Section 3.3.1, Eq. (4) was only used for evaluating outliers
assuming that n1 =1 (the most probable situation at low D/P ratio
[31]), since the relatively high concentration of available binding
sites. Table 3 provides a robust estimate of logK1 for the enan-
tiomers based on Eq. (4). To verify the parameters n1 and K1 an
Table 3
Afﬁnity constants of enantiomers of ZPC, protein-binding and enantioselectivity to
HSA.
Enantiomer logK1a PBb ESc
S-ZPC 3.38 ± 0.14 47 ± 6 1.95
R-ZPC 3.09 ± 0.19 36 ± 8
a From data estimated from Eq. (4) (median±MADe; after outliers elimination).
b Estimated at D=0.2M (total enantiomer concentration) and P=600M.
c From data estimated from the ratio between K1,S-ZPC (∼2400M−1) and K1,R-ZPC
(∼1230M−1).
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Fig. 4. Results corresponding to S-ZPC using all the data. (a) Validation plot for d
(estimated vs. experimental) and (b) d vs. D plot and model (superimposed line;
from Eq. (5), optimized by SIMPLEX).
approach based on non-linear ﬁtting (using Eq. (5)) was used. This
is an alternative to other more popular linear approaches hav-
ing recognised mathematical inconsistencies and risks ([31,40,41]
and references therein). SIMPLEX search was started with n1 =1,
logK1 =4 (based on results on Table 3), and only integer n1 values
were allowed. The logK1 estimates found were: 3.37 and 3.14 for
S- and R-ZPC, respectively, which agree with values in Table 3. In
addition, n1 =1 estimates were found for both enantiomers, verify-
ing the assumption. As an example of the model adequacy, Fig. 4
shows some results associated to S-ZPC based on Eq. (5); the valida-
tionplot ford (Fig. 4a) and thedvs.Dplot (Fig. 4b) superimposingon
it the ﬁtted model (the best SIMPLEX solution). This suggests that
logK1 estimates in Table 3, including uncertainty (based on a mini-
mum of 12 independent estimates) could be considered acceptable
values.
3.3.3. Enantioselectivity and protein binding to HSA
We combined K1 estimates for S- and R-ZPC to calculate the
enantioselectivity of ZPC–HSA interaction (ES=K1,S-ZPC/K1,R-ZPC)
which indicate a fair enantioselectivity degree (ES∼2), in favour
to the ﬁrst eluted enantiomer, S-ZPC (see Table 3). These results
can be compared with the only previous available values, obtained
using equilibrium dialysis at 4 ◦C [9], from which a quantitative
estimation of enantioselectivity, not reported by the authors, can
be derived (ES=524/293=1.8). This value is similar to that obtained
in the present work, supporting the fact that ZPC exhibit enantios-
elective binding to HSA. Attending to this agreement, enantiomers
R (the second eluted enantiomer) and S (the ﬁrst eluted one) were
assigned. On the other hand, the reported afﬁnity constants in [9]
are notably lower that those encountered here (by a factor close to
4.4). This could be explained in terms of experimental conditions,
mainly the incubation temperature.
A key parameter from a pharmacokinetic point of view is the
estimation of the percentage of protein binding. By means of Eq.
(5) and using the constants in Table 3 at preﬁxed (desired) D and
P values, it is possible to estimate the corresponding d values, and
from them, the PB according to:
PB = 100(D − d)
D
(8)
Here we have assumed values consistent with physiological
conditions, e.g.D=0.2×10−6 M (see [42]) and P=600×10−6 M (see
Section 3.3). After dS and dR estimation, PB for each enantiomerwas
calculated (see Table 3). As expected (according to the K1 values),
bindingpercentages toHSAreported in [9], 23.9±2.8 and15.0±3.5
for S- and R-ZPC, respectively, are lower than those found here
(Table 3), but also too low (in our opinion) compared with those
encountered for plasma by the authors.
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Table 4
Plasma protein binding values for racemic ZPC and its enantiomers. Some available
aspects that could potentially explain differences between results were included in
footnotes.
PB% rac-ZPC PB% S-ZPC PB% R-ZPC Ref.
45a – – Gaillot et al. [25]
78.7–91.2a,b – – Howard et al. [26]
79.3±5.5b,c 75.1±2.1b,c 86.8±5.2b,c Fernandez et al. [9]
45d – – AEMPS [27]DrugBank [28]
– 52–59d – DrugBank [28]
47±4 45±3 49±6 This work
a In vivo (presumably D/P1).
b Equilibrium dialysis was used to separate free and bound ZPC fractions.
c In vitro; plasmawith EDTAorheparin as anticoagulant; incubation at 4 ◦C (24h);
D/P=0.00043. The authors also reported other in vitro results but using citrate-
phosphate-dextrose as alternative anticoagulant (38.0±8.1, 31.8±6.6, 42.5±7.1,
respectively) and in vivo estimates for R- and S-ZPC (86.76 and 79.17, respectively;
presumably D/P1).
d No references are provided (it is assumed the values comes from in vivo exper-
iments; presumably D/P1).
3.3.4. Plasma protein binding
The total plasma protein binding was approximated for racemic
ZPC and its enantiomers, using Eq. (8) according with our exper-
imental data using human sera. These data were compared with
previous values found in the literature (Table 4), illustrating that
this was an unresolved matter. Our PB result on racemic ZPC is con-
sistent with some reported ones [25,27,28], but differs from others
[9,26]. In addition, our result for S-ZPC is reasonably close with the
one reported from the pure enantiomer [3]. Comparing our results
for plasma (Table 4) with those for HSA (Table 3), it seems that S-
ZPC binds mainly to HSA, while R-ZPC binds also to other plasma
proteins, but with a limited afﬁnity compared to HSA. This also dis-
agrees with the explanation provided in [9] forced by the large PB
differences between HSA and AGP and plasma.
3.3.5. Final remarks
The protocol used, including (i) elimination of outliers (Eq.
(4) + Eq. (7)) on K1 direct individual estimations and (ii) veriﬁca-
tion of n1 =1 and K1 (Eq. (5)) aims to provide a sufﬁcient quality
on the results. To gain in robustness we have avoided unfavourable
D/P ratios (to guaranty the validity of the assumed model along
the D-concentration interval), then using a short-D-concentration
interval [31]. The estimations from Eq. (4) increase the control over
individual data (here replicates at different D-concentration lev-
els) allowing the application of univariate statistics instead off a
regression model with a single estimation. It should be noted that
using Eq. (4) (independent estimations were obtained) the D-range
becomes irrelevant, i.e. the estimation is not based on regression
where a short range would become problematic.
D, P or D/P information, as well as the experimental d-values
and experimental details should be always clearly reported since
it could condition the reported estimates (allowing appropriate
comparison or even a different mathematical data treatment).
4. Conclusions
Due to its intrinsic characteristics such as high separation efﬁ-
ciencies, speed of analysis, low reagent consumption and small
sample requirements, EKC, combined here with CM--CD using
the partial ﬁlling technique, has been demonstrated to be adequate
for the inexpensive chiral separation of ZPC enantiomers, allowing
the evaluation of enantioselective binding of ZPC to HSA and total
plasma proteins. The results suggest that S-ZPC exhibit more afﬁn-
ity (by a factor of 2) to HSA than R-ZPC. This work provides the
second evidence of ZPC enantioselectivity to HSA, using an inde-
pendent method with more favourable experimental conditions
respect to the physiological ones, and therefore serves to conﬁrm
the previous result. Our PB results (47±4, 49±6 and 45±3% for
racemic, R- and S-ZPC, respectively) agree with other reported val-
ues, supporting the idea that the protein binding of ZPC is in the
∼45% level (e.g. the value that ﬁgures in the DrugBank database
[28]) and not in the other reported level (∼80%).
When performing protein binding studies (enantioselective, as
in this case, or not) involving HSA, the mathematical approaches
to be selected should be consistent to the selected experimental
design. Factors to be considered include total enantiomer (or drug)
and protein,D and P, concentration intervals used,which also affect
the interval of other variables used, e.g. d or r data, and D/P ratios.
When possible, model assumptions should be a priori justiﬁed, but
also veriﬁed. Theapproaches selectedhave consequences related to
both accuracy anduncertainty of the estimates. Finally, data quality
indicators should be considered (e.g. outliers) and robust statistics
are recommended.
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Electrokinetic chromatographic estimation of
the enantioselective binding of nomifensine
to human serum albumin and total
plasma proteins
Lucía Asensi-Bernardia, Yolanda Martín-Bioscaa, Salvador Sagradoa,b and
María J. Medina-Hernándeza*
ABSTRACT: This report is the ﬁrst evidence of enantioselective binding of nomifensine to human serum albumin (HSA) and
plasma proteins. The overall process with HSA included: (i) consistent experimental design along two independent sessions;
(ii) incubation of nomifensine–HSA designed mixtures; (iii) ultraﬁltration for separating the unbound enantiomers fraction; (iv)
electrokinetic chromatography (EKC) using heptakis-2,3,6-tri-O-methyl-b-cyclodextrin as chiral selector to provide experimental
data for enantiomers (ﬁrst, E1, and second, E2, eluted ones); and (v) a recent direct equation allowing univariate tests and robust
statistics to provide consistent parameters and uncertainty. A signiﬁcant enantioselectivity to HSA (2.7 0.1) was encountered,
related to a 1:1 stoichiometry and log afﬁnity constants of 3.24 0.10 and 3.67 0.08 for E1 and E2, respectively. The protein
binding (PB) estimated at physiological concentration levels was 40 5 and 634% for E1 and E2, respectively. The use of
synthetic human sera allowed in vitro estimation of the total plasma PB for the racemate (615%; coincident with in vivo values),
and its enantiomers (58 7 and 64 4% for E1 and E2, respectively). Comparison allowed the relative importance of HSA respect
to other plasma proteins for binding nomifensine to be established. Copyright © 2012 John Wiley & Sons, Ltd.
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Introduction
Pharmacokinetic in vitro studies are useful for pharmaceutical and
biomedical industry, mainly in the preclinical phases of the develop-
ment of new drugs. Pharmacokinetic studies of drugs involve
processes like intestinal absorption, distribution between blood
and tissues, metabolic reactions and elimination. All these processes
affect the pharmacological activity, because only the fraction of the
drug that can reach the target place is active. Owing to this
inﬂuence, the development of powerful methodologies at the
microscale level for the study of pharmacokinetic properties of
drugs has become an important ﬁeld in bioanalytical research. Most
of the pharmacokinetic and pharmacological processes exhibit a
high degree of enantioselectivity, owing to the characteristic
chirality of biomolecules, and this results in differences between
the pharmacological activities of drug enantiomers. In fact, very
often one of them is most active while the other may produce
side-effects and even toxicity in some cases (Asensi-Bernardi et al.,
2010). Therefore, investigation of the enantioselectivity of drugs in
their pharmacokinetic and pharmacological properties represents
a great challenge for clinical pharmacology (Escuder Gilabert et al.,
2009). Under pressure from authorities, there has been an increasing
interest in development of rapid, efﬁcient and sensitive analytical
methods to control the chiral purity of drugs and for pharmacoki-
netic studies (Cherkaoui et al., 2001). Protein binding is one of the
most important parameters affecting drug distribution. Since only
free drug is active, and can be metabolized or eliminated, drug–
plasma protein complexes serve as reservoirs to supply free drug,
prolonging the duration of the drug action (Martínez-Gómez et al.,
2007). Human serum albumin (HSA) is the most abundant protein
in human plasma, and it presents a high degree of enantioselectivity
in its interaction with drugs (Ascoli et al., 2006). Owing to this prop-
erty, it has been widely used as chiral selector in chromatographic
and electrophoretical methodologies (Millot, 2003; Zhu et al., 1999;
Domenici et al., 1990; Zhang et al., 1999; Lloyd et al., 1995; Hjerten
et al., 1998).
The most important bioanalytical approaches to characterizing
drug–protein binding have been recently reviewed, including a criti-
cal evaluation of their strengths and weaknesses (Vuignier et al.,
2010). A review of our group emphasized the microseparation
techniques for evaluating the enantioselective binding of drugs to
plasma proteins (Escuder Gilabert et al., 2009). Most in vitro studies
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concerning a racemate involve two steps: separation of the free drug
fraction from the bound drug once the drug–protein equilibrium has
been reached, and chiral analysis of enantiomers, usually on the
unbound fraction. For the ﬁrst step, dialysis equilibrium (Kwong,
1985), ultracentrifugation (Kwong, 1985) and ultraﬁltration (Kurz,
1986) have been frequently used. For the second step, various
analytical techniques have been proposed, such as HPLC, GC, CE
and supercritical ﬂuid chromatography (Chankvetadze, 2007). In this
ﬁeld, CE is one of the most used techniques, owing to its high sepa-
ration power, low amount of sample required (microvolumes), short
analysis time and ease of automation (Zhu et al., 1999; Lin et al.,
2003). One of the most common modes of chiral CE is EKC in the
presence of a chiral selector in the BGE. In the EKCmodality of partial
ﬁlling technique, proposed by Valtcheva et al. (1993), the capillary is
partially ﬁlled with the chiral selector solution, leaving all the rest,
including the detection window, free of it. In this methodology the
consumption of chiral selector per injection is minimized (from
milliliters to nanoliters), achieving advantages from the analysis cost
and environmental points of view. Among the different chiral
selectors employed in CE (proteins, glycopeptides, polysaccharides,
chiral surfactants, bile salts, etc..), cyclodextrins (CDs) are one of the
mostwidely used, owing to their UV transparency, stability and broad
enantiorecognition abilities for the various kinds of native and
derivatized CDs available (Matthijs et al., 2004).
While reports on biodifferentiation between enantiomers activity
evidence the general importance of the ﬁeld, the quantitative
estimation of enantioselective binding of chiral compounds to
HSA is an issue poorly treated in the literature. In most cases, incom-
plete data are provided with uncertain results (Asensi-Bernardi et al.,
2010; Fielding et al., 2005, and references therein). Also, methodo-
logical drawbacks are encountered, suggesting that clearer informa-
tion is needed. Quantitative enantioselectivity to HSA (of maximum
interest from the distribution point of view), implies reliable afﬁnity
data for both enantiomers (constant and stoichiometry; two depen-
dent parameters whichmust be solved from a single equation). This
justiﬁes the effort to minimize errors by the use of the racemate
instead of the pure enantiomers, an optimized experimental design
(favoring the model validity), a direct equation allowing a univariate
data treatment (avoiding the reported inconsistencies/lack of
robustness of regression/ﬁtting strategies; Asensi-Bernardi et al.,
2010; Fielding et al., 2005) or stoichiometry veriﬁcation, to improve
conﬁdence. The conversion of the protein binding data analysis into
a univariate problem, a very recent proposal in this area (Asensi-
Bernardi et al., 2010), allows a radical change in the data treatment
possibilities (i.e. outlier checking, hypothesis testing, robust statistics,
reliable uncertainty on the results). New examples are necessary to
demonstrate its usefulness with respect the classical approaches
(massively used in the past) that do not have these features.
Nomifensine (NMF) is an isoquinoline derivative that prevents do-
pamine reuptake into synaptosomes. The maleate was formerly
used in the treatment of depression but it was withdrawn
worldwide in 1986 owing to the risk of acute hemolytic anemia with
intravascular hemolysis resulting from its use (Martindale, 1993).
Nomifensine is now mainly used in scientiﬁc research as a model
of dopamine reuptake inhibitors (Yorgason et al., 2011; Stouffer
et al., 2011; Masana et al., 2011; Hadjiconstantinou et al., 2011),
although a clinical application in Parkinson’s disease study and
diagnosis has been described (Sioka et al., 2010). Parkinson’s disease
can be evaluated by studying the dopamine pathways using
positron emission tomography (PET) with different tracers to image
the presynaptic and postsynaptic sites of dopaminergic system. PET
can also contribute to the differential diagnosis of Parkinson’s
disease when clinical features are not clear. One of the tracers that
have been used for presynaptic assessment is [11 C]nomifensine,
which inhibits the reuptake of the released dopamine by blocking
the dopamine reuptake sites (dopamine transporter) in presynaptic
nerve terminals (Sioka et al., 2010). The use of nomifensine as a PET
tracer is affected by its distribution between blood and central
nervous system, where protein binding plays an important role.
Therefore, the study of its enantioselective protein binding may be
helpful in this context, since differences between the dopamine
transporter-blocking activities of the enantiomers have been shown
in the literature (Vaugeois et al., 1992; Schacht and Leven, 1984).
In this paper, nomifensine (racemate) serves as a test chiral
compound to illustrate the applicability of an overall robust-
univariate-stereoselective protein binding-approach, performed
under intermediate precision conditions, forming the ﬁrst evidence
of its enantioselective binding to HSA and plasma proteins. This
methodology includes the incubation of drug–protein mixtures at
the microliter level, their ultraﬁltration through cellulose ﬁlters and
the chiral analysis of the unbound fraction by EKC-partial ﬁlling
technique using heptakis-2,3,6-tri-O-methyl-b-cyclodextrin (TM-b-
CD) as chiral selector. A recent mathematical approach of our group
(Asensi-Bernardi et al., 2010) was used to estimate afﬁnity constants
(K1) and verify the stoichiometry (n1), for both enantiomers of
nomifensine, as well as to estimate their enantioselectivity (ES).
Protein binding in percentage (PB) to HSA at physiological
concentration levels and total plasma proteins were also estimated
and compared with in vivo literature data.
Experimental
Instrumentation
A Beckman P/ACE MDQ capillary electrophoresis system equipped with a
diode array detector (Beckman Coulter, Fullterton, CA, USA), and 32Karat
software version 8.0 was used throughout. A 50mm inner diameter (i.d.)
fused-silica capillary with total and effective lengths of 60.5 and 50cm,
respectively, was employed. Electrophoretic solutions and samples were
ﬁltered through 0.45mm pore size nylon membranes (Micron Separation,
Westboro, MA, USA) and degassed in an ultrasonic bath (JP Selecta,
Barcelona, Spain) prior to use. A Crison Micro pH 2000 pHmeter from Crison
Instruments (Barcelona, Spain) was employed to adjust the pH of buffer
solutions.
A Selecta thermostatized bath (JP Selecta, Barcelona, Spain) was used for
sample incubation. For the ultraﬁltration of samples, Microcon YM-10
cellulose ﬁlters of a molecular weight of 10,000 MWCO (Millipore
Corporation, Bedford, MA, USA) and a Heraeus Biofuge Strate centrifuge
(Heraeus, Madrid, Spain) were used.
Chemicals and standard solutions
All reagents were of analytical grade. Human serum albumin fraction V
and lyophilized human sera were purchased from Sigma (St Louis,
MO, USA); sodium dihydrogen phosphate dihydrate and TM-b-CD were
from Fluka (Buchs, Switzerland); Tris-(hydroxymethyl)-aminomethane
(Tris) was from Scharlab (Barcelona, Spain). Racemic NMF was from
Research Biochemicals International (Natick, USA). Ultra Clear TWF UV
deionized water (SG Water, Barsbüttel, Germany) was used to prepare
solutions.
Separation buffer in EKC containing Tris 50mM at pH 6.0 was obtained
by dissolving the appropriate amount of Tris in water and adjusting the
pH with 1 M HCl. For the incubation process (NMF–HSA binding), 67mM
phosphate buffer was prepared and adjusted to pH 7.4 with 1 M NaOH.
Stock solutions of 100mM TM-b-CD and 1000mM NMF were prepared in
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the separation buffer. A 1000mM HSA stock solution was prepared daily
by weighting the corresponding amount of protein powder and
dissolving it with the phosphate buffer.
Capillary conditioning
New capillaries were conditioned using a 15min ﬂush with 1M NaOH at
60 C. Then, they were rinsed for 10min with deionized water and 10min
with separation buffer at 25 C. In order to obtain good peak shapes and
reproducible migration data, the capillary was conditioned prior to each
injection, and at the beginning and the end of the working session. In all
cases, the conditioning run included the following steps: (i) 1min rinse with
deionized water; (ii) 2min rinse with 0.1M NaOH; and (iii) 1min rinse with
deionized water at 20psi. Before chiral selector and sample injection the
capillary was also rinsed with the separation buffer for 2min at 20psi.
Enantioseparation of NMF by EKC using TM-b-CD
For all experiments, the 50mM Tris solution was used as electrophoretic
buffer. A 30mM TM-b-CD solution obtained by diluting the stock solution
with the buffer was used as the chiral selector. NMF samples (ultraﬁltrated
fractions and standards) were injected hydrodinamically at 0.5psi for 3 s.
Before sample injection, the capillary was partially ﬁlled with the 30mM
TM-b-CD solution by applying 10psi for 1min. Separation was performed
in normal polarity by applying 15 kV. The capillary was thermostated at
50 C and the UV-detection wavelength was set at 220nm. Under these
conditions, a minimum resolution of 1.7 was obtained for the enantiomers
of NMF.
Incubation, separation and analysis of unbound NMF fraction
to HSA and plasma proteins
We planned an experimental design to study the binding of the enantiomers
to HSA (or synthetic human sera), keeping the concentration of protein
constant within the physiological range, varying the concentration of racemic
NMF according to the detector capabilities and keeping an excess of protein
respect to the enantiomer concentration. Five concentration levels of NMF
were used with three independent replicates per level, totalling 15 indepen-
dent mixtures for the studies with HSA. This experiment was repeated in two
different working sessions (days). For the evaluation of the total plasma
protein binding, four concentration levels of NMF, with three independent
replicates per level, totalling 12 samples, were used. Mixtures were prepared
by dilution of the stock solutions of drug and protein with the phosphate
buffer. In the sera samples case, the relation aqueous/sera solution was
100/300 (v/v). All these mixtures were allowed to reach equilibrium for
30min in a water bath at 36.5 C and ﬁltered through cellulose ﬁlters by
centrifugation at 9000 rpm for 30min. The ultraﬁltrate was directly injected
into the EKC system. Figure 1 shows the electropherograms of total and
unbound fraction of NMF obtained in the EKC conditions previously speciﬁed.
Software and calculations
For the NMF–HSA binding study, routines made/adapted in MATLABW 4.2
were used for calculations, and the results generated were veriﬁed using
EXCELW and STATGRAPHICSW. The mathematical aspects were previously
described in detail (Asensi-Bernardi et al., 2010, and references therein)
and they are brieﬂy described here. An accepted mathematical model
describing the ligand–HSA interaction, applicable for each enantiomer in
the case of a chiral molecule, considering m classes of independent active
sites on HSA, each with ni binding sites, is:
r ¼ b
P
¼ D d
P
¼
Xm
i¼1
ni
Ki d
1þ Ki d (1)
In this equation, r is the fraction of bound enantiomer per molecule of
protein, b is the bound concentration of enantiomer and P is the total
protein concentration. D and d are the total and free enantiomer
concentrations, respectively. All the concentrations must be expressed in
molar units (M). For the site i, ni represents the apparent site stoichiometry.
Two simpliﬁed approaches were used here. The ﬁrst simpliﬁed approach
assumes m=1 and n1=1. Both assumptions should be reasonably valid
for low D/P ratios (usually under in vivo conditions), as well as the indepen-
dent binding between enantiomers, since there is relatively high concen-
tration of available binding sites (Asensi-Bernardi et al., 2010), providing:
K1 ¼ 1d
r
1 r (2)
Equation (2) is a one-parameter model, allowing K1 estimation for indi-
vidual D–P–d data and then serving as a source for outlier identiﬁcation
(Asensi-Bernardi et al., 2010). To verify the previous approach an alternative
equation, it was simply assumed that m=1, providing:
d ¼
 1 K1Dþ n1K1Pð Þ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 K1Dþ n1K1Pð Þ2 þ 4K1D
q
2K1
(3)
Equation (3) is a d-isolated (dependent variable) nonlinear form of
equation (1) when m= 1. SIMPLEX optimization (nonlinear ﬁtting) was
used for estimating the parameters n1 and K1, allowing integer n1 values
(Asensi-Bernardi et al., 2010).
Results and discussion
Calibration
Calibration standard solutions containing racemic NMF in the
range 50–500 mM (25–250mM of each enantiomer; the ﬁrst, E1,
and second, E2, eluted ones) were prepared in triplicate. The lin-
ear regression equations were
corrected peak area ¼ 16 14ð Þ þ 4:27 0:09ð Þ E1½  mMð Þ; R2
¼ 0:993
Figure 1. Electropherograms of total and unbound fraction of nomifensine,
after incubation with human serum albumin and ultracentrifugation.
Electrokinetic chromatography conditions speciﬁed in Experimental section.
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corrected peak area ¼ 23 13ð Þ þ 4:39 0:08ð Þ E2½  mMð Þ; R2
¼ 0:995
These calibrationmodels were used to estimate d, by interpolating
the analytical signals (corrected peak areas) corresponding to
ultraﬁltrates from the racemic NMF–HSA mixtures, providing the
required D–P–d values.
Enantioselective binding to HSA and plasma proteins
Consistently with equation (2) suggestions, D and P (independent
variables in the experimental design) concentration levels were
designed keeping D/P< 0.5 as a preﬁxed rule, to ensure, as far as
possible, model validity (Asensi-Bernardi et al., 2010). The
minimum D (~70mM) was ﬁxed considering the adequate
analytical signals for enantiomer quantiﬁcation after the analysis
of the ultraﬁltrates (unbound fraction). P was ﬁxed around the
hypoalbuminemia–normal levels frontier (Asensi-Bernardi et al.,
2010). Table 1 shows the experimental values of D and P in the
mixtures (in micromolar units, although they were transformed
into molar units for modeling), as well as the measured ones, dE1
and dE2. The D/P ratios (from 0.15 to 0.45) should guarantee the
assumptions made above, for instance, the m=1 model for the
NMF–HSA interaction, since only at high concentration may a
single drug populate multiple sites on HSA (Asensi-Bernardi et al.,
2010; Kragh-Hansen, 1988). In Table 1, since each of the ﬁve D-
concentration levels has three independent replicates in each of
the two working sessions, we can control atypical results. Owing
to the intermediate precision conditions of the study, which are
unusual in this ﬁeld, we can also control inter-day effect.
Outlier identiﬁcation/elimination in the HSA study
We have proposed a Z-score approach as an alternative to other
tests for outliers, as an automatic criterion (Bisetty et al., 2009).
Most tests for outliers depend on good estimates of dispersion,
and become less reliable with real errors present. Robust statis-
tics is a convenient method of handling results when they are
expected to follow a near-normal distribution, but are suspected
to contain a small proportion of errors that are not representa-
tive of the bulk of the data (RobStat.xla 1.0, 2002). The median
and MADe (a robust estimation of the standard deviation) were
used to estimate a robust Z-score, Zj for each independent log
K1j estimate from equation (2):
Zj ¼ logK1j  median
 
=MADe (4)
Normally, Zj> 3 is considered unsatisfactory, while values of Zj> 2
are considered dubious. Here we have pre-ﬁxed a Zj> 2.5 criterion
to eliminate a point.
Data ID 9 and 19 (marked in Fig. 2) appear atypical for both
enantiomers, which suggests errors in the overall sample process
(other replicates at the same level were normal). These values were
found to be outliers according to double Grubbs test (a=2.5%, two
tails) for E1, but not for E2 (although close to violating the critical
value). The Z-score approach showed that data ID 9 and 19 had Z-
scores, based on robust statistics, larger than 3 (unsatisfactory) for
E1 and E2. The data were therefore considered inconsistent and
eliminated from further analyses since there were two replicate data
for the same D–P levels with consistent values. The median values
(lines into Fig. 2) suggest a larger K1 value for E2.
Table 1. Experimental design and results. Experimental
p-values were 459.6mM for the ﬁrst working session (ID 1–15)
and 459.9mM for the second one (ID 16–27). Data were trans-
formed tomolar units for calculations.Outliers appear crossedout
D-Level ID D (mM) dE1 (mM) dE2 (mM)
1 1 70.0 35.6 22.1
2 70.0 38.1 23.2
3 70.0 45.6 27.5
2 4 105.0 61.2 37.2
5 105.0 64.8 37.1
6 105.0 57.3 33.6
3 7 140.0 84.3 51.5
8 140.0 71.3 43.9
9 140.0 42.2 33.4
4 10 174.9 118.6 75.8
11 174.9 102.5 66.5
12 174.9 125.4 77.8
5 13 209.9 145.1 105.6
14 209.9 107.6 69.2
15 209.9 118.0 80.3
1a 16 70.0 43.9 25.2
2a 17 105.0 56.6 47.9
18 105.0 63.5 36.6
3 19 140.0 106.9 73.0
20 140.0 81.2 52.4
21 140.0 80.3 47.6
4 22 174.9 105.6 70.2
23 174.9 104.0 71.9
24 174.9 113.1 73.8
5 25 209.9 132.8 92.4
26 209.9 129.5 81.1
27 209.9 122.4 83.9
aMissing data for D-levels 1 and 2 in the second working
session are due to problems with the electrophoretic system.
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Figure 2. Estimated log K1 values for E1 (open circles) and E2 (crosses)
based on equation (2). Points ID=9 and 19 appear as atypical data (note they
are one of three replicates for a given D–P level; see Table 1). Horizontal lines
indicate the median value.
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Estimation of afﬁnity constants to HSA
Equation (2) was used above for evaluating outliers assuming that
n1 =1 (the most probable situation at low D/P ratio; Asensi-Bernardi
et al., 2010), owing to the relatively high concentration of available
binding sites. An initial robust estimate of log K1 for the enantiomers
was provided based on equation (2). Initially, there was no reason to
suspect that the data from a particular session were worse than the
others, so, except the outliers, all the data were combined to derive
the ﬁnal afﬁnity estimates. The log K1 robust estimates (median
MADe; Asensi-Bernardi et al., 2010), after eliminating data ID 9
and 19, were 3.24 0.10 and 3.67 0.08 for E1 and E2, respectively.
To verify the parameters n1 and K1, an approach based on
nonlinear regression [using equation (3)] was used. A SIMPLEX
search was started with n1 = 1, log K1 = 4, and only integer n1
values were allowed (Asensi-Bernardi et al., 2010). The log K1
estimates found were 3.23  0.11 and 3.64  0.09, respectively,
which agree with the values obtained using equation (2). In
addition, n1 = 1 estimates were found for both enantiomers,
verifying the assumption. As an example of the model adequacy,
Fig. 3 shows some results associated to enantiomer E1 based on
equation (3): the validation plot for d (Fig. 3a) and the response
surface estimation by SIMPLEX (Fig. 3b). This suggests that log K1
estimates using equation (2), including their uncertainty
(accounting for the overall process variability in intermediate
precision conditions), could be considered acceptable values.
Enantioselectivity and protein binding to HSA
From K1 estimates, the enantioselectivity (ES, estimated as KE2/KE1)
could be obtained [note that, as K1, individual estimations of ES
are possible using the equation (2) strategy]. The estimated ES was
2.7  0.1, indicating a fair enantioselectivity degree in favor of the
second enantiomer eluted (E2). Figure 4 shows the box-and-whisker
plots from the afﬁnity (AF, in terms of log K1) and ES estimates,
considering all the data (Fig. 4a) or two data sets corresponding to
the independent working sessions (Fig. 4b). As can be seen in Fig. 4
(a), log K1 data for E1 and E2 exhibit similar dispersion with median
and mean values almost coincident, while ES (combined data from
E1 and E2) presents larger dispersion with an appreciable difference
between the mean and median values. The K1 estimates and the ES
obtained in the twoworking sessions are similar (Fig. 4b), suggesting
that the data could be combined, providing more robust results.
Qualitatively, it was clear that E2 showed higher afﬁnity to HSA
than its antipode, so values of ES> 1 were obtained. However,
since the log K1 differences were not too high, it was convenient
to check this observation through hypothesis testing. Statistical
comparison of log K1 paired data vectors of the enantiomers was
performed. Both the parametric t-test for the means and the
nonparametric ones for the medians (the sign test and the signed
rank test) indicate signiﬁcant differences (p< 0.05) between the
averaged afﬁnity estimates, so signiﬁcant enantioselectivity was
demonstrated. The same conclusion was encountered through
the comparison between ES and the unity.
A key parameter from a pharmacokinetic point of view is the
estimation of the percentage of protein binding. By means of
equation (3) and using the estimated constants at preﬁxed (desired)
D and P values, it is possible to estimate the corresponding d values,
and from them, the PB according to:
PB ¼ 100 D dð Þ=D (5)
Here we have selected values consistent with physiological
conditions, e.g. D=0.2 106 M (Nirogi et al., 2006) and P=600
106 M (Asensi-Bernardi et al., 2010). After dE1 and dE2 estimation,
the PB for each NMF enantiomer was calculated. The estimated
values were 40  5 and 63  4% for E1 and E2, respectively.
Plasma protein binding
The total plasma protein binding was estimated for racemic NMF
and, for the ﬁrst time, its enantiomers using synthetic human sera,
using equation (5). The results for the racemate were compared
with previous in vivo values found in the literature (Kellner et al.,
1977; Heptner et al., 1978; Table 2). As can be seen, protein binding
estimation agreed with the literature values. Plasma protein
binding data can be compared with HSA data. In the case of E1
(PB to HSA, 40 5%) a contribution of other plasma proteins was
expected according to the plasma PB (58 7%), but not for E2
(PB 63 4% and 64 4 for HSA and plasma, respectively). Even
for E1, the role of HSA is the most important.
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Figure 3. Results of the nonlinear approach corresponding to E1. Validation plot, d-estimated vs d-experimental (a) and response surface estimation
(d–D–P plot) (b).
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Conclusions
The in vitro incubation of racemic nomifensine with HSA or
synthetic human sera in approximated physiological conditions
followed by ultraﬁltration and separation/determination of
enantiomers by EKC-TM-b-CD-partial ﬁlling system makes it
possible to access information unobtainable by in vivo experi-
ments. Microvolumes of analyte, HSA and sera and nanovolumes
of cyclodextrin per injection are enough to provide the results,
which constitute the ﬁrst evidence of enantioselective binding
of nomifensine to HSA and plasma proteins. A signiﬁcant
enantioselectivity to HSA (2.7 0.1) was encountered, consistent
with a conﬁrmed 1:1 stoichiometry and afﬁnity constants (log K1
3.24 0.10 and 3.67 0.08 for E1 and E2, respectively) and
protein binding (40 5 and 63 4 for E1 and E2, respectively, at
physiological concentration levels). PB results for the racemate-
synthetic human were coincident with those available in vivo.
Additionally, PB estimates for the enantiomers allowed the
predominant role of HSA respect to the rest of plasma proteins
to be established.
Consistency is favored by the direct simple strategy based on
equation (2), an adaptation of the protein-binding data analysis
into a univariate problem with intrinsic statistical advantages, as
well as the elimination of outliers tools [equation (2) + equation
(4)] and further veriﬁcation of n1 = 1 and K1 [equation (3) and
SIMPLEX]. Moreover low D/P ratios (to guarantee the validity of
the assumedmodel along theD-concentration interval) contribute
to the consistency. The proposed scheme favors control over the
individual D–P–d data, here replicated at different D-concentration
levels in two independent sessions (days), allowing reliable
uncertainty estimations accounting for the intermediate precision
conditions used.
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Screening of acetylcholinesterase inhibitors by CE
after enzymatic reaction at capillary inlet
In this study the development of a procedure based on capillary electrophoresis
after enzymatic reaction at capillary inlet methodology for the screening and in
vitro evaluation of the biological activity of acetylcholinesterase (AChE) inhibitors is
presented. The progress of the enzymatic reaction of the hydrolysis of acetylthiocho-
line at pH 8 in the presence of AChE and the inhibitor studied is determined by
measuring at 230 nm the peak area of the reaction product thiocholine (TCh). In the
method employed the capillary was first filled with 30 mM borate-phosphate buffer
(pH 8.0) and subsequently, plugs of: (i) water, (ii) AChE solution, (iii) substrate solu-
tion with or without inhibitor, (iv) AChE solution, and (v) water, were hydrodynami-
cally injected into the capillary, and were allowed to stand (and react) during a wait-
ing period of 2 min. The applicability of the proposed methodology to estimate
different kinetic parameters of interest such as inhibition constants Ki, identifica-
tion of inhibitory action mechanism and IC50, is evaluated using compounds with
known activity, tacrine edrophonium, and neostigmine. The results obtained are
compared with bibliographic values and confirm the effectiveness of the methodol-
ogy proposed. Finally a method for AChE Inhibitor screening is proposed.
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1 Introduction
The use of compounds to inhibit enzyme action is an
important possibility for therapeutic intervention. Many
drugs act by inhibiting specific enzymes which are asso-
ciated with the disease process [1]. In this context, human
acetylcholinesterase (AChE) is currently indicated as a
target enzyme for drugs to be used in the treatment of
Alzheimer's disease (AD), the most common form of
dementia in the elderly. One important change observed
in the brain of AD patients is a decrease in hippocampal
and cortical levels of the neurotransmitter acetylcholine
(ACh) by nearly 90%. This important decrease in ACh lev-
els causes impairment in cognitive function [2]. Pharma-
cological treatment of AD is currently based on AChE
inhibitors, such as tacrine, donepezil, rivastigmine, and
galantamine which maintain high levels of ACh at the
muscarinic and nicotinic receptors in the central nerv-
ous system determining beneficial effects on cognitive,
functional, and behavioral symptoms of the disease [3].
However, the adverse side effect of these drugs, often due
to inhibition of peripheral AChE, limits their use [4]. For
that reason, research on new inhibitors for the treatment
of AD with improved pharmacological properties is cur-
rently in progress.
Preliminary studies in the discovery and development
process of new drugs include the in vitro evaluation of the
biological activity of the candidate compounds. For
enzyme inhibitor screening, themost common approach
is the measurement of the reduction of the enzyme activ-
ity in the presence of candidate compounds. For in vitro
screening AChE inhibitors, the reaction of acetylthiocho-
line (AThCh, substrate) at pH 8 in the presence of AChE
(enzyme) and the inhibitor to form acetic acid and thio-
choline (TCh, product of the enzymatic hydrolysis) is con-
sidered.
Several procedures for the evaluation of AChE activity
have been described. These include static procedures
such as the titration of the acid formed in the reaction
[5], the use of radiolabeled ACh [6] or colorimetric meth-
ods using Ellman's reagent [7]. The latter method is the
most widely used to measure the activity of AChE and its
Correspondence: Dr. Maria J. Medina-Hernndez, Departmento
Qumica Analtica, Universitat de Valncia, C/Vicente Andrs Es-
tells s/n, E-46100 Burjassot (Valencia), Spain
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Abbreviations: ACh, acetylcholine; AChE, acetylcholinesterase;
AD, Alzheimer's disease; AThCh, acetylthiocholine; EMMA, elec-
trophoretically mediated microanalysis; TCh, thiocholine
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decrease in the presence of inhibitors. In this method a
yellow anion derived from the dithiobisnitrobenzoate
(Ellman's reagent) when it reacts with TCh is monitored
at 412 nm. Chemiluminiscent assays based on coupled
enzymatic reactions have also been developed for the
evaluation of AChE inhibitors [3, 8, 9].
Dynamic procedures including chromatographic and
electrophoretic techniques using AChE immobilized or
in dissolution have also been proposed for the evaluation
of AChE inhibitors. A chromatographic procedure based
on in situ AChE derivatized column has been used to
determine the inhibition potency (IC50) of known AChE
inhibitors [10]. Most recently, the authors developed an
immobilized human recombinant AChE-based microen-
zyme reactor for inhibitor screening [11, 12]. This reactor
has been applied for the evaluation of the thermody-
namic and kinetic constants, and the mechanism of
action of inhibitors [13]. Moreover, an HPLC-MS method-
ology was used for the screening of AChE inhibitors in
natural extracts [14].
A recent trend in the area of enzyme assays is the use
of CE. CE has many advantages in this field due to the
small dimensions of the capillaries used for reaction and
separation, high efficiency separations, fast analysis
times, and the ability to employ several detection tech-
niques [15]. Measurement of enzyme activity by CE
include enzyme reaction prior CE analysis (precapillary
assay), enzyme reaction and consecutive on-capillary
detection of the product(S) (on-capillary assay), and
enzyme reaction after CE separation (post-capillary assay)
[16]. The second alternative, also known as electrophor-
etically mediated microanalysis (EMMA), is of particular
interest since the assay, and all its necessary operations,
completely occurs within the capillary. The EMMA
method has been successfully used with different
enzyme systems for enzyme activity assays, kinetic stud-
ies with determination of Michaelis constants and study
of inhibitors. Recently some reviews dealing with the
basic principle, methodology, variants, and applications
of EMMA have been published [15–18].
At present the plug–plug mode of EMMA, which relies
on a plug–plug interaction of reactants in the capillary,
is probably the most frequently used in the study of enzy-
matic reactions by CE. In the classical plug–plug mode,
after the introduction of enzyme and substrate as dis-
tinct plugs, the enzymatic reaction is initiated by the
application of an electric field since the zones interpene-
trate due to the differences in their electrophoreticmobi-
lities. One of the problems of this methodology, is the
high variability in peak areas of reagents and product of
enzymatic reaction due to slight variations in the in-
capillary contact period of the enzyme and substrate
plugs which affect the extent of the reaction [19].
As an alternative to the classical plug–plug mode the
at-inlet EMMA method has been proposed [19]. In this
modality, the consecutively injected enzyme and sub-
strate plugs are mixed by simple diffusion and reacted
for a given time at the inlet part of the capillary. This var-
iant is especially suitable for enzymes not resistant to an
electric field.
For the screening of AChE inhibitors, the classical
plug–plug mode [20], as well as the use of an immobi-
lized capillary AChE reactor based on a layer-by-layer
assembly [21] has been proposed.
A general problem related with the use of dynamic
techniques, such as chromatography and electrophore-
sis, for the calculation of the inhibition kinetic param-
eters, inhibition constants, Ki, and IC50 values, is the exis-
tence of diffusion phenomena during the enzymatic
reaction. As consequence, the actual concentrations of
substrate, enzyme and inhibitors are lower than the
injected concentrations and this affect considerably to
the estimated Ki, and IC50 values [19].
The purpose of this study was the development of effec-
tive and reliable high-throughput screening (HTS) proce-
dure based on the at-inlet EMMA method for the screen-
ing and in vitro evaluation of the biological activity of
AChE inhibitors that overcomes the limitations previ-
ously indicated.
2 Materials andmethods
2.1 Instrumentation
An HP3D CE system (Helwlett-Packard, Waldbronn, Ger-
many) equipped with an on-column diode array detector
(DAD) and an HP3D CE Chemstation software was used to
carry out all CZE separations. A 50 lm inner diameter
(id) and 363 lm outer diameter (od) fused-silica capillary
with total and effective length of 56 and 47.5 cm, respec-
tively was employed (Agilent Technologies, Germany).
The capillary temperature was set at 378C and a running
voltage of 15 kV was used. Detection was performed at
230 nm due to the maximum absorption of the substrate
and the reaction product. A Crison Micro-pH 2000 pH
meter from Crison Instruments (Alella, Barcelona, Spain)
was employed to adjust the pH of the separation buffer.
2.2 Chemicals and samples
All reagents were of analytical grade. AChE from Electro-
phorus electricus (EC.3.1.1.7), tacrine (9-amino-1,2,3,4-tetra-
hydroacridine hydrochloride), neostigmine bromide,
eserine, edrophonium chloride, pyridostigmine bro-
mide, and alprenolol were purchased from Sigma–
Aldrich (Steinheim, Germany). AThCh chloride was
obtained from Acros Organics (Geel, Belgium), boric acid
magnesium sulfate heptahydrate from Scharlau (Barce-
lona, Spain), and sodium dihydrogen phosphate dehy-
drate from Fluka (Barcelona, Spain).
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All solutions were prepared by Barnstead E-pure deion-
ized water (Sybron, Boston, MA, USA) and filtered prior
to use through 0.45 lm pore size nylon membranes
(Micron Separation, Westborough, MA, USA).
2.3 Solution preparation
The running buffer in all EMMA experiments was 30 mM
borate-phosphate buffer at pH 8.0 and was prepared by
dissolving the appropriate amounts of boric acid and
sodium dihydrogen phosphate in water and adjusting
the pH with 1 M NaOH. To prepare the working enzyme
solution AChE was diluted to 115.2 U/mL with borate-
phosphate buffer. Stock solutions of inhibitors
(5000 lM), substrate AThCh (100 mM), MgSO4 (200 mM),
and alprenolol used as an internal standard (50 mM)
were prepared in borate-phosphate buffer.
The assay solutions for kinetic and inhibitory studies
containing increasing inhibitor concentration, a concen-
tration of substrate in the range of 2–20 mM, 20 mM
MgSO4, and 2 mM alprenolol were obtained by diluting
the stock solutions in borate-phosphate buffer.
2.4 Procedures
New capillaries were conditioned for 10 min flush with
1 M NaOH at 608C. Then, they were rinsed for 5 min with
water and 15 min with borate-phosphate buffer at 378C.
In order to obtain good peak shapes and reproducible
migration times, the capillary was conditioned at the
beginning of each day with the following sequence: (i)
2 min rinse with deionized water, (ii) 2 min rinse with
1 M sodium hydroxide, (iii) 2 min rinse with deionized
water, and (iv) 5 min rinse with running buffer at
1000 mbar. Between runs, the capillary was conditioned
with deionized water for 1 min, and running buffer for
2 min.
The enzyme solution and the substrate solution, with
or without inhibitor, were introduced into the inlet part
of the capillary by a sandwich injection mode (Fig. 1), i.e.,
enzyme solution (50 mbar for 2 s)-substrate solution
(50 mbar for 2 s)-enzyme solution (50 mbar for 2 s).
Before and after the sandwich injection mode a small
plug of water was injected hydrodynamically (20 mbar
for 2 s). The consecutively injected plugs were allowed to
stand during a predetermined waiting period. Then, a
voltage of 15 kV was applied for the separation.
2.5 Software and data processing
AChE activity (initial reaction velocity) was determined
by the peak area of the product TCh since the reaction
time was constant due to the identical lengths of the
enzyme and substrate plugs during all experiments. The
percentage of inhibition was calculated according to the
following equation:
%inhibition ¼ 100 x
blank
100
 
ð1Þ
where x represents the peak area of the product (TCh)
determined at a given concentration of inhibitor, and
the blank is the peak are of the product (TCh) determined
without inhibitor being present.
The values of peak area of the product TCh determined
in this study were averages of triplicate measurements.
Microsoftm Excel 2000 and Statgraphics plus version 5.1
were used to perform the statistical analysis of the regres-
sions.
3 Results and discussion
3.1 Method development and optimization of
experimental conditions
In order to develop a screening methodology for AChE
inhibitors, the use of at-inlet EMMA mode has been eval-
i 2009WILEY-VCH Verlag GmbH &Co. KGaA,Weinheim www.jss-journal.com
Figure 1. (A) Schematic diagram of the introduction of the different plugs to the inlet of a capillary for AChE activity assay. (B)
AChE-catalyzed reaction.
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uated as alternative to the classical plug–plug mode.
Tacrine, a well-known AChE inhibitor, was used for opti-
mization. It has been reported in the literature that
AChE displayed maximum activity in 30 mM borate-
phosphate buffer (pH 8) at 378C and in the presence of
20 mM of MgSO4 [20]. Therefore these conditions were
fixed and used for the enzyme reaction and for electro-
phoretic separation. The progress of the enzymatic reac-
tion (Fig. 1) was determined by measuring at 230 nm the
peak area of the product TCh.
Figure 1 shows a schematic illustration of the disposi-
tion used in this work for the at-inlet EMMA analysis. As
it was commented previously in the at-inlet EMMA anal-
ysis, unlike in the classical mode, the compounds were
not electrophoretically mixed prior to reaction. In the
method employed the capillary was first filled with
30 mM borate-phosphate buffer (pH 8.0). Subsequently,
plugs of (i) water, (ii) AChE solution, (iii) substrate solu-
tion with or without inhibitor, (iv) AChE solution, and
finally (v) a plug of water were hydrodynamically
injected into the capillary, and were allowed to stand
(and react) during a waiting period. With the aim to con-
trol variations in the sandwich injection, alprenolol was
introduced in the substrate solution as an internal stand-
ard.
First the waiting time, the time necessary to allow the
injected enzyme and substrate plugs be mixed by simple
diffusion and react at the inlet part of the capillary was
optimized. Figure 2 shows the influence of mixing and
reaction time (waiting time) over the percentage of AChE
inhibition for two concentrations of the inhibitor
tacrine. As can be observed, the maximum inhibition
was achieved for a waiting time of 2 min, therefore, this
period was selected for further studies. Figure 3 shows
typical electropherograms after at-inlet reaction of AChE
and substrate AThCh, introduced by sandwich injection
mode in the absence of inhibitor (Fig. 3A) and in the pres-
ence of edrophonium (Fig. 3B). As can be observed in Fig.
3A, in absence of the inhibitor, the substrate is com-
pletely converted into TCh (reaction product). However,
in presence of edrophonium (Fig. 3B), the reaction is not
complete and the peak corresponding to the unreacted
substrate appears, whereas the product peak area dimin-
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Figure 2. Effect of the incubation time on the percentage of
inhibition: (0) tacrine 5 lM; (9) tacrine 10 lM. Conditions:
fused-silica capillary, 50 lm id6363 lm od, 47.5 cm of effec-
tive length; running buffer, 30 mM borate-phosphate buffer
(pH 8.0); concentration of AChE, 0.4 mg/mL; AThCh,
10 mM; MgSO4 in the substrate solution, 20 mM; capillary
temperature, 378C; running voltage, 15 kV; deteccion wave-
length, 230 nm.
Figure 3. Typical electropherograms obtained after enzy-
matic reaction at the capillary inlet, in the absence (A) and
presence (B) of the inhibitor edrophonium (100 lM) in the
substrate solution (AThCh). Alprenolol (50 mM) was used as
an internal standard. Conditions: waiting time, 2 min; other
conditions as in Fig. 2.
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ishes. Due to the low concentration of edrophonium
used, the peak of the inhibitor does not appear in the
electropherogram. As can be seen, no product peak split-
ting was observed that could be an indication of com-
plete mixing [19].
In order to evaluate the dilution originated during the
mixing of the plugs and reaction process, the inhibitory
potency of tacrine using the at-inlet EMMAmethod devel-
oped was obtained. For this purpose assay solutions con-
taining increasing inhibitor concentration in the range
of 10– 3–103lM in the presence of a fixed AThCh concen-
tration (10 mM), and AChE solution of 0.4 mg/mL were
prepared. Figure 4 shows the inhibition curve for tacrine
obtained by plotting the %inhibition versus the logarithm
of inhibitor concentration in the assay solution injected.
As can be seen in Fig. 4, complete inhibition was not
reached, even at high inhibitor concentrations. Using
nonlinear regression the fitted parameters were deter-
mined and the IC50 value calculated for tacrine was
9.16 lM. Table 1 shows the bibliographic values reported
for this compound. As can be observed, the IC50 values
obtained using inline chromatographic and EMMA
methodologies were larger than those obtained with the
static Ellman method considered in bibliography as
reference method. From the IC50 value for tacrine
obtained with the Ellman method 0.25 lM [3, 10, 22] and
the IC50 calculated from the inhibition curves using the
at-inlet EMMA method a dilution factor, f, of 0.03 was
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Figure 4. Inhibition plot of AChE in the presence of tacrine.
Experimental conditions: fused-silica capillary, 50 lm
id6363 lm od, 47.5 cm of effective length; running buffer,
30 mM borate-phosphate buffer (pH 8.0); concentration of
AChE, 0.4 mg/mL; AThCh, 10 mM; MgSO4 in the substrate
solution, 20 mM; capillary temperature, 378C; running volt-
age, 15 kV; detection wavelength, 230 nm; waiting time
2 min.
Table 1. Values of inhibitory potency (IC50) for tacrine
obtained by different assays reported in the literature
Method IC50, lM Ref.
Ellman 0.25 l 0.02 [22]
Ellman 0.25 l 0.01 [10]
Chemiluminescent assay 0.20 l 0.03 [3]
EMMA 0.83 [20]
Immobilized AChE-HPLC 450 l 30 [10]
Immobilized AChE-capillary 1.97 [21]
Table 2. Structures and apparent mobilities for the substrate
AThCh, the product TCh, and the different inhibitors
Compound l (cm2/V/s)
AThCh 7.574610 – 4
TCh 6.382610 – 4
Tacrine 6.846610 – 4
Edrophonium 6.605610 – 4
Neostigmine 6.464610 – 4
Pyridostigmine 6.329610 – 4
Eserine 6.411610 – 4
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estimated. Obviously the calculated dilution factor cor-
rection assumes that the reported literature value is a
true value. This dilution factor was applied in all of the
subsequent calculations related with the at-inlet EMMA
method developed.
3.2 Estimation of kinetic parameters
The applicability of the proposed methodology to esti-
mate different kinetic parameters of interest such as
inhibition constants Ki, identification of inhibitory
action mechanism and IC50, was evaluated using com-
pounds with known activity, tacrine edrophonium, and
neostigmine. Since, the velocity of the enzymatic reac-
tion is measured by the peak area of the formed TCh, it is
important to guarantee that no other component co-
eluted with the product. Table 2 shows the apparent
mobilities of substrate, product and some AChE inhibi-
tors in the 30 mM borate-phosphate buffer (pH 8.0; 378C).
The apparent mobility was calculated from the migra-
tion time of the compound, taking into account the
capillary length and the applied voltage. As can be seen,
all the inhibitors had different apparent mobilities than
the product TCh.
Reversible inhibition can be described quantitatively
in terms of the inhibitor's binding to the enzyme (dissoci-
ation constant Ki) and to the enzyme-substrate complex
(dissociation constant K 9i), and its effects on the kinetic
constants of the enzyme. In the presence of a reversible
inhibitor Michaelis–Menten equation can be described
as
v0 ¼ vmax S½ 
aKm þ a9 S½  ð2Þ
where vmax and Km are the typical parameters for an enzy-
matic reaction, [S] the substrate concentration, and a and
a9 are the modifying factors defined by the inhibitor con-
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Figure 5. Michaelis–Menten (upper part) and corresponding Lineweaver–Burk plots (lower part) for the enzymatic reaction of
AChE inhibited by: (A) tacrine, (0) 0 lM, (G) 5 lM, (9) 10 lM; (B) edrophonium (0) 0 lM, (G) 10 lM, (9) 50 lM, (h) 100 lM and
varying concentrations of substrate AThCh. Experimental conditions as in Fig. 4.
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centration, [I], and its two dissociation constants Ki and
K 9i
a ¼ 1þ I½ 
Ki
ð3Þ
a9 ¼ 1þ I½ 
K 9i
ð4Þ
In order to consider the dilution originated in the mix-
ing process of the plugs during the at-inlet reaction, cor-
rected concentrations for reagents (substrate, inhibitor,
enzyme) were introduced. For a compound A the cor-
rected concentration can be calculated as [A]corr =
f[A]injected, where f is the dilution factor and [A]injected the
concentration in the vial. Therefore taking in account
the dilution at the capillary inlet, Michaelis–Menten
equation can be rewritten as
v0 ¼ vmax S½ corr
aKm þ a9 S½ corr
¼ vmaxf S½ injected
aKm þ a9f S½ injected
¼ 1=a9ð Þvmax S½ injected
a=a9ð Þ1=f Km þ S½ injected
ð5Þ
and themodifying factors a and a9
a ¼ 1þ I½ corr
Ki
¼ 1þ f I½ injected
Ki
ð6Þ
a9 ¼ 1þ I½ corr
K 0i
¼ 1þ f I½ injected
K 0i
ð7Þ
For kinetic studies, two reversible reference inhibitors
with known potency and mechanism of action (tacrine
and edrophonium) were selected as model compounds.
To obtain estimates of the competitive inhibition con-
stant, Ki, Michaelis–Menten plots (v vs. [S]injected) and recip-
rocal plots (1/v vs. 1/[S]injected) were constructed by injecting
in triplicate different substrate solutions, in the range of
2–20 mM, containing increasing reversible inhibitor
concentrations, 0–10 and 0–100 lM for tacrine and
edrophonium, respectively.
Figure 5 shows the Michaelis–Menten and their corre-
sponding Lineweaver–Burk plots obtained for tacrine
and edrophonium. The Michaelis–Menten plots and fit-
ted parameters were assessed by a nonlinear regression
analysis according to Eq. 8:
vo ¼
1=a9ð Þvmax S½ injected
a=a9ð Þ 1
f
Km þ S½ injected
¼ a½Sinjected
bþ ½Sinjected
ð8Þ
The ratio of the fitted parameters b/a, were then plot-
ted against inhibitor injected concentration, and Ki was
determined as the ratio of the replot intercept to the
replot slope.
b
a
¼ Km
vmax
1
f
a ¼ Km
vmax
1
f
þ Km
vmax
1
Ki
½Iinjected ð9Þ
Table 3 shows the estimated inhibition constants Ki for
tacrine and edrophonium calculated from the fitted
parameters of themodels obtained and bibliographic val-
ues. As can be observed, the values obtained were in good
agreement with those reported in the literature obtained
using static procedures [13, 23, 24]. The use of other
dynamic methodologies provided higher and inaccurate
results.
Mechanism of action was qualitatively evaluated by
comparing Lineweaver–Burk plot trend to the theoreti-
cal ones [1]. Reciprocal plots for tacrine inhibition (Fig.
5B) showed increase in slopes (decreased vmax) and
increase in intercepts (higher Km) with higher inhibitor
concentration, indicating a mixed-type inhibition. In the
case of edrophonium inhibition (Fig. 6B) unvaried vmax
and increasing x-intercepts (higher Km) at increasing
inhibitor concentrations were obtained. This behavior
indicates that edrophonium acts as a pure competitive
AChE inhibitor.
The results obtained were consistent with data
reported in the literature and well reflect the relative
potency of the inhibitors, suggesting that this assay
could be suitable for the first screening of new potential
AChE inhibitors.
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Table 3. Inhibition constants of AChE by tacrine and edrophonium
Compound Method Ki (lM) Mechanism Ref
Tacrine At-inlet EMMA 0.138 l 0.012 Mixed This work
Ellman 0.151 l 0.016 Mixed [22]
Ellman 0.23 l 0.02 Mixed [23]
Immobilized AChE HPLC reactor 2.40 l 0.36 Mixed [13]
EMMA 9 Mixed [20]
Immobilized AChE-capillary 10 Mixed [21]
Edrophonium At-inlet EMMA 3.3 l 0.2 Competitive This work
Ellman 1.9 l 1.3 Competitive [24]
Ellman 1.63 l 0.23 Competitive [13]
Immobilized AChE HPLC reactor 5.38 l 0.52 Competitive [13]
Values obtained using the developed at-inlet EMMA methodology and reported in the literature.
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The inhibitory potency of edrophonium and neostig-
mine was also determined using the proposed at-inlet
EMMA method. For this purpose assay solutions contain-
ing increasing inhibitor concentration and a fixed sub-
strate concentration of 10 mM were prepared and the
inhibition curves were obtained by plotting the %inhibi-
tion versus the logarithm of inhibitor concentration in
the assay solution injected in the electrophoretic system
(Fig. 6). The IC50 values calculated from these curves were
0.68 and 1.06 lM for edrophonium and neostigmine,
respectively.
3.3 Method for AChE inhibitor screening
In order to obtain a rapid and efficient method for the
screening of new potential AChE inhibitors a new proce-
dure based on at-inlet EMMA analysis was evaluated. The
method for screening results used the methodology and
electrophoretic conditions previously optimized and
fixed concentrations of substrate; 10 mM, inhibitor,
10 lM, and AChE, 0.4 mg/mL. Table 4 shows the screen-
ing results, presented in terms of percentage of inhibi-
tion, obtained for five known AChE inhibitors. According
to the results obtained, the order of inhibitory potency
was tacrine > edrophonium > neostigmine > eserine >
pyridostigmine. The results obtained agree with the Ki
values reported in bibliography for tacrine and edropho-
nium [13, 22–24]. For neostigmine, pyridostigmine, and
eserine no kinetic data have been found in the bibliogra-
phy. The results obtained can be used as an automated
fast screening in the first step of the drug discovery pro-
cess.
4 Conclusions
The developed procedure based on CE after enzymatic
reaction at capillary inlet proved to be useful for the
screening and in vitro evaluation of the biological activity
of AChE inhibitors. The proposed method allows online
evaluation of kinetic parameters of interest such as deter-
mination the inhibitory constant (Ki), identification of
mechanism of action and evaluation of IC50 values with
increased accuracy and reproducibility and with saving
of time and materials. The results obtained were found
in agreement with data reported in the literature.
The advantages over the static conventional methods
are the system automation which allows a large number
of compounds to be processed continuously. Over the
dynamic procedures reported in bibliography, the pro-
posed methodology corrects adequately the dilution
effects that take place in the columns/capillary providing
similar results compared to the reference/static proce-
dures. Due to the reduced analysis time, less than 5 min,
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Figure 6. Inhibition curves for (A) edrophonium and (B) neo-
stigmine. Experimental conditions as in Fig. 4.
Table 4. Inhibitor screening resultsa)
Compoundb) Percent of inhibition (%)
Tacrine 54.2
Edrophonium 33.7
Neostigmine 31.1
Pyridostigmine 6.1
Eserine 20.1
a) Conditions as in Fig. 4.
b) Concentration of 10 lM.
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the at-inlet EMMA procedure proposed can be used as an
effective screeningmethodology.
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a  b s  t  r  a  c t
In this paper  a methodology  for the in-line  evaluation  of  enantioselective  metabolism  by  capillary  elec-
trophoresis has  been developed  and  applied  to the  study of  verapamil metabolism  by  cytochrome P3A4.
The developed  methodology  comprises  an  in-capillary  reaction  step carried out  by  electrophoretically
mediated microanalysis  and a  separation  step in which  highly  sulfated -cyclodextrin  with partial ﬁlling
technique has  been  employed  as chiral selector  for verapamil  and  norverapamil enantiomers resolution,
joining the  advantages  of both methodologies  in  a  unique  assay.  Kinetic  parameters  of  the  enzymatic
reaction (Km and  Vmax) have been evaluated  for both  verapamil enantiomers by  non-linear  ﬁtting  of
experimental data  obtained  under intermediate  precision  conditions  to Michaelis–Menten  equation.  Km
and Vmax estimated values  were  51 ± 9  M  and 22  ± 2  pmol  min−1 (pmol  CYP)−1 for S-VER  and  47  ±  9 M
and 21  ±  2  pmol min−1 (pmol  CYP)−1 for  R-VER.  Consequently, slight  enantioselectivity was  found for the
CYP3A4 metabolism of verapamil.  However, since  conﬁdence  intervals  of estimates  overlap, we  cannot
assure a signiﬁcant  enantioselectivity.  Intrinsic clearance values  were  also estimated  from  Km and Vmax
for  both enantiomers.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
The study of xenobiotics metabolism is a key  feature for the
pharmaceutical and chemical industries since is a determining fac-
tor both in the preclinical development of new drugs and  in the
toxicity evaluations of chemicals. CYP450 is the main metabolic
enzymatic system of the mammals, being responsible for the
metabolism of a large number of drugs, steroids, carcinogens and
other chemicals. There are different isoforms of CYP450 that cat-
alyze the oxidation of different substrates. Human cytochrome
P3A4, one of the four most important CYP isozymes in the human
liver, is involved in the metabolism of a large number of compounds
and its reactions are categorized as oxidation, mainly hydroxyl-
ation, N-demethylation and N-dealkylation of its substrates [1].
The oxidation of xenobiotic substances by CYP450 is a signiﬁcant
focus of scientists in the areas of toxicology, drug metabolism, and
pharmacology. The effects of  these oxidations can be manifested in
poor drug bioavailability and various acute and  chronic toxicities,
∗ Corresponding author at: Departamento de Química Analítica, Facultat de  Far-
macia, Universitat de Valencia, C/Vicent Andrés Estellés s/n, E-46100 Burjassot,
Valencia, Spain. Tel.: +34 963544899.
E-mail address: maria.j.medina@uv.es (M.J. Medina-Hernández).
including adverse drug interactions, cancer susceptibility, and birth
defects [2].
Enzymatic metabolism of chiral xenobiotics can show a high
degree of  stereoselectivity as a consequence of the sterereoselec-
tive interaction with optically active macromolecules involved in
the process [3].  Stereoselectivity in the enzyme–xenobiotic interac-
tion has been extensively reported and is the subject of a number
of reviews  [3–5]. Some metabolic reactions catalyzed by  CYP450
isoforms have shown a certain degree of enantioselectivity for dif-
ferent racemic drugs, such as ketamine [6,7] or amphetamines
[8,9],  leading to differences in the pharmacokinetic proﬁle of enan-
tiomers, which can affect their concentration in the target organ
and their pharmacological activity. To evaluate the enantioselective
metabolism of racemic drugs, it  is necessary to integrate method-
ologies that allow, ﬁrst, the interaction of racemic xenobiotic with
the enzymatic system and  later the determination of the enan-
tiomers of intact xenobiotic or its metabolites in the reaction
mixture.
Metabolism studies can be performed in vivo,  by administering
the drug to  the living system and  monitoring the free concentration
of xenobiotic and its metabolites in body ﬂuids and  tissues, or  by
in vitro assays. In vitro methods are based on  the use of liver  sub-
cellular fractions as liver microsomes, isolated hepatocytes, liver
slices or individual  forms of enzymes, predominantly isoforms of
0021-9673/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.chroma.2013.05.038
140 L. Asensi-Bernardi et al. / J. Chromatogr. A  1298 (2013) 139– 145
Fig. 1. Major routes of  VER metabolism by CYP3A4.
CYP450. In these studies, the components of  the enzymatic system
are mixed and after an incubation period one or more compo-
nents of the enzymatic reaction are monitored mainly using liquid
chromatography. More recently capillary electrophoresis (CE) has
become very useful for enzymatic assays since it  is fully automated,
requires small sample volumes, provides high peak efﬁciencies
and is environmentally friendly [10,11]. In the electrophoreti-
cally mediated microanalysis (EMMA) approach the reaction is
carried out in a nanoliter volume of the capillary which serves
simultaneously as microreactor, separation system and  detection
cell, allowing a higher degree of  automation and miniaturization
[12,13].
Several approaches have been proposed to conduct enzymatic
studies in CE [10,12,14] that include off-line assays, microchip
methodologies and electrophoretically mediated microanalysis
(EMMA) approach. Unless EMMA  is the denomination commonly
employed, most of these in-capillary reactions are performed
in a nanoliter scale. EMMA  has been successfully employed for
the evaluation of non chiral drugs metabolism by CYP450 and
other enzymes: dextromethorphan oxidation by  CYP3A4 [15];
phenacetin, dextromethorphan, tramadol and midazolam oxida-
tion by different CYP450 isoforms [16]; testosterone and nifedipine
by CYP3A4 [17];  diclofenac by  CYP2C9 [18,19] and clozapine
metabolism by FMO3 [20]. Inhibition studies with CYP450 [21] have
been also investigated by CE-EMMA.
There are only two applications that use the EMMA approach
for the characterization of the enantioselective metabolism
of compounds, the chiral oxidation of cimetidine by ﬂavin-
containing monooxygenases (FMOs) [22] and the enantioselective
N-demethylation of ketamine by cytochrome P450 [23]. In  these
papers, the inclusion of a cyclodextrin in the background elec-
trolyte allows the separation of the substrate and/or metabolite
enantiomers after in-line EMMA  incubation reactions.
Verapamil (VER) is a Ca2+-channel blocker, used for the treat-
ment of different cardiovascular diseases [1,24]. It  has been used as
a model substrate of the CYP3A4 metabolism to evaluate in vitro
reaction systems and study metabolic pathways, and  its major
metabolic routes, (Fig. 1),  including its N-demethylation reac-
tion that forms the active metabolite norverapamil (NOR), are
well known. These reactions are catalyzed by CYP3A4 among
other isozymes [25]. Different off-line chromatographic and  elec-
trophoretic methodologies have been employed for the in vitro
evaluation of the metabolism of verapamil [1,24–28], in some cases
including enantioselective evaluation of these metabolic reac-
tions. However, relatively different results are obtained suggesting
inﬂuence of the methodology used on the kinetic parameter esti-
mations.
The aim of this work is to develop a methodology for the in-
line study of enantioselective metabolism, and apply it  to the
study of the verapamil metabolism by  CYP3A4. The development
of the methodology comprises the study of the EMMA  reaction
conditions, the separation of verapamil and  norverapamil enan-
tiomers employing highly sulfated -cyclodextrin (HS--CD) as
chiral selector and  the partial ﬁlling technique, and the coupling
of both parts  in a unique step carried out in the CE system. As far
as we know, this  is the ﬁrst time in which EMMA  (for enzymatic
reactions) and partial ﬁlling technique (for enantioseparation) are
joined in an  enantioselective in-line CYP450 metabolic assay.
The metabolic reaction is evaluated by  the estimation of kinetic
parameters (Km and Vmax)  of each enantiomer from non-linear ﬁt-
ting to the  Michaelis–Menten equation of data obtained in two
different sessions  under intermediate precision conditions.
2. Materials and methods
2.1. Instrumentation
A  Beckman P/ACE MDQ  Capillary Electrophoresis System
equipped with a  diode  array detector (Beckman Coulter, Fullterton,
CA, USA),  and  32Karat  software version 8.0 was used throughout.
A 50  m inner diameter (I.D.) fused-silica capillary with total and
effective lengths of 60.2 and 50 cm,  respectively, was employed
(Beckman Coulter, Fullterton, CA, USA). The CE system is equipped
with a  temperature controlled garage for sample trays, so sam-
ples could  be  kept  cooled during all the experiments. Detection
wavelength was  ﬁxed at 200 nm for all experiments.
Electrophoretic solutions and samples were ﬁltered through
0.45 m  pore size  nylon membranes (Micron Separation, West-
boro, MA,  USA) and degassed in an ultrasonic bath (JP Selecta,
Barcelona, Spain) prior to use. A  Crison Micro pH  2000 pH-meter
from Crison Instruments (Barcelona, Spain) was employed to  adjust
the pH  of  buffer solutions.
2.2. Chemicals and solutions
All reagents  were of analytical grade. NaH2PO4·2H2O was  from
Fluka (Buchs,  Switzerland); KH2PO4 from Panreac (Barcelona,
Spain); HS--CD  (20%, m/v) aqueous solution was  purchased from
Beckman Coulter (Fullterton, CA, USA); Ultra Clear TWF  UV deion-
ized water (SG  Water, Barsbüttel, Germany) was used to prepare
solutions. Verapamil hydrochloride, R-verapamil hydrochloride
(employed for enantiomers identiﬁcation) and norverapamil
hydrochloride were purchased from Sigma Aldrich (St.  Louis,
MO, USA). Human CYP3A4 +  P450 reductase +  cythocrome b5
SUPERSOMES and  nicotinamide adenine dinucleotide phosphate
(NADPH) regenerating system were from BD Gentest (Erem-
bodegem, Belgium). This regenerating system consists of two
independent solutions: solution A (26 mM NADP+,  66 mM  glucose
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Fig. 2. Scheme of the reaction and separation zones in  the proposed enantioselective EMMA assay.
6-phosphate (G6P), 66 mM  MgCl2) and B (40 U/mL glucose 6-
phosphate dehydrogenase (G6PDH)). SUPERSOMES and  NADPH
regenerating system were aliquoted to minimize freeze–thaw
cycles and the aliquots were stored at −80 ◦C until their use.
Background electrolyte (BGE) containing 50 mM  NaH2PO4 was
prepared by dissolving the appropriate amount of NaH2PO4 in
water and adjusting the pH to 8.8 with 1 M NaOH. The  same pro-
cedure was employed to prepare the incubation buffer: 100 mM
KH2PO4 at pH 7.4. Verapamil, R-verapamil and norverapamil
1000 M stock solutions were prepared by  dissolving the appro-
priate amount of each drug in a few drops of  methanol (taking into
account that the organic solvent concentration should be under 1%
(v/v) for CYP450 assays) and bringing to ﬁnal  volume with incuba-
tion buffer. For the chiral separation of VER and NOR, 2.5% (m/v)
HS--CD was prepared by dilution in the BGE.
For EMMA  assays, two independent solutions were daily pre-
pared in each case in the incubation buffer. The ﬁrst one contained
200 nM CYP3A4 and 0.4 U mL−1 G6PDH (NADPH regenerating sys-
tem solution B). The second one contained verapamil in the
adequate concentration for each assay and the reagents of the
solution A (1.3 mM  NADP+, 3.3 mM G6P and  3.3 mM  MgCl2).  These
solutions were kept at 10 ◦C  in the CE system.
2.3. Methodology
2.3.1. Capillary conditioning
New capillaries were conditioned for 15 min  ﬂush with 1 M
NaOH at 60 ◦C. Then, they were rinsed for 5  min  with deionized
water and 10 min  with separation buffer at 25 ◦C. In order to obtain
good peak shapes and repeatable migration data, the capillary was
conditioned prior to each injection. In  all cases, the conditioning run
included the following steps: (i)  1 min  rinse with deionized water;
(ii) 1 min  rinse with 1 M NaOH, to prevent protein adsorption to the
capillary wall; (iii) 1 min  rinse with deionized water and  (iv) 2  min
rinse with separation buffer, all of them at 1.38 ×  105 Pa (20 psi).
2.3.2. CE separation
For the achiral separation of reagents and products after the
incubation step, the experimental conditions were  ﬁxed according
to the literature [27], as following: 50 mM NaH2PO4 at pH  8.8 as
BGE; capillary temperature: 25 ◦C;  applied voltage: 20 kV. These
conditions allowed the separation of VER and NOR, a priori difﬁcult
due to the similarity of the molecules.
For the enantioselective kinetic study, the separation of the
enantiomers was carried out by  partially ﬁlling the capillary with a
2.5% (m/v) HS--CD solution (by  applying pressure of 6.89 × 104 Pa
(10 psi) for 2 min) previously to the injection of the reagents and
adding a pressure of 1.38 ×  103 Pa (0.2 psi) to the separation volt-
age. No HS--CD was included in the BGE vials employed for  the
separation.
2.3.3. EMMA  procedure
After ﬁlling the capillary with the 2.5%  (m/v) HS--CD solu-
tion, ﬁve plugs of different length were introduced by  applying a
pressure  of  3.45 ×  103 Pa (0.5 psi) for different times (Fig. 2). The
order, composition and time of pressure application was as fol-
lows: (i)  incubation buffer solution (100 mM  KH2PO4 at pH  7.4),
20 s;  (ii)  enzyme plug containing 200 nM CYP3A4 and the solution
B of the NADPH regenerating system (0.4 U mL−1 G6PDH), 3 s;  (iii)
substrate plug containing racemic verapamil, and the solution A  of
the NADPH regenerating system (1.3 mM  NADP+,  3.3 mM  G6P  and
3.3 mM MgCl2), 7 s; (iv) enzyme plug, 3  s; and  (v) incubation buffer
solution, 10 s.  Between injections of  plugs, the capillary was shortly
dipped into water to avoid carry-over of samples. To determine the
kinetic parameters the incubation was performed at 37 ◦C for  5 min.
2.3.4. Estimation of Michaelis–Menten parameters
The estimation of  kinetic parameters was carried out by vary-
ing the concentration of verapamil in the reaction system. Six VER
concentrations between 20 and  200 M (10–100 M of each enan-
tiomer) were processed under intermediate precision conditions:
two working sessions were carried out, each one with two repli-
cates of  each  concentration level. All data were combined for the
estimations. The use of two short working sessions instead of  one
long session with more replicates helps to prevent possible degra-
dation or sedimentation of  CYP3A4 in the CE vial, which may  affect
the reaction progress.
The quantiﬁcation of the reaction turnover was  done consider-
ing the consumption of VER enantiomers, providing information
about the overall VER metabolization by  all the major routes
described in Fig. 1. With this aim, a  calibration curve with six VER
concentration levels in the 10–400 M range (for racemic drug;
each point in duplicate) was done in each working session. Cor-
rected peak area  of S-  and R-VER was  employed as  response variable
to subsequently calculate the reaction rate data. 50 M racemic
NOR was  added to all  calibration solutions to  check that the four
peaks were  adequately separated.
2.4.  Software and calculations
The  calculation of the reaction rate includes the number of moles
of each  reagent involved in the enzymatic reaction. This estimation
was done  by  calculating the injected volume of each plug with the
following equation:
Vol = P  ·  d
4 ·  ·  t
128 ·  · LTOT
(1)
where Vol  (m3)  is the injected volume, P (Pa) is the applied pres-
sure, d  (m)  is the internal diameter of  the capillary, t (s) is the
duration of pressure application,   (Pa s) is the viscosity of the
injected solution and LTOT (m)  is the total length of the capillary.
Velocity rate data (expressed in pmol min−1 (pmol CYP)−1) were
obtained from the corrected area of S- and R-VER peaks, and plot-
ted vs. the  initial enantiomer substrate concentration following the
Michaelis–Menten equation.
Microsoft Ofﬁce EXCEL® (Microsoft, Redmond, WA,  USA) and
STATGRAPHICS Plus® (Statpoint Technologies, Warrenton, VA,
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USA) were employed for calculations. Chemical structures of VER
and NOR were drawn with ChemBioDraw® (PerkinElmer Informat-
ics, Waltham, MA,  USA).
3. Results and discussion
3.1. Optimization of EMMA  experimental conditions
The EMMA assays carried out in this paper comprise two steps:
the incubation of the reaction mixture in the capillary and the
separation of reagents and products by electrophoresis. For the
optimization of the EMMA  experimental conditions, the corrected
area of the metabolite norverapamil, NOR peak, was employed as
response variable, since this is the major metabolite formed in this
reaction and the only one that could be detected. For the incuba-
tion step, some experimental conditions were ﬁxed (temperature
37 ◦C; the enzyme plug containing 200 nM CYP3A4 and the solution
B of the NADPH regenerating system (0.4 U mL−1 G6PDH), injected
at 3.45 × 103 Pa (0.5 psi) for  3 s and  incubation buffer: 100 mM
KH2PO4 at pH 7.4) and the incubation time and substrates plug
length were optimized in order to achieve a good development of
the enzymatic reaction.
Two experimental injection modes were assayed: the at-inlet
EMMA and the plug-plug modes. In the at-inlet EMMA  mode,
the solutions are introduced consecutively into the capillary and
are allowed to mix  by diffusion during an  incubation time. With
this conﬁguration, both longitudinal and  transverse diffusion are
responsible for the mixing of reagents [29]. In the plug-plug mode,
little voltages are applied to mix  the plugs. The results obtained
using both experimental modes did not show signiﬁcant differ-
ences, so for further experiences the reagents were allowed to mix
by simple diffusion (at-inlet mode).
The injected order plugs was chosen trying to maximize the
contact between the enzyme, cofactor and substrate. A “sand-
wich” mode was selected. In this modality, a plug of substrate is
introduced between two plugs of enzyme, which allows the exist-
ence of two contact zones in which the enzymatic reaction can take
place. The use of the opposite conﬁguration, that is a plug of enzyme
between two substrate plugs, was discarded due to the split of VER
and NOR peaks. Fig. 2 shows a scheme of the injected plugs and
different zones in the CE capillary for the proposed in-line EMMA
enantioselective assay.
The  NADPH regenerating system employed in this work com-
prises two solutions (A and  B) that  allow the in situ NADPH
formation. Solution A contains G6P, NADP+ and  MgCl2,  and solution
B contains G6PDH. When these solutions are put into contact, the
G6PDH oxidizes G6P and forms NADPH, which can act as cofactor
for the CYP3A4 reaction. Two  conﬁgurations were tested for  the
inclusion of these solutions in the CYP and  substrate vials. In the
ﬁrst one, both solutions A and B were included in the substrate vial,
to form NADPH before the injection in the CE system. This strategy
allows the  immediate starting of the reaction due to the fact that
the NADPH formed is present when the CYP and VER plugs con-
tact in the capillary, but  it  presents the disadvantage of a possible
degradation of  NADPH. The  other conﬁguration studied consisted
on the in-line formation of NADPH by  the inclusion of solution B
in the  CYP vial  and solution A  in the VER vial, which allows always
the presence of  native NADPH, but can retard the beginning of  the
enzymatic CYP reaction. The use of both conﬁgurations leads to
the same  metabolite (NOR) formation in short incubation times, so
the in-line formation of NADPH was selected in order to preserve
NADPH from degradation.
To evaluate the metabolism of drugs in physiological conditions,
the enzymatic reaction has to take place  at physiological pH  and
temperature. For this purpose the incubation buffer pH was ﬁxed
to 7.4 and the capillary temperature at 37 ◦C during the reaction
progress. The  use  of high pH  values in the background electrolyte
can affect the  enzymatic activity of CYP3A4. Therefore, in order to
avoid the contact of CYP3A4 plug with the background electrolyte,
the partial-ﬁlling technique was used by  injecting two plugs of
incubation buffer before and after reagents injection [10,12]. The
second plug  also assists to mix  the plugs and  move the reaction
zone to the thermostated zone of the capillary.
One of the most  difﬁcult aspects of  EMMA  assays is the selection
of the reaction conditions. The adequate mixture of the reagents is
critical for  the  reaction turnover, so the length of the injected plugs
and the incubation time are important variables that have to be
adjusted carefully. When reagents are mixed by simple diffusion,
the incubation time has to be  enough to assure their mixture and
reaction. However, an  excessive incubation time will decrease peak
efﬁciencies (due  to the diffusion), that decreases sensitivity and
increases the  total analysis time. In this paper, ﬁve different incu-
bation times were tested: 1, 5, 10, 20 and 30 min. VER concentration
was ﬁxed at  200 M, and  other conditions were kept as described
in Section 2.3.2. As can be observed in Fig. 3a,  although the amount
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Fig. 3. Effect of (a) incubation time and (b) plug injection time on  NOR  formation for the in-line EMMA  assay. Other experimental conditions are described in Section 2.3.3.
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of NOR formed slightly increased as  incubation times increased,
the broadening of the peak due to diffusion, provoked overlapping
with VER peaks and hindered the measurement of NOR formed. So
an incubation time of 5  min  was selected.
In order to allow a  good substrate–enzyme mixture, the injec-
tion sequence comprised a substrate plug between two  enzyme
plugs. The length of the substrate plug may  be adjusted to maximize
the reaction turnover, considering that an excessive plug length
will not provide best results if  part of the substrate does not con-
tact with the enzyme. The injection of substrate plug was  ﬁxed at
a pressure of 3.45 × 103 Pa (0.5 psi), and three injection times: 3, 5
and 7 s were assayed. Other conditions were ﬁxed as previously.
As can be observed in Fig. 3b  the amount of NOR formed increased
with the injection time, so the selected injection of substrate plug
was 0.5 psi/7 s. With this injection, the reaction progress was  con-
sidered enough for the quantitation of the VER consumption in the
kinetic study (see Section 2.3.4).
3.2. Electrophoretic separation of  VER and NOR enantiomers from
the reaction mixture
Initial conditions for the achiral separation of reagents and prod-
ucts after the incubation step were taken from [27] as following:
50 mM NaH2PO4 at pH 8.8 as BGE;  capillary temperature: 25 ◦C;
applied voltage: 20 kV. Under these conditions, racemic VER and
racemic NOR were well separated from NADP+ and  NADPH and
baseline separated themselves.
For the chiral separation of ±VER and ±NOR enantiomers,
the same BGE was employed and  HS--CD was chosen as  chiral
selector because this cyclodextrin has  proved to have good enan-
tiorecognition abilities for basic  drugs and it  has been employed
successfully by our research group [30,31]. As described in those
papers the use of the partial ﬁlling technique for the enantiomers
separation extremely decreases the consumption of chiral selec-
tor (comparing with the inclusion of  the cyclodextrin in the
BGE, which is the conventional methodology). Also, highly sul-
fated cyclodextrins have proved to be powerful stereoselectors for
enantiomers of many other basic and neutral organic compounds
[32–35].
Different HS--CD concentrations, injected at 6.89 ×  104 Pa
(10 psi) for 2 min, were tested in the range of 0.25–2.5% (m/v)
HS--CD. The use of 0.25% (m/v) HS--CD did not provide separa-
tion of the ±VER and ±NOR enantiomers. With 2% (m/v) HS--CD,
each pair of enantiomers was adequately separated but  S-NOR
and R-VER were overlapped. The  increase of the CD concentra-
tion to 2.5% (m/v) allowed baseline separation of the four peaks.
With 2.5% (m/v) HS--CD and  an applied voltage of 20 kV, migra-
tion times were 18.2, 19.9, 20.6 and  21.5 min  for S-VER, S-NOR,
R-VER and R-NOR, respectively. To reduce the analysis times and
improve peaks shape, a little pressure of  1.38 × 103 Pa (0.2 psi)
was added to the separation step, leading to migration times
of 9.8, 10.5, 10.8 and 11.2 min, for  S-VER, S-NOR, R-VER and
R-NOR, respectively. With these conditions, the enantiomers, com-
plexed with the HS--CD, migrate anionically to the detector.
For enantiomers identiﬁcation pure R-verapamil enantiomer was
used.
Fig. 4 shows the electropherogram corresponding to the sep-
aration of VER and NOR enantiomers under selected conditions.
NADP+ and NADPH had longer migration times and did not affect
the quantiﬁcation of VER and NOR enantiomers. As those peaks
were not measured, a stoptime of 20  min  was chosen for  further
experiences to shorten the analysis time. In  the selected condi-
tions, the total analysis time (including pre-conditioning, injection,
incubation and separation) was less than 35 min.
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Fig.  4. Electropherogram showing the separation of  the components of  the enzy-
matic EMMA  assay. The concentrations of racemic VER and NOR are,  respectively,
200 and 100 M.  Other experimental conditions are described in  Sections 2.3.2 and
2.3.3.
3.3.  Estimation of  Michaelis–Menten parameters for CYP3A4
metabolism of VER
For many  enzyme-catalyzed reactions, the relationship between
initial reaction rate (V)  and  substrate concentration ([S]), can be
described by Michaelis–Menten equation [5,12]:
V = Vmax · [S]
Km + [S] (2)
where Vmax is the maximum reaction velocity and Km is the
Michaelis constant, i.e. the substrate concentration at half the max-
imum velocity.
The  estimation of kinetic parameters was carried out by  varying
the concentration of racemic verapamil in the range of 20–200 M
(10–100 M of  each enantiomer) in the reaction system. Six VER
concentrations were processed under intermediate precision con-
ditions: two  working sessions were carried out, each one with two
replicates of each concentration level. All data were combined for
the estimations.
The  quantiﬁcation of the reaction turnover was  done consider-
ing the consumption of VER enantiomers, providing information
about the overall metabolism of VER by  CYP3A4. For this purpose
calibration curves for S- and  R-VER were done in both working ses-
sions. The experimental procedure for the calibration was the same
employed for  the reaction study (Section 2.3.2),  including the injec-
tion of enzymes and incubation times, in order to obtain the VER
and NOR peaks in the same conditions of diffusion as in the enzy-
matic assay.  However, the reagents of solution A were not included
in the  calibration solutions, avoiding the advance of the enzymatic
reaction.
Corrected (migration time normalized) peak area of S- and R-
VER was  used  as dependent variable to subsequently calculate the
reaction rate data. 50 M racemic NOR was added to all calibration
solutions to check  that  the four peaks were adequately separated.
Table  1  shows the regression statistics for the linear calibration
curves of each VER enantiomer together with their corresponding
conﬁdence intervals. In both cases the calibration curves showed
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Table  1
Calibration model statisticsa for S- and R-VER under the selected separation condi-
tions using corrected peak area as dependent variable.
b0 ± ts b1 ± ts R2
Session 1 S-VER −50 ± 80  15.9 ± 0.8  0.996
R-VER −40 ± 80  13.8 ± 0.8  0.994
Session 2 S-VER −1 ± 60  20.1  ± 0.6  0.998
R-VER −1 ± 60  19.2 ± 0.6  0.997
a b0, intercept; b1, slope; ts, conﬁdence interval at the 95% probability level; R2,
squared correlation coefﬁcient.
adequate regression coefﬁcients. Calculations for each experimen-
tal data set were done employing its corresponding calibration
curve.
Non-linear ﬁtting of the rate (V) experimental data to the
Michaelis–Menten equation was carried out for each VER enan-
tiomer employing a Mardquardt algorithm [36]. It should be
mentioned that data obtained by  duplicate from two independent
sessions (intermediate precision conditions) were combined, so  the
results become more realistic than those from  a single experiment.
The use of two short working sessions instead of one long session
with more replicates helps to prevent possible degradation or sed-
imentation of CYP in the CE vial, which may  affect the reaction
progress.
Michaelis–Menten graphics for both VER  enantiomers are
shown in Fig. 5. Km values for the overall metabolism of
VER by  CYP3A4 were found to be 51 ± 9  M for S-VER and
47 ± 9 M for  R-VER. Vmax values were 22 ± 2  and 21 ± 2  in
pmol min−1 (pmol CYP)−1 units, 2800 ± 200 and  2600 ±  200 in
pmol min−1 (mg  CYP)−1 units, respectively. The expressed uncer-
tainty is the asymptotic standard error obtained from the
Mardquardt non-linear ﬁtting. Determination coefﬁcients (R2) of
the model were 0.98 for S-VER and  0.97 for R-VER. At  all  con-
centrations studied, S-VER showed slightly faster metabolism than
R-VER. This conclusion is in agreement with other reported values
(Table 2),  which shows the capability of the proposed methodology
described in this  paper.
As can  be observed in Table 2 the Km values obtained with
the different  in vitro estimations [1,24–26] are different. Never-
theless, the Michaelis constant cannot be compared exactly with
values from other  studies, because it depends on the origin of the
CYP3A4 and the exact conditions of the enzymatic assay. Even using
the same source of enzyme, different batches can produce differ-
ent results [27]. Additionally the proposed methodology involves
a dilution step as a consequence of the in-capillary reaction which
can affect the Km estimated values. To estimate the dilution fac-
tor the peak areas of  standards obtained in the reaction conditions
were compared with those obtained in zonal CE. A  dilution factor
of 1.4 ±  0.2  was estimated. By applying this dilution factor the Km
values for S- and R-VER enantiomers were about 73 and 67 M,
respectively, results more closed to the reported values. On the
other hand,  as  can be  observed in Table 2, the Km values for  S- and
R-VER enantiomers were similar. By comparing the Vmax values,
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Fig. 5. Michaelis–Menten results for (a) S-VER and (b)  R-VER. V  represents the mean rate and standard  deviation (s)  from four replicates in  intermediate precision conditions
(two  replicates in two independent sessions) and [S] represents the enantiomer concentration.
Table 2
Michaelis–Menten parameters for CYP3A4 enantioselective metabolism of verapamil.
Substrate Enzyme source Methodology Km ±  SD (M) Vmax a,b ±  SD Ref.
S-VER R-VER S-VER R-VER ESc
Racemic VER Supersomes (Gentest) In vitro-EMMA  51 ± 9 47  ±  9 22 ±  2a 2800 ± 200b 21 ± 2a 2600 ±  200b 1.08  This work
Racemic VER Supersomes (Gentest) In vitro + off-line CE 170 ± 20 170 ±  35 26.7 ±  1.8a3400 ± 200b 19.5 ± 2.0a2500 ± 300b 1.36 [1]
R-VER S-VER Supersomes (Gentest) In vitro + LC 97 ± 13 100 ±  40  2930 ± 190b 2500 ±  500b 1.17 [24]
R-VER S-VER Human HEpG2 cells
infected by vaccinia virus
In vitro + LC 120 ± 30 130 ±  30  7.9 ± 0.6a 6.9 ± 0.7a 1.14 [25]
R-VER S-VER Human liver microsomes In vitro + LC 50 ± 40d 60  ±  50d 800 ±  600b,d 800 ± 700b,d 1 [26]
a Vmax expressed in (pmol min−1 (pmol CYP)−1).
b Vmax expressed in (pmol min−1 (mg  CYP)−1).
c Enantioselectivity (ES), estimated as the ratio between Vmax values.
d Values obtained for norverapamil formation.
L.  Asensi-Bernardi et  al. / J. Chromatogr. A  1298 (2013) 139– 145 145
S-VER is slightly more extensively metabolized than R-VER. How-
ever, since conﬁdence intervals of estimates overlap, we cannot
assure a signiﬁcant enantioselectivity. On the other hand, this
observation agrees with other previous results obtained for VER
(see Table 2). As can be observed in Table 2  the results obtained in
this paper agree with others obtained using Vmax values previously
reported.
Intrinsic clearance is an interesting pharmacokinetic param-
eter deﬁned as the amount of plasma from which a  xenobiotic
is removed in a certain time. It reﬂects the capacity of the body
to remove a xenobiotic. The in vitro intrinsic clearance Cli can
be estimated from the Km and Vmax values as Vmax/Km [26]. The
enantioselective Cli values for  verapamil by  CYP3A4 have been
estimated as 55 ± 10 and 55 ±  11 mL  min−1 (mg  CYP)−1 for S-  and
R-VER, respectively. Bibliographic Cli values for verapamil enan-
tiomers (expressed as sum of individual metabolites formed) are
53.5 and 40.5 mL  min−1 (mg  CYP)−1 for  S-  and R-VER, respectively
[26].
4. Conclusions
Due to its intrinsic characteristics such as high separation efﬁ-
ciencies, speed of analysis, low reagent consumption and  small
sample requirements, CE has proved to be a good technique for
the evaluation of in vitro enantioselective metabolism of drugs. The
combination of the EMMA  methodology for the in-line develop-
ment of the enzymatic reaction and  the partial ﬁlling technique
with HS--CD for the separation of VER and NOR enantiomers
has been employed successfully for the evaluation of enantioselec-
tive metabolism of VER by  CYP3A4. The methodology developed
and applied in this work allows the enantioselective estimation of
Michaelis–Menten kinetic parameters in a fast, fully automated and
non-expensive way that joins the intrinsic advantages of EMMA
and partial ﬁlling technique. This methodology can be  applied to the
estimation of enantioselective kinetic parameters of other CYP450
substrates.
In agreement with previous literature data, in this work we
have found that there are slight differences between the CYP3A4
metabolisms of S- and R-verapamil. However, since conﬁdence
intervals of estimates overlap, we  cannot assure a signiﬁcant
enantioselectivity. Working in intermediate precision conditions
provides more realistic conclusions from the experimental results.
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Research Article
Fast evaluation of enantioselective drug
metabolism by electrophoretically mediated
microanalysis: Application to ﬂuoxetine
metabolism by CYP2D6
In this work, a capillary electrophoretic methodology for the enantioselective in vitro eval-
uation of drugs metabolism is applied to the evaluation of ﬂuoxetine (FLX) metabolism by
cytochrome 2D6 (CYP2D6). This methodology comprises the in-capillary enzymatic reac-
tion and the chiral separation of FLX and its major metabolite, norﬂuoxetine enantiomers
employing highly sulfated -CD and the partial ﬁlling technique. The methodology em-
ployed in this work is a fast way to obtain a ﬁrst approach of the enantioselective in
vitro metabolism of racemic drugs, with the additional advantage of an extremely low con-
sumption of enzymes, CDs and all the reagents involved in the process. Michaelis–Menten
kinetic parameters (Km andVmax) for themetabolism of FLX enantiomers by CYP2D6 have
been estimated by nonlinear ﬁtting of experimental data to the Michaelis–Menten equa-
tion. Km values have been found to be 30 ± 3 M for S-FLX and 39 ± 5 M for R-FLX.
Vmax estimations were 28.6 ± 1.2 and 34 ± 2 pmol·min−1·(pmol CYP)−1 for S- and R-FLX,
respectively. Similar results were obtained using a single enantiomer (R-FLX), indicating
that the use of the racemate is a good option for obtaining enantioselective estimations.
The results obtained show a slight enantioselectivity in favor of R-FLX.
Keywords:
CYP2D6 / EMMA / Enantioselective metabolism / Fluoxetine
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1 Introduction
The development of new drugs is a long, complex, and
expensive process that involves the evaluation of the phar-
macokinetic and pharmacodynamic properties of the new
molecule in different stages. In the early stages of drug
development, methods for the high-throughput screening of
new molecules’ properties are commonly employed, in order
to have preliminary data about the potential pharmacological
activity of a molecule and also its pharmacokinetics. When
racemic molecules are employed, both pharmacokinetic and
pharmacodynamic properties can show a certain degree
of enantioselectivity due to the interaction with optically
active biomacromolecules, so the methods applied in these
preclinical early stages may allow to evaluate these properties
in an enantioselective way [1]. This need comes from the
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growing interest of the pharmaceutical industry in the devel-
opment of single-enantiomer formulations, and also from
the regulations concerning racemic drugs, which indicate
that enantioselective analysis should be performed also over
racemates [2].
One of the most important pharmacokinetic parameters
to evaluate is themetabolism by different enzymatic systems.
Although a deﬁnitive measurement of metabolic rates is
performed in vivo, by administering the drug to the living
system and monitoring the free concentration of xenobiotic
and its metabolites in body ﬂuids and tissues, in preclinical
stages in vitro assays are performed in order to obtain
a ﬁrst approach to the drug metabolism and to explore
different metabolic routes individually. In vitro methods
are based on the use of liver subcellular fractions as liver
microsomes, isolated hepatocytes, liver slices or individual
forms of enzymes, predominantly isoforms of cytochrome
P450 [3]. In these studies, the components of the enzymatic
system are mixed and after an incubation period one or
more components of the enzymatic reaction are monitored
mainly using LC. More recently CE has become very useful
for enzymatic assays since it is fully automated, requires
small sample volumes, provides high peak efﬁciencies and
is environmentally friendly [4, 5]. CE can be employed just
for the separation and detection of substrates or metabolites,
after off-line incubation, or also for the enzymatic reaction
with the Electrophoretically mediatedmicroanalysis (EMMA)
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methodology. In the EMMA approach the reaction is carried
out in a nanoliter volume of the capillary, which serves simul-
taneously as microreactor, separation system and detection
cell, allowing a higher degree of automation and miniatur-
ization [6,7]. Several applications of EMMA to the evaluation
of nonchiral drug metabolism with different CYP450
isoforms or ﬂavin-containing monooxygenases (FMOs) have
been reported in the literature [8–14]: dextromethorphan
metabolism by CYP3A4 [8], phenacetin, dextromethorphan,
tramadol, and midazolam by different CYP450 isoforms [9],
testosterone and nifedipine by CYP3A4 [10], diclofenac by
CYP2C9 [11, 12], clozapine metabolism by FMO3 [13], and
also inhibition studies with CYP450 [14]. There are only few
references about the use of EMMA procedure to study the
enantioselective metabolism of drugs. This procedure has
been applied to evaluate the chiral oxidation of cimetidine
enantiomers by FMOs [15] and to study the enantioselective
metabolism of ketamine by CYP450 [16]. In both cases a CD
has been added to the BGE to perform the chiral separation.
Recently a methodology for the enantioselective evaluation
of drugs metabolism by EMMA employing CYP3A4 as
model enzyme has been proposed by our research group
and applied to the study of enantioselective metabolism of
verapamil [17].
Fluoxetine (FLX) is a potent and selective inhibitor of
the neuronal serotonin-uptake carrier, used commonly as an
antidepressant but also indicated for other psychiatric disor-
ders such as obsessive compulsive disorder or bulimia ner-
vosa [18]. It is used therapeutically as a racemate, although
a stereospeciﬁcity associated with its interactions with the
serotonin-uptake carrier has been demonstrated [19]. FLX is
extensively metabolized in the liver, via different metabolic
routes. The major active metabolite, norﬂuoxetine (NFLX) is
formed by a N-demethylation pathway with the cytochrome
P450. Other metabolites, obtained with different phase II en-
zymatic systems, are inactive conjugates of FLX or NFLX.
Different isoforms of CYP450 have been described in vitro
as responsible for FLX metabolism, although in vivo is cy-
tochrome P2D6 (CYP2D6), which plays a major role in the
N-demethylation reaction [18]. Also, FLXandNFLXare potent
inhibitors of the CYP2D6, so they are important candidates
for causing drug–drug interactions of clinical relevance, since
several psychoactive drugs are substrates of CYP2D6 and fre-
quently co-administered with FLX.
To our knowledge, in bibliography there is only one
reference about the metabolism of FLX enantiomers by
CYP2D6. These kinetic data were obtained in vitro, by
incubating at 37C single enantiomers of FLX with the
baculovirus-expressed human CYP2D6. In that procedure,
after the incubation step, a liquid–liquid extraction of the
enantiomers of NFLX, followed by evaporation of the extract,
reconstitution of the residue and analysis by HPLC-MS/MS,
was performed [20].
In this work, the EMMA methodology for the enantios-
elective evaluation of drugs metabolism developed recently
by our research group employing CYP3A4 as model enzyme
[17], is applied to the enantioselective metabolism of FLX
using other CYP450 isoform, CYP2D6, conﬁrming the ade-
quacy of the methodology for the evaluation of enantioselec-
tive drugs metabolism by different isoforms of CYP450. In
this methodology the enzymatic reaction and the enantiosep-
aration using highly sulfated -CD (HS--CD) and a partial
ﬁlling technique (PFT) are joined in a unique step carried out
in the CE system, allowing a high degree of automation and
an extremely low consumption of all the reagents involved
both in the enzymatic reaction and the enantioseparation.
Kinetic data are estimated via Michaelis–Menten equation,
and also an estimation of the intrinsic clearance of FLX enan-
tiomers by CYP2D6 is provided. The results are compared
with those obtained using a single enantiomer.
2 Materials and methods
2.1 Instrumentation
A Beckman P/ACE MDQ Capillary Electrophoresis System
equipped with a DAD (Beckman Coulter, Fullerton, CA,
USA), and 32Karat software version 8.0 was used through-
out. A 50 m id fused-silica capillary with total and effec-
tive lengths of 60.2 and 50 cm, respectively, was employed
(Beckman Coulter, Fullterton, CA, USA). The CE system is
equipped with a temperature-controlled garage for sample
trays, so samples could be kept cooled at 10C during all the
experiments. Detection wavelength was ﬁxed at 200 nm for
all experiments.
Electrophoretic solutions and samples were ﬁltered
through 0.45 m pore size nylon membranes (Micron Sep-
aration, Westboro, MA, USA) and degassed in an ultrasonic
bath (JP Selecta, Barcelona, Spain) prior to use. A Crison Mi-
cro pH 2000 pH-meter from Crison Instruments (Barcelona,
Spain) was employed to adjust the pH of buffer solutions.
2.2 Chemicals and reagents
All reagents were of analytical grade. NaH2PO4·2H2O was
from Fluka (Buchs, Switzerland); KH2PO4 from Panreac
(Barcelona, Spain); HS--CD (20% w/v) aqueous solution
was purchased from Beckman Coulter (Fullerton, CA, USA);
Ultra Clear TWF UV deionized water (SG Water, Barsbu¨ttel,
Germany) was used to prepare solutions.
FLX hydrochloride was kindly donated by Alter (Madrid,
Spain). R-FLX hydrochloride (employed for enantiomers
identiﬁcation) andNFLX hydrochloride were purchased from
Sigma Aldrich (St Louis, MO, USA). Human CYP2D6 +
P450 reductase SUPERSOMES and NADPH regener-
ating system were from BD Gentest (Erembodegem,
Belgium). This regenerating system consists of two inde-
pendent solutions: solution A (26 mM NADP+, 66 mM glu-
cose 6-phosphate (G6P), 66 mM MgCl2) and B (40 U/mL
G6PDH). SUPERSOMES, and NADPH regenerating
system were aliquoted to minimize freeze-thaw cycles and
the aliquots were stored at −80C until their use.
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Figure 1. Scheme of the re-
action and separation zones
in the capillary, showing all
the reagents injected for the
EMMA procedure. Injection
parameters are detailed in
Section 2.3.2.
BGE containing 50 mM NaH2PO4 was prepared by
dissolving the appropriate amount of NaH2PO4 in water
and adjusting the pH to 8.8 with 1 M NaOH. The same
procedure was employed to prepare the incubation buffer:
100 mM KH2PO4 at pH 7.4. FLX, R-FLX and NFLX 1000 M
stock solutions were prepared by dissolving the appropriate
amount of each drug in a few drops of methanol (taking into
account that the organic solvent concentration should be un-
der 1% v/v for CYP450 assays) and bringing to ﬁnal volume
with incubation buffer. For the chiral separation of FLX and
NFLX, 1.25% w/v HS--CD was prepared by dilution in the
BGE.
For EMMA assays, two independent solutions were daily
prepared in each case in the incubation buffer. The ﬁrst one
contained 100 nM CYP2D6 and 0.4 U/mL G6PDH (dilution
1/100 of the NADPH regenerating system solution B). The
second one contained FLX in the adequate concentration for
each assay and a dilution 1/20 of the reagents of the solution
A (1.3 mMNADP+, 3.3 mMG6P, and 3.3 mMMgCl2). These
solutions were kept at 10C in the CE system.
2.3 Methodology
2.3.1 Capillary conditioning
New capillaries were conditioned by rinsing with 1 M NaOH
at 60C during 15 min. Then, they were rinsed for 5 min with
deionized water and 10 min with separation buffer at 25C.
In order to obtain good peak shapes and repeatable migration
data, the capillary was conditioned prior to each injection. In
all cases, the conditioning run included the following steps:
(i) 1 min rinse with deionized water; (ii) 1 min rinse with 1 M
NaOH, to prevent protein adsorption to the capillary wall; (iii)
1 min rinse with deionized water; and (iv) 2 min rinse with
separation buffer. All steps were carried out at 20 psi.
2.3.2 EMMA assay and CE enantioseparation of FLX
and NFLX
The methodology employed joins an EMMA assay for the en-
zymatic reaction and a chiral separation of FLX and NFLX
enantiomers by CE-PFT. With this purpose, a complex injec-
tion sequence is employed, which is schematized in Fig. 1
showing the injection and separation zones in the capillary.
First, a 1.25% w/v HS--CD solution in BGE was introduced
in the capillary by applying 20 psi for 2 min. Therefore,
different plugs of reagents and enzymes were injected for
the EMMA assay, as in reference [17], as follows: (i) incu-
bation buffer (100 mM KH2PO4, pH 7.4), 0.5 psi/20 s; (ii)
100 nM CYP2D6 + 0.4 U/mL G6PDH (dilution 1/100 of sol.
B), 0.5 psi/3s; (iii) FLX + 1.3 mM NADP+ + 3.3 mM G6P +
3.3mMMgCl2 (dilution 1/20 of sol. A), 0.5 psi/7s; (iv) 100 nM
CYP2D6 + 0.4 U/mL G6PDH (sol. B), 0.5 psi/3s; and (v) in-
cubation buffer (100 mM KH2PO4, pH 7.4), 0.5 psi/10 s. The
incubation of the reagents in the capillary was performed dur-
ing 5 min at 37C. Between injections of plugs, the capillary
was shortly dipped into water to avoid carry over of samples.
The incubation buffer plugs, (i) and (v), are introduced to
protect the enzyme from the higher pH of the BGE; the last
plug also helps to mix the enzyme and substrate plugs and
to bring the reaction mixture to the thermostatized part of
the capillary. After incubation, electrophoretic separation of
the reaction mixture was carried out employing the following
experimental conditions: BGE, 50 mM NaH2PO4 at pH 8.8;
capillary temperature, 25C, voltage, 20 kV. A little pressure
of 0.4 psi was added to the separation voltage in order to
decrease migration times and improve peak shapes.
2.3.3 Procedure for the estimation of
Michaelis–Menten parameters
For the estimation of Michaelis–Menten parameters employ-
ing themethodology described above, FLX concentration was
varied in the reaction system. Seven FLX concentrations be-
tween 10 and 200 M (5–100 M of each enantiomer) were
processed under intermediate precision conditions: two in-
dependent working sessions were carried out, each one with
two replicates of each concentration level. All data were com-
bined for estimations. The aim of performing two short ses-
sions instead of one longer with more replicates is to prevent
the CYP from degradation and sedimentation in the CE vial,
which can affect the reaction progress. Similar experiments
were carried out employing only R-FLX in order to check
possible interactions between enantiomers.
In order to measure the reaction turnover, the consump-
tion of FLX enantiomers was quantiﬁed, providing informa-
tion about the overall metabolism of FLX by CYP2D6. With
this purpose, calibration curves were made in each session,
employing six concentration levels of racemic FLX (range:
10–200 M). Corrected (migration time normalized) peak
area was used as response variable. The injection procedure
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employed for the calibration was the same as that employed
for the reaction samples, in order to obtain FLX peaks in the
same conditions. However, the reagents of solution A were
not included in the calibration solution, avoiding the advance
of the enzymatic reaction. As no signiﬁcant differences were
found between both sessions, all calibration and reaction data
were employed together for estimations.
2.4 Software and calculations
For the calculation of the reaction rate, it is necessary to
estimate the number of moles of each reagent involved in
the enzymatic reaction. This estimation was done by calcu-
lating the injected volume of each plug with the following
equation:
Vol = P · d
4 ·  · t
128 ·  · LTOT (1)
where Vol (m3) is the injected volume, P (Pa) is the applied
pressure, d (m) is the internal diameter of the capillary, t (s) is
the duration of pressure application,  (Pa·s) is the viscosity
of the injected solution and LTOT (m) is the total length of the
capillary.
Velocity rate data (expressed in pmol·min−1·(pmol
CYP)−1) were obtained from the corrected area of S- and
R-FLX peaks, and plotted versus the initial enantiomer sub-
strate concentration following the Michaelis–Menten equa-
tion. Microsoft Ofﬁce EXCEL R© (Microsoft, Redmond, WA,
USA) and STATGRAPHICS Plus R© (Statpoint Technologies,
Warrenton, VA, USA) were employed for calculations.
3 Results and discussion
3.1 Electrophoretic separation of the reaction
mixture
Initial conditions for the electrophoretic separation (BGE,
50 mM NaH2PO4 at pH 8.8; capillary temperature, 25C,
separation voltage, 20 kV + 0.2 psi of pressure; HS--CD
2.5% w/v injected at 20 psi/2 min) were taken from [17].
However, based on our previous experience about the chiral
separation of FLX with HS--CD, the CD concentration used
there (2.5% w/v) was considered too high due to the strong
interaction between the FLX enantiomers and the HS--CD
[21]. Therefore, a study was performed in order to select the
adequate CD concentration, which allows the separation of
all components of the enzymatic reaction. For this purpose
variable CD concentrations in the range 0.1–1.25% were as-
sayed, employing also a pressure slightly higher than in [17],
0.4 psi instead of 0.2. The CD concentration range used was
selected taking into account that the separation of FLX enan-
tiomers with HS--CD implies the formation of an anionic
complex with the CD, and the equilibrium between the free
and complexed drug fractions provides the enantiosepara-
tion and affects the effective electrophoretic mobility of the
enantiomers. When theHS--CD concentration is increased,
the equilibrium is shifted to the complexed form and the ef-
fective mobility of the enantiomers becomes more negative,
resulting in longermigration times. Consequently, in order to
obtain a better separation of the substrates and products from
the other reagents, and assuming that the mobility of bigger
molecules such as the cytochrome or the NADP+/NADPH
system is not (or slightly) affected by the CD concentration,
different CD concentrations were tested.
Figure 2 shows some of the results obtained. As can be
observed in Fig. 2A, the use of 0.1% CD concentration pro-
vided baseline resolution of the four enantiomers peaks of
S-NFLX, S-FLX, R-NFLX, and R-FLX, but the peaks cor-
responding to S-enantiomers overlapped with the CYP2D6
peaks (see Fig. 3 for all peaks identiﬁcation).
The use of 0.15% m/v CD concentration (Fig. 2B), pro-
duced the overlapping of the R-FLX and the NADP+ peak.
Additionally, when a 0.5% w/v CD concentration was em-
ployed (Fig. 2C), the FLX and NFLX peaks migrate after the
NADP+/NADPH system, but the peak of S-NFLX still over-
lapped with that. Finally, using a HS--CD 1.25% w/v con-
centration, all the reagents and products of the reaction were
baseline separated in an analysis time shorter than 30 min.
Figure 3 shows the electropherogram corresponding to the
separation of all the reaction components under the selected
conditions.
3.2 Estimation of Michaelis–Menten parameters
The Michaelis–Menten equation Eq. (2), describes the rela-
tionship between the initial reaction rate (V) and the sub-
strate concentration ([S]) for many enzyme-catalyzed reac-
tions [6, 22]:
V = Vmax · [S]
Km + [S] (2)
In this equation, Vmax is the maximum reaction veloc-
ity and Km is the Michaelis constant, which is deﬁned as the
substrate concentration at half themaximum velocity. The es-
timation of kinetic parameters was carried out by varying the
concentration of the racemic FLX in the range of 10–200 M,
employing seven concentration levels. The samples were pro-
cessed under intermediate precision conditions: two working
sessionswere carried out, each onewith two replicates of each
concentration level. All data were combined for estimations,
so the results become more realistic than those from a sin-
gle experiment. The use of two short sessions instead of one
longer is also useful to prevent possible sedimentation and/or
degradation of the CYP in the CE vial, which can affect the
reaction progress. The interday repeatability was evaluated.
Averaged intermediate precision coefﬁcients for peak areas of
calibration curves and samples, for both enantiomers, were
9 and 16%, respectively. Taking into account the concentra-
tion levels and the intrinsic variability of enzymatic reactions,
these coefﬁcients can be considered acceptable.
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Figure 3. Electropherogram showing the separation of the re-
action mixture. Concentrations of racemic FLX and NFLX were,
respectively, 100 and 50 M. Other experimental conditions as
described in Section 2.3.2.
Nonlinear ﬁtting of the rate (V) experimental data to
the Michaelis–Menten equation was carried out for each
FLX enantiomer employing a Mardquardt algorithm [23].
Michaelis–Menten plots for S- andR-FLX are shown in Fig. 4.
Km values (mean ± SD) have been found to be 30 ± 3 M for
S-FLX and39± 5MforR-FLX.Vmax estimationswere 28.6±
1.2 pmol·min−1·(pmol CYP)−1 (3630 ± 150 pmol·min−1·(mg
CYP)−1) and 34 ± 2 pmol·min−1·(pmol CYP)−1 (4300 ±
200 pmol·min−1·(mg CYP)−1) for S- and R-FLX, respectively.
These results show a slight enantioselectivity in favor of
R-FLX, that we have estimated as the ratio between their
Vmax values (Vmax−R/Vmax−S), giving a value of 1.18.
As indicated in the introduction section, only one es-
timation of the in vitro enantioselective metabolism of FLX
by CYP2D6 has been found in the literature [20]. In that pa-
per, the estimated kinetic parameters were: Km, 3.8 ± 0.4
and 1.4 ± 0.3 M for S- and R-FLX, and Vmax, 8.5 ± 0.3
pmol·min−1·(pmol CYP)−1 and 4.1 ± 0.2 pmol·min−1·(pmol
CYP)−1 for S- and R-FLX, respectively. The differences with
our kinetic data are considerable. However, the Michaelis
parameters can only be compared with values obtained us-
ing the same enzyme source and identical conditions in the
enzymatic assay. Even using the same source of enzyme,
different batches can produce different results [24]. In that
work, baculovirus-expressed human CYP enzymes, prepared
 Figure 2. Effect of the HS--CD concentration on the separation
of the reaction mixture (FLX and NFLX enantiomers, enzymes,
cofactors). HS--CD concentrations were: (A) 0.1% w/v; (B) 0.15%
w/v and (C) 0.5% w/v. Other experimental conditions as described
in Section 2.3.2 and Fig. 3.
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Figure 4. Michaelis–Menten plots for S-FLX (A) and R-FLX (B). V represents the mean rate and SD (s) from four replicates in intermediate
precision conditions and [S] represents the enantiomer concentration.
following a published procedure, were used and the experi-
mental conditions of the assay were very different from ours
(see Section 1).
An interesting parameter from a pharmacokinetic point
of view is the intrinsic clearance of the drug, deﬁned as the
amount of plasma from which a xenobiotic is removed in
a certain time. It reﬂects the capacity of the body (or of
a single enzyme, like in this case) to eliminate a xenobi-
otic. The in vitro intrinsic clearance, Cli, can be estimated
from the Km and Vmax values as Vmax/Km [25]. Enantiose-
lective Cli values for FLX by CYP2D6 have been estimated
as 121 ± 13 mL·min−1·(mg CYP)−1 for S-FLX and 111 ±
16 mL·min−1·(mg CYP)−1 for R-FLX.
3.3 Single versus racemic kinetic data estimations
In order to check a possible interaction of the enantiomers
in their metabolism, an experiment was carried out by in-
cubating only a single enantiomer, R-FLX, instead of the
racemic mixture. Kinetic parameters were also estimated for
R-FLX, obtaining a Km of 38 ± 9 M and a Vmax of 33 ±
4 pmol·min−1·(pmol CYP)−1. Comparing these data with
those obtaining forR-FLX employing the racemates (Km, 39±
5 M, and Vmax, 34 ± 2 pmol·min−1·(pmol CYP)−1), the dif-
ferences were really small: 1.6% for Km and 3.9% for Vmax, so
we can conclude that the use of a racemate for the evaluation
of enantioselective metabolism of a drug provides the same
results as the use of single enantiomers, with the advantage
of that no single enantiomers available are needed, which is
especially important in the case of new molecules in the early
stages of drug development.
4 Concluding remarks
The combination of EMMA for the in-line development of
an enzymatic assay and PFT with HS--CD for the chiral
separation of substrates and/or metabolites has proved to be
a powerful tool for a fast evaluation of in vitro enantiose-
lective metabolism of FLX by CYP2D6, conﬁrming that this
methodology, recently developed by our research group, can
be extended to other enzymes and substrates. The main ad-
vantages of this methodology, comparing with other reported
procedures, are its speed of analysis, low consumption of en-
zymes and other expensive reagents, enantioselective estima-
tions obtained from racemic compounds, and high degree
of automation, joining the intrinsic advantages of EMMA
and PFT in a unique step carried out in the CE system, and
making this method an interesting approach for screening
procedures in preliminary phases of drug development. The
results obtained in this paper indicate a slight enantioselec-
tivity in favor of the R-enantiomer for the metabolism of FLX
enantiomers by CYP2D6.
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